identifier
stringlengths 1
43
| dataset
stringclasses 3
values | question
stringclasses 4
values | rank
int64 0
99
| url
stringlengths 14
1.88k
| read_more_link
stringclasses 1
value | language
stringclasses 1
value | title
stringlengths 0
200
| top_image
stringlengths 0
125k
| meta_img
stringlengths 0
125k
| images
listlengths 0
18.2k
| movies
listlengths 0
484
| keywords
listlengths 0
0
| meta_keywords
listlengths 1
48.5k
| tags
null | authors
listlengths 0
10
| publish_date
stringlengths 19
32
⌀ | summary
stringclasses 1
value | meta_description
stringlengths 0
258k
| meta_lang
stringclasses 68
values | meta_favicon
stringlengths 0
20.2k
| meta_site_name
stringlengths 0
641
| canonical_link
stringlengths 9
1.88k
⌀ | text
stringlengths 0
100k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6044
|
dbpedia
|
1
| 10
|
https://www.bloomberg.com/profile/company/1383184D:CH
|
en
|
China Sinopharm International Corp - Company Profile and News
|
[] |
[] |
[] |
[
"1383184D",
"China Sinopharm International Corp",
"NYSE",
"Nasdaq",
"S&P",
"FTSE",
"DJIA",
"DAX",
"1383184D news",
"1383184D stock",
"1383184D stock price",
"stock",
"stock price"
] | null |
[] | null |
Company profile page for China Sinopharm International Corp including stock price, company news, executives, board members, and contact information
|
en
|
Bloomberg.com
|
https://www.bloomberg.com/profile/company/1383184D:CH
|
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
|
|||||
6044
|
dbpedia
|
2
| 12
|
https://newsinfo.inquirer.net/1426977/heres-what-you-need-to-know-about-sinopharms-covid-19-vaccine
|
en
|
Here’s what you need to know about Sinopharm’s COVID-19 vaccine
|
[
"https://www.facebook.com/tr?id=607491687857238&ev=PageView&noscript=1",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/twok-menu.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/twok-menu.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/inq2016.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/inq2016.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/paper.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/paper.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/twok-search.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/twok-search.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/inq2016-blue.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/inq2016-blue.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/inq-close.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/inq-close.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/fb-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/fb-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/twitter-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/twitter-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/yt-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/yt-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/ig-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/ig-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/tiktok-exp.svg",
"https://newsinfo.inquirer.net/inq2016/nav2022/images/tiktok-exp.svg",
"https://newsinfo.inquirer.net/files/2021/01/News112751-620x413.jpg 620w, https://newsinfo.inquirer.net/files/2021/01/News112751-300x200.jpg 300w, https://newsinfo.inquirer.net/files/2021/01/News112751-129x86.jpg 129w, https://newsinfo.inquirer.net/files/2021/01/News112751-768x512.jpg 768w, https://newsinfo.inquirer.net/files/2021/01/News112751-1536x1024.jpg 1536w, https://newsinfo.inquirer.net/files/2021/01/News112751-2048x1365.jpg 2048w",
"https://newsinfo.inquirer.net/files/2021/01/News112751-620x413.jpg",
"https://newsinfo.inquirer.net/files/2021/05/Duterte-Sinopharm-vaccine-05032021.jpg 397w, https://newsinfo.inquirer.net/files/2021/05/Duterte-Sinopharm-vaccine-05032021-300x215.jpg 300w, https://newsinfo.inquirer.net/files/2021/05/Duterte-Sinopharm-vaccine-05032021-129x92.jpg 129w",
"https://newsinfo.inquirer.net/files/2021/05/Duterte-Sinopharm-vaccine-05032021.jpg",
"https://newsinfo.inquirer.net/files/2021/05/table-2-620x158.png 620w, https://newsinfo.inquirer.net/files/2021/05/table-2-300x77.png 300w, https://newsinfo.inquirer.net/files/2021/05/table-2-129x33.png 129w, https://newsinfo.inquirer.net/files/2021/05/table-2-768x196.png 768w, https://newsinfo.inquirer.net/files/2021/05/table-2.png 1217w",
"https://newsinfo.inquirer.net/files/2021/05/table-2-620x158.png",
"https://newsinfo.inquirer.net/single2017/images/sm_share_fb.svg",
"https://newsinfo.inquirer.net/single2017/images/sm_share_fb.svg",
"https://newsinfo.inquirer.net/single2017/images/sm_share_twt.svg",
"https://newsinfo.inquirer.net/single2017/images/sm_share_twt.svg",
"https://newsinfo.inquirer.net/single2017/images/sm-share-email2.svg",
"https://newsinfo.inquirer.net/single2017/images/sm-share-email2.svg",
"https://newsinfo.inquirer.net/single2017/images/sm_share_bookmark.svg",
"https://newsinfo.inquirer.net/single2017/images/sm_share_bookmark.svg"
] |
[] |
[] |
[
""
] | null |
[
"@inquirerdotnet INQUIRER.net",
"Cristina Eloisa Baclig"
] |
2021-05-04T13:00:07
|
Despite that it has yet to secure an EUA from the FDA, President Rodrigo Duterte gave his ultimate seal of approval for the Chinese...
|
en
|
https://newsinfo.inquirer.net/icon/images/favicon.ico
|
INQUIRER.net
|
https://newsinfo.inquirer.net/1426977/heres-what-you-need-to-know-about-sinopharms-covid-19-vaccine
|
MANILA, Philippines — Notwithstanding its pending application for emergency use authorization (EUA) from the country’s Food and Drug Administration (FDA), President Rodrigo Duterte gave his ultimate seal of approval for the Chinese coronavirus vaccine produced by Sinopharm when he had himself inoculated Monday night.
A video of Duterte getting his vaccine of choice was released by his longtime aide, Senator Christopher “Bong” Go prior to the President’s public address Monday night. In the video, no less than Health Secretary Francisco Duque III administered the vaccine on the President on the basis of a compassionate special permit (CSP).
Duterte’s inoculation was contrary to an earlier statement by Malacañang which stated that the President will wait for the China-based pharmaceutical group to secure an EUA before receiving its jab.
So far, the regulator has granted an EUA to COVID-19 vaccines developed and produced by six pharmaceutical groups including Pfizer-BioNTech, AstraZeneca, Sinovac, Gamaleya Research Institute, Johnson & Johnson, and Bharat Biotech.
Presidential spokesperson Harry Roque previously said that the Palace will no longer seek inclusion of the President in the compassionate use license of Sinopharm issued to the Presidential Security Group (PSG) by the FDA.
Article continues after this advertisement
Chinese state-owned company Sinopharm started putting the inactivated coronavirus vaccine created by the Beijing Institute of Biological Products into clinical trials last year.
Article continues after this advertisement
The company has also tested a similar vaccine developed by the Wuhan Institute of Biological Products.
Article continues after this advertisement
Below is the side-by-side comparison of Beijing-Sinopharm’s BBIP-CorV vaccine and Wuhan-Sinopharm vaccine based on data from the COVID-19 vaccine tracker by the Vaccine Centre at the London School of Hygiene & Tropical Medicine.
How does it work?
Similar to Sinovac’s CoronaVac and Bharat Biotech’s Covaxin, the vaccines developed by Sinopharm in Beijing and Wuhan also use inactivated virus to make antibodies against SARS-CoV-2 – the virus that causes COVID-19.
According to the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4), these inactivated pathogens are grown in culture and killed in laboratories to reduce their virulence or the ability to infect and cause damage to a host.
Since the viruses in the vaccine are already dead, they can be injected into a person without causing COVID-19.
Inactivated viruses, which do not have the ability to replicate themselves, are also being used in polio and influenza vaccines. It also stands as the bases for vaccines against other diseases such as rabies and hepatitis A.
Efficacy rate
Sinopharm reported in December last year that the vaccine developed by its Beijing unit was 79.34 percent effective at protecting people from COVID-19.
According to the company, this is based on an interim analysis of the vaccine’s Phase 3 clinical trials. It is, however, lower than the 86 percent efficacy rate earlier announced by UAE based on preliminary data from trials there.
On the other hand, Sinopharm’s Wuhan unit in February said that its vaccine had shown an efficacy rate of 72.51 percent against COVID-19 based on an interim analysis of its Phase 3 clinical trials.
Clinical trials and approvals
Data from the World Health Organization’s (WHO) COVID-19 vaccine landscape and tracker as of April 30 showed that the vaccine by Sinopharm’s Beijing unit is currently at Phase 4 clinical trial while the vaccine produced by the Wuhan unit is still at Phase 3.
There are four trials registered for the Phase 3 clinical trials of Sinopharm-Beijing’s BBIBP-CorV. These trials are located in Bahrain, Egypt, Jordan, UAE, Peru, and Argentina.
Meanwhile, data from ClinicalTrials.gov – a website maintained by the US National Library of Medicine (NLM) at the National Institutes of Health (NIH) – bared that the Phase 4 trial for BBIBP-CorV has not yet started.
The Phase 3 trials for Wuhan’s vaccine, on the other hand, are likewise located in Bahrain, Egypt, Jordan, UAE, Peru, including Morocco.
In terms of vaccine approval, Beijing’s BBIBP-CorV has been so far approved for full or emergency use in at least 40 countries.
The Chinese government in February announced the approval of Wuhan’s COVID-19 for vaccine use while UAE has issued an EUA for the vaccine.
Sinopharm in PH
During a televised speech last December 26, Duterte said several military personnel were already inoculated with a vaccine against COVID-19 developed by China’s Sinopharm.
Both Interior and Local Government Secretary Eduardo Año and AFP spokesperson Maj. Gen. Edgard Arevalo then confirmed that that the Presidential Security Group (PSG) has received jabs of the Sinopharm vaccine.
Commander Brig. Gen. Jesus Durante III further said that some of the PSG’s personnel have already been vaccinated against COVID-19 as early as September, despite the non-issuance of an EUA or compassionate use authorization.
Amid fierce criticisms from lawmakers and several groups, Malacañang explained there was no violation of the anti-graft law when PSG received the vaccines because these were only “tokens” and no public funds were used for it.
In December, 2020, Justice Secretary Menardo Guevarra said he had ordered an investigation into the use of Sinopharm to inoculate presidential guards for COVID-19 as it might have violated several laws, contrary to administration officials’ claims that it was not unlawful.
Guevarra said he had directed the National Bureau of Investigation to look into the use of the vaccine developed by the Chinese pharmaceutical company Sinopharm and how it was brought into the Philippines, and unauthorized inoculation on military troops.
In January, 2021, the AFP called off its own investigation on PSG’s use of unauthorized Chinese coronavirus vaccines.
That same month, the Senate said it will proceed with an inquiry into the government’s vaccination program despite Duterte’s threat of a “crisis” if the senators insist on questioning the PSG’s inoculation with Sinopharm.
In February, FDA issued a compassionate use license for 10,000 doses of China-based Sinopharm’s COVID-19 vaccine.
The compassionate use license allows the PSG to get access to unregistered vaccines sans an EUA from the FDA, which is required before a vaccine can be administered legally in the country.
Meanwhile, both the FDA and the Department of Health (DOH) vowed to probe the vaccination of President Rodrigo Duterte’s former special envoy to China Mon Tulfo using smuggled vaccines from Sinopharm.
Tulfo had admitted to using the vaccine, further saying that he would quit his post should he be appointed by Sinopharm as its distributor in the country.
Last month, vaccine czar Carlito Galvez Jr. said that UAE is planning to donate 500,000 doses of the Sinopharm vaccine to the Philippines.
As to what would happen to these government investigations on the use of Sinopharm is unknown after Duterte’s endorsement of the locally unregistered vaccine.
EDV
|
||||
6044
|
dbpedia
|
1
| 47
|
https://pubmed.ncbi.nlm.nih.gov/35987605/
|
en
|
world study of the effectiveness of BBIBP
|
[
"https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png",
"https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg",
"https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg",
"https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg",
"https://cdn.ncbi.nlm.nih.gov/pubmed/a266f1b7-df1a-4da4-b828-cfe0d573f6ff/core/images/pubmed-logo-blue.svg",
"https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--s3-service-broker-live-ddda94b7-dbb0-4917-917d-776dae91ebba.s3.amazonaws.com-bmc-linkout-fulltext.png",
"https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9392920/bin/12889_2022_14016_Fig1_HTML.gif",
"https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--s3-service-broker-live-ddda94b7-dbb0-4917-917d-776dae91ebba.s3.amazonaws.com-bmc-linkout-fulltext.png"
] |
[] |
[] |
[
"pmid:35987605",
"PMC9392069",
"doi:10.1186/s12889-022-14016-9",
"Yaowen Zhang",
"Jihane Belayachi",
"Xiaoming Yang",
"Adolescent",
"Adult",
"Aged",
"Aged",
"80 and over",
"COVID-19 Vaccines",
"COVID-19* / epidemiology",
"COVID-19* / prevention & control",
"Critical Illness",
"Humans",
"Influenza Vaccines*",
"Middle Aged",
"Morocco / epidemiology",
"Retrospective Studies",
"SARS-CoV-2",
"Young Adult",
"PubMed Abstract",
"NIH",
"NLM",
"NCBI",
"National Institutes of Health",
"National Center for Biotechnology Information",
"National Library of Medicine",
"MEDLINE"
] | null |
[] |
2022-08-29T00:00:00
|
Effectiveness of Sinopharm's BBIBP-CorV was consistent with phase III clinical trial results. Two doses of BBIBP-CorV was highly protective against COVID-19-associated serious or critical hospitalization in working-age adults under real-world conditions and moderately effective in older adults. Boos …
|
en
|
https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico
|
PubMed
|
https://pubmed.ncbi.nlm.nih.gov/35987605/
|
Skip to main page content
An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Save citation to file
Format:
Email citation
Subject: 1 selected item: 35987605 - PubMed
To:
From:
Format:
MeSH and other data
Add to Collections
Create a new collection
Add to an existing collection
Name your collection:
Name must be less than 100 characters
Choose a collection:
Unable to load your collection due to an error
Please try again
Add to My Bibliography
My Bibliography
Unable to load your delegates due to an error
Please try again
Your saved search
Name of saved search:
Search terms:
Would you like email updates of new search results?
Saved Search Alert Radio Buttons
Yes
No
Email: (change)
Frequency:
Which day?
Which day?
Report format:
Send at most:
Send even when there aren't any new results
Optional text in email:
Create a file for external citation management software
Your RSS Feed
Name of RSS Feed:
Number of items displayed:
RSS Link
|
||||
6044
|
dbpedia
|
2
| 86
|
https://www.fitchratings.com/research/corporate-finance/limited-margin-growth-likely-for-top-chinese-drug-distributors-22-09-2019
|
en
|
[] |
[] |
[] |
[
""
] | null |
[] | null |
/favicon-32x32.png?v=b699907ea1d10d61f36bdbb9f4d8a203
| null | |||||||||
6044
|
dbpedia
|
0
| 70
|
https://www.latimes.com/world-nation/story/2020-07-16/china-firm-tests-coronavirus-vaccine-own-employees
|
en
|
Chinese firm says it has tested a COVID-19 vaccine on its own workers, without official permission
|
https://ca-times.brightspotcdn.com/dims4/default/d15fbba/2147483647/strip/true/crop/4832x2537+0+343/resize/1200x630!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F68%2Fd8%2Ff92f9ad365fa18a23b836492b207%2F1bd25766c1ef4fb7bea146b3eb1807bc
|
https://ca-times.brightspotcdn.com/dims4/default/d15fbba/2147483647/strip/true/crop/4832x2537+0+343/resize/1200x630!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F68%2Fd8%2Ff92f9ad365fa18a23b836492b207%2F1bd25766c1ef4fb7bea146b3eb1807bc
|
[
"https://ca-times.brightspotcdn.com/dims4/default/bf3ca91/2147483647/strip/true/crop/4832x3222+0+0/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F68%2Fd8%2Ff92f9ad365fa18a23b836492b207%2F1bd25766c1ef4fb7bea146b3eb1807bc 320w,https://ca-times.brightspotcdn.com/dims4/default/a3a657c/2147483647/strip/true/crop/4832x3222+0+0/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F68%2Fd8%2Ff92f9ad365fa18a23b836492b207%2F1bd25766c1ef4fb7bea146b3eb1807bc 568w,https://ca-times.brightspotcdn.com/dims4/default/4afd4a9/2147483647/strip/true/crop/4832x3222+0+0/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F68%2Fd8%2Ff92f9ad365fa18a23b836492b207%2F1bd25766c1ef4fb7bea146b3eb1807bc 768w,https://ca-times.brightspotcdn.com/dims4/default/ba7a806/2147483647/strip/true/crop/4832x3222+0+0/resize/1024x683!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F68%2Fd8%2Ff92f9ad365fa18a23b836492b207%2F1bd25766c1ef4fb7bea146b3eb1807bc 1024w,https://ca-times.brightspotcdn.com/dims4/default/31c7463/2147483647/strip/true/crop/4832x3222+0+0/resize/1200x800!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F68%2Fd8%2Ff92f9ad365fa18a23b836492b207%2F1bd25766c1ef4fb7bea146b3eb1807bc 1200w",
"https://ca-times.brightspotcdn.com/dims4/default/b18783a/2147483647/strip/true/crop/4299x2866+1+0/resize/110x73!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fd6%2F9f%2Fe95b58554613b917b134826b9131%2Fvirus-outbreak-vaccine-race-21728.jpg 110w,https://ca-times.brightspotcdn.com/dims4/default/7428a50/2147483647/strip/true/crop/4299x2866+1+0/resize/180x120!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fd6%2F9f%2Fe95b58554613b917b134826b9131%2Fvirus-outbreak-vaccine-race-21728.jpg 180w,https://ca-times.brightspotcdn.com/dims4/default/20d9f03/2147483647/strip/true/crop/4299x2866+1+0/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fd6%2F9f%2Fe95b58554613b917b134826b9131%2Fvirus-outbreak-vaccine-race-21728.jpg 320w,https://ca-times.brightspotcdn.com/dims4/default/f88b1ea/2147483647/strip/true/crop/4299x2866+1+0/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fd6%2F9f%2Fe95b58554613b917b134826b9131%2Fvirus-outbreak-vaccine-race-21728.jpg 568w,https://ca-times.brightspotcdn.com/dims4/default/b404228/2147483647/strip/true/crop/4299x2866+1+0/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fd6%2F9f%2Fe95b58554613b917b134826b9131%2Fvirus-outbreak-vaccine-race-21728.jpg 768w,https://ca-times.brightspotcdn.com/dims4/default/56f5b6a/2147483647/strip/true/crop/4299x2866+1+0/resize/840x560!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fd6%2F9f%2Fe95b58554613b917b134826b9131%2Fvirus-outbreak-vaccine-race-21728.jpg 840w",
"https://ca-times.brightspotcdn.com/dims4/default/e205f48/2147483647/strip/true/crop/599x399+21+0/resize/110x73!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F12%2Fc4%2F681c2e9dc70cac905573985a8eb1%2Fle-heb-flu-influenza-vaccine-pregnant-20110604-001 110w,https://ca-times.brightspotcdn.com/dims4/default/5c92ffb/2147483647/strip/true/crop/599x399+21+0/resize/180x120!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F12%2Fc4%2F681c2e9dc70cac905573985a8eb1%2Fle-heb-flu-influenza-vaccine-pregnant-20110604-001 180w,https://ca-times.brightspotcdn.com/dims4/default/7f1a82b/2147483647/strip/true/crop/599x399+21+0/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F12%2Fc4%2F681c2e9dc70cac905573985a8eb1%2Fle-heb-flu-influenza-vaccine-pregnant-20110604-001 320w,https://ca-times.brightspotcdn.com/dims4/default/0407f57/2147483647/strip/true/crop/599x399+21+0/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F12%2Fc4%2F681c2e9dc70cac905573985a8eb1%2Fle-heb-flu-influenza-vaccine-pregnant-20110604-001 568w,https://ca-times.brightspotcdn.com/dims4/default/02d77bb/2147483647/strip/true/crop/599x399+21+0/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F12%2Fc4%2F681c2e9dc70cac905573985a8eb1%2Fle-heb-flu-influenza-vaccine-pregnant-20110604-001 768w,https://ca-times.brightspotcdn.com/dims4/default/ae705cc/2147483647/strip/true/crop/599x399+21+0/resize/840x560!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F12%2Fc4%2F681c2e9dc70cac905573985a8eb1%2Fle-heb-flu-influenza-vaccine-pregnant-20110604-001 840w",
"https://ca-times.brightspotcdn.com/dims4/default/a3f318d/2147483647/strip/true/crop/5192x3461+0+80/resize/110x73!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F01%2Ff7%2F77764bfe17ad7df904240803fc35%2Fd78a4f6b7fa149aaa94aa7966bfcb1ba 110w,https://ca-times.brightspotcdn.com/dims4/default/8211315/2147483647/strip/true/crop/5192x3461+0+80/resize/180x120!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F01%2Ff7%2F77764bfe17ad7df904240803fc35%2Fd78a4f6b7fa149aaa94aa7966bfcb1ba 180w,https://ca-times.brightspotcdn.com/dims4/default/de86b53/2147483647/strip/true/crop/5192x3461+0+80/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F01%2Ff7%2F77764bfe17ad7df904240803fc35%2Fd78a4f6b7fa149aaa94aa7966bfcb1ba 320w,https://ca-times.brightspotcdn.com/dims4/default/f1e4a61/2147483647/strip/true/crop/5192x3461+0+80/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F01%2Ff7%2F77764bfe17ad7df904240803fc35%2Fd78a4f6b7fa149aaa94aa7966bfcb1ba 568w,https://ca-times.brightspotcdn.com/dims4/default/503b55c/2147483647/strip/true/crop/5192x3461+0+80/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F01%2Ff7%2F77764bfe17ad7df904240803fc35%2Fd78a4f6b7fa149aaa94aa7966bfcb1ba 768w,https://ca-times.brightspotcdn.com/dims4/default/6d95c0d/2147483647/strip/true/crop/5192x3461+0+80/resize/840x560!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F01%2Ff7%2F77764bfe17ad7df904240803fc35%2Fd78a4f6b7fa149aaa94aa7966bfcb1ba 840w",
"https://ca-times.brightspotcdn.com/dims4/default/ebddf55/2147483647/strip/true/crop/8510x5691+13+0/resize/320x214!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F3c%2F81%2F25a0f741580507bf4bf0f602392a%2F0ea092fc938e44ef99dc4151268b7f06 320w,https://ca-times.brightspotcdn.com/dims4/default/b2d92b5/2147483647/strip/true/crop/8510x5691+13+0/resize/568x380!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F3c%2F81%2F25a0f741580507bf4bf0f602392a%2F0ea092fc938e44ef99dc4151268b7f06 568w,https://ca-times.brightspotcdn.com/dims4/default/cd15c0c/2147483647/strip/true/crop/8510x5691+13+0/resize/768x514!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F3c%2F81%2F25a0f741580507bf4bf0f602392a%2F0ea092fc938e44ef99dc4151268b7f06 768w,https://ca-times.brightspotcdn.com/dims4/default/4ce76cc/2147483647/strip/true/crop/8510x5691+13+0/resize/1024x685!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F3c%2F81%2F25a0f741580507bf4bf0f602392a%2F0ea092fc938e44ef99dc4151268b7f06 1024w",
"https://ca-times.brightspotcdn.com/dims4/default/ceadda3/2147483647/strip/true/crop/5981x4000+9+0/resize/320x214!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F02%2F96%2F839316be468cad650531a1c12689%2Fap23006505174921.jpg 320w,https://ca-times.brightspotcdn.com/dims4/default/501e95f/2147483647/strip/true/crop/5981x4000+9+0/resize/568x380!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F02%2F96%2F839316be468cad650531a1c12689%2Fap23006505174921.jpg 568w,https://ca-times.brightspotcdn.com/dims4/default/ab46b38/2147483647/strip/true/crop/5981x4000+9+0/resize/768x514!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F02%2F96%2F839316be468cad650531a1c12689%2Fap23006505174921.jpg 768w,https://ca-times.brightspotcdn.com/dims4/default/800470e/2147483647/strip/true/crop/5981x4000+9+0/resize/1024x685!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F02%2F96%2F839316be468cad650531a1c12689%2Fap23006505174921.jpg 1024w",
"https://ca-times.brightspotcdn.com/dims4/default/d6e7220/2147483647/strip/true/crop/4232x2830+0+0/resize/320x214!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F4e%2F26%2F6a2d733140c4bdcb7c639d29956a%2Fvirus-outbreak-china-vaccinating-the-elderly-83924.jpg 320w,https://ca-times.brightspotcdn.com/dims4/default/f630d2a/2147483647/strip/true/crop/4232x2830+0+0/resize/568x380!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F4e%2F26%2F6a2d733140c4bdcb7c639d29956a%2Fvirus-outbreak-china-vaccinating-the-elderly-83924.jpg 568w,https://ca-times.brightspotcdn.com/dims4/default/99010c6/2147483647/strip/true/crop/4232x2830+0+0/resize/768x514!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F4e%2F26%2F6a2d733140c4bdcb7c639d29956a%2Fvirus-outbreak-china-vaccinating-the-elderly-83924.jpg 768w,https://ca-times.brightspotcdn.com/dims4/default/c81fa02/2147483647/strip/true/crop/4232x2830+0+0/resize/1024x685!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F4e%2F26%2F6a2d733140c4bdcb7c639d29956a%2Fvirus-outbreak-china-vaccinating-the-elderly-83924.jpg 1024w",
"https://ca-times.brightspotcdn.com/dims4/default/410bb80/2147483647/strip/true/crop/5472x3648+0+0/resize/110x73!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fac%2Fcf%2Fdb87a1a795e3892b8903e33c4536%2F55c91c7d49314db6954779be5d6721c3 110w,https://ca-times.brightspotcdn.com/dims4/default/7381789/2147483647/strip/true/crop/5472x3648+0+0/resize/180x120!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fac%2Fcf%2Fdb87a1a795e3892b8903e33c4536%2F55c91c7d49314db6954779be5d6721c3 180w,https://ca-times.brightspotcdn.com/dims4/default/c47112b/2147483647/strip/true/crop/5472x3648+0+0/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fac%2Fcf%2Fdb87a1a795e3892b8903e33c4536%2F55c91c7d49314db6954779be5d6721c3 320w,https://ca-times.brightspotcdn.com/dims4/default/5032a53/2147483647/strip/true/crop/5472x3648+0+0/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fac%2Fcf%2Fdb87a1a795e3892b8903e33c4536%2F55c91c7d49314db6954779be5d6721c3 568w,https://ca-times.brightspotcdn.com/dims4/default/6d5bb89/2147483647/strip/true/crop/5472x3648+0+0/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fac%2Fcf%2Fdb87a1a795e3892b8903e33c4536%2F55c91c7d49314db6954779be5d6721c3 768w,https://ca-times.brightspotcdn.com/dims4/default/9c77797/2147483647/strip/true/crop/5472x3648+0+0/resize/840x560!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fac%2Fcf%2Fdb87a1a795e3892b8903e33c4536%2F55c91c7d49314db6954779be5d6721c3 840w",
"https://ca-times.brightspotcdn.com/dims4/default/ca3d55a/2147483647/strip/true/crop/5578x3719+0+0/resize/110x73!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fa3%2F6e%2F14c4cece471493b765301db91a0e%2F1466077-la-me-lax-tsa-record-passengers-jja-0001.jpg 110w,https://ca-times.brightspotcdn.com/dims4/default/717a35f/2147483647/strip/true/crop/5578x3719+0+0/resize/180x120!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fa3%2F6e%2F14c4cece471493b765301db91a0e%2F1466077-la-me-lax-tsa-record-passengers-jja-0001.jpg 180w,https://ca-times.brightspotcdn.com/dims4/default/bb30960/2147483647/strip/true/crop/5578x3719+0+0/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fa3%2F6e%2F14c4cece471493b765301db91a0e%2F1466077-la-me-lax-tsa-record-passengers-jja-0001.jpg 320w,https://ca-times.brightspotcdn.com/dims4/default/f620f86/2147483647/strip/true/crop/5578x3719+0+0/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fa3%2F6e%2F14c4cece471493b765301db91a0e%2F1466077-la-me-lax-tsa-record-passengers-jja-0001.jpg 568w,https://ca-times.brightspotcdn.com/dims4/default/45c7ace/2147483647/strip/true/crop/5578x3719+0+0/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fa3%2F6e%2F14c4cece471493b765301db91a0e%2F1466077-la-me-lax-tsa-record-passengers-jja-0001.jpg 768w,https://ca-times.brightspotcdn.com/dims4/default/dcabb8a/2147483647/strip/true/crop/5578x3719+0+0/resize/840x560!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2Fa3%2F6e%2F14c4cece471493b765301db91a0e%2F1466077-la-me-lax-tsa-record-passengers-jja-0001.jpg 840w",
"https://ca-times.brightspotcdn.com/dims4/default/a74963a/2147483647/strip/true/crop/5428x3619+0+0/resize/110x73!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F87%2F7b%2Fd85c841f44dcb84256e773fd2474%2F1358890-me-cdc-director-cohen-004.jpg 110w,https://ca-times.brightspotcdn.com/dims4/default/a380f7d/2147483647/strip/true/crop/5428x3619+0+0/resize/180x120!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F87%2F7b%2Fd85c841f44dcb84256e773fd2474%2F1358890-me-cdc-director-cohen-004.jpg 180w,https://ca-times.brightspotcdn.com/dims4/default/80b8aea/2147483647/strip/true/crop/5428x3619+0+0/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F87%2F7b%2Fd85c841f44dcb84256e773fd2474%2F1358890-me-cdc-director-cohen-004.jpg 320w,https://ca-times.brightspotcdn.com/dims4/default/1915b71/2147483647/strip/true/crop/5428x3619+0+0/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F87%2F7b%2Fd85c841f44dcb84256e773fd2474%2F1358890-me-cdc-director-cohen-004.jpg 568w,https://ca-times.brightspotcdn.com/dims4/default/86f3fd3/2147483647/strip/true/crop/5428x3619+0+0/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F87%2F7b%2Fd85c841f44dcb84256e773fd2474%2F1358890-me-cdc-director-cohen-004.jpg 768w,https://ca-times.brightspotcdn.com/dims4/default/b36fc64/2147483647/strip/true/crop/5428x3619+0+0/resize/840x560!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F87%2F7b%2Fd85c841f44dcb84256e773fd2474%2F1358890-me-cdc-director-cohen-004.jpg 840w",
"https://ca-times.brightspotcdn.com/dims4/default/526faa0/2147483647/strip/true/crop/4050x2700+1575+0/resize/110x73!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F70%2F95%2F52a42e15416b942d4af0d9e12278%2Fla-me-christopher-john-badsey-seized-goods-comp2.jpg 110w,https://ca-times.brightspotcdn.com/dims4/default/913102e/2147483647/strip/true/crop/4050x2700+1575+0/resize/180x120!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F70%2F95%2F52a42e15416b942d4af0d9e12278%2Fla-me-christopher-john-badsey-seized-goods-comp2.jpg 180w,https://ca-times.brightspotcdn.com/dims4/default/c70050f/2147483647/strip/true/crop/4050x2700+1575+0/resize/320x213!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F70%2F95%2F52a42e15416b942d4af0d9e12278%2Fla-me-christopher-john-badsey-seized-goods-comp2.jpg 320w,https://ca-times.brightspotcdn.com/dims4/default/ec33a30/2147483647/strip/true/crop/4050x2700+1575+0/resize/568x379!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F70%2F95%2F52a42e15416b942d4af0d9e12278%2Fla-me-christopher-john-badsey-seized-goods-comp2.jpg 568w,https://ca-times.brightspotcdn.com/dims4/default/86fc608/2147483647/strip/true/crop/4050x2700+1575+0/resize/768x512!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F70%2F95%2F52a42e15416b942d4af0d9e12278%2Fla-me-christopher-john-badsey-seized-goods-comp2.jpg 768w,https://ca-times.brightspotcdn.com/dims4/default/304c571/2147483647/strip/true/crop/4050x2700+1575+0/resize/840x560!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F70%2F95%2F52a42e15416b942d4af0d9e12278%2Fla-me-christopher-john-badsey-seized-goods-comp2.jpg 840w",
"https://ca-times.brightspotcdn.com/a6/d6/eea0f1094fb281dbea09e0aa79cd/art-caltimes-trademark-3x.png"
] |
[] |
[] |
[
""
] | null |
[
"Associated Press",
"www.latimes.com",
"associated-press"
] |
2020-07-16T00:00:00
|
A state-owned Chinese company is boasting that its employees received doses of an experimental COVID-19 vaccine even before the government approved testing in people
|
en
|
/apple-touch-icon.png
|
Los Angeles Times
|
https://www.latimes.com/world-nation/story/2020-07-16/china-firm-tests-coronavirus-vaccine-own-employees
|
In the global race to make a coronavirus vaccine, a state-owned Chinese company is boasting that it has tested its prototype on its own employees, including top executives, before the government approved testing in people.
“Giving a helping hand in forging the sword of victory,” reads an online post from SinoPharm, alongside photos of workers who it says helped “pre-test” its vaccine.
Whether it’s viewed as heroic sacrifice or a violation of international ethical norms, the claim underscores the enormous stakes as China competes with U.S. and British companies to be the first with a vaccine to help end the pandemic — a feat that would be both a scientific and political triumph.
“Getting a COVID-19 vaccine is the new Holy Grail,” said Lawrence Gostin, a global public health law expert at Georgetown University. “The political competition to be the first is no less consequential than the race for the moon between the United States and Russia.”
China has positioned itself to be a strong contender. Eight of the nearly two dozen potential vaccines in various stages of human testing worldwide are from China, the most of any country. And SinoPharm and another Chinese company already have announced they’re entering final testing.
Both China and SinoPharm have invested heavily in a tried-and-true technology: an “inactivated” vaccine made by growing the whole virus in a lab and then killing it, which is how polio shots are made. Leading Western competitors use newer, less proven technology to target the “spike” protein that coats the virus.
That protein is “a good place to make our bet,” Dr. Gary Nabel, chief scientific officer of the French pharmaceutical company Sanofi, said at a U.S. biotechnology industry meeting. But “it’s good to have some diversity. I like the fact that there is an inactivated, whole vaccine. That provides an alternative in case one of these should fail.”
SinoPharm’s claim that 30 “special volunteers” rolled up their sleeves even before the company got permission for its initial human study raises ethical concerns among Western observers. The company’s post cites a “spirit of sacrifice” and shows seven men in suits and ties — a mix of scientists, businessmen and one Communist Party official with a background in military propaganda.
“The idea of people willing to sacrifice themselves ... is pretty much expected in China,” said Yanzhong Huang, a global health expert at the Council on Foreign Relations, a U.S. nonprofit organization.
But with corporate and government officials getting vaccinated, other employees “might feel pressure to participate. That would violate the voluntary principle” that is a bedrock of modern medical ethics, Huang said.
The first round of human testing, a Phase 1 trial, requires permission from a country’s drug regulators, who decide whether there is enough laboratory and animal evidence to justify the attempt.
SinoPharm, which declined to comment for this story, is testing two vaccine candidates that received government permission for Phase 1 trials in mid- to late April. In a post on its subsidiary’s official WeChat account, the company says it conducted its “pre-test” at the end of March “to make the vaccines hit the market as early as possible.”
It would not be the only shortcut China is taking. In late June, the government gave special approval for the military to use an experimental vaccine made by another company, CanSino Biologics, skipping the final testing needed to prove if it really works. CanSino now says it’s in talks with four other countries about doing that research.
Some participants in the first CanSino clinical trial in March said in social media posts that researchers on the project claimed they had been injected Feb. 29, before regulators gave the study the go-ahead. A researcher said team leader Chen Wei, a renowned military virologist, was the first to receive the experimental vaccine, one of the participants told state-owned Beijing News.
CanSino and Chen’s Academy of Military Medical Sciences turned down requests for information and interviews. The National Medical Products Administration, which approves vaccine trials, also declined to comment.
In May, a Russian scientist told the RIA Novosti news agency that he and fellow researchers also had vaccinated themselves ahead of approved studies. “It’s self-defense in order for us to continue working” on a vaccine, said Alexander Gintsburg of the Moscow-based Gamaleya research institute.
“Everyone is alive and well and cheerful,” he added.
Russia’s own Assn. of Clinical Research Organizations condemned the action as a “crude violation of the very foundations of clinical research, Russian law and universally accepted international regulations.” But about a month later, Russia launched its first vaccine study, using the Gamaleya product.
With a COVID-19 vaccine, national pride is at stake. Chinese President Xi Jinping pledged that any Chinese-made vaccine would be a “global public good.”
All this is taking place as China strives to overcome years of drug scandals — the latest coming in 2018 when authorities recalled a rabies vaccine and later announced that batches of children’s DPT vaccines, for diphtheria, pertussis and tetanus, were ineffective.
Modern international ethics require participants in medical research to be fully informed and to freely consent. In the U.S., studies involving people must receive approval from an “investigational review board,” and most U.S. research institutions explicitly state that there is no exception to board approval for self-experimenting.
“Employees may not be the best volunteers because employees are in a relationship which is not equal,” said Dr. Derrick Au, bioethics director at the Chinese University of Hong Kong.
Still, he said questions about China’s medical ethics might disappear if one of its COVID-19 vaccines ultimately proves to work. “It’s difficult to argue against success,” Au said.
|
||
6044
|
dbpedia
|
2
| 69
|
https://brieflands.com/articles/archcid-122097
|
en
|
Short-time Safety of the Sinopharm COVID-19 Vaccine in Patients with Hemophilia
|
[
"https://services.brieflands.com/cdn/serve/315dd/5ec5c7e1998795b51983d773ec341906cbcd8e8a/thumbnail.jpg",
"https://www.gravatar.com/avatar/6178a3c292c80b6842a4b883fe375847?d=mm&s=54",
"https://services.brieflands.com/assets/img/orcid.png",
"https://www.gravatar.com/avatar/d57b14cc4aa9b455f586f6ef46738335?d=mm&s=54",
"https://services.brieflands.com/assets/img/orcid.png",
"https://www.gravatar.com/avatar/057eded9c1010a346a40651986977a91?d=mm&s=54",
"https://www.gravatar.com/avatar/e54d13903fe020f578100167f1964ec2?d=mm&s=54",
"https://www.gravatar.com/avatar/4e8874e86cc08578a9c621aeaf8411b8?d=mm&s=54",
"https://services.brieflands.com/assets/img/orcid.png",
"https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_square_no_text.svg"
] |
[] |
[] |
[
"COVID-19",
"Drug Toxicity",
"Hemophilia",
"SARS-CoV-2",
"Vaccines"
] | null |
[
"Meysam Yousefi says:",
"Meysam Yousefi",
"Reza Sinaei",
"Amirabbass Shafiei Zadeh",
"Mehrdad Farrokhnia",
"Behnam Dalfardi"
] |
2022-05-30T00:00:00
|
The COVID-19 pandemic, caused by SARS-Cov-2, has affected the care of patients with hemophilia, indicating the necessity of their vaccination. Nevertheless,...
|
en
|
/assets/img/apple-touch-icon.png
|
Archives of Clinical Infectious Diseases
|
https://brieflands.com/articles/archcid-122097
|
1. Background
COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has resulted in significant mortality and morbidity all around the world. To date, there is no proven treatment for this disease. The recent development of vaccines to prevent SARS-CoV-2 infection gave us a glimmer of hope for overcoming this global issue (1). Nevertheless, there are ongoing discussions about the possible adverse effects of these vaccines and their efficacy, particularly about their administration for people with an underlying chronic disease. Persons with hemophilia are among those patients whose vaccination may be debatable.
Cases with hemophilia have no priority compared to the general population for SARS-CoV-2 vaccination, and they will be vaccinated based on the risks related to their general state of health, age group, and occupation (2). However, the impact of the COVID-19 pandemic on the availability and accessibility of laboratory and treatment facilities for patients with hemophilia makes their vaccination a necessity (3).
Due to the potential risk of bleeding following intramuscular injection in cases with hemophilia, the subcutaneous route is the principal recommended method of vaccination in this group of patients (4). However, currently, intramuscular administration is the only approved route of injection for available anti-SARS-CoV-2 vaccines (4). On the other hand, few reports of acquired hemophilia following SARS-CoV-2 vaccination are available, which caused concerns about the aggravation of bleeding complications in hemophilic people (5).
4. Results
Overall, 51 persons with hemophilia were included (33 men (64.7%) and 18 women (35.3%)). Participantsâ mean age was 37.07 ± 11.45 (19 to 67) years old. 27 (61.4 %) patients experienced at least one adverse reaction following vaccination. Local pain at the injection site was the most frequently reported adverse event, and 20 (39.2%) and 15 (29.4%) patients reported this complaint after the 1st and 2nd doses, respectively. Flu-like symptoms, headache, and myalgia were the most frequent systemic adverse events following both doses of the vaccine. Data are summarized in Table 1.
Table 1.
Frequency of Vaccine-related Adverse Events in Patients with Hemophilia a
1st Dose2nd DoseLocal pain20 (39.2)15 (29.4)Local swelling5 (9.8)5 (9.8)Local erythema2 (3.9)0Flu-like symptoms15 (29.4)7 (13.7)Myalgia14 (27.5)7 (13.7)Headache14 (27.5)6 (11.8)Sore throat7 (13.7)2 (3.9)Fever7 (13.7)1 (2)Chilly sensation6 (11.8)1 (2)Rhinorrhea5 (9.8)4 (7.8)Dizziness6 (11.8)2 (3.9)Shortness of breath2 (3.9)1 (2)Cough1 (2)0Diarrhea1 (2)0Abdominal pain1 (2)1 (2)Hoarseness2 (3.9)0Epistaxis1 (2)1 (2)Urticaria01 (2)Muscle spasm (neck)1 (2)1 (2)Muscle spasm (upper extremity)01 (2)Arthritis1 (2)0Menometrorrhagia2 (3.9)0
Two participants (3.9%) experienced menometrorrhagia following vaccine injection. One of them was admitted to the hospital and received one unit of packed red blood cells. One case (2%) had complaint of epistaxis. One patient (2%), who suffered from systemic lupus erythematous in addition to hemophilia, experienced arthritis of the knees following receipt of the 1st dose of vaccine.
During the follow-up period, no major cardiac event (including heart failure, cardiac arrhythmias, or myocarditis), acute liver or renal failure, any thromboembolic event, loss of smell, loss of taste, or mortality was reported. None of the study participants had a new documented infection with the SARS-CoV-2 virus within the follow-up period.
Data on vaccine-related adverse events, separated by gender, are provided in Table 2. As seen, complaints, including local pain (P-value: 0.003), headache (P-value: 0.045), and fever (P-value: 0.031), were significantly more frequent among female participants than males after injection of the 1st dose (Table 2).
Table 2.
Frequency of Vaccine-related Adverse Events in Patients with Hemophilia According to the Patientsâ Gender
1st Dose2nd DoseP-ValueFemaleMaleP-ValueFemaleMaleLocal pain0.003 a12 (60)8 (40)0.0519 (60)6 (40)Local swelling0.4511 (20)4 (80)0.2243 (60)2 (40)Local erythema0.28702 (100)-00Flu-like symptoms0.3466 (40)9 (60)0.6892 (28.6)5 (71.4)Myalgia0.1767 (50)7 (50)0.1934 (57.1)3 (42.9)Headache0.045 a8 (57.1)6 (42.9)0.4423 (50)3 (50)Sore throat0.6892 (18.6)5 (71.4)0.28702 (100)Fever0.031 a5 (71.4)2 (28.6)0.1711 (100)0Chilly sensation0.0874 (66.7)2 (33.3)0.1711 (100)0Rhinorrhea0.2243 (60)2 (40)0.5212 (50)2 (50)Dizziness0.9152 (33.3)4 (66.7)0.6571 (50)1 (50)Shortness of breath0.6571 (50)1 (50)0.45601 (100)Cough0.1711 (100)0-00Diarrhea0.45601 (100)-00Abdominal pain0.45601 (100)0.1711 (100)0Hoarseness0.45601 (100)-00Epistaxis0.45601 (100)0.45601 (100)Urticaria-000.45601 (100)Muscle spasm (neck)0.1711 (100)00.1711 (100)0Muscle spasm (upper extremity)-000.1711 (100)0Arthritis0.1711 (100)0-00Menometrorrhagia0.1711 (100)0-00
To the best of our knowledge, this is the first report on the short-term safety of the Sinopharm COVID-19 vaccine and its related adverse reactions in patients with hemophilia. We found that local pain at the site of vaccine injection, either after the 1st dose or following the 2nd dose, was the most frequent adverse event. Overall, three patients experienced bleeding tendency in the forms of epistaxis and menometrorrhagia.
Previous phase one and two clinical trials, which intended to evaluate the safety of inactivated Sinopharm COVID-19 vaccine, reported an incidence rate of 15% for adverse events among all participants. According to these trials, mild and self-limiting injection site pain was the most common adverse reaction (6). Similarly, another cross-sectional study from UAE reported pain at the site of vaccine injection (42.2% of participants) as the most common side effect (7). Our research showed a similar finding in hemophilic patients, as local pain was the most frequent side effect.
Hemorrhagic complications are the main concern regarding the use of COVID-19 vaccines in persons with hemophilia. These complications can be divided into local (ie, hematoma formation following intramuscular injection of vaccine) and systemic. These concerns are intensified when we see previous case reports of acquired hemophilia following the administration of anti-SARS-CoV-2 vaccines or SARS-CoV-2 infection (8). Farley et al. reported a 67-year-old African-American male with acquired hemophilia type A whose complications presented about 19 days after injection of 2nd dose of Pfizer-BioNTech anti-SARS-CoV-2 vaccine. This case was complicated with a large hematoma of his left lower extremity, and a small ecchymosis on his right upper extremity. His laboratory investigations showed an abnormal and elevated activated partial thromboplastin time (aPTT) (9). Another case was reported by Radwi and colleagues, whose bleeding tendency presented about nine days after injection of the 1st dose of Pfizer-BioNTech SARS CoV-2 mRNA vaccine (10). Development of acquired hemophilia A is related to the formation of autoantibodies against clotting factor VIII (10). Wang et al. reported another 65-year-old male patient whose presentation was compartment syndrome secondary to severe subcutaneous bleeding of the arm. Laboratory investigations of this patient revealed acquired hemophilia type A following an asymptomatic SARS-CoV-2 infection (11). In our study, none of the patients experienced local hematoma formation at the site of vaccine injection. However, two cases experienced menometrorrhagia, and one patient had complaint of epistaxis.
It is necessary to mention some limitations of our study, including not evaluating changes in serum levels of coagulation factors 8 and 9 following vaccination, particularly for participants who experienced hemorrhagic adverse events and a short follow-up period.
In summary, according to our results, use of the Sinopharm COVID-19 vaccine in patients with hemophilia seems to be safe regarding bleeding adverse events. Further studies with larger sample size and longer follow-up period are needed to get a closer look at the possible side effects of this vaccine in hemophilic patients.
|
||||
6044
|
dbpedia
|
3
| 25
|
https://apnews.com/article/world-news-europe-budapest-coronavirus-pandemic-china-99cac1cd39c6f21e7cf152526cf870f2
|
en
|
Hungary rolls out China’s Sinopharm jab amid lagging trust
|
https://dims.apnews.com/dims4/default/ff1aa42/2147483647/strip/true/crop/3000x1688+0+156/resize/1440x810!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F28085edb6de345c48f4194ab43bfd93b%2F3000.jpeg
|
https://dims.apnews.com/dims4/default/ff1aa42/2147483647/strip/true/crop/3000x1688+0+156/resize/1440x810!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F28085edb6de345c48f4194ab43bfd93b%2F3000.jpeg
|
[
"https://assets.apnews.com/fa/ba/9258a7114f5ba5c7202aaa1bdd66/aplogo.svg",
"https://dims.apnews.com/dims4/default/94c503b/2147483647/strip/true/crop/640x236+0+0/resize/320x118!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc3%2F4c%2F65482a7b452db66043542c093eaf%2Fpromo-2x.png 1x,https://dims.apnews.com/dims4/default/6e4b276/2147483647/strip/true/crop/640x236+0+0/resize/640x236!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc3%2F4c%2F65482a7b452db66043542c093eaf%2Fpromo-2x.png 2x",
"https://dims.apnews.com/dims4/default/e810947/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F28085edb6de345c48f4194ab43bfd93b%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/7209c69/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F28085edb6de345c48f4194ab43bfd93b%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/c7850c0/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2Fd61caa317a384ee1adee93dfb81600c2%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/2f62ce7/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2Fd61caa317a384ee1adee93dfb81600c2%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/da332b6/2147483647/strip/true/crop/3000x4500+0+0/resize/399x599!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7688a4bc017d457ea456f447b380c4fc%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/7ada4d0/2147483647/strip/true/crop/3000x4500+0+0/resize/798x1198!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7688a4bc017d457ea456f447b380c4fc%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/3b8b903/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F009753a9f7d54d1590fac232bb826460%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/6604c69/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F009753a9f7d54d1590fac232bb826460%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/e810947/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F28085edb6de345c48f4194ab43bfd93b%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/7209c69/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F28085edb6de345c48f4194ab43bfd93b%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/c7850c0/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2Fd61caa317a384ee1adee93dfb81600c2%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/2f62ce7/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2Fd61caa317a384ee1adee93dfb81600c2%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/da332b6/2147483647/strip/true/crop/3000x4500+0+0/resize/399x599!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7688a4bc017d457ea456f447b380c4fc%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/7ada4d0/2147483647/strip/true/crop/3000x4500+0+0/resize/798x1198!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7688a4bc017d457ea456f447b380c4fc%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/3b8b903/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F009753a9f7d54d1590fac232bb826460%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/6604c69/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F009753a9f7d54d1590fac232bb826460%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/8650001/2147483647/strip/true/crop/992x617+0+0/resize/225x140!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Ffc%2F24%2F7ff11448446fb8500bc984551325%2Faplogo-with-tagline.png 1x,https://dims.apnews.com/dims4/default/6669a9d/2147483647/strip/true/crop/992x617+0+0/resize/450x280!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Ffc%2F24%2F7ff11448446fb8500bc984551325%2Faplogo-with-tagline.png 2x",
"https://sb.scorecardresearch.com/p?c1=2&c2=3005041&cv=4.4.0&cj=1"
] |
[] |
[] |
[
"Europe",
"COVID-19",
"Asia Pacific",
"Russia",
"China",
"Budapest",
"Hungary",
"Health",
"Business",
"World News"
] | null |
[] |
2021-02-24T16:25:53+00:00
|
BUDAPEST, Hungary (AP) — Doctors in Hungary on Wednesday began administering a COVID-19 vaccine developed in China, making the country the first European Union nation to use a Chinese jab as officials aim to bolster trust in its safety and effectiveness.
|
en
|
/apple-touch-icon.png
|
AP News
|
https://apnews.com/article/world-news-europe-budapest-coronavirus-pandemic-china-99cac1cd39c6f21e7cf152526cf870f2
|
BUDAPEST, Hungary (AP) — Doctors in Hungary on Wednesday began administering a COVID-19 vaccine developed in China, making the country the first European Union nation to use a Chinese jab as officials aim to bolster trust in its safety and effectiveness.
General practitioners around the Central European country were instructed to administer the shots, developed by Chinese state-owned company Sinopharm, to elderly patients. The Sinopharm jab brings the number of vaccines currently in use in Hungary to five including the Russian-developed Sputnik V, more than in any other country in the 27-nation EU.
But for the country’s expanded palette of vaccines to be put to full use, officials are seeking to increase lagging public trust in those produced in Eastern countries.
“I ask for all fears to be dispelled about the Chinese and Russian vaccines, because more than 30 million people have received these vaccines without any particular problems,” Hungary’s chief medical officer, Cecilia Muller, said at a virtual media briefing Wednesday.
Hungary’s government has sharply criticized the speed of the EU’s vaccine procurement program, and sought to purchase doses from countries like China and Russia despite polling that shows trust in those vaccines is low among Hungarians.
A survey of 1,000 people in the capital of Budapest by pollster Median and the 21 Research Center showed that among those willing to be vaccinated, only 27% would take a Chinese vaccine and 43% a Russian vaccine, compared to 84% who would take a jab developed in Western countries. The poll, which was conducted at the end of January, had a margin of error of plus or minus 3%.
Still, Hungarian officials expect that the Sinopharm vaccine, which received final approval last week, will provide a sharp boost in the country’s vaccination rate: as many as 368,000 people could be inoculated this week alone, compared with 471,000 that have received a shot since vaccinations began in December, state secretary Dr. Istvan Gyorgy said Tuesday, adding that 275,000 people will receive the Sinopharm jab this week.
“Every vaccine available in Hungary is safe and able to provide protection against virus infection. This is true of the Eastern vaccines as well despite all rumors to the contrary,” Gyorgy said.
In Budapest, Dr. Zoltan Komaromi began administering the Sinopharm vaccine Wednesday despite his personal concerns over the size of its trial samples and what he perceived as pressure from high-ranking government officials on Hungary’s health care authorities to approve the vaccine.
“There is uncertainty because of politicians talking back and forth about the vaccines,” he said. “It looked very bad to ordinary people that the foreign minister and prime minister effectively called on authorities to give official approval.”
Komaromi, who is also a health spokesman for a Hungarian opposition party, received 55 doses of the vaccine on Wednesday and sent emails to his patients informing them of all possible risks and side effects. Of the 120 patients he contacted, 22 said they would take the vaccine and 75 refused.
The Hungarian government has accused opposition parties of fomenting distrust of its vaccination program, especially concerning those vaccines procured outside of the EU framework.
A steady decline in new coronavirus cases and deaths that began in late December reversed course early this month, and the government has emphasized that speeding up vaccinations is the only way to head off an apparent “third wave” of the pandemic. Hungary’s procurement efforts have placed it in first place in the EU in the number of vaccine doses distributed to the country per 100 inhabitants, according to data from the European Centre for Disease Prevention and Control, an EU agency.
Hungary has agreed to purchase 5 million doses of the Sinopharm vaccine over the next four months, enough to inoculate 2.5 million people with the two-round shot in the country of around 10 million. Successfully administering that quantity will depend on the level of public trust in Chinese and Russian vaccines, which Komaromi said has eroded after they were approved in Hungary without being inspected by the European Medicines Agency, the EU’s medicines regulator.
“The patients feel this, they know, they follow the news and unfortunately we (doctors) have to overcome this feeling of resentment in them one by one,” he said.
As of Wednesday, 550,000 doses of Sinopharm had been delivered so far, compared with 774,000 doses of the Pfizer-BioNtech vaccine, and smaller shipments of vaccines from AstraZeneca, Moderna, and Russia’s Sputnik V.
In an interview with public radio late last month, Hungary’s prime minister, Viktor Orban, said he would personally choose to be inoculated with the Sinopharm vaccine.
“I’m waiting for the Chinese vaccine, I trust in that the most,” Orban said. “I think the Chinese have known this virus for the longest, and they probably know it the best.”
Hajnalka Miklos, a retiree who received her first dose of the Sinopharm vaccine on Wednesday, said she was relieved to be vaccinated so she could spend more time with her parents and grandchildren, and that she had no reservations about receiving the Chinese jab.
“I would have liked the Russian vaccine, or Pfizer, but this came, and I’m very glad,” she said.
|
||
6044
|
dbpedia
|
1
| 84
|
http://english.www.gov.cn/news/topnews/202004/14/content_WS5e952a66c6d0c201c2cc0dd5.html
|
en
|
China approves inactivated COVID
|
[
"http://english.www.gov.cn/static/common/img/GOV_Logo.png",
"http://english.www.gov.cn/static/common/img/Mobile/mMenu_Close.png",
"http://english.www.gov.cn/static/common/img/Mobile/mGOV_Logo.png",
"http://english.www.gov.cn/static/common/img/Mobile/mMenu_Icon.png",
"http://english.www.gov.cn/static/common/img/Mobile/mMenu_Search.png",
"http://english.www.gov.cn/static/2023GW/images/Artical_Print.jpg",
"http://english.www.gov.cn/images/202004/15/5e96a1e2c6d0c20169fcd733.jpeg",
"http://english.www.gov.cn/images/202004/15/5e96a1e2c6d0c20169fcd735.jpeg",
"http://english.www.gov.cn/images/202004/15/5e96a1e2c6d0c20169fcd737.jpeg",
"http://english.www.gov.cn/images/202004/15/5e96a1e2c6d0c20169fcd739.jpeg",
"http://english.www.gov.cn/images/202004/15/5e96a1e2c6d0c20169fcd73b.jpeg",
"http://english.www.gov.cn/images/202004/15/5e96a1e2c6d0c20169fcd73d.jpeg",
"http://english.www.gov.cn/images/202004/15/5e96a1e2c6d0c20169fcd73f.jpeg",
"http://certify.alexametrics.com/atrk.gif?account=noGfn1aMp4107i"
] |
[] |
[] |
[
""
] | null |
[] | null |
China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the joint prevention and control mechanism of the State Council.
|
//english.www.gov.cn/favicon.ico
| null |
BEIJING — China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus on April 13.
The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co Ltd, a company based in Beijing. Clinical trials of the two vaccines have started.
The two vaccines are China's first batch of inactivated vaccines for COVID-19 that have obtained clinical trial approval. Using killed pathogenic microorganisms for enhancing the immunogenicity, inactivated vaccines have advantages of mature production process, controllable quality standards and wide protection range.
They can be used for large-scale vaccination, and their safety and effectiveness can be judged by internationally accepted standards.
China has laid a solid foundation for research in inactivated vaccines over the past years. Inactivated vaccines have been widely used to fight hepatitis A, influenza, hand-foot-and-mouth disease and poliomyelitis.
The vaccine developers have the capacity for large-scale production.
According to sources from the Sinopharm, the company has allocated one billion yuan (about $142 million) for vaccine research and development in two technological approaches. Besides the approved inactivated vaccine, the company is also working on another inactivated vaccine and a genetic engineering vaccine.
Drawing on previous experience in SARS vaccine research and development, the other vaccine developer Sinovac has maintained close cooperation with many institutions, including Zhejiang Provincial Center for Disease Control and Prevention and the Institute of Laboratory Animal Sciences under the Chinese Academy of Medical Sciences.
Sinovac's inactivated vaccine has shown a good cross-neutralization reaction to different COVID-19 strains at home and abroad.
The National Medical Products Administration has also accelerated the approval procedures for COVID-19 vaccines on the premise of their safety and efficacy.
China adopts five technological approaches to develop COVID-19 vaccines, including inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza viruses as vectors.
The recombinant adenovirus vector vaccine developed by the Institute of Military Medicine under the Academy of Military Sciences started its clinical trial on March 16.
|
||||||
6044
|
dbpedia
|
3
| 72
|
https://m.economictimes.com/news/international/world-news/top-scientist-behind-chinas-first-covid-19-vaccine-expelled-from-parliament-for-graft/articleshow/109692648.cms
|
en
|
Top scientist behind China's first COVID-19 vaccine expelled from Parliament for graft
|
[
"https://img.etimg.com/photo/msid-76920425,quality-100/et-logo.jpg",
"https://img.etimg.com/photo/104857408.cms",
"https://img.etimg.com/thumb/msid-109692690,width-300,height-225,imgsize-59946,resizemode-75/takeaways-from-ap-report-on-how-the-search-for-the-coronavirus-origins-turned-toxic.jpg",
"https://img.etimg.com/thumb/msid-112530195,imgsize-350085,width-138,height-104,quality-100/prime/money-and-markets/15-atmanirbhar-stocks-to-include-in-your-portfolio-this-independence-day.jpg",
"https://img.etimg.com/thumb/msid-112542962,imgsize-73036,width-138,height-104,quality-100/prime/technology-and-startups/five-reasons-why-indias-economic-survey-mentioned-apple-five-times.jpg",
"https://img.etimg.com/thumb/msid-112332057,imgsize-1561660,width-138,height-104,quality-100/prime/technology-and-startups/bhavish-aggarwals-long-road-from-kabul-to-koramangala.jpg",
"https://img.etimg.com/thumb/msid-112448594,imgsize-1486952,width-138,height-104,quality-100/prime/transportation/why-akasas-losses-are-mounting-when-indigo-is-posting-record-profits.jpg",
"https://img.etimg.com/thumb/msid-112476086,imgsize-1028686,width-138,height-104,quality-100/prime/transportation/your-ev-is-40-chinese-and-will-remain-so-if-this-jigsaw-is-not-solved.jpg",
"https://img.etimg.com/thumb/msid-112476679,imgsize-29536,width-138,height-104,quality-100/prime/technology-and-startups/why-success-of-blackstones-repeat-it-bet-depends-on-these-ifs-and-buts.jpg",
"https://img.etimg.com/photo/msid-109982599,imgsize-67937/desktop-rhs-on-rise-section.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-35152,msid-112549717/kolkata-guard-recounts-vandalism-incident-at-rg-kar-hospital.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-22488,msid-112549171/cji-chandrachud-on-importance-of-freedom-and-liberty.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-30110,msid-112548217/pm-meets-and-felicitates-indias-paris-olympics-contingent.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-28540,msid-112546066/we-want-to-bring-1-lakh-youth-into-political-system-.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-30644,msid-112542406/who-declares-mpox-a-global-health-emergency.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-38310,msid-112541359/india-worried-for-safety-of-hindus-in-bangladesh-pm-modi.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-23710,msid-112543379/kolkata-doctor-murder-case-protest-turns-violent.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-35732,msid-112538942/kolkata-murder-vandals-attack-rg-kar-hospital-amid-protests.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-24336,msid-112537874/kolkata-doctor-rape-murder-case-sparks-midnight-stir.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-17976,msid-112540135/current-civil-code-is-communal-secular-civil-code-is-need-of-the-hour.jpg",
"https://img.etimg.com/photo/msid-74462387,quality-100/et-logo.jpg",
"https://img.etimg.com/photo/msid-74451948,quality-100/et-logo.jpg",
"https://img.etimg.com/photo/47865640.cms"
] |
[] |
[] |
[
"COVID-19 vaccine",
"Yang Xiaoming",
"China National Pharmaceutical Group",
"corruption",
"Sinopharm"
] | null |
[] |
2024-04-29T16:11:00+05:30
|
Yang Xiaoming, developer of China's first COVID-19 vaccine, was dismissed for corruption amid President Xi Jinping's anti-corruption campaign. Investigation ongoing on Sinopharm executives, highlighting widespread corruption in China's healthcare system.
|
en
|
https://economictimes.indiatimes.com/icons/etfavicon.ico
|
The Economic Times
|
https://m.economictimes.com/news/international/world-news/top-scientist-behind-chinas-first-covid-19-vaccine-expelled-from-parliament-for-graft/articleshow/109692648.cms
|
Synopsis
Yang Xiaoming, developer of China's first COVID-19 vaccine, was dismissed for corruption amid President Xi Jinping's anti-corruption campaign. Investigation ongoing on Sinopharm executives, highlighting widespread corruption in China's healthcare system.
Beijing, China's top scientist, who developed the first inactivated COVID-19 vaccine at the height of the pandemic in the country in 2020, has been dismissed from Parliament for alleged corruption. Yang Xiaoming, the chairman of China National Pharmaceutical Group's vaccine subsidiary China National Biotec Group (CNBG), has been stripped of his membership in the National People's Congress (NPC) due to serious discipline and law violations, official media reported here on Monday.
The charge of serious discipline and law violations is a common euphemism for corruption under the ruling Communist Party of China (CPC) disciplinary practice.
Yang, 62, is a veteran researcher who headed the CNBG - a vaccine subsidiary of state-owned Sinopharm - and led a team that developed Sinopharm's BBIBP-CorV vaccine, China's first coronavirus shot approved for general use.
Coronavirus first surfaced in the Chinese city of Wuhan in March 2020 and later spread to the world, becoming the pandemic of the century and claiming millions of lives.
According to a statement by NPC, Yang is already being investigated by the party disciplinary body - the Central Commission for Discipline Inspection.
The Sinopharm shot and Sinovac Biotech's CoronaVac were the most widely used in China and the leading COVID-19 vaccines exported by the country.
Yang's dismissal comes amid the biggest crackdown on China's healthcare system, expanding a sweeping anti-corruption drive launched by President Xi Jinping in the last few years.
The crackdown aims to root out widespread corruption in a system plagued by kickbacks. It targets hospitals, drug companies and insurance funds, with dozens of hospital chiefs detained since last year, Hong Kong-based South China Morning Post reported.
Another former Sinopharm senior executive, Zhou Bin, who once served as the company's deputy general manager, was placed under investigation by the CCDI in January.
China's national 863 programme is a state-funded and administered platform for developing advanced technologies.
The Covid-19 vaccine developed by Yang's team was approved for general use in December 2020.
Yang was among the recipients of a national award in September 2020 for his role in fighting the pandemic and was later recognised by the Chinese Society of Immunology as an outstanding scholar. He was also awarded the Ho Leung Ho Lee Foundation award, which recognises Chinese scholars in science and medical fields, the Post reported.
(You can now subscribe to our Economic Times WhatsApp channel)
(Catch all the Business News, Breaking News, Budget 2024 Events and Latest News Updates on The Economic Times.)
Subscribe to The Economic Times Prime and read the ET ePaper online.
...moreless
(You can now subscribe to our Economic Times WhatsApp channel)
(Catch all the Business News, Breaking News, Budget 2024 Events and Latest News Updates on The Economic Times.)
Subscribe to The Economic Times Prime and read the ET ePaper online.
...moreless
15 Atmanirbhar stocks to include in your portfolio this Independence Day
Five reasons why India’s Economic Survey mentioned Apple five times
The Ola Electric story: What makes Bhavish Aggarwal India's most impatient man?
Why Akasa’s losses are mounting when IndiGo is posting record profits
Your EV is 40% Chinese, and will remain so if this jigsaw is not solved
Why success of Blackstone’s repeat IT bet depends on these ifs and buts
1
2
3
|
||||
6044
|
dbpedia
|
3
| 7
|
https://www.nature.com/nature-index/institution-outputs/china/china-national-pharmaceutical-group-sinopharm/5ed9eb814672c6720e31f02d
|
en
|
China National Pharmaceutical Group (Sinopharm)
|
[
"https://www.facebook.com/tr?id=1657480634564902&ev=PageView&noscript=1",
"https://www.nature.com/nature-index/dist/img/header-logo.svg",
"https://www.nature.com/nature-index/dist/img/nature-navigator-horizontal-logo.svg",
"https://www.nature.com/nature-index/file/nature-index-2024-south-korea/hero.jpg"
] |
[] |
[] |
[
"China National Pharmaceutical Group (Sinopharm)"
] | null |
[] | null |
Research outputs, collaborations and relationships for China National Pharmaceutical Group (Sinopharm)
|
en
|
/nature-index/dist/img/favicons/apple-touch-icon.png
|
Nature Index
| null |
Nature Index 2024 South Korea
South Korea stands out among the leading countries in the Nature Index for its big investments in research and development and strong history in innovation. But the country is facing major challenges, including dwindling student numbers, stark gender imbalances and cultural factors that undermine its ability to foster a more diverse research ecosystem. As it doubles down on international collaborations in strategic areas, South Korea is now looking to reaffirm its place as a global leader in science.
|
||||
6044
|
dbpedia
|
0
| 31
|
https://www.cnbc.com/2020/12/09/chinas-covid-vaccine-from-sinopharm-is-86percent-effective-uae-says-.html
|
en
|
China's Covid vaccine from Sinopharm is 86% effective, UAE says
|
[
"https://static-redesign.cnbcfm.com/dist/7821ea3cb72f88388591.svg",
"https://static-redesign.cnbcfm.com/dist/2469ed0a9a4cafdf055e.svg",
"https://static-redesign.cnbcfm.com/dist/2469ed0a9a4cafdf055e.svg",
"https://image.cnbcfm.com/api/v1/image/105390270-1533915418989natashaturak2.jpg?v=1533915460&w=60&h=60&ffmt=webp",
"https://image.cnbcfm.com/api/v1/image/106807771-16074335942020-12-08t090448z_722051655_rc2xik975sm5_rtrmadp_0_health-coronavirus-britain-rollout.jpeg?v=1607433629&w=750&h=422&vtcrop=y",
"https://static-redesign.cnbcfm.com/dist/7821ea3cb72f88388591.svg",
"https://static-redesign.cnbcfm.com/dist/17269f1b6083fd5f61be.svg",
"https://static-redesign.cnbcfm.com/dist/09c161b9810767a7849e.svg"
] |
[] |
[] |
[
"Dubai",
"United Arab Emirates",
"Health care industry",
"Pharmaceuticals",
"Biotech and Pharmaceuticals",
"Emerging markets",
"business news"
] | null |
[
"Natasha Turak",
"www.facebook.com"
] |
2020-12-09T00:00:00
|
The announcement was thin on details, however, and did not mention any side effects experienced by patients.
|
en
|
https://sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/favicon.ico
|
CNBC
|
https://www.cnbc.com/2020/12/09/chinas-covid-vaccine-from-sinopharm-is-86percent-effective-uae-says-.html
|
DUBAI, United Arab Emirates — Human trials of a Chinese vaccine in the United Arab Emirates have yielded positive results, the UAE's national health authorities said Wednesday, citing an 86% efficacy rate.
The figure was announced by the UAE Ministry of Health via state news agency WAM, detailing an "interim analysis" conducted by Sinopharm's China National Biotec Group (CNBG). The Gulf state of 10 million began Phase 3 human trials of the experimental vaccine in July, and in September approved its emergency use for health workers.
"The registration of this vaccine is a decision in response to the application from Sinopharm CNBG. The announcement is a significant vote of confidence by the UAE's health authorities in the safety and efficacy of this vaccine," the health ministry said Wednesday, without elaborating on what "registration" meant. The vaccine itself was developed by CNBG's Beijing Institute of Biological Product.
The Phase 3 trials included 31,000 volunteers across 125 nationalities, the ministry said, highlighting the UAE's diverse and large expatriate population — comprising roughly 90% of the country's total population — as an advantage in carrying out human tests. The volunteers, between the ages of 18 and 60, took two doses of the vaccine over 28 days.
The announcement was thin on details, however; it did not elaborate on the parameters of the trials like how many patients were given the vaccine dosage versus placebos, and did not mention any side effects experienced by patients.
After citing the 86% efficacy figure, the ministry said: "The analysis also shows the vaccine to have 99 percent seroconversion rate of neutralising antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease." Seroconversion is the process by which an antibody becomes identifiable in a patient's blood.
It added that "the analysis shows no serious safety concerns."
It is unclear how the 86% efficacy figure was calculated. CNBC has reached out to Sinopharm for comment.
Dubai ruler Sheikh Mohammed bin Rashid al Maktoum in early November reported that he received the trial vaccine, shortly after the UAE's Minister of Foreign Affairs Sheikh Abdullah bin Zayed al Nahyan received it, both tweeting images of themselves being vaccinated and praising the work of the medical workers behind the effort.
|
||||
6044
|
dbpedia
|
2
| 90
|
http://www.xinhuanet.com/english/2020-07/03/c_139185575.htm
|
en
|
Construction of COVID-19 vaccine production workshop completed in Wuhan - Xinhua
|
[
"http://www.newsimg.cn/english/20170321/images/banner.png",
"http://www.newsimg.cn/english/20170321/images/menu.png",
"http://www.newsimg.cn/english/20170321/images/close.png",
"http://www.xinhuanet.com/english/20161108new/images/logo.jpg",
"http://www.xinhuanet.com/english/2020-07/03/139185575_15937518814861n.jpg",
"http://webd.home.news.cn/1.gif?z=1&_wdxid=010020070750000000000000011102121391855751"
] |
[
" "
] |
[] |
[
""
] | null |
[] |
2020-07-03T00:00:00
| null |
A staff member takes out samples of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 11, 2020. (Xinhua/Zhang Yuwei)
WUHAN, July 3 (Xinhua) -- China has completed the construction of a complex consisting of a research laboratory and a COVID-19 vaccine production workshop in Wuhan, which was hit hard during the epidemic, according to the China National Pharmaceutical Group (Sinopharm).
With a total floor area of 7,260 square meters, the complex is located at the Wuhan Institute of Biological Products (WIBP), which is affiliated to the China National Biotec Group (CNBG), Sinopharm.
The lab is capable of studying pathogenic virus vaccines, and the workshop can produce over 100 million doses of the inactivated COVID-19 vaccine per year, according to Sinopharm.
The construction team, which built two makeshift hospitals, Huoshenshan and Leishenshan in Wuhan at fast speed, finished building the complex in just over 100 days and nights.
With another CNBG workshop previously built in Beijing, the total annual production capacity of inactivated COVID-19 vaccines is expected to exceed 200 million doses, which will help ensure adequate supply, said Yang Xiaoming, president of CNBG.
WIBP started the phase 1 and 2 clinical trials for its inactivated COVID-19 vaccine candidate on April 12. A total of 1,120 volunteers, aged between 18 and 59, were involved.
The results showed a good safety record, and no severe adverse reactions were found in clinical trials. Vaccine receivers, inoculated with two injections in different procedures and doses, have all produced high titers of antibodies. For those receiving two injections at an interval of 28 days, the seroconversion rate of neutralizing antibodies reached 100 percent. ■
|
||||||||
6044
|
dbpedia
|
0
| 89
|
https://medicalxpress.com/news/2020-12-china-sinopharm-vaccine-effective-covid-.html
|
en
|
China's Sinopharm says vaccine '79% effective' against Covid-19
|
[
"https://medx.b-cdn.net/tmpl/v6/img/logo.png",
"https://scx1.b-cdn.net/csz/news/800a/2020/chinesefirms.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/researchers-identify-b-3.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/like-treading-honey-fl-1.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2019/2-dementia.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/new-insights-into-the-21.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/small-rnas-boost-immun-2.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/migraine-2.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/t-cell.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/uva-research-cracks-th.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/autistic-traits-behavi.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/people-experiencing-re.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2020/uae.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2020/21-coronavirusv.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2019/4-vaccine.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2020/2-vaccine.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2020/21-coronavirusv.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2020/10-covid19vacci.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/preventive-vaccination-1.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2017/influenzaa.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/game-changing-needle-f.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/multipurpose-vaccine-s.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2024/vaccine-shows-promise-1.jpg",
"https://scx1.b-cdn.net/csz/news/tmb/2021/19-covid19vacci.jpg",
"https://medx.b-cdn.net/tmpl/v6/img/Physorg.svg",
"https://medx.b-cdn.net/tmpl/v6/img/TechXplore.png",
"https://medx.b-cdn.net/tmpl/v6/img/ScienceX.svg",
"https://pixel.quantserve.com/pixel?a.1=p-522H9WlBHUNiI.gif&?a.2=p-5dNhPAnM9r0yY"
] |
[] |
[] |
[
"Medicine Research News",
"Medicine Research",
"Health Research News",
"Health Research",
"Health Science",
"Medicine Science"
] | null |
[
"Science X"
] |
2020-12-30T01:27:54-05:00
|
Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said Wednesday, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia.
|
en
|
https://medicalxpress.com/favicon.ico
|
https://medicalxpress.com/news/2020-12-china-sinopharm-vaccine-effective-covid-.html
|
Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said Wednesday, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia.
China has been racing against the West to develop its own Covid-19 vaccines, with five already in large-scale Phase 3 clinical trials.
But Wednesday's announced was the first data released regarding the efficacy of a Chinese vaccine candidate.
"The protective effect of the (Sinopharm CNBG Beijing) vaccine against Covid-19 is 79.34 percent," said the Beijing Institute of Biological Products, a Sinopharm subsidiary.
Sinopharm has applied to China's drug regulator for approval of the inactivated coronavirus vaccine, the statement said, a type of inoculation using particles of the pathogen.
But China has struggled to gain international trust for its vaccine candidates, hindered by a lack of transparency on test results.
It has also been slow to complete Phase 3 trials, which had to be conducted abroad due to China's success at curbing the spread of Covid-19 within its own borders.
Chinese officials have repeatedly assured the public of the vaccines' safety, claiming that there have been no serious adverse reactions.
More than one million people have already been vaccinated with unapproved vaccines in China under its emergency use programme, including frontline health workers, state-owned enterprise employees and workers planning to travel abroad.
The United Arab Emirates approved a Sinopharm vaccine earlier this month, becoming the first foreign country to approve a China-developed Covid-19 vaccine. It said the vaccine was 86 percent effective, according to interim results of a Phase 3 trial.
Beijing has pledged to share the vaccine at a fair cost—a potential boost for poorer Asian countries who are otherwise reliant on limited distribution offered by the COVAX scheme.
"China has made the firm commitment that after China's new coronavirus vaccines are completed and put into use, they will serve as a global public product and be supplied to the world at a fair and reasonable price," foreign ministry spokesman Zhao Lijian said Friday.
"We will also give priority to developing countries for vaccines. This will be made through a variety of ways, including through donations and aid."
© 2020 AFP
|
|||||
6044
|
dbpedia
|
3
| 33
|
https://www.aljazeera.com/news/2021/2/28/iran-receives-chinas-sinopharm-jabs-as-covid-deaths-reach-60000
|
en
|
Iran receives China’s Sinopharm jabs as COVID deaths reach 60,000
|
[
"https://www.aljazeera.com/wp-content/uploads/2021/02/1.jpeg?resize=770%2C513&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2021/02/IranVac.jpeg?w=770&resize=770%2C513",
"https://www.aljazeera.com/wp-content/uploads/2021/02/AP_20149282488374.jpg?resize=770%2C513&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2021/02/2021-02-26T191137Z_1609913315_RC2J0M9VRK0Y_RTRMADP_3_USA-BIDEN-TEXAS.jpg?resize=770%2C513&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2021/02/2021-02-21T090325Z_1023036465_RC2XWL9S461Z_RTRMADP_3_IRAN-NUCLEAR-USA.jpg?resize=770%2C513&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/2024-08-15T075802Z_396608106_RC27G9AZVXXO_RTRMADP_3_GERMANY-AIRPORT-PROTESTS-1723711203.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/2024-08-11T183206Z_127039775_RC2MD9AL8YDQ_RTRMADP_3_UKRAINE-CRISIS-RUSSIA-KURSK-BORDER-1723504934.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/AFP__20240306__34KU6DD__v1__HighRes__PalestinianIsraelConflictSettlement-1723705364.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/2024-08-14T102017Z_632152906_RC2KF9A4VKXC_RTRMADP_3_THAILAND-POLITICS-1723706181.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/AFP__20240814__36E928L__v1__HighRes__PalestinianIsraelConflict-1723708160.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/AP24226474215392-1723632656.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/2024-08-13T212428Z_1512419108_RC2HD9AVF054_RTRMADP_3_UKRAINE-CRISIS-USA-1723627209.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2024/08/AP24213819022428-1723659146.jpg?resize=270%2C180&quality=80",
"https://www.aljazeera.com/static/media/aj-footer-logo.bac952ad.svg"
] |
[
"https://www.youtube.com/embed/SgPGsZ9Pc3s?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent"
] |
[] |
[
"News",
"Coronavirus pandemic",
"Iran",
"Middle East"
] | null |
[
"Maziar Motamedi"
] |
2021-02-28T00:00:00
|
Iran will receive several million more doses of foreign vaccines while advancing work on promising local candidates.
|
en
|
/favicon_aje.ico
|
Al Jazeera
|
https://www.aljazeera.com/news/2021/2/28/iran-receives-chinas-sinopharm-jabs-as-covid-deaths-reach-60000
|
Tehran, Iran – Iran received 250,000 doses of the Sinopharm vaccine on Sunday that have been donated by the government of China.
“This act and those similar to it by the government and nation of China are admirable and will of course remain in the historical memory of the Iranian nation,” Kianoush Jahanpour, spokesman of the Food and Drug Administration, told state TV.
The delivery came on the same day that Iran’s total deaths from COVID-19 surpassed 60,000. The country has also recorded more than 1.6 million cases.
After Russia’s Sputnik V, the first doses of which were delivered earlier this month and used to inoculate front-line healthcare workers, the Sinopharm vaccine is the second foreign vaccine imported to Iran.
It is also to be used as part of the country’s national vaccination programme, which from Wednesday moved to vulnerable groups after front-line healthcare workers.
According to Alireza Raisi, spokesman of the national anti-coronavirus task force, the government hopes to begin inoculating an estimated 1.3 million vulnerable Iranians before the end of the current Iranian calendar year on March 20, and finish their vaccination one month later.
He also said on Saturday that Iran will know soon when exactly it will take delivery of 4.2 million doses of the Oxford-AstraZeneca vaccine as part of COVAX, a global vaccine initiative by the World Health Organization.
Iranian officials have also hinted at the possibility of importing a vaccine from India’s Bharat Biotech.
Second local vaccine starts human trials
But to rein in the deadly virus in a country of almost 85 million people, Iranian officials are mainly banking on locally manufactured vaccines. The country’s second vaccine candidate, Razi COV-Pars, began human trials on Sunday.
In a ceremony aired live on state television, Agriculture Minister Kazem Khavazi issued the order for the first volunteer to receive the first dose.
As part of the vaccine’s first phase of human trials, 133 volunteers will receive two doses via injection and one dose via inhalation, officials have said.
The mRNA vaccine has been developed by the Razi Vaccine and Serum Research Institute, Iran’s oldest vaccine institute with a history of almost 100 years, and is said to be able to stop COVID-19 transmissions while having few side effects.
Iran’s first vaccine candidate, COVIran Barekat, finished its first phase of human trials earlier this month and the team behind it said preliminary results indicated it is 90 percent effective while being capable of fully countering the COVID-19 variant first found in the United Kingdom.
Officials have said Iran is building “the largest vaccine production site in the Middle East” and expects to produce 10 million doses of the Barekat vaccine per month by early spring.
|
||||
6044
|
dbpedia
|
2
| 74
|
https://synapse.patsnap.com/drug/9b2db20b467747bbb9ae4aabb7045e55
|
en
|
Sinopharm vaccine(Ain Shams University)
|
[
"https://res.cloudinary.com/crunchbase-production/image/upload/iahzqqdu0rqhg98c3rgq",
"https://res.cloudinary.com/crunchbase-production/image/upload/iahzqqdu0rqhg98c3rgq",
"https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/80af/065d/ac05/03b4/80af065dac0503b4_48w.webp",
"https://res.cloudinary.com/crunchbase-production/image/upload/iahzqqdu0rqhg98c3rgq",
"https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-translational-medicine.3a3e2795.png",
"https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-drug-deal.a0b20458.png",
"https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-core-patent.b641c7b0.png",
"https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-clinical-trial.0b31c1c7.png",
"https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-approval.afa46671.png",
"https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-regulation.1032cd3e.png"
] |
[] |
[] |
[
"Sinopharm vaccine(Ain Shams University)",
"Immunostimulants"
] | null |
[] | null |
Sinopharm vaccine(Ain Shams University): a Immunostimulants Drug, Initially developed by Ain Shams University, Now, its global highest R&D status is Pending, Mechanism: Immunostimulants, Therapeutic Areas: Infectious Diseases,Respiratory Diseases.
|
en
|
/favicon.ico
|
https://synapse.patsnap.com/drug/9b2db20b467747bbb9ae4aabb7045e55
|
Not Applicable
177
bhfcxlewel(negbvtkwyf) = 23 patients (13%) had confirmed COVID-19 infection (post AstraZeneca 1, Pfizer 13, Sinopharm 8, Sinovac 1) nyeyeutmiu (dgbrvhlysk )
View more
Positive
|
|||||
6044
|
dbpedia
|
3
| 38
|
https://blog.wego.com/sinopharm-approved-countries/
|
en
|
Sinopharm Approved Countries List: Which Countries Have Accepted Sinopharm for Use and Travellers' Entry?
|
[
"https://blog.wego.com/wp-content/icons/linkedin.svg",
"https://blog.wego.com/wp-content/uploads/wegotravelblog.png",
"https://blog.wego.com/wp-content/uploads/sinopharm-confirmed-countries-featured_vb0olc-1080x675.jpg",
"https://secure.gravatar.com/avatar/2435fca2c80084725b5009e0e6db34cc?s=60&d=mm&r=g",
"https://blog.wego.com/wp-content/uploads/travel-covid-banner1.jpg",
"https://blog.wego.com/wp-content/uploads/travel-quarantine-banner1.jpg",
"https://blog.wego.com/wp-content/uploads/countries-confirmed-covaxine-featured_kevgoj-400x250.jpg",
"https://blog.wego.com/wp-content/uploads/countries-confirmed-covishield-featured_kavgmy-400x250.jpg",
"https://blog.wego.com/wp-content/uploads/Johnson-Johnson-approved-countries-featured_mvyhbm-400x250.jpg",
"https://blog.wego.com/wp-content/uploads/pfizer-approved-countries-featured_jpkwqh-400x250.jpg",
"https://blog.wego.com/wp-content/uploads/cansino-vaccine-pakistan-featured_kn26zs-400x250.jpg",
"https://blog.wego.com/wp-content/uploads/parsi-new-year-featured_fo8vzc-400x250.jpg",
"https://blog.wego.com/wp-content/uploads/visa-free-countries-from-egypt-featured-400x250.webp",
"https://blog.wego.com/wp-content/uploads/pakistan-e-visas-126-countries-visa-free-gcc-featured-400x250.webp",
"https://blog.wego.com/wp-content/uploads/incheon-airport-guide-featured-400x250.webp",
"https://blog.wego.com/wp-content/uploads/move-from-india-to-japan-featured-400x250.webp",
"https://blog.wego.com/wp-content/uploads/wego-logo-white-1.png",
"https://blog.wego.com/wp-content/icons/linkedin.svg"
] |
[] |
[] |
[
""
] | null |
[
"Wego Travel"
] |
2021-10-05T11:41:04+08:00
|
This article is reviewed regularly (on a monthly basis) by Wego’s editorial team to ensure that the content is up to date & accurate. Reviewed 26 November 2021 The Chinese Sinopharm vaccine has been one of the front-runners from the start of the COVID-19 vaccine race. By now, it has been approved in over 70 countries and […]
|
en
|
Wego Travel Blog
|
https://blog.wego.com/sinopharm-approved-countries/
|
This article is reviewed regularly (on a monthly basis) by Wego’s editorial team to ensure that the content is up to date & accurate.
Reviewed 26 November 2021
The Chinese Sinopharm vaccine has been one of the front-runners from the start of the COVID-19 vaccine race. By now, it has been approved in over 70 countries and is being distributed across the globe. It has also come to the aid of several low and middle-income countries through the COVAX agreement.
Keep reading to find out where the Sinopharm vaccine has been approved.
About Sinopharm
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).
Sinopharm relies on the older but tested inactivated virus technology, which involves taking dead coronavirus and injecting them into the body. The process essentially forces the body to produce antibodies against the SARS-CoV-2 coronavirus.
Once vaccinated, the immune system will be able to respond to an infection of live coronaviruses. Antibodies can stick to and prevent the invading virus from entering the cells in the body.
Based on the available data, the Sinopharm vaccine is reported to have 100 per cent protection from moderate and severe forms of Covid-19. Its overall efficacy rate is 86 per cent. The side effects associated with vaccination in volunteers include pain at the injection site, headache, high temperature or fatigue.
WHO Approval
Sinopharm got the WHO’s approval on 7 May 2021 for emergency use, giving the green light for this vaccine to be rolled out globally.
WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. Vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined.
The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency, while adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.
For COVID-19 vaccines, the UN’s health branch has set the bar for minimum efficacy at 50% in its considerations for evaluation of COVID-19 vaccines. So far, 8 vaccines are approved for use by WHO:
Pfizer/BioNTech: Comirnaty
Oxford/AstraZeneca: Vaxzevria
Johnson & Johnson: Ad26.COV2.S
Moderna: mRNA-1273
Sinopharm: BBIBP-CorV
Sinovac: CoronaVac
Covishield: Oxford/ AstraZeneca formulation
Covaxin: Bharath Biotech
Sinopharm approved countries
According to the WHO, the following countries have approved the use of Sinopharm.
Algeria
The other vaccines approved in the country are Sputnik V, Oxford/AstraZeneca, Sinovac.
Angola
The other vaccines approved in the country are Sputnik V, Sputnik Light, and AstraZeneca.
Argentina
The other vaccines approved in the country are Pfizer, Moderna, Sinovac, CanSino, AstraZeneca, Sputnik V, and Covishield.
Bahrain
The other vaccines approved in the country are Pfizer, Sputnik V, Sputnik Light, Janssen, and Covishield.
Bangladesh
The other vaccines approved in the country are Moderna, Pfizer, Sputnik V, Janssen, Covishield, and Sinovac.
Belarus
The other vaccines approved in the country are Sputnik V and Sputnik Light.
Belize
The other vaccine approved in the country is AstraZeneca.
Bolivia
The other vaccines approved in the country are Sputnik V, Pfizer, Janssen and Covishield.
Brazil
The other vaccines approved in the country are Pfizer, Sputnik V, Janssen, AstraZeneca, Covishield, and Sinovac.
Brunei
The other vaccines approved in the country are Moderna, Pfizer, and AstraZeneca.
Cambodia
The other vaccines approved in the country are AstraZeneca and Sinovac.
Cameroon
The other vaccine approved in the country is Sputnik V.
Chad
Sinopharm is the only vaccine approved in the country.
China
The other vaccines approved in the country are RBD-Dimer, CanSino, SARS-Cov-2 Vaccine (Vero Cells), Sinovac and Sinopharm (Wuhan) Inactivated (Vero Cells).
Comoros
Sinopharm is the only vaccine approved in the country.
Cuba
The other vaccine approved in the country is Abdala.
Egypt
The other vaccines approved in the country are Sputnik V, AstraZeneca, Sputnik Light, Janssen, Covishield, and Sinovac.
Equatorial Guinea
Sinopharm is the only vaccine approved in the country.
Gabon
The other vaccine approved in the country is Sputnik V.
The Gambia
The other vaccine approved in the country is AstraZeneca.
Georgia
The other vaccines approved in the country are Pfizer, AstraZeneca, and Sinovac.
Guyana
The other vaccines approved in the country are AstraZeneca, Covaxin, and Sputnik V.
Hungary
The other vaccines approved in the country are Moderna, Pfizer, CanSino, Sputnik V, Janssen, AstraZeneca, and Covishield.
Indonesia
The other vaccines approved in the country are CanSino, Sputnik V, Janssen, Moderna, Pfizer, AstraZeneca, Sinovac and ZF2001.
Iran
The other vaccines approved in the country are Sputnik Light, Janssen, Sputnik V, AstraZeneca, Covaxin, Shifa Pharmed Industrial’s COVID-19 inactivated vaccine, and COVAX-19.
Iraq
The other vaccines approved in the country are Sputnik V, Pfizer, and AstraZeneca.
Jordan
The other vaccines approved in the country are Sputnik V, Pfizer, and AstraZeneca.
Kenya
The other vaccines approved in the country are Pfizer, Janssen, Sputnik V, Moderna, and AstraZeneca.
Kyrgyzstan
The other vaccines approved in the country are QazVac, Sputnik V, and Sputnik Light.
Laos
The other vaccines approved in the country are Sputnik V and Sinovac.
Lebanon
The other vaccines approved in the country are Pfizer, Sputnik V, and Covishield.
Malaysia
The other vaccines approved in the country are Moderna, Pfizer, CanSino, Janssen, AstraZeneca and Sinovac.
Maldives
The other vaccines approved in the country are Moderna, Pfizer, Covishield, Janssen, and Sputnik V.
Mauritania
Sinopharm is the only vaccine approved in the country.
Mauritius
The other vaccines approved in the country are Sputnik V, Sputnik Light, AstraZeneca, and Covaxin.
Mexico
The other vaccines approved in the country are Sputnik V, AstraZeneca, Pfizer, Moderna, Janssen, Covaxin, Sinovac and CanSino.
Mongolia
The other vaccines approved in the country are Pfizer, Moderna, Sputnik V, Sputnik Light, and AstraZeneca.
Montenegro
The other vaccine approved in the country is Sputnik.
Morocco
The other vaccines approved in the country are Sputnik V, AstraZeneca, and Covishield.
Mozambique
Sinopharm is the only vaccine approved in the country.
Namibia
The other vaccines approved in the country are Sputnik V and Covishield.
Nepal
The other vaccines approved in the country are Covishield, Covaxin, Sputnik V, and Sinovac.
Niger
The other vaccine approved in the country is AstraZeneca.
Nigeria
The other vaccines approved in the country are Moderna, Pfizer, Sputnik V, Janssen, AstraZeneca and Covishield.
North Macedonia
The other vaccines approved in the country are Pfizer, Sputnik V, and AstraZeneca.
Oman
The other vaccines approved are Pfizer-BioNTech, Oxford-AstraZeneca, AstraZeneca / Covishield, Johnson & Johnson, Sinovac, Moderna, Sputnik V and Covaxin.
Pakistan
The other vaccines approved in the country are CanSino, Pfizer, AstraZeneca, Moderna, Sputnik V, and Sinovac.
Papua New Guinea
The other vaccines approved in the country are AstraZeneca and Janssen.
Paraguay
The other vaccines approved in the country are Pfizer, Sputnik V, AstraZeneca, Covaxin, and Sinovac.
Peru
The other vaccines approved in the country are Pfizer, Janssen and AstraZeneca.
Philippines
The other vaccines approved in the country are Moderna, Pfizer, AstraZeneca, Janssen, Sputnik V, Sputnik Light, Covaxin, Sinovac, and Sinopharm (Wuhan) Inactivated (Vero Cells).
Republic of the Congo
The other vaccine approved in the country is Sputnik V and Sputnik Light.
Senegal
The other vaccine approved in the country is AstraZeneca and Janssen.
Serbia
The other vaccines approved in the country are Pfizer, Sputnik V, and AstraZeneca.
Seychelles
The other vaccines approved in the country are Moderna, Sputnik V, and Covishield.
Sierra Leone
The other vaccine approved in the country is AstraZeneca.
Solomon Islands
The other vaccine approved in the country is Covishield.
Somalia
The other vaccine approved in the country is Covishield.
Sri Lanka
The other vaccines approved in the country are Covishield, Moderna, AstraZeneca, Pfizer, Sinovac, and Sputnik V.
Thailand
The other vaccines approved in the country are Moderna, Pfizer, Janssen, AstraZeneca, and Sinovac.
Trinidad and Tobago
The other vaccines approved in the country are Pfizer and Covishield.
Tunisia
The other vaccines approved in the country are Pfizer, Sputnik V, Janssen, AstraZeneca and Sinovac.
United Kingdom
The other vaccines approved in the country are Oxford/AstraZeneca, Pfizer BioNTech, Moderna, Janssen, Sinovac, Covaxin.
United Arab Emirates
The other vaccines approved in the country are Moderna, Pfizer, Sputnik V, AstraZeneca, and Sputnik Light.
Vanuatu
The other vaccine approved in the country is AstraZeneca.
Venezuela
The other vaccines approved in the country are Sputnik V, CIGB-66 vaccine and Sputnik Light.
Vietnam
The other vaccines approved in the country are Moderna, CIGB-66 vaccine, Pfizer, Janssen, AstraZeneca and Sputnik V.
Westbank
The other vaccines approved in the country are Moderna, Pfizer, Janssen, Sputnik Light and Sputnik V.
Zimbabwe
The other vaccines approved in the country are Janssen, Sputnik V, Covaxin, and Sinovac.
Approved as valid proof of vaccination
The following are a list of countries that recognise the Sinopharm vaccine as valid proof of vaccination:
Austria
The other vaccines recognised are Pfizer/BioNTech, Vaxzevria – AstraZeneca, Covishield, Janssen, Moderna, and Sinovac.
Australia
The other vaccines recognised are Pfizer, Vaxzevria-AstraZeneca, Covishield, Moderna, Janssen, Sinovac and Covaxin
Cyprus
The other vaccines recognised are Pfizer/BioNTech, Vaxzevria – AstraZeneca, Covishield, Janssen, Moderna, and Sinovac.
Canada
The country has stated that the Sinopharm vaccine will be recognised as valid proof of vaccination starting November 30 2021. The other vaccines recognised are Pfizer, Moderna, AstraZeneca, Johnson and Johnson, Sinovac (starting November 30) and Covaxin (starting November 30).
Finland
The other vaccines recognised are Pfizer/BioNTech, Oxford/AstraZeneca, Covishield, Janssen, Moderna and Covaxin.
Greece
The other vaccines recognised are Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinovac, Covishield, Novavax, Sputnik V, Cansino Biologics
Iceland
The other vaccines recognised are Pfizer/BioNTech, Vaxzevria – AstraZeneca, AstraZeneca/SK Bio, Covishield, Janssen, Moderna, Sinovac
Netherlands
The other vaccines recognised are Pfizer/BioNTech, AstraZeneca-SK Bio (Vaxzevria), AstraZeneca EU (Vaxzevria), Covishield, Janssen, Moderna, and Sinovac.
Spain
The other vaccines recognised are Pfizer/BioNTech, Vaxzevria – AstraZeneca, AstraZeneca/SK Bio, Covishield, Janssen, Moderna and Sinovac.
Sweden
The other vaccines recognised are Pfizer/BioNTech, Vaxzevria – AstraZeneca, AstraZeneca/SK Bio, Covishield, Janssen, Moderna and Sinovac.
Switzerland
The other vaccines recognised are Pfizer/BioNTech, Moderna, Vaxzevria, Janssen, Covishield, and Sinovac.
United States
The other vaccines recognised in the country are Johnson & Johnson, Pfizer-BioNTech, Moderna, Oxford-AstraZeneca, Covishield, and Sinovac.
|
|||||
6044
|
dbpedia
|
2
| 23
|
https://www.healthspringsgroup.com.sg/difference-between-sinopharm-and-sinovac/
|
en
|
Difference between Sinopharm and Sinovac – Healthsprings
|
https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/favicon.ico
|
https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/favicon.ico
|
[
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/search-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/search-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/plugins/wp-multilang/flags/sg.png",
"https://www.healthspringsgroup.com.sg/wp-content/plugins/wp-multilang/flags/sg.png",
"https://www.healthspringsgroup.com.sg/wp-content/plugins/wp-multilang/flags/cn.png",
"https://www.healthspringsgroup.com.sg/wp-content/plugins/wp-multilang/flags/cn.png",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2019/08/healthsprings-group-logo.png",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2019/08/healthsprings-group-logo.png",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/115864072_gettyimages-1229946482-300x169.jpg 300w, https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/115864072_gettyimages-1229946482-768x432.jpg 768w, https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/115864072_gettyimages-1229946482.jpg 976w",
"https://healthspringsgroup.com.sg/wp-content/uploads/2021/11/115864072_gettyimages-1229946482-300x169.jpg",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/Sinopharm_COVID-vaccines-300x200.jpg 300w, https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/Sinopharm_COVID-vaccines-768x512.jpg 768w, https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/Sinopharm_COVID-vaccines.jpg 790w",
"https://healthspringsgroup.com.sg/wp-content/uploads/2021/11/Sinopharm_COVID-vaccines-300x200.jpg",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/content-post-Oct-4-470x400.png",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2021/11/content-post-Oct-4-470x400.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon2.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon2.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon2.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon2.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon2.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/map-icon2.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-1.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/mobile-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-3.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/icon-4.png",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2019/08/healthsprings-group-logo.png",
"https://www.healthspringsgroup.com.sg/wp-content/uploads/2019/08/healthsprings-group-logo.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/read-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/read-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/read-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/read-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/read-icon.png",
"https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/read-icon.png"
] |
[] |
[] |
[
""
] | null |
[
"healthadmusr"
] |
2021-11-22T00:00:00
|
en
|
https://www.healthspringsgroup.com.sg/wp-content/themes/oom_default/assets/images/favicon.ico
|
https://www.healthspringsgroup.com.sg/difference-between-sinopharm-and-sinovac/
|
Difference between Sinopharm and Sinovac
People who are unable to take Pfizer or Moderna as a vaccine, are now able to go for Sinopharm or Sinovac. They are both vaccines from China and there are relevant reports and data that shows that they are safe and reliable based on China’s Foreign Ministry.
If you are still considering which vaccine to take, let us break down the details before you make the decision.
Sinovac
Sinovac, developed by Beijing-based biopharmaceutical company, is an inactivated virus technology that injects dead coronavirus particles into the body. It will trigger our body’s immune system to produce antibodies by itself to counter COVID-19.
During May this year, Sinovac has shown vaccine effectiveness of 66 per cent against variants such as Alpha and Gamma based on the real-world effectiveness study in Chile. It showed that it is capable of offering more than 86 per cent protection against outcomes like hospitalisation, admission to intensive care units and even death.
However, there is insufficient data on the vaccine protection for Delta variant, immunocompromised patients and patients with comorbidities which includes cancers, cardiovascular diseases and diabetes.
There is currently no data on the breakthrough infections but a Sinovac study that is not from Chile has shown that this vaccine was not as effective as Pfizer-BioNTech and Moderna at preventing infection among vaccinated individuals.
Sinopharm
Similar to Sinovac, Sinopharm is also an inactivated virus technology that teaches your body to produce antibodies with your immune system.
Sinopharm developed with Beijing Institute of Biological Products has an efficacy rate of 78.1 per cent while Sinovac has an efficacy rate of 51 per cent in preventing symptomatic Covid-19 infection.
Based on the data from Mongolia, Sinopharm was also more protective than Russian vaccine according to the Health Ministry. Also, most of the other Covid-19 vaccines have side-effects such as fever and fatigue but they were uncommon for Sinovac or Sinopharm.
However, as of now there is no data on the effectiveness of Sinopharm against any variant of concern despite its use in more than 50 countries.
Book your Sinopharm vaccine appointment at our clinics here:
1 Dose – https://my.setmore.com/bookingpage/8b8eade7-6816-4232-b0f9-d16b48c9a390/services/53431128-d92c-4320-822f-986a8ea9de2f?source=easyshare
2 Doses – https://my.setmore.com/bookingpage/8b8eade7-6816-4232-b0f9-d16b48c9a390/services/s34271fa47e41eae12ca8799ad23ec131c5348739?source=easyshare
Sinopharm Vaccine are available at these clinics:
Orchard
Healthsprings Medical Associates
Address: 541 Orchard Road #10-02, Liat Towers Singapore 238881
Contact number: +65 6734 5260 / +65 9728 7793
Woodleigh
Healthsprings Medical and Laser Clinic
105A Bidadari Park Drive #01-09, Singapore 341105
Contact number: +65 6970 7933 / +65 8338 8800
Sources:
-https://www.straitstimes.com/singapore/health/is-sinovac-safe-5-questions-about-the-covid-19-vaccine
-https://www.straitstimes.com/world/they-relied-on-chinese-vaccines-now-theyre-battling-outbreaks
-https://theconversation.com/what-are-the-sinopharm-and-sinovac-vaccines-and-how-effective-are-they-two-experts-explain-162258
How To Deal With Long COVID?
A growing population of individuals who have had an acute COVID-19 infection experience a wide range of persistent symptoms. Such patients may experience symptoms for […]
January 6, 2023
Bivalent Covid Vaccine is now available at our clinic
The Health Science Authority (HSA) has granted interim authorization under Pandemic Special Access Route (PSAR) for Bivalent COVID-19 vaccines in October 2022. The following are […]
December 9, 2022
The Tale of the Two Diseases of 2022 – COVID-19 and Dengue
There is an outbreak of both COVID-19 and dengue. How do we differentiate the two? It can be hard to separate these 2 […]
August 24, 2022
Prolonged Coughing Post-COVID 19 Infection
Persistent cough and other long COVID symptoms affect many patients who have been infected by the virus. It is frustrating and can be embarrassing to […]
August 17, 2022
Resumption of Physical Activity After COVID 19 Infection
How soon can we start exercising again after contracting COVID 19 must be a common patient’s concern. Even after one has recovered, the inflammation […]
August 10, 2022
There is Oral Antiviral Medications (OAV) for COVID 19 Now?
Is there other ways to fight COVID 19 infection apart from vaccination? Currently, Paxlovid and Molnupiravir are the 2 antiviral agents available in Singapore for […]
July 8, 2022
What to do before you travel? – Travel vaccines and advice
1. Apart from the COVID-19 vaccine, what other travel vaccines should I consider? Everyone’s immunisation needs are different! They are based on a […]
June 1, 2022
My child contracted COVID-19 from her childcare. I have heard about MIS-C. What is it?
MIS-C or Multisystem Inflammatory Syndrome in Children is an uncommon complication of COVID-19, occurring in < 1% of children with confirmed COVID-19 infection. How [...]
May 6, 2022
If I am still tested COVID-positive after 7 days, can I still go back to work?
Last month, Singapore modify its COVID-19 protocols after the Omicron wave hit. The Ministry of Health (MOH) stated that the maximum self-isolation period will be […]
February 10, 2022
Do I need to get an MC if I have COVID?
According to an advisory issued by tripartite partners – the Ministry of Manpower (MOM), it is mentioned that we DO NOT need to take […]
February 9, 2022
How to be COVID-safe during this Chinese New Year?
It’s a brand new year (Year of the Tiger) and here comes one of our most looking forward event – Chinese new year. Also known […]
January 26, 2022
Covid-19 Booster Shot needed to Maintain Fully Vaccinated Status
13 Jan 2022 From Feb 14, 2022, a booster shot will be needed for those who are aged 18 and above within 270 days of […]
January 13, 2022
Will the COVID-19 pandemic end in 2022?
2021 is coming to an end and even though the COVID-19 pandemic has been a bummer to all of us, World Health Organisation (WHO) forecasted […]
December 27, 2021
How To Prepare Your Kids For COVID Vaccination?
Vaccination can be a very scary thing to the kids, as most of them are afraid of needles and the pain from injections. It will […]
December 24, 2021
Will you lose vaccinated status if you don’t get a third Sinopharm/Sinovac dose?
People who took Sinopharm or Sinovac vaccine for their two doses on or before August 31, please be reminded to take your third dose before […]
December 10, 2021
Travelers can now use Saliva Testing as COVID-19 pre-departure tests for certain countries
Taking swab tests can sound really daunting to some. From nasal swab test to throat test, individuals may experience discomfort or slight pain during the […]
December 8, 2021
Is It Safe To Travel During The Covid-19 Pandemic?
Is it safe to travel overseas? What do we need to prepare for safe travels? (Travel lanes, taking boosters before travel, regular ART while overseas, […]
November 30, 2021
How can I check my immunity to COVID-19? What is the cPass antibody test?
As booster shots for COVID-19 vaccine are recommended 6 months after the initial 2 doses, many people are wondering if it is possible to check […]
November 24, 2021
Should I be getting a Covid Booster Jab?
Are you wondering why there is a need to get a booster vaccine? Does the need for getting a booster mean the vaccines do not […]
November 2, 2021
The Sinopharm Vaccines Have Arrived!
The Sinopharm vaccines have arrived! You may now book an appointment for the vaccination. Before you book an appointment, please kindly read through the […]
October 14, 2021
What is COVID-19 Antibody Test?
What is COVID-19 Antibody Test? Also known as Antibody (Serology) test, it conduct samples to look for antibodies to decide if an individual have […]
October 14, 2021
What queries do you have for Home Recovery Programme (HRP)?
Who is suitable for HR? HR is the standard procedure for fully vaccinated, who are: Persons of aged 12 to 69 No other severe […]
October 4, 2021
What do you do if you have NO SYMPTOMS, but your Antigen Rapid Test (ART) is positive?
Asymptomatic case of COVID-19 An asymptomatic case of an individual refers to someone who has no symptoms during the complete course of infection. […]
October 3, 2021
What is Antigen Rapid Test (ART)?
ART self-test kits are made available for people who are worried about the possibility of getting COVID-19. ART is a quick screening tool that […]
October 1, 2021
Our Clinic Is Accepting Appointments For The Sinopharm Vaccinations
UPDATE: Sinopharm vaccines (second batch) has arrived! You may now book your vaccination appointment via this link – https://healthspringsgroup.com.sg/sinopharm/ 国药集团疫苗已经来了！您现在可以预约接种疫苗了。使用此链接预约 – https://healthspringsgroup.com.sg/sinopharm/..
September 1, 2021
Private Clinics in Singapore are offering China’s Sinopharm COVID-19 vaccine
*Update: Healthsprings is currently one of the vaccination clinics in Singapore that is offering the Sinopharm vaccinations. Kindly book a Sinopharm vaccination appointment with us […]
August 18, 2021
COVID Tests at GP Clinics: Swab-And-Send-Home (SASH)
With effect from 1 July 2020, anyone aged 13 and above who has fever or flu symptoms will have to undergo swab test for COVID-19. Your..
August 11, 2021
What does it mean to live with Endemic Covid-19 in Singapore?
It has been close to 2 years ever since Singapore reported its first COVID case on 23 January 2020. Many say that this pandemic will […]
August 11, 2021
Should I get the COVID-19 vaccine? I am afraid of the side effects!
Should I get the COVID-19 vaccine? I am afraid of the side effects! That is probably the most in-vogue discussion nowadays. As with any vaccine, […]
April 5, 2021
Can I take the COVID vaccine if I have face fillers?
Can I take the COVID vaccine if I have face fillers? Some of you might have read about the three patients with dermal fillers […]
February 26, 2021
Will COVID-19 affect my pregnancy or baby?
During this COVID-19 pandemic, many couples who are planning for parenthood are worried about the risk of contracting COVID-19 and its possible impact on pregnancy. […]
February 10, 2021
Have You Redeemed Your FREE $100 Vouchers?
We all know that every Singapore citizens are entitled to $100 SingapoRediscovers vouchers from our Singapore government, as an effort to recover the local […]
January 18, 2021
Will you take the COVID-19 vaccination?
Singapore started the COVID-19 vaccination program on 30th December, starting with healthcare workers from the National Centre of Infectious Diseases (NCID). The vaccination jointly […]
January 6, 2021
COVID-19 vaccine, how far are we away from one?
In the last 2 weeks, both Pfizer and Moderna announced that their vaccines are respectively 90% and 94.5% effective, and both appear to be safe. […]
November 26, 2020
|
||||
6044
|
dbpedia
|
3
| 80
|
https://www.ft.com/content/99c7a9de-fc11-45ab-890b-f6733ccb4186
|
en
|
Subscribe to read
|
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
|
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
|
[
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_standard.svg?source=next-barrier-page&format=svg",
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_premium.svg?source=next-barrier-page&format=svg",
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_bundle.svg?source=next-barrier-page&format=svg",
"https://spoor-api.ft.com/px.gif?data=%7B%22category%22%3A%22page%22%2C%22action%22%3A%22view%22%2C%22system%22%3A%7B%22source%22%3A%22non-ctm%22%7D%2C%22context%22%3A%7B%22name%22%3A%22barrier-page%22%2C%22product%22%3A%22next%22%2C%22data%22%3A%7B%22source%22%3A%22%5BSOURCE%5D%22%7D%7D%7D"
] |
[] |
[] |
[
""
] | null |
[] | null |
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
| null |
Try unlimited access
Only €1 for 4 weeks
Then €69 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.
Why the FT?
See why over a million readers pay to read the Financial Times.
|
|||||
6044
|
dbpedia
|
1
| 76
|
https://apnews.com/article/europe-middle-east-business-science-health-4b770731d5995e3bb49a1d8ec63febbd
|
en
|
Study: Chinese COVID shot may offer elderly poor protection
|
https://dims.apnews.com/dims4/default/cafe9c7/2147483647/strip/true/crop/3000x1688+0+156/resize/1440x810!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg
|
https://dims.apnews.com/dims4/default/cafe9c7/2147483647/strip/true/crop/3000x1688+0+156/resize/1440x810!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg
|
[
"https://assets.apnews.com/fa/ba/9258a7114f5ba5c7202aaa1bdd66/aplogo.svg",
"https://dims.apnews.com/dims4/default/94c503b/2147483647/strip/true/crop/640x236+0+0/resize/320x118!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc3%2F4c%2F65482a7b452db66043542c093eaf%2Fpromo-2x.png 1x,https://dims.apnews.com/dims4/default/6e4b276/2147483647/strip/true/crop/640x236+0+0/resize/640x236!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc3%2F4c%2F65482a7b452db66043542c093eaf%2Fpromo-2x.png 2x",
"https://dims.apnews.com/dims4/default/6094c65/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/aa46f0c/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/36bf4cc/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/d10bffb/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/6094c65/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/aa46f0c/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/36bf4cc/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/d10bffb/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/6fae603/2147483647/strip/true/crop/500x500+0+0/resize/100x100!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F66%2F1d%2F54d056f94e5e80755dde33a1d45c%2Frsz-img-20220211-093250-edit-justin-spike.jpg",
"https://dims.apnews.com/dims4/default/bc1ddbf/2147483647/strip/true/crop/2851x1534+0+0/resize/240x129!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F22%2F25%2F9576fafb4e768552fed602a60238%2Fap-pri-wordmarktagline-rgb-dbg.png 1x,https://dims.apnews.com/dims4/default/84565e0/2147483647/strip/true/crop/2851x1534+0+0/resize/480x258!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F22%2F25%2F9576fafb4e768552fed602a60238%2Fap-pri-wordmarktagline-rgb-dbg.png 2x",
"https://sb.scorecardresearch.com/p?c1=2&c2=3005041&cv=4.4.0&cj=1"
] |
[] |
[] |
[
"General news",
"COVID-19",
"Middle East",
"Europe",
"Budapest",
"Beijing",
"Hungary",
"Asia Pacific",
"Health",
"Science",
"Business",
"World News"
] | null |
[
"JUSTIN SPIKE",
"Huizhong Wu",
"Hungary. twitter mailto",
"apnews.com",
"justin-spike"
] |
2021-07-23T08:15:40+00:00
|
A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly.
|
en
|
/apple-touch-icon.png
|
AP News
|
https://apnews.com/article/europe-middle-east-business-science-health-4b770731d5995e3bb49a1d8ec63febbd
|
BUDAPEST, Hungary (AP) — A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.
A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.
The study by two Hungarian researchers was posted online this week but not yet reviewed by other scientists. Three outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm’s Beijing Institute of Biological Products.
“This is very, very worrying that these people, who are high-risk, have a poor antibody response,” said Jin Dong-yan, a Hong Kong University virologist who was not affiliated with the study.
Antibody levels are not a direct measure of how protected a person is from COVID-19, but there is growing evidence that they are a good proxy. One expert cautioned that the choice of test kits could have limited the accuracy of the measurements.
Still, the study’s findings have value and are the first public, scientific attempt to analyze the effect of the Sinopharm vaccine in the elderly, said Wang Chenguang, a former professor at Peking Union Medical College and an immunology expert.
China’s National Health Commission declined to comment on the study, saying it would only respond to studies by governments or major research institutions.
This is not the first time questions have been raised about the efficacy of the vaccine, which was given a greenlight by the World Health Organization in May and is being used in more than 50 countries, many of which seized upon it when other vaccines were tough to come by.
A spokesperson for the WHO said Wednesday that its experts “are aware of the study and continue to look at all available evidence.” The agency’s advisers raised questions months ago about whether it provided protection in people 60 and over, but when it was OK’d a WHO expert said that there was no reason to think it would work differently in the elderly.
The vaccine is one of two similar shots developed by Sinopharm. The state-owned Chinese company’s research showed that almost all the participants in final-stage clinical trials were under 60 — and its own researchers said there was insufficient evidence to say whether the vaccines work in the elderly. Overall, the Beijing Institute vaccine was found to be 78% effective.
In Hungary, concern about the shots led many to seek out private antibody tests. Eventually the capital city of Budapest offered free testing to elderly residents as part a bid to ratchet up pressure on the government to conduct its own wider survey and provide booster shots to those who need them.
After initially rebuffing calls for a government response to efficacy concerns — including from the antibody study’s authors Balazs Sarkadi and Tamas Ferenci — Prime Minster Viktor Orban finally acquiesced last week in the face of growing public anger. He announced that the government would provide its citizens with an optional third shot.
His office said, though, that all vaccines authorized by Hungary are effective.
The United Arab Emirates and Bahrain both announced in May that they, too, would offer a third dose of Sinopharm amid concerns about an insufficient antibody response. Bahrain recommended that people over 50 and some other vulnerable people receive Pfizer-BioNTech’s vaccine as their booster regardless of whether they got Sinopharm initially.
CNBG, the Sinopharm subsidiary that oversees the Beijing Institute, has said a third dose is not part of the company’s clinical guidance.
It’s not clear how many doses of the Beijing Institute Sinopharm vaccine have been exported. Overall, China exported 500 million vaccines doses in the first half of the year, and the company is one of country’s two major COVID vaccine makers, along with privately owned Sinovac.
The Global Alliance for Vaccines and Immunization recently ordered 550 million doses from the two companies for the U.N.-backed COVAX program.
Both Sinopharm vaccines are also in wide use in China, including in the elderly. The country’s National Health Commission said in April that the shots provide some protection, even though it acknowledged that early stages of clinical trials of Sinopharm’s vaccines and two others found fewer antibodies in people 60 and over.
In Budapest, Beata Englohner became concerned for her 76-year-old mother after hearing that people who had been vaccinated with Sinopharm were shown to have no antibodies.
Englohner started a Facebook group to press the government to address the issue. She is cautiously optimistic now that Hungary will offer a third dose.
“We’re very glad that we achieved our aim and that we were heard,” she said. “Though we’re a bit afraid that we’ll receive what we already got before.”
___
Wu reported from Taipei, Taiwan.
|
||
6044
|
dbpedia
|
2
| 35
|
https://u.ae/en/information-and-services/justice-safety-and-the-law/handling-the-covid-19-outbreak/vaccines-against-covid-19-in-the-uae
|
en
|
The Official Portal of the UAE Government
|
https://u.ae/assets/images/favicon.ico
|
https://u.ae/assets/images/favicon.ico
|
[
"https://u.ae/assets/images/government-ae-logo-english.png",
"https://u.ae/assets/images/UAEPASS_Sign_in_Btn_Outline_Pill_Active.png",
"https://u.ae/assets/images/government-ae-logo-english.png",
"https://u.ae/-/media/Vaccine-centres/Private-Hospitals-Final--04.jpg?h=350&w=350&hash=9FBE51564707FBE7D1D5DDE09C76EC0C",
"https://u.ae/-/media/Vaccine-centres/Private-Hospitals-Final--05.jpg?h=350&w=350&hash=FF0FE23041CCB70E051B17A8A4F9855E",
"https://u.ae/-/media/Vaccine-centres/Private-Hospitals-Final--06.jpg?h=350&w=350&hash=D41039D395477F6A1DE883CDA824F7AF",
"https://u.ae/assets/images/TDRALogo.png",
"https://u.ae/assets/images/UAEPASS_Sign_in_Btn_Outline_Pill_Active.png",
"https://u.ae/assets/images/accessibility.svg",
"https://u.ae/assets/images/U-1.svg"
] |
[
"https://www.google.com/maps/d/embed?mid=153net1PG-I9TS68e2tTB-qtn1NSNVugI"
] |
[] |
[
"Vaccines against COVID-19 in the UAE",
"Book an appointment for the COVID-19 vaccine",
"COVID-19 vaccine for children",
"Exemption from COVID-19 vaccine",
"Vaccination centres",
"National Policy on Vaccinations",
"Sinopharm",
"Pfizer-BioNTech",
"Sputnik V",
"Oxford-AstraZeneca",
"Moderna"
] | null |
[] | null |
There are five vaccines in the UAE against the COVID-19 infection. They are: Sinopharm, Pfizer-BioNTech, Sputnik V, Oxford-AstraZeneca and Moderna. The UAE is offering these vaccines to its citizens and residents free of charge.
|
en
|
/assets/images/favicon.ico
| null |
Book an appointment for the COVID-19 vaccine
Vaccines against COVID-19 are available throughout the UAE, free of charge for medically eligible citizens and residents, according to the priority announced by the UAE’s health authorities from time to time.
Book an appointment with any one of the authorities:
Emirates Health Services (EHS) through the COVID-19 EHS app available on Google Play and App Store
SEHA through the SEHA app available on Google Play and App Store for vaccination at their drive-through centres and temporary sites across the UAE
Dubai Health Authority through the DHA app available on App Store and Google Play or the call centre by calling on the toll-free number 800-342.
Vaccines will be administered to the following people on priority. They are eligible to walk into most vaccination centres and clinics without an appointment:
UAE nationals and their domestic helpers
senior citizens and residents (those who are 60 years old and above)
people of determination
people with chronic illnesses
those working in the health and education centres.
What are the procedures to get the vaccine? What are the possible symptoms after vaccination?
Watch this video on steps and priorities to take the vaccine.
Find out more details in COVID-19 Vaccine Awareness Guide (PDF, 2.45 MB) which was released by DHA and from the website of Weqaya.
For emergencies or any side effects from the vaccine, call MoHaP on 800-111-1.
Note: For latest news and updates about COVID-19 vaccines, location and appointments, follow the health authorities on Twitter via the following handles:
@mohapuae
@DoHSocial
@adphc_ae
@DHA_Dubai
@weqayauae
@SHA_GOV.
Find more information about COVID-19 vaccines and boosters on the website of Emirates Health Services (EHS).
Related links
FAQs about COVID-19 vaccine - National Emergency Crisis and Disasters Management Authority.
COVID-19 vaccine for children
In November 2021, Ministry of Health and Prevention (MoHaP) approved the emergency local use of Pfizer vaccine for children between the ages of 5 and 11 following clinical trials and a strict assessment.
In May 2021, Ministry of Health and Prevention (MoHaP) approved the emergency local use of Pfizer vaccine for children between the ages of 12 and15 following clinical trials and a strict assessment.
As of May 2021, Dubai Health Authority (DHA) is administering Pfizer-BioNTech Covid-19 vaccine to the following groups on priority:
children with chronic diseases
those who live with vulnerable family members
those living with members who cannot receive the vaccine due to medical reasons.
Children are exempt from taking the vaccine if they have any of the following conditions:
experiencing an active COVID-19 infection
needing a specialised treatment for COVID-19
experienced severe allergic reaction to any vaccine or vaccine component within four hours of taking it.
In Abu Dhabi, you do not need an appointment for your children for the Pfizer vaccine. Department of Health - Abu Dhabi provides the Pfizer-BioNTech vaccine to children aged 12 years and above at all of Mubadala and SEHA vaccination centres.
Exemption from COVID-19 vaccine
Criteria for exemption from COVID-19 vaccine
The following categories of people are exempt from COVID-19 vaccine according to Ministry of Health and Prevention (MoHaP) and Department of Health - Abu Dhabi (DoH):
those who are currently infected with COVID-19
participants of the vaccine’s clinical trials
pregnant women
those who were previously infected with COVID-19 (after medical evaluation)
those who received the COVID-19 vaccine outside the UAE
those who have experienced severe allergies to vaccines or components of vaccines or those who may have an illness that conflicts with the vaccine
children below the age of 16.
Read about exempted categories in Dubai in this COVID-19 Vaccine Awareness Guide (PDF, 5 MB).
How to apply for COVID-19 vaccine exemption certificate
In Abu Dhabi, you can apply for an exemption certificate by visiting a medical centre. The centre will submit a report to Department of Health - Abu Dhabi for approval. You will receive a text message on whether your application is approved. If approval is granted, it will be reflected on the Al Hosn app.
In Dubai, contact the Dubai Health Authority (DHA) at toll free number 800342 to learn how to apply for vaccine exemption certificate.
If you are a UAE citizen or resident from the emirates of Sharjah, Ajman, Umm Al Quwain or Ras Al Khaimah, and are eligible for exemption from the COVID-19 vaccine, you can apply for a COVID-19 vaccine exemption certificate to MoHaP.
Vaccination centres
View the list of EHS vaccination centres in the emirate of Abu Dhabi and the rest of the UAE.
The vaccines are also available at several private hospitals across the UAE free of charge.
View SEHA's vaccination centres.
Sinopharm’s COVID-19 vaccine
On 9 December 2020, Ministry of Health and Prevention (MOHAP) announced that it had officially registered the ‘Beijing Institute of Biological Products’ inactivated vaccine’, known as the ‘Sinopharm' vaccine which was developed jointly with Sinopharm - CNBG (China National Biotec Group).
A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79 per cent against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79 per cent.
Who can get the vaccine?
Priority is given to citizens and residents above the age of 18, particularly, the elderly and those suffering from chronic diseases.
Sinopharm vaccine requires two doses. The first dose is taken following an assessment of the patient’s health and the second dose is taken after a period averaging between 21 to 28 days.
Where can I get the Sinopharm vaccine?
Sinopharm vaccine is available throughout the UAE.
Refer to the list of COVID-19 vaccination centres in:
Urdu (PDF, 3.26 MB)
Filipino (PDF, 2.05 MB)
Mandarin (1.80 MB).
The vaccine is also available at SEHA's drive-through centres and the following locations:
Abu Dhabi Cruise Terminal, Abu Dhabi City - from 7 am to 10 pm
Al Ain Convention Center, Al Ain City - from 7 am to 10 pm
Dubai Parks & Resort, Dubai - from 9 am to 5 pm
Madinat Zayed Wedding Hall, Al Dhafra - from 8 am to 7:30 pm.
Find more information on SEHA’s website.
View the list of DHA vaccination centres in Dubai.
The vaccine is also available at several private hospitals across the UAE, free of charge.
Earlier, in September 2020, the UAE authorised the emergency use of the Sinopharm vaccine for frontline workers, as they are the most at risk of getting COVID-19. The Sinopharm vaccine was used in the UAE’s ‘4Humanity’ campaign, which hosted the first global clinical Phase-III of an inactivated vaccine to combat COVID-19 back in July 2020.
Contact MoHaP for queries and appointments.
Pfizer-BioNTech’s COVID-19 vaccine
On 22 December 2020, MoHaP announced the emergency registration of Pfizer-BioNTech’s COVID-19 vaccine and on the next day, Dubai Health Authority (DHA) started its free vaccination drive against COVID-19 using this vaccine.
Who is the vaccine for?
The first phase of Dubai’s campaign targets the following:
Emiratis and Dubai residents who are aged 60 years and above
People who are 18 years and above, and suffer from chronic diseases
People of determination
Frontline workers.
Vaccination consists of two doses, taken separately. The gap between the two doses is 21 days.
Where can I get the Pfizer-BioNTech’s vaccine?
Pfizer-BioNTech vaccine will be available at these healthcare centres across Dubai.
The vaccine was first approved for emergency use by the US Food and Drug Administration on 11 December 2020 and later by World Health Organisation (WHO) on 31 December 2020.
Find out more details in COVID-19 Vaccine Awareness Guide (PDF, 2.45 MB) which was released by DHA.
Related links from Weqaya:
Dubai’s COVID-19 vaccination campaign
MOHAP allows COVID-19 vaccine for UAE citizens and residents.
Sputnik V COVID-19 vaccine
On 21 January 2021, Ministry of Health and Prevention (MoHAP) announced its approval of Russia’s Sputnik V COVID-19 vaccine for emergency use in the UAE. The vaccine is based on human adenoviral vector-based platform. As of April 2021, it's effectiveness against COVID-19 is 97.6 per cent, according to analysis of data from 3.8 million vaccinated people in Russia.
The vaccine was registered under the emergency use authorisation based on Russia’s Phase III clinical trials on more than 33,000 participants. The UAE also participated in the vaccine’s phase III clinical trials with more than 1,000 volunteers who received the first dose under the supervision of MoHAP and Department of Health - Abu Dhabi.
Sputnik V COVID-19 Vaccine was developed by The Gamaleya National Centre of Epidemiology and Microbiology and Ministry of Health of the Russian Federation.
Emergency use of COVID-19 vaccine approved for heroes in the first line of defence
In September 2020, the UAE Government authorised the emergency use of the COVID-19 vaccine; making it available to heroes in the first line of defence. The decision aims to protect the heroes since they are at most risk due to the nature of their work. The use of the vaccine will be fully compatible with the regulations and laws that allow a faster review of licensing procedures.
The evaluation of the vaccine for emergency use was based on:
a declaration by the global health authorities of an emergency leading to a serious or life-threatening disease or condition
the availability of scientific evidence that proves the effectiveness of the product intended for emergency response
the safety of the use of the vaccine
the evidence that the known and potential benefits of the product outweigh the known and potential risks.
The evaluation was carried out for emergency use, taking into account the following:
the target groups
product characteristics
preclinical and clinical study data
population study and all relevant available scientific evidence.
Read news coverage on WAM.
National Policy on Vaccinations
Also, read about the National Policy on Vaccinations.
Updated on 18 Dec 2023
|
|||
6044
|
dbpedia
|
1
| 60
|
https://www.japantimes.co.jp/news/2020/12/31/asia-pacific/china-vaccine-approval-sinopharm/
|
en
|
China gives its first COVID-19 vaccine approval to Sinopharm
|
[
"https://www.japantimes.co.jp/theme_japantimes/images/burger_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/search_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/logo.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/user_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/loggedin_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/search_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/logo-white-2.png",
"https://www.japantimes.co.jp/theme_japantimes/images/search_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/logo-with-slogan.svg",
"https://www.japantimes.co.jp/uploads/imported_images/uploads/2020/12/np_file_60833.jpeg",
"https://www.japantimes.co.jp/theme_japantimes/images/fb-footer.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/send_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/fb-footer.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/send_icon.svg",
"https://www.japantimes.co.jp/theme_japantimes/images/logo-white-2.png"
] |
[] |
[] |
[
"China",
"vaccinations",
"pharmaceuticals",
"COVID-19",
"COVID-19 vaccines",
"Sinopharm",
"medicine"
] | null |
[
"The Japan Times",
"No Author",
"int-no_author"
] |
2020-12-31T00:00:00
|
While China has been slower in approving COVID-19 vaccines, it has been inoculating some citizens for months with three different shots still undergoing late-stage trials.
|
en
|
https://www.japantimes.co.jp/theme_japantimes/images/favicon.ico
|
The Japan Times
|
https://www.japantimes.co.jp/news/2020/12/31/asia-pacific/china-vaccine-approval-sinopharm/
|
China approved its first COVID-19 vaccine for general public use Thursday, a shot developed by an affiliate of state-backed pharmaceutical giant Sinopharm, as it braces for greater transmission risks over the winter.
No detailed efficacy data of the vaccine has been publicly released but its developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said Wednesday its vaccine was 79.34% effective in preventing people from developing the disease based on interim data.
The approval, announced by the National Medical Products Administration, comes after the United Arab Emirates this month became the first country to roll out the vaccine to the public, and as Pakistan announced a 1.2 million dose purchase deal with Sinopharm.
|
||||
6044
|
dbpedia
|
3
| 79
|
https://brandfinance.com/press-releases/sinopharm-is-chinas-most-valuable-pharma-brand-gpc-tops-ranking-of-traditional-chinese-medicine-brands
|
en
|
Sinopharm is China’s Most Valuable Pharma Brand; GPC Tops Ranking of Traditional Chinese Medicine Brands
|
[
"https://brandfinance.com/wp-content/uploads/2020/07/Brand-Finance.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/solid/share-alt.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/solid/share-alt.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/linkedin-in.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/x-twitter.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/facebook-f.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/solid/envelope.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/solid/clone.svg",
"https://brandfinance.com/wp-content/uploads/2021/07/china-pharma-1-1.jpg",
"https://brandfinance.com/wp-content/uploads/2021/07/china-pharma-2-1.jpg",
"https://brandfinance.com/wp-content/uploads/2021/07/china-pharma-3-1.jpg",
"https://brandfinance.com/wp-content/uploads/2024/04/33a73901-41ad-4a81-8b00-9052fc1117bc-150x150.webp",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/linkedin.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/x-twitter.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/facebook-square.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/instagram.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/youtube.svg",
"https://brandfinance.com/wp-content/uploads/2020/08/Brand-Finance-Bridge-Logo-White.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/linkedin.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/x-twitter.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/facebook-square.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/instagram.svg",
"https://brandfinance.com/wp-content/uploads/icons/fa/brands/youtube.svg"
] |
[] |
[] |
[
""
] | null |
[
"Florina Cormack-Loyd",
"fb.com",
"Brand.Finance"
] |
2021-07-01T08:22:55+01:00
|
View the full Brand Finance Chinese Pharma 2021 report here
|
en
|
Brand Finance
|
https://brandfinance.com/press-releases/sinopharm-is-chinas-most-valuable-pharma-brand-gpc-tops-ranking-of-traditional-chinese-medicine-brands
|
Sinopharm tops ranking of most valuable Chinese pharma brands, brand value US$3.2 billion
GPC claims title of second most valuable Chinese pharma brand and top spot in sub ranking of top 5 most valuable traditional Chinese medicine brands, brand value US$1.5 billion
SPH completes podium with its commitment to R&D paying off
Brand Finance conducted original market research on perceptions of Chinese pharma brands, surveying opinions of 1,000 respondents aged 18-75 across nation
Overall consumer perceptions of Chinese pharma brands are largely positive: brands scored well for quality and respondents in general think Chinese pharma brands care more about customers than profits
Yunnan Baiyao is strongest Chinese pharma brand with AA brand strength rating
Sinopharm, Tong Ren Tang, 999, and GPC round off top 5 for brand strength
View the full Brand Finance Chinese Pharma 2021 report here
Leading the fight against the nation’s health emergency, Chinese pharma brands have performed extremely well over the previous year. According to the Brand Finance China 500 2021 ranking, the pharma sector recorded an impressive 123% cumulative brand value increase – a result bolstered by solid performances across the board, as well as from the eight new brands that entered the ranking this year. Furthermore, four of these brands feature in the Brand Finance Pharma 25 2021 ranking – a ranking of the world’s top 25 most valuable and strongest pharma brands - Sinopharm, Guangzhou Pharmaceuticals Corporation, SPH and, Yunnan Baiyao.
Now, for the first time Brand Finance has ranked the top 15 most valuable and strongest Chinese pharma brands.
Scott Chen, Managing Director, Brand Finance China, commented:
“There is no denying the importance of the role of Chinese pharma brands over the previous year as they spearheaded the fight against the nation’s health emergency and their operations were propelled to the centre of society like never before. This newly-released ranking of the top 15 most valuable and strongest Chinese pharma brands demonstrates the true strength of the sector, with extremely positive results recorded across the board.”
Vaccine development reaps benefits for Sinopharm
Topping the new ranking of China’s most valuable pharma brands is Sinopharm, which has recorded a 58% brand value increase to US$3.2 billion. Sinopharm is making major strides in the global race to produce COVID-19 vaccinations and has since developed a vaccine with a high efficacy rate, which has already been distributed to millions worldwide.
GPC sits in 2nd
Sitting in second is Guangzhou Pharmaceuticals Corporation, boasting a 74% increase in brand value to US$1.5 billion. GPC - one of China’s largest drug makers – has recently entered a partnership with PepsiCo to jointly develop healthy oatmeal products. Furthermore, as one of the top Chinese medicine manufacturers, GPC has been making significant developments by contributing its knowledge of the traditional Chinese medicine – Banlangen – towards controlling the pandemic.
SPH completes podium
Completing the podium in 3rd spot is SPH (brand value up 50% to US$1.4 billion). The brand prides itself on being a leader for research and development across the industry, spending US$194.9 million on research in 2019 alone.
SPH has placed itself in a strong position to reap the rewards of the pandemic-induced shift away from traditional healthcare towards the online and technological side of the sector, through recently securing funding for its online prescription and pharmacy businesses. This funding will also allow the brand to consolidate its network of hospital-centred Chinese pharmacies.
Top 5 traditional Chinese medicine brands
GPC is most valuable traditional Chinese medicine brand
Brand Finance has also created a sub ranking from the Chinese pharma ranking for traditional Chinese medicines brands, given their rise in popularity in recent years.
GPC claims the top spot in this ranking, with Yunnan Baiyao sitting in 2nd. 999 claims third position, following a 50% brand value increase to US$243 million. 999 has recently entered a partnership with insurance giant Ping An, enabling users to directly enjoy 999 Ganmaoling Granules through the Ping An Health app.
Tasly (brand value US$228 million) and Tong Ren Tang (brand value US$207 million) round off the top 5 in 4th and 5th positions, respectively. Tasly continues to focus heavily on R&D and innovation across its operations - the company currently has 75 research projects, 38 category 1 innovative drugs, as well as 46 that have entered the clinical research stage.
Yunnan Baiyao is the strongest Chinese pharma brand
In addition to measuring overall brand value, Brand Finance also determines the relative strength of brands through a balanced scorecard of metrics evaluating marketing investment, stakeholder equity, and business performance.
Brand Finance also conducted original market research on the Chinese pharma sector, where 1000 respondents were asked about the 15 Chinese pharma brands that feature in the ranking and their opinions on a variety of metrics including reputation, recommendation, and trust.
Results from the market research directly funnel into the Brand Strength Index and therefore the responses impact how brands perform in terms of brand strength.
Yunnan Baiyao is the strongest Chinese pharma brand with a Brand Strength Index (BSI) score of 73.2 out of 100 and a corresponding AA brand strength rating. Sinopharm (BSI 69.1), Tong Ren Tang (BSI 68.9), 999 (BSI 67.4) and GPC (BSI 66.0) round off the top 5 for brand strength.
Brand Image
Quality
Overall, brands scored well and generally received high scores for quality. Yunnan Baiyao and Tong Ren Tang ranked first, both scoring 4.2 out of 5, followed by GPC and Baiyunshan scoring 4.0 out of 5. Some consumers have complained, however, about Tong Ren Tang using its brand to increase profits, by developing and selling irrelevant products, which may bring complications to its branded products in the future.
In general, respondents from the older age group tend to give higher quality scores to brands, compared with the lower two age categories. This is not the case for Sinopharm, which has higher quality perceptions (4.0/5.0) among the younger age group of respondents (18-34), a score higher than the mid-age group (35-54)’s perceptions at 3.9 and the older age group (55-75)’s result at 3.8. This is potentially the result of the younger generation having more trust in the COVID-19 vaccination than their older counterparts.
Closeness
Humanwell performs strongly in the 18-34 age group (7.0/10) compared with the two older age groups (35-54 and 55-75), scoring 6.3 and 6.8 out 10, respectively. This is predominantly due to the popularity of its women’s health products, as a leading brand in fertility space.
Genuinely offer something different
Yunnan Baiyao and Joincare pharma rank first in this measure due to their unique product offering in the market. For example, Baiyao series products are exclusive to Yunnan Baiyao and the formula remains a nationwide top secret. Its core variations have been selected into the National Medical Insurance Class A drug catalogue for many years.
Positive perceptions around profits versus costumer well-being
Respondents in general do not think that Chinese pharma brands care more about profits than their customers. This is largely due to the medicine regulation in China, as well as the increasing availability of public health insurance.
Good product range
The top three pharma brands - Sinopharm, SPH and GPC rank top in this measure, with scores of 49%, 51%, and 44% respectively. GPC also benefits from producing both Western medicine and traditional Chinese medicine, unlike the other two which largely focus on Western medicine.
Brand Funnels
Awareness: Yunnan Baiyao leads, scoring impressive 97% across all age groups
Yunnan Baiyao boasts the highest awareness score (97%) across all three age groups, followed by Tong Ren Tang (94%). Humanwell performs worst (23%) among all three age groups.
The three biggest pharma groups researched - Sinopharm, SPH, and GPC - scored 85%, 56%, and 63% respectively. Sinopharm’s contribution to the Covid vaccine race has propelled it to become a household name across the nation.
Some brands, such as CSPC, have a strong regional focus and presence. It scored 79% in Jinan and 72% in Beijing in northern China, but did not perform well in the southern provinces. The same trend is witnessed with Tasly. Trends like this are often the result of brands simply not reaching awareness levels on a national scale yet and therefore they naturally fall behind the sector leaders Sinopharm, SPH, and GPC in this metric.
Familiarity: Once again Yunnan Baiyao leads pack
The familiarity metric follows a similar trend to the awareness metric, with Yunnan Baiyao ranking first (67%) among all three-age group respondents, followed by Tong Ren Tang (63%). Sinopharm and Bai Yun Shan also perform well, scoring 45% and 41% respectively.
Humanwell Healthcare, Tasly, and Joincare Pharma score the lowest – ranging from a 5% to 10% familiarity level, largely a result of their limited consumer-facing branded product range.
Consideration: Yunnan Baiyao and Tong Ren Tang score 99% and 98% respectively
Among those who are familiar with the Yunnan Baiyao and Tong Ren Tang brands, 99% and 98% would consider choosing to use their products. Sinopharm, SPH, 999, Harbin Pharmaceutical, and GPC also boast high consideration scores (all over 90%).
GPC own products that consumers use in their everyday lives – such as Wanglaoji and Banlangen granules – therefore earning them a high consideration score. GPC is also the largest manufacturer in China for digestible antibiotics, owning the first brand of digestible antibiotics, Kangzhiba. Furthermore, its leading product cefathiamidine is currently the only cephalosporin developed by the Chinese themselves.
Reputation Versus Recommendation
Reputation
GPC scores 7.7. Brands within the GPC group including Chenliji and Wanglaoji have a long history and products from these brands including Banlangeng and xiaocaihu granules have played an important role in fighting the pandemic, therefore contributing to the strong reputation score.
The average score in the traditional Chinese medicine group is 7.8, which is higher than the Western medicine group at 7.5, demonstrating that generally traditional medicine has a higher reputation due to its history and culture accumulation.
Sinopharm ranks top in the Western medicine group with a score of 8.0. Sinopharm owns over 1,100 subsidiaries as well as six listed companies and has built a nationwide logistic and distributing network for providing quality service to more than 230,000 corporate clients.
Recommendation
Yunnan Baiyao and Tong Ren Tang rank joint first with a score of 8.3 out of 10. GPC also boasts a high recommendation score of 7.8. Ten traditional Chinese medicines from the GPC group were selected for use in the diagnosis and treatment of Covid by the government, showcasing strong endorsement of GPC products.
Sinopharm and Fosun Pharma are the only two brands with a recommendation score higher than 8 out of 10 in the Western medicine group. Fosun Pharma has recently won a new partnership with BioNTech – German biotechnology company behind the globally known Pfizer–BioNTech Covid vaccine - and is commercialising its mRNA technology in producing vaccine products across China.
Buchang Pharma surprisingly performs best among the 18-34 age group with a score of 8.5 for recommendation. The company is focusing on the modernisation of traditional Chinese medicine, explaining its popularity among the younger age category.
View the full Brand Finance Chinese Pharma 2021 report here
ENDS
Note to Editors
Every year, Brand Finance puts 5,000 of the biggest brands to the test, evaluating their strength and quantifying their value, and publishes nearly 100 reports, ranking brands across all sectors and countries. The top 15 most valuable Chinese pharma most valuable and strongest brands are included in the Brand Finance Chinese Pharma 2021 report here.
The full Brand Finance China 500 2021 ranking, additional insights, charts, more information about the methodology, as well as definitions of key terms are available in the Brand Finance Chinese Pharma 2021 report here.
Brand value is understood as the net economic benefit that a brand owner would achieve by licensing the brand in the open market. Brand strength is the efficacy of a brand’s performance on intangible measures relative to its competitors. Please see below for a full explanation of our methodology.
|
|||||
6044
|
dbpedia
|
0
| 7
|
https://www.bbc.com/news/world-asia-china-55498197
|
en
|
Covid-19: China approves Sinopharm vaccine for general use
|
[
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/11F11/production/_116298437_gettyimages-1230209584.jpg.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/11F11/production/_116298437_gettyimages-1230209584.jpg.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/11F11/production/_116298437_gettyimages-1230209584.jpg.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/11F11/production/_116298437_gettyimages-1230209584.jpg.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/11F11/production/_116298437_gettyimages-1230209584.jpg.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/11F11/production/_116298437_gettyimages-1230209584.jpg.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/11F11/production/_116298437_gettyimages-1230209584.jpg.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/126CB/production/_115976457_mediaitem115976456.jpg.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/126CB/production/_115976457_mediaitem115976456.jpg.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/126CB/production/_115976457_mediaitem115976456.jpg.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/126CB/production/_115976457_mediaitem115976456.jpg.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/126CB/production/_115976457_mediaitem115976456.jpg.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/126CB/production/_115976457_mediaitem115976456.jpg.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/126CB/production/_115976457_mediaitem115976456.jpg.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/11C84/production/_115863827_untitled.png.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/11C84/production/_115863827_untitled.png.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/11C84/production/_115863827_untitled.png.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/11C84/production/_115863827_untitled.png.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/11C84/production/_115863827_untitled.png.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/11C84/production/_115863827_untitled.png.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/11C84/production/_115863827_untitled.png.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/4BEB/production/_112953491__108802839_624_transparent-nc.png.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/4BEB/production/_112953491__108802839_624_transparent-nc.png.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/4BEB/production/_112953491__108802839_624_transparent-nc.png.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/4BEB/production/_112953491__108802839_624_transparent-nc.png.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/4BEB/production/_112953491__108802839_624_transparent-nc.png.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/4BEB/production/_112953491__108802839_624_transparent-nc.png.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/4BEB/production/_112953491__108802839_624_transparent-nc.png.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/B898/production/_111165274_cps_web_banner_top_640x3-nc.png.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/B898/production/_111165274_cps_web_banner_top_640x3-nc.png.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/B898/production/_111165274_cps_web_banner_top_640x3-nc.png.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/B898/production/_111165274_cps_web_banner_top_640x3-nc.png.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/B898/production/_111165274_cps_web_banner_top_640x3-nc.png.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/B898/production/_111165274_cps_web_banner_top_640x3-nc.png.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/B898/production/_111165274_cps_web_banner_top_640x3-nc.png.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/a5c1/live/351264a0-4a7d-11ef-a0d4-af0fa324f0f6.jpg.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/a5c1/live/351264a0-4a7d-11ef-a0d4-af0fa324f0f6.jpg.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/a5c1/live/351264a0-4a7d-11ef-a0d4-af0fa324f0f6.jpg.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/a5c1/live/351264a0-4a7d-11ef-a0d4-af0fa324f0f6.jpg.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/a5c1/live/351264a0-4a7d-11ef-a0d4-af0fa324f0f6.jpg.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/a5c1/live/351264a0-4a7d-11ef-a0d4-af0fa324f0f6.jpg.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/a5c1/live/351264a0-4a7d-11ef-a0d4-af0fa324f0f6.jpg.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/35f1/live/db2d8170-451f-11ef-96a8-e710c6bfc866.jpg.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/35f1/live/db2d8170-451f-11ef-96a8-e710c6bfc866.jpg.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/35f1/live/db2d8170-451f-11ef-96a8-e710c6bfc866.jpg.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/35f1/live/db2d8170-451f-11ef-96a8-e710c6bfc866.jpg.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/35f1/live/db2d8170-451f-11ef-96a8-e710c6bfc866.jpg.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/35f1/live/db2d8170-451f-11ef-96a8-e710c6bfc866.jpg.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/35f1/live/db2d8170-451f-11ef-96a8-e710c6bfc866.jpg.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/7611/live/18254680-4377-11ef-9e1c-3b4a473456a6.jpg.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/7611/live/18254680-4377-11ef-9e1c-3b4a473456a6.jpg.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/7611/live/18254680-4377-11ef-9e1c-3b4a473456a6.jpg.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/7611/live/18254680-4377-11ef-9e1c-3b4a473456a6.jpg.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/7611/live/18254680-4377-11ef-9e1c-3b4a473456a6.jpg.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/7611/live/18254680-4377-11ef-9e1c-3b4a473456a6.jpg.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/7611/live/18254680-4377-11ef-9e1c-3b4a473456a6.jpg.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/6f8a/live/c4ee5750-3ac4-11ef-8341-6dcaac9f55ad.jpg.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/6f8a/live/c4ee5750-3ac4-11ef-8341-6dcaac9f55ad.jpg.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/6f8a/live/c4ee5750-3ac4-11ef-8341-6dcaac9f55ad.jpg.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/6f8a/live/c4ee5750-3ac4-11ef-8341-6dcaac9f55ad.jpg.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/6f8a/live/c4ee5750-3ac4-11ef-8341-6dcaac9f55ad.jpg.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/6f8a/live/c4ee5750-3ac4-11ef-8341-6dcaac9f55ad.jpg.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/6f8a/live/c4ee5750-3ac4-11ef-8341-6dcaac9f55ad.jpg.webp 1536w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/news/240/cpsprodpb/5251/live/05e1c670-356b-11ef-b6d9-e13f185918e1.jpg.webp 240w,https://ichef.bbci.co.uk/news/320/cpsprodpb/5251/live/05e1c670-356b-11ef-b6d9-e13f185918e1.jpg.webp 320w,https://ichef.bbci.co.uk/news/480/cpsprodpb/5251/live/05e1c670-356b-11ef-b6d9-e13f185918e1.jpg.webp 480w,https://ichef.bbci.co.uk/news/640/cpsprodpb/5251/live/05e1c670-356b-11ef-b6d9-e13f185918e1.jpg.webp 640w,https://ichef.bbci.co.uk/news/800/cpsprodpb/5251/live/05e1c670-356b-11ef-b6d9-e13f185918e1.jpg.webp 800w,https://ichef.bbci.co.uk/news/1024/cpsprodpb/5251/live/05e1c670-356b-11ef-b6d9-e13f185918e1.jpg.webp 1024w,https://ichef.bbci.co.uk/news/1536/cpsprodpb/5251/live/05e1c670-356b-11ef-b6d9-e13f185918e1.jpg.webp 1536w"
] |
[] |
[] |
[
""
] | null |
[
"BBC News"
] |
2020-12-31T13:21:30+00:00
|
The Sinopharm vaccine is the first in China to be approved beyond emergency use.
|
en
|
/bbcx/apple-touch-icon.png
|
https://www.bbc.com/news/world-asia-china-55498197
|
Chinese authorities have given conditional approval for general public use of a coronavirus vaccine developed by state-owned drugmaker Sinopharm.
The move came a day after the firm said interim data showed its leading vaccine had a 79% efficacy rate in phase three trials, without providing more details.
Several Chinese-made vaccines at a late trial stage are already in use in China after being granted emergency licences.
The pandemic emerged in the central Chinese city of Wuhan in December 2019.
It has since spread around the world, but China has managed to bring infection rates down to very low levels through strict anti-virus measures.
The search for the source of the coronavirus has led to tensions with the West. The US - among a number of other countries - raised questions about whether China was fully transparent when the virus first emerged there.
What has China said about the vaccine?
Thursday's announcement concerning the vaccine made by the China National Pharmaceutical Group, or Sinopharm, is China's first general approval of a homemade jab - and it is being seen as potentially a major step towards inoculating the world's largest population.
The deputy commissioner of China's National Medical Products Administration, Chen Shifei, announced the decision at a news conference in Beijing.
"After a series of strict reviews, verification, test and data analysis in accordance with the law and procedures, it is concluded that the known and potential benefits of Sinopharm's new inactivated coronavirus vaccine are bigger than the known and potential risks, and it fully meets the pre-set requirements of conditional marketing standards," he said.
Vice Minister of the National Health Commission Zeng Yixin said approval would allow the government to "extend vaccination to high-risk groups, those susceptible to a severe viral infection... and the elderly".
In July, China approved three different jabs for emergency use in key workers and other people at high risk. More than 4.5 million doses have so far been administered.
Beijing hopes to inoculate tens of millions more people by mid-February, the start of the Chinese New Year.
Sinopharm is also working on a second vaccine, and a number of other Chinese vaccines are in production. These include CoronaVac, made by the Beijing-based biopharmaceutical company Sinovac.
What do experts say?
Some experts have given a cautious welcome to the approval of the Sinopharm vaccine in China, but they also point out that no detailed data from trials have been publicly released.
"The lack of fully reviewed papers or data published by official institutions makes it difficult to comment on the efficacy of the Chinese or Russian vaccines," Song Man-ki from the International Vaccine Institute in Seoul, told Reuters news agency.
"We can't simply evaluate a vaccine based on a drugmaker's statement... More data will be compiled once some countries begin vaccinations."
Prof Paul Griffin, an expert in infectious diseases at the University of Queensland, said: "A conditional approval like this is obviously very much contingent on the ongoing clinical trial results as well as the close-up observation of the people who were receiving the vaccine.
"I think it's acceptable, but it's really important for people to understand... there's further research currently under way."
It is thought that 60-70% of the global population must be immune to stop the virus spreading easily.
Rival vaccines made in the West by Pfizer-BioNTech and Moderna have been approved for public use after trials showed they had 95% and 94% efficacy rates respectively.
Who will use China's vaccines?
China has vowed to share its vaccines with other, less-developed countries at a "fair price" so they are likely to end up being used by huge numbers of people around the world.
Earlier this month, the United Arab Emirates became the first other country to roll the Sinopharm vaccine out to the public, saying it was 86% effective in a phase-three trials. Bahrain then followed suit, allowing adults to register online to receive the jab for free.
On Thursday, within hours of the Sinopharm vaccine being approved in China, Pakistan announced a 1.2 million dose purchase deal with the company.
Analysts point to China's bid to win the vaccine diplomacy race, which has also reportedly seen China's President Xi Jinping pledge to set aside $2bn (£1.5bn) for the African continent, while also offering Latin American and Caribbean countries a $1bn loan to buy vaccines. It's unclear what the terms of such a deal might be.
What other vaccines are being developed?
Data on the Russian Sputnik V vaccine, which works like the Oxford one, suggests it is 92% efficient
Janssen's trial is recruiting 6,000 people across the UK, in a total of 30,000 volunteers worldwide, to see if two jabs give stronger and longer-lasting immunity than one
Wuhan Institute of Biological Products in China, and Russia's Gamaleya Research Institute are all in final testing
|
|||||
6044
|
dbpedia
|
2
| 62
|
https://rxglobal.com/reed-sinopharm-exhibitions-acquires-majority-stake-china-hospital-construction-conference
|
en
|
Reed Sinopharm Exhibitions acquires majority stake in the China Hospital Construction Conference
|
https://rxglobal.com/themes/rx/favicon.ico
|
https://rxglobal.com/themes/rx/favicon.ico
|
[
"https://rxglobal.com/themes/rx/logo.svg",
"https://rxglobal.com/themes/rx/images/magnifying-glass.svg",
"https://rxglobal.com/themes/rx/images/location.svg",
"https://rxglobal.com/themes/rx/logo.svg",
"https://rxglobal.com/themes/rx/logo.svg",
"https://rxglobal.com/themes/rx/images/fb-icon.png",
"https://rxglobal.com/themes/rx/images/twitter-icon.png",
"https://rxglobal.com/themes/rx/images/linkedin-icon.png",
"https://rxglobal.com/themes/rx/images/black-left-arrow.png",
"https://rxglobal.com/themes/rx/images/black-right-arrow.png",
"https://rxglobal.com/themes/rx/images/awards/best-sales-teams-of-2024-large.svg",
"https://rxglobal.com/themes/rx/images/awards/best-global-culture-2024-large.svg",
"https://rxglobal.com/themes/rx/images/awards/best-ceo-2023-large.svg",
"https://rxglobal.com/themes/rx/images/awards/best-company-for-women-2023-large.svg",
"https://rxglobal.com/themes/rx/images/awards/best-diversity-2023-large.svg",
"https://rxglobal.com/themes/rx/images/awards/best-ceo-for-diversity-2023-large-branded.svg",
"https://rxglobal.com/themes/rx/images/awards/best-ceo-for-women-2023-large-branded.svg",
"https://rxglobal.com/themes/rx/images/awards/best-leadership-teams-2024-large.svg",
"https://rxglobal.com/themes/rx/images/awards/best-leadership-teams-2023-large-branded.svg",
"https://rxglobal.com/themes/rx/images/awards/best-marketing-teams-of-2023-large-branded.svg",
"https://rxglobal.com/themes/rx/images/awards/work-life-balance-2023-large.svg",
"https://rxglobal.com/themes/rx/images/awards/Wave 4 - Successful Bronze Trailblazer Logo-small.png",
"https://rxglobal.com/themes/rx/images/aoe2023.png",
"https://rxglobal.com/sites/default/files/2021-10/tm-logo.png"
] |
[] |
[] |
[
""
] | null |
[] | null |
en
|
/themes/rx/favicon.ico
|
https://rxglobal.com/reed-sinopharm-exhibitions-acquires-majority-stake-china-hospital-construction-conference
|
Reed Sinopharm Exhibitions, the joint venture between RX Global and the Sinopharm Group, has signed a definitive agreement to acquire a majority stake in the China Hospital Construction Conference (CHCC).
CHCC is Asia’s leading event in comprehensive and innovative solutions for Hospital Design, Build and Management. Launched in 1999, the event spans over 100,000sqm featuring over 600 exhibitors and 16 themed displays. In addition to the trade show exhibition, CHCC also produces over 80 conference sessions and offers excellent learning opportunities, knowledge sharing and information exchange for over 10,000 hospital designers and managers every year.
Commenting on the acquisition, Hugh Jones, CEO of RX Global, said: “We have been very impressed by the CHCC team’s continuous drive to innovate and build a broad platform for the coordinated development of the whole industry. I firmly believe that in adding the CHCC brand to Reed Sinopharm Exhibitions’ health sector portfolio, we will bring our expertise in face-to-face and virtual experiences, global reach and resources, to bear on CHCC’s members, stakeholders, academics and industry leaders, ensuring growth, development and value for all our partners."
Michael Cheng, CEO of RX Global China, said: “I’m excited to welcome the CHCC team to the family and look forward to working together with Reed Sinopharm Exhibitions and our new partner to enhance this leading show and adding value to the CHCC audience.”
The 22nd CHCC will take place at Shenzhen World Exhibition &Convention Center from 19th to 21st June, 2021. Thousands of hospital construction decision-makers and more than 800 outstanding enterprises will gather together to discuss the construction of the next generation hospitals.
ENDS
About Reed Sinopharm Exhibitions
Reed Sinopharm Exhibitions is one of the most renowned event organisers dedicated to pharmaceutical and medical sectors in China. The company is a joint venture between China National Pharmaceutical Group Corporation (Sinopharm) – the largest medical and healthcare group in China, and RX Global – one of the world's leading event organisers. RSE runs a portfolio of 30 highly recognized events, which serve the entire value chain of healthcare with an extended market reach into education and scientific research sectors. www.reed-sinopharm.com
About RX Global Global
RX Global is a leading global events business. It combines face-to-face with data and digital tools to help customers learn about markets, source products and complete transactions at over 400 events in 22 countries across 43 industry sectors, attracting more than 7 million participants. Our events leverage industry expertise, large data sets and technology to enable our customers to connect face-to-face or digitally and generate billions of dollars of revenues for the economic development of local markets and national economies around the world. RX Global is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.www.reedexhibitions.com
About RELX
RELX is a global provider of information-based analytics and decision tools for professional and business customers. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs over 33,000 people, of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £37.4bn, €43.3bn, $51.8bn.*
|
||||
6044
|
dbpedia
|
0
| 94
|
https://www.newsweek.com/study-determines-chinas-sinopharm-covid-vaccine-78-effective-1595508
|
en
|
Study Determines China's Sinopharm COVID Vaccine Up to 78% Effective
|
[
"https://g.newsweek.com/www/images/newsweek-desktop-tablet.svg",
"https://d.newsweek.com/en/full/1808921/sinopharm-vaccine.jpg?w=1200&f=01f70155d006bad29f402e8bf2d892c2",
"https://d.newsweek.com/en/full/1808929/vaccination-site-china.jpg?w=1200&f=34fb55af2d5e4a9a1e8d5b55e42a9167",
"https://d.newsweek.com/en/full/2443371/hannah-cox.png?w=80&h=80&f=a2248774735bbbdc94c56f6f186a243d",
"https://d.newsweek.com/en/full/2289964/aron-solomon.png?w=80&h=80&f=9f9a2d1056fd18b125c78dc2a199a854",
"https://g.newsweek.com/www/images/newsletter-white.svg",
"https://d.newsweek.com/en/full/2280621/subscription-newsweek-premium.png",
"https://d.newsweek.com/en/full/2222596/subscription-digital.png",
"https://d.newsweek.com/en/full/2450707/whos-showing-dnc.png",
"https://d.newsweek.com/en/full/2451125/donald-trump-flailing-wildly-david-axelrod-election.jpg",
"https://d.newsweek.com/en/full/2450875/social-security.jpg",
"https://d.newsweek.com/en/full/2451169/adam-schiff-lands-new-polling-win-overgarvey.png",
"https://g.newsweek.com/img/footer/NW-LOGO-001.svg",
"https://g.newsweek.com/img/footer/linkedin.svg",
"https://g.newsweek.com/img/footer/instagram.svg",
"https://g.newsweek.com/www/images/twitter-icon-white.svg",
"https://g.newsweek.com/img/footer/facebook.svg",
"https://d.newsweek.com/en/full/2443047/cover-august-16-23-2024.jpg?w=400&f=58a090a65411b186a00e386fe33eab38"
] |
[] |
[] |
[
""
] | null |
[
"Zoe Strozewski"
] |
2021-05-27T11:46:50-04:00
|
A study found that two Sinopharm vaccines are 73% and 78% effective against COVID-19, which aligns with previous reports from the company. Some still have doubts about the effectiveness of the
|
en
|
Newsweek
|
https://www.newsweek.com/study-determines-chinas-sinopharm-covid-vaccine-78-effective-1595508
|
A Journal of the American Medical Association study found that two vaccines from the China-owned company Sinopharm are 73% and 78% effective against COVID-19, the Associated Press reported.
Distribution of the two vaccines has begun in many countries, and the World Health Organization has authorized emergency use of one of the vaccines. The study's conclusion on the vaccines' effectiveness aligns with previous reports from Sinopharm.
Sinopharm researchers and Middle East partners conducted the trial using both vaccines and a placebo with over 40,000 participants across Bahrain, the United Arab Emirates, Egypt and Jordan. Jin Dong-yan, a University of Hong Kong medical professor separate from the trial, said that the study's results were unsurprising but still don't totally negate potential drawbacks.
Dong-yan mentioned the recent virus outbreaks in Seychelles, where the majority of residents had received one of the Sinopharm vaccines. Additionally, the study participants were 85% male and mostly younger men, which leaves uncertainty on the vaccine's effects on women and ability to prevent severe disease.
"It's important to make sure you have tested it in enough women to be able to start seeing any possible safety concerns," said Ashley St. John, an associate professor at Duke-NUS Medical School in Singapore.
For more reporting from the Associated Press, see below.
A spokesperson for the company did not immediately respond to a request for comment.
The vaccines, both of which are made with inactivated viruses, have already been given to millions of people across the world.
The World Health Organization cleared the Beijing Institute of Biological Products' shot for emergency use in early May, making it the first Chinese vaccine to receive the certification.
Chinese Foreign Minister Wang Yi said in April that China has provided vaccines to more than 100 countries, although it has not identified them. While China has six vaccines in use, the majority of its exports come from two companies: Sinopharm and Sinovac.
|
|||||
6044
|
dbpedia
|
1
| 37
|
https://www.aljazeera.com/news/2021/3/29/uae-to-manufacture-chinese-covid-vaccine-in-abu-dhabi
|
en
|
UAE to manufacture Chinese COVID vaccine in Abu Dhabi
|
[
"https://www.aljazeera.com/wp-content/uploads/2021/03/000_926879.jpg?resize=770%2C513&quality=80",
"https://www.aljazeera.com/wp-content/uploads/2021/03/000_8XQ2U6.jpg?w=770&resize=770%2C513",
"https://www.aljazeera.com/static/media/aj-footer-logo.bac952ad.svg"
] |
[] |
[] |
[
"Economy",
"News",
"Coronavirus pandemic",
"Health",
"Asia Pacific",
"China",
"Middle East",
"United Arab Emirates"
] | null |
[
"Al Jazeera"
] |
2021-03-29T00:00:00
|
The new plant, a joint venture with Sinopharm, will have a production capacity of 200 million doses a year.
|
en
|
/favicon_aje.ico
|
Al Jazeera
|
https://www.aljazeera.com/news/2021/3/29/uae-to-manufacture-chinese-covid-vaccine-in-abu-dhabi
|
A new factory in Abu Dhabi will start manufacturing Sinopharm’s COVID-19 vaccine later this year.
The production will be under a joint venture between the Chinese pharmaceutical giant and Abu Dhabi-based technology company Group 42 (G42).
The venture is an expansion of Chinese diplomacy in the Gulf region and helps the United Arab Emirates’ quest to diversify its economy away from hydrocarbon production.
The new plant, which is being built in the Khalifa Industrial Zone of Abu Dhabi (KIZAD), will have a production capacity of 200 million doses a year with three filling lines and five automated packaging lines, a statement from the joint venture said on Monday.
The vaccine will be called Hayat-Vax when manufactured in the UAE but is the same inactivated vaccine from the Beijing Institute of Biological Product (BiBP), a unit of Sinopharm’s China National Biotec Group (CNBG), that the UAE approved for general use in December.
“Hayat-Vax is the first COVID-19 vaccine to be produced in the Arab world,” the statement said.
While the new plant scales up, interim production of the vaccine has already begun in the emirate of Ras al-Khaimah by Gulf Pharmaceutical Industries PSC (Julphar).
That interim production line has an initial capacity of two million doses per month and no details were given about how long production will continue there.
Julphar’s share price surged 14.4 percent to 1.4 dirhams ($0.3812), its biggest single-day gain since June.
The UAE, through G42, hosted phase-three clinical trials of the Sinopharm vaccine from July, which later expanded to other countries in the region including Bahrain.
The UAE approved the vaccine for front-line workers in September before making it available to the general public in December.
The UAE has said its trials showed the vaccine has 86-percent efficacy, while Sinopharm reports 79.34-percent efficacy based on interim results.
Some people in the UAE failed to develop sufficient antibodies after a second dose of the Sinopharm vaccine and were given a third dose, the UAE health ministry said this month. It said the number was “minimal” compared with the number of vaccines administered.
|
||||
6044
|
dbpedia
|
2
| 19
|
https://bridgebeijing.com/our-publications/our-publications-1/china-covid-19-vaccines-tracker/
|
en
|
19 Vaccine Distribution
|
[
"https://evye.co/clients/bridgebeijing/wp-content/uploads/2020/12/BRIDGE-logo_plain.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/seyFz-deliveries-by-geographical-region-in-millions-7.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/seyFz-deliveries-by-geographical-region-in-millions-7.png",
"https://bridgebeijing.com/wp-content/uploads/2022/11/2VFQb-sales-by-geographical-region-in-millions-.png",
"https://bridgebeijing.com/wp-content/uploads/2022/11/2VFQb-sales-by-geographical-region-in-millions-.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/II9Bm-donations-by-geographical-region-in-millions-6.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/II9Bm-donations-by-geographical-region-in-millions-6.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/4Tc77-top-10-doses-delivered-in-millions-2.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/4Tc77-top-10-doses-delivered-in-millions-2.png",
"https://bridgebeijing.com/wp-content/uploads/2022/11/KwEh6-top-10-doses-purchased-from-china-in-millions-nbsp-.png",
"https://bridgebeijing.com/wp-content/uploads/2022/11/KwEh6-top-10-doses-purchased-from-china-in-millions-nbsp-.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/SkeF4-top-10-in-pledged-donations-of-doses-from-china-in-millions-4.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/SkeF4-top-10-in-pledged-donations-of-doses-from-china-in-millions-4.png",
"https://bridgebeijing.com/wp-content/uploads/2022/11/yaUqA-sales-by-manufacturers.png",
"https://bridgebeijing.com/wp-content/uploads/2022/11/yaUqA-sales-by-manufacturers.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/0GEmq-deliveries-by-manufacturers-7.png",
"https://bridgebeijing.com/wp-content/uploads/2022/12/0GEmq-deliveries-by-manufacturers-7.png",
"https://evye.co/clients/bridgebeijing/wp-content/uploads/2020/12/BRIDGE-logo_white.png"
] |
[
"https://datawrapper.dwcdn.net/jpvLA/20/",
"https://datawrapper.dwcdn.net/uaIY1/129/",
"https://datawrapper.dwcdn.net/1Rksk/26/",
"https://datawrapper.dwcdn.net/ZjWLF/69/",
"https://datawrapper.dwcdn.net/5SSJz/56/",
"https://datawrapper.dwcdn.net/GvRu5/47/",
"https://datawrapper.dwcdn.net/x1cGC/21/",
"https://datawrapper.dwcdn.net/RHG1r/24/",
"https://datawrapper.dwcdn.net/K8SgT/56/",
"https://datawrapper.dwcdn.net/h97kz/62/",
"https://datawrapper.dwcdn.net/v1KCE/2/",
"https://datawrapper.dwcdn.net/729jp/19/"
] |
[] |
[
""
] | null |
[
"bridge admin"
] |
2021-03-05T11:55:02+08:00
|
Examining China's Promise to Make Its Vaccines A Global Public Good
|
en
|
/wp-content/uploads/2020/12/bridgebeijing-favicon.png
|
Bridge Beijing -
|
https://bridgebeijing.com/our-publications/our-publications-1/china-covid-19-vaccines-tracker/
|
China COVID-19 Vaccine Tracker
(No longer being updated since December 28, 2022)
Our follow-up project – China’s Emerging Global Vaccine Footprint – looks at how China and other countries are supporting local vaccine manufacturing in the post-COVID era.
Since the outbreak of the pandemic, China has committed to making its COVID-19 vaccines a global public good. On multiple occasions, high-level Chinese officials have declared that China is fulfilling this pledge by exporting and donating its COVID-19 vaccines to as many countries that it can. This has generated a great deal of interest and discussion amongst experts from various fields. As an independent, mission-driven consultancy that tracks China’s impact on global health, Bridge Consulting aims to examine and offer a comprehensive picture of China’s vaccine outreach, hopefully enabling more informed discussions on this issue worldwide.
Read more about our methodology here.
1.853B (+0M) DOSES SOLD
328M (+0M) DOSES DONATED
1.653B (+0M) DOSES DELIVERED
Updated as of 13:00 pm (GMT+8), December 28, 2022.
This tracker is no longer being updated.
It includes all bilateral and multilateral sales, donations, and deliveries that have been officially reported through publicly accessible sources.
Contents
1 Total and Weekly Tracker Highlights
2 China’s Vaccines Around the World
3 Timeline of Vaccines Delivered by China
4 China’s Vaccines Across Regions
5 Top 10 Doses Delivered, Purchased, and Donated
5.1 China’s Vaccines in Africa
5.2 China’s Vaccines in Latin America
5.3 China’s Vaccines in Asia Pacific
5.4 China’s Vaccines in Europe
6 China’s Multilateral Vaccine Contributions
7 COVAX Deliveries of Chinese Vaccines
8 China’s Vaccines by Manufacturers
8.1 Sinovac – CoronaVac COVID-19 Vaccine
8.2 Sinopharm – Beijing Bio-Institute of Biological Products Co-Ltd. (BBIBP) COVID-19 Vaccine
8.3 CanSino – CONVIDECIA Ad5-nCoV-S recombinant vaccine
9 Overseas Manufacturers of Chinese Vaccines
10 Notes
11 Methodology
Total and Weekly Tracker Highlights
Africa Update: Total Sales – 126.4M (+0) | Total Pledged Donations – 152.8M (+0) | Total Deliveries – 153.2M (+0)
Asia Pacific Update: Total Sales – 944.9M (+0) | Total Pledged Donations – 143M (+0) | Total Deliveries – 909.8M (+0)
Europe Update: Total Sales – 123.5M (+0) | Total Pledged Donations – 5.6M (+0) | Total Deliveries – 59.5M (+0)
Latin America Update*: Total Sales – 397.9M (+o) | Total Pledged Donations – 13.4M (+0) | Total Deliveries – 296.8M (o)
COVAX Update*: Total Sales – 259.8M (+0) | Total Deliveries – 234.0M (+0)
*Weekly updates in brackets.
See #ChinaCOVID19Tracker on Twitter
[custom-twitter-feeds]
China’s Vaccines Around the World
This interactive map tracks the vaccine sales and donations that China and Chinese vaccine developers have made. It also tracks the number of delivered vaccines.
Timeline of Vaccines Delivered by China
Multiple global developments have impacted the amount of Chinese COVID-19 vaccine deliveries over time. The timeline illustrates the deliveries made to various countries since the beginning of the pandemic and below are some notable events since China started exporting COVID-19 vaccines in 2020.
Notable Events Impacting China’s Vaccine Delivery:
December 2020. First batch of Sinovac vaccine delivery to Indonesia and Turkey, kickstarting China’s global vaccine distribution.
March 2021. India’s vaccine export ban. China announced multiple pledges of donation and vaccine sales, which led to the first peak in deliveries. Notably, large quantities were pledged to the following countries: Indonesia (26M), Brazil (14M), Chile (7M), Mexico (7M).
June 2021. WHO’s Emergency Use Listing (EUL) of Sinopharm and Sinovac COVID-19 vaccine for emergency use gave the green light for these vaccines to be rolled out worldwide. Together with higher global vaccine demand and newer production facilities being built by Sinovac to boost yearly production capacity, this led to a sharp increase.
July 2021. Gavi, the Vaccine Alliance and other COVAX partners announced the signing of a deal for 550 million Chinese COVID-19 vaccines.
August 2021. First Meeting of the International Forum on COVID-19 Vaccine Cooperation. President Xi Jinping pledged 2 billion vaccine doses to be provided by the end of the year and $100 million to COVAX.
September 2021. Partnerships established with overseas vaccine manufacturers to boost local productions such as with Egypt’s VACSERA to become a hub for further vaccine exports to Africa and joint vaccine manufacturing efforts with Morocco further increased the total amount of Chinese vaccines delivered.
October 2021. The highest peak in vaccine deliveries for 2021 was driven by consistent deliveries to key recipient countries. However, it was Iran’s effort to ramp up vaccination efforts in the country, by importing a large amount of Sinopharm vaccines (86.3M) which played the most important role for this sharp increase.
January 2022. Significant decline in Chinese vaccine deliveries. This can directly or indirectly be attributed to the following possible factors:
Many big vaccine purchase contracts such as that with Brazil and Indonesia ended in 2021 and was not renewed;
The pace of global exports by other vaccine producers such as Pfizer and Moderna had picked up in the second half of 2021;
The gradual lifting of the vaccine export ban by India meant more vaccine access for COVAX, thus possibly reducing the demand for Chinese vaccines among other countries.
More
China’s Vaccines Across Regions
China has directly provided vaccines to four geographical regions – a total of 119 countries around the world. Out of these four regions, Asia Pacific has received the most significant number of Chinese vaccines, with 39 countries receiving vaccines from China. Latin America has received the second most considerable number of Chinese vaccines, though only 22 countries have received them. In contrast, while Africa has 48 countries receiving vaccines from China, the region has received few Chinese vaccines.
Take a look at our slideshow below to see deliveries, sales, and donations of Chinese vaccines by Geographical Region.
Please press the arrows below to alternate between graphs.
Top 10 Doses Delivered, Purchased, and Donated
Here is a slideshow that shows the countries that have received the most doses through deliveries, purchases, and donations.
Please press the arrows below to alternate between tables.
China’s Vaccines in Africa
As part of the South-South Cooperation, China pledged in late February 2021 to provide COVID-19 vaccines to 19 African countries. Following the 8th FOCAC Ministerial Meeting that took place on 30 November 2021, China made a new pledge to provide 1 billion doses of vaccines to Africa, including 600 million doses as donation and 400 million doses to be provided through such means as joint production by Chinese companies and relevant African countries. To date, 47 African countries have been receiving vaccines from China. While the pace of these deals has picked up on several occasions, China’s total number of vaccines delivered to Africa has constantly remained low.
Out of the 186 million doses sold and 80 million pledged donations to Africa, China has delivered 125 million, of which 31 million have been donations. However, issues of affordability and accessibility are particularly critical for African countries with limited financial resources at their disposal. Alongside bilateral agreements, Africa has also been receiving vaccines through the COVAX initiative.
China’s Vaccines in Latin America
Latin America has received the second-largest quantity of Chinese vaccines, despite only 22 countries having vaccine deals with China. Like Africa, Latin America and China are also working under the South-South Cooperation and the Belt and Road Initiative. While China has donated only 12 million doses to the region, it has sold 396 million doses, and to date, delivered 293 million doses. China also provides the region with active ingredients to make Chinese and other vaccines, such as the AstraZeneca vaccine.
Latin America plays an especially significant role to Chinese vaccine developer Sinovac, which has sold 230 million doses (out of 848 million doses sold globally) to 8 Latin American countries.
China’s Vaccines in Asia Pacific
Asia has received the most significant number of Chinese vaccines out of all regions in donations and sales. Thus far, the continent has received delivery of 890 million doses, out of the 938 million sold and 141 million donated. 97 million of the delivered doses have been donations.
In recent months, there has been a shift in the perception of Chinese vaccines in the region as local cases surge despite healthcare workers and citizens being inoculated with these vaccines. These surges have been attributed to the rise of the Delta and Omicron variants, which is more contagious, and the latter is able to evade immune protection from vaccines as well. In light of this, some countries are considering administering booster shots or mixing Chinese vaccines with other vaccine brands to enhance immunity, especially for vulnerable populations like the elderly and frontline workers.
In November 2021, President Xipledged an additional 150 million doses to be provided to the ASEAN bloc as well as $5 million to its COVID-19 response fund.
In January 2022, at a virtual summit celebrating the 30th anniversary of diplomatic relations between China and five Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan), President Xi pledged an additional 50 million vaccine doses to be donated to the region.
In March 2022, atthe 48th session of the Council of Foreign Ministers of the Organization of Islamic Cooperation (OIC) in Pakistan, Chinese State Councilor and Foreign Minister Wang Yi pledged to provide an additional 300 million vaccine doses to Islamic countries and support the OIC’s member countries in Africa fighting the pandemic.
China’s Vaccines in Europe
As a region, Europe has received the fewest number of deliveries of Chinese vaccines. Thus far, only 59 million doses of Chinese vaccines have been delivered to 10 European countries, of which 5 million are donations. However, altogether China has sold 123 million doses to the region, most of which came from Turkey who penned a deal in November 2020 to buy 100 million doses of Sinovac. Turkey has redistributed doses via donations and sales to Bosnia and Herzegovina, Azerbaijan, Albania, and more.
One possible factor why Chinese vaccines are not widely used in European countries is because they have not yet received approval from the European Medicines Agency (EMA). The EMA is an agency of the European Union in charge of the evaluation and supervision of medicinal products. However, national medical regulators may authorize the vaccines for emergency use which some Central and Eastern European countries have done.
China’s Multilateral Vaccine Contributions
In recent months, Chinese vaccines have been endorsed by an increasing list of international organizations, making these vaccines available through multilateral streams.
June 30, 2021. Gavi announced that it had signed an advance purchase agreement (APA) with Clover Biopharmaceuticals for its SCB-2019 protein-based adjuvanted vaccine, the R&D of which is funded by (CEPI), making up to 414 million doses available to participants of the COVAX Facility.
July 12, 2021. Gavi, the Vaccine Alliance, announced that it had signed APAs with Sinopharm for its BBIBP-CorV inactivated virus vaccine and Sinovac for its CoronaVac inactivated virus vaccine. These agreements made 110 million doses immediately available to participants of the COVAX Facility, with options for additional doses, providing up to 550 million doses to the program.
February 8, 2022. CEPI, the Coalition for Epidemic Preparedness Innovations, announced that it will expand its collaboration with Shanghai Zerun Bio and its parent company Walvax to advance the development of a COVID-19 variant vaccine. CEPI will invest up to an additional US$8.15 million to support a Phase I/II clinical trial in Mali which will evaluate the safety and immunogenicity of Zerun Bio’s prototype and multi-variant vaccine candidates.
March 22, 2022. The BRICS Vaccine R&D Center was launched as a joint effort between the five BRICS countries, and Sinovac took a leading role as the Chinese branch.
Chinese leaders have repeatedly emphasized that China wants to promote multilateral cooperation in the global response to COVID-19. China’s increasing participation in vital multilateral mechanisms is an encouraging step forward in fulfilling its promise of making Chinese COVID-19 vaccines a global public good and promoting multilateralism, on top of its many bilateral vaccine distribution deals.
COVAX Deliveries of Chinese Vaccines
COVAX is a partnership with CEPI, Gavi, the WHO, and UNICEF (a delivery partner). This initiatives has widened access to COVID-19 vaccines in an equitable manner, and also has improved the development and manufacturing of these vaccines. Read more about the initiative here.
China’s Vaccines by Manufacturers
Sinopharm and Sinovac have been the most prominent manufacturers of Chinese COVID-19 vaccines sold and donated worldwide. Outside of these two, CanSino and Anhui Zhifei have also provided vaccines, though fewer.
Sinovac remains the leading supplier of vaccine sales by China, having sold 848 million doses and supplied vaccines to 48 countries in total. On the other hand, Sinopharm has been the leading supplier of vaccine donations from China, supplying 103 million doses of donated vaccines to 79 countries.
Take a look at our slideshow to see sales and deliveries of manufacturers. Please press the arrows below to alternate between graphs.
Sinovac – CoronaVac COVID-19 Vaccine
On June 1, 2021, the World Health Organization officially listed the inactivated COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac Biotech Ltd. for emergency use. This is the second Chinese COVID-19 vaccine to receive this approval after the inactivated Sinopharm COVID-19 vaccine was approved for emergency use in May 2021.
Sinopharm – Beijing Bio-Institute of Biological Products Co-Ltd. (BBIBP) COVID-19 Vaccine
On May 7, the World Health Organization officially listed the inactivated COVID-19 vaccine developed by Beijing Bio-Institute of Biological Products Co-Ltd. (BBIBP) under the China National Pharmaceutical Group Corporation (Sinopharm) for emergency use, marking a significant milestone as the first Chinese COVID-19 vaccine to receive this approval.
CanSino – CONVIDECIA Ad5-nCoV-S recombinant vaccine
On May 19, 2022, the World Health Organization officially listed the CanSino (CONVIDECIA) vaccine developed by CanSino Biologics Inc., the Beijing Institute of Biotechnology, and the Academy of Military Medical Sciences for emergency use. This is the third vaccine developed by China to receive this approval. CanSino uses protein-coding technology delivered to the body by adenoviruses to create antibodies that fight COVID-19. This differs from the Sinovac and Sinopharm vaccines, which use the inactivated COVID-19 virus to generate an immune response against the disease.
Overseas Manufacturers of Chinese Vaccines
In addition to vaccine deliveries, Chinese COVID-19 vaccine manufacturers have been partnering with various developing countries to build up their local vaccine production capacities. At the Global Health Summit 2021, Chinese President Xi Jinping reiterated China’s support for its vaccine developers to transfer technologies to other developing countries and to carry out joint production. A total of 15 countries currently host vaccine joint production facilities: Algeria, Egypt, Morocco, Indonesia, Malaysia, Myanmar, Pakistan, UAE, Uzbekistan, Serbia, Brazil, Chile, Columbia and Mexico.
Additional countries have only signed agreements but have not yet indicated production of vaccines or construction of vaccine facilities: Hungary, Russia, Bangladesh, Argentina, Turkey and Sri Lanka.
More Details on Overseas Manufacturers of Chinese Vaccines:
Manufacturing of Chinese COVID-19 vaccines has started or is about to start for these countries.
Algeria. Algerian pharmaceutical company Saidal received the green light to produce Sinovac vaccines domestically, with an aim to produce five million vaccine doses per month by January 2022 and to export vaccines to the rest of Africa. In late September 2021, Saidal started manufacturing the CoronaVac doses, with 20,000 produced in the first week, and by January 2022, was marketing the vaccine for sale. Currently, Saidal is producing vaccines at a rate of 60 million vaccines per year, however have stated that they can scale up production to 96 million vaccines per year depending on increased demand from other African countries.
Brazil. The local Butantan Institute initially planned for 100% domestic production of COVID-19 vaccines in early 2022 . On March 25, 2022, Butantan finished construction and opened a new vaccine plant which was meant to create locally produced COVID-19 vaccines. Sinovac Coronavac vaccines were subsequently produced at this site. However, experts state that the plant may only produce other types of vaccines depending on the demands of Brazil’s government agencies. Production in the plant on a large scale is scheduled to start in early 2023. In late June, 2022, the Butantan Institute reported that they had officially ended production of the CoronaVac vaccine as of October 2021 due to a lack of demand. The last batch of 110 million doses was sent to Brazil’s Ministry of Health in February 2022.
Cambodia. In May 2022, an MOU was signed between the Cambodian Pharmaceutical Enterprise and Sinovac for the construction of a vaccine packaging facility and license to fill and finish the Sinovac vaccines. The Cambodian government has already ordered over 104 million doses that the plant is projected to produce between 2024-2026.
Chile. In August 2021, Sinovac formed a partnership with the Innovation Center of the Pontifical Catholic University of Chile, with the support of the government and the Millennium Institute for the planned construction of a fill-and-finish site near Santiago, a R&D research centre in the Antogafasta region and office spaces for scientists in the University. Construction for the vaccine plant started in May 2022 with an expected completion date in early 2023, considerably later than previous plans for the start of operations in the second quarter of 2022. It will have an estimated 50 million doses per year capacity while the R&D centre will benefit future development and production of other vaccines.
Colombia. In August 2021, an MOE was signed between the Ministry of Science, Technology and Innovation and Sinovac for the packaging and filling of vaccines in the next 8 months following selection of a suitable plant, and a planned production of other vaccines over the next 2 years as part of a long-term plan to help Colombia rebuild its vaccine industry. In May 2022, Sinovac announced a USD $100 million investment for the project, including the construction of a vaccine plant in Bogotá with the capacity to package 50-60 million doses annually. Sinovac stated that the company is in the process of purchasing land in the country in order to create the vaccine plant.
Egypt. Under an agreement with Sinovac, Egypt’s state-owned VACSERA company produced its first batch of 1 million doses of the VACSERA-Sinovac vaccine in July 2021 using raw materials from China. By February 2022, it has produced over 30 million doses of the vaccine. It plans to fill and finish 200 million doses a year for national needs, and build a second factory that can produce 3 million doses every day for regional export needs. This would make Egypt the largest vaccine producer in Africa and in the Middle East. In October 2021, they approved an increase of 250 million doses of raw materials to be sent for 2023. In January 2022, they also signed a new cooperation agreement for the construction of an automated vaccine cold storage facility at VACSERA that is projected to be able to hold 150 million vaccine doses. The construction of this facility started in April and was completed into operation on September 25, 2022. On the same day, 10 million doses of Sinovac vaccines donated by China became the first batch handled by the cold storage facility.
Indonesia. On September 29, 2022, Indonesia’s National Agency of Drug and Food Control issued an Emergency Use Authorization for ‘AWcorna’ – an mRNA vaccine developed in China by Abogen-Yuxi Walvax. The AWcorna vaccine was registered by Jakarta-based bio-pharmaceuticals producer PT Etana Biotechnologies Indonesia (PT Etana). The vaccine will be locally produced by PT Etana through a vaccine-technology transfer with China. AWcorna received a halal fatwa (Islamic legal ruling on permits) from the Indonesian Ulema Council (MUI) and halal certification from the Halal Product Guarantee Agency (BPJPH). On October 7, Chinese Ambassador to Indonesia Lu Kang attended the opening ceremony of the vaccine manufacturing base which is the first mRNA-based COVID-19 vaccine factory in Southeast Asia. The facility can achieve 100 million doses per year.
Malaysia. On April 23, 2021, the filled-and-finished Sinovac vaccine by local company Pharmaniaga received conditional approval from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA), allowing its use in mass vaccinations. As of November, over 20 million doses have been supplied to the National Immunisation Programme in both manufactured and finished form, and the vaccine has been exported overseas to Myanmar. In a joint press conference with Chinese Foreign Minister Wang Yi, Malaysian Foreign Minister Saifuddin Abdullah emphasized that Malaysia and China would collaborate in vaccine research, development and production. The Malaysian government has discussed the possibility to setting up production plants in Malaysia with several Chinese vaccine manufactures.
Mexico. Mexico partnered with Mexico to export active ingredients for its vaccines, which are then packaged in the country by Drugmex. CanSino stated that in 2021, it expected to make 1.2 million shots available per week to fulfil its agreement for 35 million doses. The deal was prematurely ended in May 2022 due to issues with meeting product delivery deadlines. Out of the 35 million doses in the deal, 14.1 million were completed.
Morocco. On July 6, 2021, Morocco announced that their local pharmaceutical firm Sothema would soon be producing 5 million doses of Sinopharm per month under a fill-and-finish license. Morocco has started the production of more than three million doses of Sinopharm vaccine each month. The production capacity will reach five million doses starting from February 2022, and more than 20 million by the end of 2022.
Myanmar. On December 13, 2021, Chairman of the State Administration Council and Prime Minister Senior General Min Aun Hlaing announced that Myanmar was currently looking to produce Chinese COVID-19 vaccines domestically. Joint production of Sinopharm vaccines, was planned to start from January with a target of producing five million units of vaccine per month. During April 29-30, 2022, Myanmar administered 1 million of the locally-produced ‘Myancopharm’ doses to individuals within the country.
Pakistan. Pakistan’s National Institute of Health (NIH) partnered with CanSino to process its vaccines locally from bulk ingredients. Local media reported that locally filling vaccine vials will reduce the vaccine price by up to 30 percent. The locally finished ‘PakVac’ started national rollout in June 2021, and later in October, CanSino expressed their support for “enhancing the existing local filling and production capacity of the not only for Covid-19 vaccine but also for some other vaccines.”
Serbia. On July 12, 2021, an official memorandum of understanding and cooperation was signed between Serbia, China, and the United Arab Emirates to co-finance and construct a vaccine-finishing factory in Serbia. The factory started construction in October 2021.
United Arab Emirates. After hosting clinical trials of their vaccine, the UAE’s G42 launched a joint venture with Sinopharm to locally package the vaccine as ‘Hayat-Vax’ in March 2021. A new plant in the UAE, built in the Khalifa Industrial Zone of Abu Dhabi (KIZAD), will have a production capacity of 200 million doses a year with three filling lines and five automated packaging lines. Hayat-Vax has already been exported to countries including Kazakhstan and Vietnam. On June 30th, 2022, Ali Obaid Al Dhaheri (UAE Ambassador to China) met with Liu Jinchen (the President of Sinopharm) to discuss how to further collaborate regarding COVID-19 vaccines.
Uzbekistan. In August 2021, Uzbek company Jurabek Laboratories JV LLC signed an agreement with China’s Anhui Zhifei Longcom Biopharmaceutical Co., Ltd to locally manufacture their vaccine, with an expected initial output of up to 10 million doses a month. It has rolled out the vaccines since October 2021.
Several Chinese vaccine manufacturers have initial stage agreements (MOUs, license to produce vaccines, public statements of intent) with these countries, however have yet to deliver concrete results. We will continue to monitor the situation with these agreements.
Argentina. In May 2021, Sinopharm and Argentinian pharmaceutical Sinergium Biotech agreed to produce vaccines in Argentina with discussions on technology transfer to follow. Political negotiations were initiated between the two countries regarding production, however no further updates have been announced.
Bangladesh. Under a Memorandum of Understanding (MoU) signed between the government, China’s Sinopharm and Bangladesh’s Incepta pharmaceutical firm in August 2021, the local vaccine producer will supply five million doses of the vaccine a month from its plant in Savar. So far, production has yet to begin.
Hungary. On September 10, 2021, Hungary’s government signed a letter of intent with Sinopharm executives to develop the required infrastructure within the next 10 months to produce the Chinese COVID-19 vaccine. No further updates regarding this have been announced.
Nigeria. Cui Jianchun, Ambassador of the People’s Republic of China to Nigeria, announced on December 14, 2021, that China and Nigeria are currently undergoing talks regarding a potential collaboration to domestically produce Chinese COVID-19 vaccines.
Russia. In 2020, CanSino carried out a phase 3 trial of its vaccine in partnership with Petrovax in Russia, and in August 2021, Petrovax agreed to partner with the developer to carry out local manufacturing. No further updates have been announced.
Sri Lanka. In August 2021, Sinovac agreed to set up a manufacturing plant in Hambantota, Sri Lanka, with an initial plan to produce 13 million doses of the vaccine through Kelun Lifesciences. No further updates have been announced.
Turkey. Turkey was one of the first five countries to receive a license to locally manufacture vaccines from Sinovac in May 2021. No further updates have been announced.
Uganda. Ugandan President Yoweri Museveni met with Sinovac’s Ugandan representative and team in May 2022 to discuss plans for Sinovac to establish a vaccine and biotechnology centre in the country.
Notes
Additional information on procurements of Chinese vaccines:
Vaccine procurements:
Some vaccines procured by various countries with joint production agreements will be produced locally using active ingredients delivered by China.
The Chinese military has also donated vaccines to the military in countries including Cambodia, Congo Republic, Ethiopia, Mongolia, Pakistan, the Philippines, Sudan, North Macedonia, Zimbabwe, Guinea, and Tunisia; some quantities are included in the reported data above, while others are undisclosed. Egypt has reportedly received an undisclosed amount of an undisclosed vaccine from the People’s Liberation Army.
Thailand’s total vaccine quantities might be higher than recorded, as specific numbers were undisclosed. The Chulabhorn Royal Academy has purchased some.
Turkey’s total vaccine quantities might be higher than recorded, as specific numbers were undisclosed.
China has offered vaccines to Nepal under “grant assistance”, which is not a complete donation.
Iraq and Kazakhstan have received vaccines that are assumed to be purchased from China.
Several countries have received donated vaccines directly from the Chinese Red Cross Society.
Some Sinovac vaccines were purchased by the Filipino-Chinese Chambers of Commerce and Industry Inc for the “Spring Sprout” program (春苗行动) in The Philippines.
There have been conflicting reports on the total number of delivered vaccines to Zimbabwe and Colombia. Our team has tracked the individual delivery batches, but some numbers might be undisclosed.
The Kachin Independence Army in Myanmar alleges that they have received 10,000 doses of an undisclosed Chinese vaccine from Yunan authorities. Among these doses, an unknown number of doses were donated by China. These numbers have temporarily not been included above.
In Vietnam, the Ministry of Health has licensed the state-owned Saigon Pharmaceutical Company Limited (Sapharco) to procure 5 million doses of Sinopharm. As of August 16, 2021, 2 million doses have been delivered to Ho Chi Minh City, where the firm is based.
China has directly donated 3,000 doses of Sinopharm to the National United Front for an Independent, Neutral, Peaceful, and Cooperative Cambodia (FUNCINPEC) Party of Cambodia.
Egypt has reportedly received an undisclosed amount of an undisclosed vaccine from the People’s Liberation Army.
Additional procurements:
Turkey and Azerbaijan, two member states of the Turkic Council, and observer Hungary have announced that they will donate COVID-19 vaccines to the African countries in need. The vaccine shipment will include 211,000 doses of Sinopharm from Hungary, 200,000 Sinovac doses from Turkey and 100,000 Sinovac doses from Azerbaijan.
The UAE has donated vaccines to Seychelles, Jordan, Belize, Paraguay, Mauritius, and Indonesia; the quantities have been omitted from all charts and graphics above.
Turkey has provided vaccines to Libya, North Macedonia, and Azerbaijan; the quantities have been omitted from all charts and graphics above.
Chile has donated vaccines each to Ecuador and Paraguay; the quantities have been omitted from all charts and graphics above.
Antigua and Barbuda has donated vaccines to Trinidad and Tobago; the quantities have been omitted from all charts and graphics above.
China and Egypt have jointly pledged to donate 500,000 doses of Sinovac to the Gaza Strip.
Paraguay has received 20,000 doses of Sinovac from Colombia; the quantity has been omitted from all charts and graphics above.
Senegal has donated Sinopharm doses to Guinea-Bissau and Gambia; the quantities have been omitted from all charts and graphics above.
More
Methodology
This vaccine tracker is based entirely on data from reliable publicly accessible sources collected and compiled by Bridge Consulting with the help of Global Health Strategies (Brazil) and is updated every Monday by 7:00 PM (BJT GMT+8).
Where do we get our data?
Bridge collects and verifies data on Chinese vaccine sales, donations and deliveries every week. We source all our data from reliable, publicly accessible sources such as official government press releases, credible international and local news sources, and social media posts by government offices and verified officials.
How do you define ‘sales’, ‘donations’, ‘deliveries’?
Vaccine sales refers to the contractually committed vaccine doses that recipient countries have commercially purchased from Chinese vaccine developers.
Vaccine donations refers to the doses that a Chinese entity (government, vaccine developer, Red Cross etc.) has pledged to donate to a recipient country.
Vaccine deliveries refers to the doses that have physically been shipped from China to the recipient country.
How are countries and regions defined?
Our data is compiled and organized by country according to the United Nations’ M49 standard.
Why does our data change sometimes?
With the help of Global Health Strategies (Brazil), we constantly review our data for irregularities and correct them whenever new information becomes available.
Why does our data differ from other sources?
All our data is sourced manually by our team from publicly available sources. If you find that we have missed out on something, please let us know at vaccinetracker@bridgebeijing.com.
|
||||
6044
|
dbpedia
|
3
| 55
|
https://www.scmp.com/topics/sinopharm
|
en
|
Sinopharm: Latest News and Updates
|
[
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2024/02/22/e6527e37-cd95-44fc-b9c9-16b8b56712bf_126cb206.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2023/01/20/e751448b-0e18-4f5c-9129-d5835ed74452_aad713d7.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2022/02/23/917a3501-c9be-4415-8af6-5522ab430066_24e0ec0e.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2022/01/05/9ea0ae1e-7934-401e-b45e-bc596f7105d4_e0f97d7c.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2021/12/20/35e30765-cdd6-4c21-b37d-65813746ff34_4d6659a7.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/09/17/58386f50-1787-11ec-ab69-f2bfe93835cf_image_hires_165847.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/08/26/e57fba10-057d-11ec-a83e-ec0670db1017_image_hires_075759.jpeg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/05/28/c9531632-bebc-11eb-9b2e-758b3029e26f_image_hires_153934.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/05/13/dc0380c4-b2fe-11eb-93b7-03206dd91175_image_hires_042523.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/05/08/e0181666-af48-11eb-9c9f-63ba12e765d1_image_hires_180430.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2021/03/23/54fd05e1-2eb3-4347-8db5-2bbc9de8d271_d590c3ea.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/03/17/cd4b5f5c-8734-11eb-b55b-f690abcc0fed_image_hires_233054.jpg",
"https://assets-v2.i-scmp.com/production/_next/static/media/wheel-on-gray.af4a55f9.gif"
] |
[] |
[] |
[
"Sinopharm"
] | null |
[] |
2024-02-22T01:36:21+00:00
|
Sinopharm is a joint venture between state-owned China National Pharmaceutical Group and privately run Fosun Pharmaceutical. The company is the largest wholesaler and retailer of pharmaceuticals and medical devices in China. It produced the first Chinese vaccine against Covid-19.
|
en
|
https://assets-v2.i-scmp.com/production/favicon.ico
|
South China Morning Post
|
https://www.scmp.com/topics/sinopharm
|
Experimental jab is similar to more effective foreign vaccines and is designed to target the Omicron variant.
Sun Yat-sen University research, which has not been peer-reviewed, suggests immune response cannot be endlessly boosted and there will be a ‘turning point’ after repeated vaccination.
The jab shows significantly weaker neutralising activity against the variant than against an older strain, researchers say.
It is being developed to provide protection against Delta and Beta strains, and clinical trials of a booster shot are also under way, CNBG vice-president says.
Interim phase 3 results suggest two products have efficacy above 70 per cent for symptomatic cases but there is little data on elderly and vulnerable groups.
The green light given to Sinopharm comes more than four months after the WHO handed out its first emergency use listing for a Covid-19 vaccine to US pharmaceutical company Pfizer and German company BioNTech.
Elsewhere, Taiwan will form its first travel bubble of the pandemic with the tiny Pacific nation of Palau, and Japan is to lift a state of emergency in the Tokyo area.
|
||||
6044
|
dbpedia
|
0
| 57
|
https://m.economictimes.com/news/international/world-news/top-scientist-behind-chinas-first-covid-19-vaccine-expelled-from-parliament-for-graft/articleshow/109692648.cms
|
en
|
Top scientist behind China's first COVID-19 vaccine expelled from Parliament for graft
|
[
"https://img.etimg.com/photo/msid-76920425,quality-100/et-logo.jpg",
"https://img.etimg.com/photo/104857408.cms",
"https://img.etimg.com/thumb/msid-109692690,width-300,height-225,imgsize-59946,resizemode-75/takeaways-from-ap-report-on-how-the-search-for-the-coronavirus-origins-turned-toxic.jpg",
"https://img.etimg.com/thumb/msid-112835099,imgsize-45114,width-138,height-104,quality-100/prime/money-and-markets/tata-consumer-products-needs-a-starbucks-shot-to-increase-its-market-value-exponentially.jpg",
"https://img.etimg.com/thumb/msid-112820962,imgsize-32332,width-138,height-104,quality-100/prime/corporate-governance/ports-to-power-what-companies-facing-insolvency-mean-for-adani-group.jpg",
"https://img.etimg.com/thumb/msid-112816869,imgsize-136900,width-138,height-104,quality-100/prime/money-and-markets/a-list-of-20-large-cap-stocks-where-you-have-lost-money-big-time-.jpg",
"https://img.etimg.com/thumb/msid-112836086,imgsize-135016,width-138,height-104,quality-100/prime/prime-decoder/the-challenges-dotting-indias-push-for-6g-leadership.jpg",
"https://img.etimg.com/thumb/msid-112824907,imgsize-19764,width-138,height-104,quality-100/prime/money-and-markets/are-yamaha-dealer-ipo-investors-and-sir-isaac-newton-on-the-same-page.jpg",
"https://img.etimg.com/thumb/msid-112800245,imgsize-150820,width-138,height-104,quality-100/prime/corporate-governance/the-many-gaps-in-conflict-of-interest-allegations-against-sebi-chief-other-indian-regulators.jpg",
"https://img.etimg.com/photo/msid-109982599,imgsize-67937/desktop-rhs-on-rise-section.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-31346,msid-112845278/ex-us-navy-seal-explains-secret-service-failures.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-46648,msid-112843570/jay-shah-becomes-youngest-icc-chairman.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-27748,msid-112844062/polaris-dawn-mission-set-for-first-private-spacewalk.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-41634,msid-112841199/meta-chiefs-sensational-claim-biden-govt-forced-us.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-26710,msid-112838682/excise-policy-case-sc-grants-bail-to-k-kavitha.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-22718,msid-112838859/starmer-calls-rioters-mindless-minority-of-thugs.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-32878,msid-112836099/after-biden-pm-modi-speaks-to-vladimir-putin.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-18536,msid-112836120/champai-soren-meets-amit-shah-in-delhi.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-31960,msid-112834512/why-was-telegrams-founder-arrested.jpg",
"https://economictimes.indiatimes.com/thumb/width-152,height-114,resizemode-75,imgsize-14794,msid-112835397/hema-committee-report-mohanlal-resigns-as-amma-president.jpg",
"https://img.etimg.com/photo/msid-74462387,quality-100/et-logo.jpg",
"https://img.etimg.com/photo/msid-74451948,quality-100/et-logo.jpg",
"https://img.etimg.com/photo/47865640.cms"
] |
[] |
[] |
[
"COVID-19 vaccine",
"Yang Xiaoming",
"China National Pharmaceutical Group",
"corruption",
"Sinopharm"
] | null |
[] |
2024-04-29T16:11:00+05:30
|
Yang Xiaoming, developer of China's first COVID-19 vaccine, was dismissed for corruption amid President Xi Jinping's anti-corruption campaign. Investigation ongoing on Sinopharm executives, highlighting widespread corruption in China's healthcare system.
|
en
|
https://economictimes.indiatimes.com/icons/etfavicon.ico
|
The Economic Times
|
https://m.economictimes.com/news/international/world-news/top-scientist-behind-chinas-first-covid-19-vaccine-expelled-from-parliament-for-graft/articleshow/109692648.cms
|
Synopsis
Yang Xiaoming, developer of China's first COVID-19 vaccine, was dismissed for corruption amid President Xi Jinping's anti-corruption campaign. Investigation ongoing on Sinopharm executives, highlighting widespread corruption in China's healthcare system.
Beijing, China's top scientist, who developed the first inactivated COVID-19 vaccine at the height of the pandemic in the country in 2020, has been dismissed from Parliament for alleged corruption. Yang Xiaoming, the chairman of China National Pharmaceutical Group's vaccine subsidiary China National Biotec Group (CNBG), has been stripped of his membership in the National People's Congress (NPC) due to serious discipline and law violations, official media reported here on Monday.
The charge of serious discipline and law violations is a common euphemism for corruption under the ruling Communist Party of China (CPC) disciplinary practice.
Yang, 62, is a veteran researcher who headed the CNBG - a vaccine subsidiary of state-owned Sinopharm - and led a team that developed Sinopharm's BBIBP-CorV vaccine, China's first coronavirus shot approved for general use.
Coronavirus first surfaced in the Chinese city of Wuhan in March 2020 and later spread to the world, becoming the pandemic of the century and claiming millions of lives.
According to a statement by NPC, Yang is already being investigated by the party disciplinary body - the Central Commission for Discipline Inspection.
The Sinopharm shot and Sinovac Biotech's CoronaVac were the most widely used in China and the leading COVID-19 vaccines exported by the country.
Yang's dismissal comes amid the biggest crackdown on China's healthcare system, expanding a sweeping anti-corruption drive launched by President Xi Jinping in the last few years.
The crackdown aims to root out widespread corruption in a system plagued by kickbacks. It targets hospitals, drug companies and insurance funds, with dozens of hospital chiefs detained since last year, Hong Kong-based South China Morning Post reported.
Another former Sinopharm senior executive, Zhou Bin, who once served as the company's deputy general manager, was placed under investigation by the CCDI in January.
China's national 863 programme is a state-funded and administered platform for developing advanced technologies.
The Covid-19 vaccine developed by Yang's team was approved for general use in December 2020.
Yang was among the recipients of a national award in September 2020 for his role in fighting the pandemic and was later recognised by the Chinese Society of Immunology as an outstanding scholar. He was also awarded the Ho Leung Ho Lee Foundation award, which recognises Chinese scholars in science and medical fields, the Post reported.
(You can now subscribe to our Economic Times WhatsApp channel)
(Catch all the Business News, Breaking News, Budget 2024 Events and Latest News Updates on The Economic Times.)
Subscribe to The Economic Times Prime and read the ET ePaper online.
...moreless
(You can now subscribe to our Economic Times WhatsApp channel)
(Catch all the Business News, Breaking News, Budget 2024 Events and Latest News Updates on The Economic Times.)
Subscribe to The Economic Times Prime and read the ET ePaper online.
...moreless
Tata Consumer Products needs a Starbucks ‘shot’ to increase its market value exponentially
Ports to power, what companies facing insolvency mean for Adani Group
A list of 20 large-cap stocks where you have lost money big time.
The challenges dotting India’s push for 6G leadership
Are Yamaha dealer IPO investors and Sir Isaac Newton on the same page?
The many gaps in conflict of interest allegations against Sebi chief, other Indian regulators
1
2
3
|
||||
6044
|
dbpedia
|
2
| 58
|
https://www.shanghai.gov.cn/nw48081/20210204/a5c87683127840eeaf9704d17048d111.html
|
en
|
Vaccinated SISU teacher upbeat
|
[
"https://www.shanghai.gov.cn/english2019/assets/img/img-lg.jpg"
] |
[] |
[] |
[
""
] | null |
[] | null |
/english2019/assets/img/ico/favicon.png
| null |
A Group of international teachers from Shanghai International Studies University recently received China-made COVID-19 vaccines.
The Chinese government has encouraged vaccinations for COVID-19 since last month for those in key front-line positions.
Vaccines produced in China have been developed by Sinopharm and Sinovac.
The efficacy rate of Sinopharm’s vaccine is 79 percent, according to the National Medical Products Administration, while researchers in Brazil said Sinovac’s is 100 percent effective in preventing severe infections.
As of Sunday, more than 24 million vaccine doses have been administered in the country.
Shanghai Daily reached out to one of the SISU recipients, Svi Septimus, who received two doses of Sinopharm’s vaccine earlier this month.
Septimus, an American teacher of Hebrew literature, shared his thoughts on the vaccination experience.
Q: How was the inoculation process?
A: The first time it was totally fine — it didn’t even hurt my arm. I got the vaccine in a ping pong stadium and waited 30 minutes afterwards to see if there would be a reaction.
The second injection made my arm hurt for three days. Other than that, everything was totally fine.
Q: Why did you choose to receive the vaccine?
A: It eases the anxiety so I don’t have to worry about getting the virus any more.
I was stuck in the United States for seven months after the virus broke out, and I didn’t come back to China until last September. The entire time I was very anxious. I was living with my mother who contracted the virus, but she’s fine now.
When I came back to China, the anxiety left because everyone here is living like it’s normal. You can go to a restaurant and live your daily life. The only thing you have to do is wear a mask on public transportation.
No one knows what’s going to happen in the future. Now we have some cases in China, and there’s been more tension over the last couple of weeks because of the upcoming Spring Festival. Plus, I’m planning to visit the States with my wife soon, and I hope she can receive the vaccine, too.
Q: Have any of your friends abroad received vaccines produced in other countries?
A: My niece, who’s also a teacher, got it in the US. Elderly people can also get vaccinated, but my father chose not to.
Q: There are different statistics for the efficacy rate of vaccines. What’s your view?
A: I was initially concerned that the efficacy rate of the vaccine developed by Pfizer in the US is 95 percent, higher than Sinopharm’s 79 percent.
But then I found out that 79 percent only represents your chances of not contracting the virus.
It’s a much higher percentage than 79 that you won’t get sick, and even higher that you won’t die if you receive the vaccine.
On the other hand, the technology they’re using in America is new compared with the inactivate vaccine here in China. I know a lot of people in America are afraid to take vaccines made with the new technology, and are more willing to take the Chinese vaccines.
|
|||||||
6044
|
dbpedia
|
3
| 14
|
https://www.statista.com/statistics/1307001/sinopharm-covid19-vaccine-delivery-distribution-by-country-income-group/
|
en
|
Sinopharm: COVID-19 vaccine delivery distribution by country income group 2021
|
[
"https://cdn.statcdn.com/Study/160000/162257-standard.png",
"https://cdn.statcdn.com/Statistic/1190000/1194939-blank-100.png",
"https://cdn.statcdn.com/Statistic/1195000/1196142-blank-100.png",
"https://cdn.statcdn.com/Statistic/1190000/1194934-blank-100.png",
"https://cdn.statcdn.com/Statistic/1275000/1279024-blank-100.png",
"https://cdn.statcdn.com/static/img/modalEmployeeGroup.png",
"https://cdn.statcdn.com/static/icons/blank.gif",
"https://cdn.statcdn.com/Topic/9385.jpg",
"https://cdn.statcdn.com/Topic/5898.jpg",
"https://cdn.statcdn.com/Topic/5001.jpg",
"https://cdn.statcdn.com/Topic/5305.jpg",
"https://cdn.statcdn.com/Topic/5994.jpg"
] |
[] |
[] |
[
""
] | null |
[
"Wenyi Zhang"
] | null |
In 2021, the Chinese pharmaceutical giant Sinopharm delivered almost 75 percent of its COVID-19 vaccines to upper-middle-income countries, while lower-middle-income countries received around 24 percent.
|
en
|
Statista
|
https://www.statista.com/statistics/1307001/sinopharm-covid19-vaccine-delivery-distribution-by-country-income-group/
|
* For commercial use only
|
|||||
6044
|
dbpedia
|
0
| 16
|
https://www.cnbc.com/2021/05/07/who-approves-covid-vaccine-made-by-chinas-sinopharm-for-emergency-use.html
|
en
|
WHO approves Covid vaccine made by China's Sinopharm for emergency use
|
[
"https://static-redesign.cnbcfm.com/dist/7821ea3cb72f88388591.svg",
"https://static-redesign.cnbcfm.com/dist/2469ed0a9a4cafdf055e.svg",
"https://static-redesign.cnbcfm.com/dist/2469ed0a9a4cafdf055e.svg",
"https://image.cnbcfm.com/api/v1/image/107134029-1666702125940-107134029-1665672176847-2022_Headshots-0874.jpg?v=1666702277&w=60&h=60&ffmt=webp",
"https://static-redesign.cnbcfm.com/dist/7821ea3cb72f88388591.svg",
"https://static-redesign.cnbcfm.com/dist/17269f1b6083fd5f61be.svg",
"https://static-redesign.cnbcfm.com/dist/09c161b9810767a7849e.svg"
] |
[] |
[] |
[
"Health care industry",
"Johnson & Johnson",
"Moderna Inc",
"BioNTech SE",
"Pfizer Inc",
"Politics",
"business news"
] | null |
[
"Kevin Breuninger",
"www.facebook.com"
] |
2021-05-07T00:00:00
|
The new addition to the list could hasten efforts to control the spread of Covid, which has recently spread to record high infection levels in some countries.
|
en
|
https://sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/favicon.ico
|
CNBC
|
https://www.cnbc.com/2021/05/07/who-approves-covid-vaccine-made-by-chinas-sinopharm-for-emergency-use.html
|
The World Health Organization said Friday it has approved for emergency use a coronavirus vaccine developed by Chinese state-owned pharmaceutical group Sinopharm.
Beijing's Covid vaccine is recommended for adults 18 years and up with a two-dose regimen, WHO Director-General Tedros Adhanom Ghebreyesus said at a press briefing.
The new addition to the list of usable vaccine options could hasten efforts to control the spread of Covid-19 and its variant forms, which are driving new infections in many parts of the world.
"Solving the vaccine crisis requires that we pull out all the stops," Tedros said.
Sinopharm's shot is the sixth to receive the WHO's approval for "safety, efficacy and quality," he said.
"Vaccines remain a vital tool. But right now, the volume and distribution of vaccines is insufficient to end the pandemic, without the sustained and tailored application of public health measures that we know work," Tedros said.
"The pandemic has shown that when health is at risk, everything is at risk. But when health is protected and promoted, individuals, families, communities, economies and nations can thrive," he said.
|
||||
6044
|
dbpedia
|
3
| 34
|
https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19
|
en
|
China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says
|
[
"https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iZ4X73Rd53xI/v1/-1x-1.jpg"
] |
[] |
[] |
[
"China",
"Coronavirus",
"United Arab Emirates",
"Public Health",
"Media",
"Developing Countries",
"Beijing",
"Abu Dhabi",
"Tourism",
"PFIZER INC",
"business"
] | null |
[] |
2020-12-09T00:00:00
|
China’s state-backed coronavirus vaccine protected 86% of people against Covid-19 in trials conducted in the United Arab Emirates, state media there reported, giving credence to the quickly developed shot that Beijing intends to distribute around the developing world.
|
en
|
Bloomberg.com
|
https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19
|
China’s state-backed coronavirus vaccine protected 86% of people against Covid-19 in trials conducted in the United Arab Emirates, state media there reportedBloomberg Terminal, giving credence to the quickly developed shot that Beijing intends to distribute around the developing world.
The data was from trials that included 31,000 volunteers in the UAE, which found the vaccine was highly effective in preventing moderate and severe cases of Covid-19 and had no serious safety concerns, according to the report, which cited the country’s Ministry of Health and Prevention.
|
|||||
6044
|
dbpedia
|
1
| 95
|
https://www.npr.org/sections/coronavirus-live-updates/2020/12/31/952269135/china-approves-its-homegrown-covid-19-vaccine-for-widespread-use
|
en
|
China Approves Its Homegrown COVID-19 Vaccine For Widespread Use
|
[
"https://media.npr.org/chrome_svg/npr-logo.svg",
"https://media.npr.org/chrome/programs/logos/morning-edition.jpg",
"https://media.npr.org/assets/img/2019/02/26/we_otherentitiestemplatesat_sq-cbde87a2fa31b01047441e6f34d2769b0287bcd4-s100-c85.png",
"https://media.npr.org/assets/img/2019/02/26/we_otherentitiestemplatesun_sq-4a03b35e7e5adfa446aec374523a578d54dc9bf5-s100-c85.png",
"https://media.npr.org/chrome/programs/logos/all-things-considered.png",
"https://media.npr.org/chrome/programs/logos/fresh-air.png",
"https://media.npr.org/chrome/programs/logos/up-first.jpg?version=2",
"https://media.npr.org/assets/img/2024/01/11/podcast-politics_2023_update1_sq-be7ef464dd058fe663d9e4cfe836fb9309ad0a4d-s100-c100.jpg",
"https://media.npr.org/assets/img/2024/05/15/throughline_tile-art_sq-b72bcfb6d8705d7761d4f421f0be3047631b709c-s100-c100.jpg",
"https://media.npr.org/assets/img/2023/11/10/trumps-trial_tile-art_small_sq-71cfb7f3a96f3029db4ca7230c5704c61a351b81-s100-c100.jpg",
"https://media.npr.org/assets/img/2024/04/19/tile-wild-card-with-rachel-martin_sq-c9e842a167bab21c50f45fbde9d7d33776e87eda-s100-c100.jpg",
"https://media.npr.org/chrome_svg/music-logo-dark.svg",
"https://media.npr.org/chrome_svg/music-logo-light.svg",
"https://media.npr.org/assets/img/2020/03/19/c_virus_outbreak_sq-da13c5d35151937526bb15807fbc7e93183fa9b1.jpg?s=100&c=85&f=jpeg",
"https://media.npr.org/assets/img/2020/12/31/gettyimages-1230368003-d04d62f7b7a7a21a7fdf0997f0fd3afde407eb43.jpg?s=1100&c=85&f=jpeg",
"https://media.npr.org/assets/img/2020/03/19/c_virus_outbreak_sq-da13c5d35151937526bb15807fbc7e93183fa9b1.jpg?s=100&c=85&f=jpeg"
] |
[] |
[] |
[
""
] | null |
[
"Bill Chappell"
] |
2020-12-31T00:00:00
|
The state-owned Sinopharm says its vaccine has a 79% efficacy rate — surpassing the widely accepted standard of 50% efficacy.
|
en
|
NPR
|
https://www.npr.org/sections/coronavirus-live-updates/2020/12/31/952269135/china-approves-its-homegrown-covid-19-vaccine-for-widespread-use
|
China's medical products agency has given market approval to the country's first COVID-19 vaccine, made by state-owned Sinopharm. The conglomerate says its vaccine has a 79% efficacy rate — surpassing the widely accepted standard of 50% efficacy.
The approval is conditional, requiring Sinopharm to continue collecting data about the vaccine and its long-term effects. But the arrival of another mass-produced vaccine could provide relief in countries that have been unable to secure doses of the vaccines made by Pfizer-BioNTech and Moderna. China's approval came one day after the U.K. approved a vaccine made by AstraZeneca and Oxford University.
The Sinopharm vaccine uses inactivated coronavirus that causes the body to produce antibodies, a more conventional approach to inoculation. Pfizer's and Moderna's vaccines use a revolutionary gene-based platform.
The Chinese vaccine requires two injections. It was created by a Sinopharm subsidiary, the China National Biotec Group, or CNBG. The drugmaker says it has been conducting clinical studies in China as well as in other countries such as the United Arab Emirates, Bahrain, Egypt, Jordan, Peru, Argentina and Morocco.
"During the summer, Beijing gave a green light for emergency use of the Sinopharm vaccine and several others," NPR's John Ruwitch reported for our Newscast unit. "State media say that millions of doses have already been administered, including to front-line medical staff and people going abroad for work. Emergency use is set to expand."
Both Bahrain and the UAE — where large-scale trials of the Sinopharm vaccine took place — approved the vaccine earlier this month.
China's new approval for widespread use moves the country closer to its goals of vaccinating millions more people in the coming months. To protect itself from COVID-19, China must vaccinate at least 700 million residents, CNBG Chairman Yang Xiaoming told Chinese state-run media.
Yang also said that he and hundreds of other CNBG employees were inoculated with a version of the company's vaccine in March — the same month COVID-19 was declared a global pandemic.
Along with the efficacy rate, a vaccine's ability to protect public health is tied to another figure: vaccine coverage — the number of people who get the shot and develop antibodies to the virus.
"The percentage of people who need to have antibodies in order to achieve herd immunity against a particular disease varies with each disease," the World Health Organization says. It notes that for measles, around 95% of a population must be vaccinated to achieve herd immunity, while for polio, the threshold is much lower: about 80%.
In addition to those differences, a vaccine's efficacy rate directly affects the amount of coverage a population must have to prevent or curtail an epidemic. Researchers have been studying how high an efficacy rate must be to protect the public without any other interventions.
|
|||||
6044
|
dbpedia
|
0
| 36
|
https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html
|
en
|
Serbia Becomes First European Nation To Use China's Sinopharm Vaccine
|
[
"https://ssc.rferl.org/b/ss/bbgprod,bbgentityrferl/1/G.4--NS/1173707255?pageName=rfe%3aeng%3aw%3aarticle%3aserbia%20becomes%20first%20european%20nation%20to%20use%20china%27s%20sinopharm%20vaccine&c6=serbia%20becomes%20first%20european%20nation%20to%20use%20china%27s%20sinopharm%20vaccine&v36=8.33.0.0.342&v6=D=c6&g=https%3a%2f%2fwww.rferl.org%2fa%2fserbia-covid-vaccine-china-sinopharm%2f31053091.html&c1=D=g&v1=D=g&events=event1,event52&c16=rferl%20english&v16=D=c16&c5=serbia&v5=D=c5&ch=serbia&c15=english&v15=D=c15&c4=article&v4=D=c4&c14=31053091&v14=D=c14&v20=no&c17=web&v17=D=c17&mcorgid=518abc7455e462b97f000101%40adobeorg&server=www.rferl.org&pageType=D=c4&ns=bbg&v29=D=server&v25=rfe&v30=420&v105=D=User-Agent ",
"https://www.rferl.org/Content/responsive/img/player-spinner.png",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo-compact.svg",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo.svg",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo-print.gif",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo-print_color.png",
"https://gdb.rferl.org/3da039d2-7098-4df2-b547-b197e38a55ac_w250_r1_s.jpg",
"https://gdb.rferl.org/01000000-0a00-0242-88ae-08dc16a2f407_w100_r5.png",
"https://gdb.rferl.org/01000000-0a00-0242-88ae-08dc16a2f407_w66_r5.png",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w100_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w33_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-d2c5-08dcbb9f1d5c_w100_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-d2c5-08dcbb9f1d5c_w33_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-3b22-08dcabbc41f5_w100_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-3b22-08dcabbc41f5_w33_r1.jpg",
"https://gdb.rferl.org/f22a3e38-3380-4e2c-a344-32fb631c77a9_cx0_cy6_cw0_w100_r1.jpg",
"https://gdb.rferl.org/f22a3e38-3380-4e2c-a344-32fb631c77a9_cx0_cy6_cw0_w33_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-7053-08dcbbb11a7a_cx15_cy29_cw80_w100_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-7053-08dcbbb11a7a_cx15_cy29_cw80_w33_r1.jpg",
"https://gdb.rferl.org/f8bbd50a-a99f-4564-937f-e63ae931bdc7_w50_r5.jpg",
"https://gdb.rferl.org/f8bbd50a-a99f-4564-937f-e63ae931bdc7_w50_r5.jpg",
"https://gdb.rferl.org/f8bbd50a-a99f-4564-937f-e63ae931bdc7_w50_r5.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w100_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w33_r1.jpg"
] |
[] |
[] |
[
"News",
"Serbia"
] | null |
[
"RFE/RL"
] |
2021-01-20T00:46:52+00:00
|
Serbia became the first European country to begin a mass inoculation campaign using China’s Sinopharm COVID-19 vaccine, with health officials and hundreds of uniformed soldiers lining up to get their jabs in the capital, Belgrade.
|
en
|
/Content/responsive/RFE/img/webApp/favicon.svg
|
RadioFreeEurope/RadioLiberty
|
https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html
|
Serbia became the first European country to begin a mass inoculation campaign using China’s Sinopharm COVID-19 vaccine, with health officials and hundreds of uniformed soldiers lining up to get their jabs in the capital, Belgrade.
"It is the only way to return to normal life," Health Minister Zlatibor Loncar said on January 19 as he became the first person to receive the vaccine in an event broadcast live on state television.
"These are all very safe vaccines," Loncar said from Belgrade’s virology institute.
Meanwhile, at an exhibition hall in the capital, hundreds of soldiers in camouflage uniforms bared their arms to receive their shots from dozens of nurses.
Defense Minister Nebojsa Stefanovic said that he and more than 700 members of the military had been vaccinated with the Chinese-made vaccine.
The Sinopharm vaccine has become a source of controversy in many Western countries.
China approved the shot developed by Sinopharm's BIBP late last year. No detailed efficacy data has been released, but BIBP has said the vaccine is 79 percent effective based on interim data.
That number is below the efficacy rates of around 95 percent reported by Western-made vaccines, such as those produced by Pfizer/BioNTech or Moderna.
Serbia, which last week received 1 million doses of the Sinopharm vaccine, has close ties with Beijing, and Chinese companies have invested billions of euros in the Western Balkan country of 7 million people.
"I have been inoculated with the Chinese vaccine, which we completely trust.... I've said I will get the same vaccine as our troops," defense chief Stefanovic told reporters.
Serbia, which also has close ties to Russia, began using the Sputnik-V vaccine on January 6, with top officials getting the first jabs to boost public trust in the shot.
Russians are also being inoculated with the Sputnik-V vaccine after it was approved by Moscow in August 2020 despite a lack of large-scale clinical trials and perceived shortcomings in data to support its safety and efficacy.
Serbia and Belarus are the only European countries using the Russian vaccine, which does not have the approval of the European Medicines Agency or the World Health Organization.
Serbia launched its coronavirus vaccination program using the Pfizer-BioNTech vaccine in December 2020 when Prime Minister Ana Brnabic received the shot, which alongside the Moderna vaccine has been approved for use in the EU and North America.
But with supplies of the Pfizer-BioNTech limited for now, Serbia is seeking to diversify its sourcing of vaccines.
Serbian President Aleksandar Vucic over the weekend said the country expects to get another 250,000 doses of the Sputnik-V vaccine and 20,000 doses of the Pfizer-BioNTech vaccine in the coming days.
Vucic on January 19 said vaccinations will be administered at some 300 locations in Serbia's biggest cities. He added that he will receive his dose this weekend.
Serbia is vaccinating essential workers such as police officers, teachers, and soldiers after it last month began to treat the elderly in care homes and medical workers.
Serbia has recorded 3,771 deaths from COVID-19 and 347,111 overall cases.
In the Western Balkan region, vaccinations have begun in Serbia and Albania, but Bosnia-Herzegovina, Kosovo, Montenegro, and North Macedonia have not yet received vaccine supplies.
|
||||
6044
|
dbpedia
|
3
| 0
|
https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
|
en
|
The Sinopharm COVID-19 vaccine: What you need to know
|
[
"https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue.svg?sfvrsn=aaed4f35_20",
"https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue.svg?sfvrsn=aaed4f35_20",
"https://www.who.int/images/default-source/fallback/maps/africa.png?sfvrsn=3204f957_18",
"https://www.who.int/images/default-source/fallback/maps/americas.png?sfvrsn=9efd6df3_18",
"https://www.who.int/images/default-source/fallback/maps/south-east-asia.png?sfvrsn=68e76dc2_16",
"https://www.who.int/images/default-source/fallback/maps/europe.png?sfvrsn=c7d5c5a5_18",
"https://www.who.int/images/default-source/fallback/maps/eastern-mediterranean.png?sfvrsn=71211e18_16",
"https://www.who.int/images/default-source/fallback/maps/western-pacific.png?sfvrsn=88cbdcd5_16",
"https://www.who.int/ResourcePackages/WHO/assets/dist/images/logos/en/h-logo-blue.svg",
"https://www.who.int/ResourcePackages/WHO/assets/dist/images/logos/en/h-logo-white.svg"
] |
[] |
[] |
[
""
] | null |
[] | null |
The WHO Strategic Advisory Group of Experts (SAGE) on Immunization has issued Interim recommendations for the use of the inactivated COVID-19 vaccine BIBP developed by Sinopharm/China National Pharmaceutical Group.
|
en
|
/favicon.ico
|
https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
|
Updated on 10 June 2022, pursuant to revised interim recommendations.
The WHO Strategic Advisory Group of Experts (SAGE) has issued interim recommendations for the use of the Sinopharm vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance document here.
Here is what you need to know.
Who can be vaccinated?
The vaccine is safe and effective for all individuals aged 18 and above. In line with the WHO Prioritization Roadmap and the WHO Values Framework, older adults, health workers and immunocompromised persons should be prioritised.
The Sinopharm vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to delay vaccination for 3 months following the infection.
Should pregnant and breastfeeding women be vaccinated?
The available data on the COVID-19 vaccine Sinopharm in pregnant women are insufficient to assess either vaccine efficacy or vaccine-associated risks in pregnancy. However, this vaccine is an inactivated vaccine with an adjuvant that is routinely used in many other vaccines with a documented good safety profile, including in pregnant women. The effectiveness of the COVID-19 vaccine Sinopharm in pregnant women is therefore expected to be comparable to that observed in non-pregnant women of similar age.
In the interim, WHO recommends the use of the COVID-19 vaccine Sinopharm in pregnant women when the benefits of vaccination to the pregnant woman outweigh the potential risks. To help pregnant women make this assessment, they should be provided with information about the risks of COVID-19 in pregnancy; the likely benefits of vaccination in the local epidemiological context; and the current limitations of safety data in pregnant women. WHO does not recommend pregnancy testing prior to vaccination. WHO does not recommend delaying pregnancy or considering terminating pregnancy because of vaccination.
Vaccine effectiveness is expected to be similar in breastfeeding women as in other adults. WHO recommends the use of the COVID-19 vaccine Sinopharm in breastfeeding women as in other adults. WHO does not recommend discontinuing breastfeeding after vaccination.
Who is the vaccine not recommended for?
Individuals with a history of anaphylaxis to any component of the vaccine should not take it.
Anyone with a body temperature over 38.5ºC should postpone vaccination until they no longer have a fever.
Is it safe?
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.
Safety data are limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared to younger age groups can be anticipated, countries considering using this vaccine in persons older than 60 years should maintain active safety monitoring.
How efficacious is the vaccine?
A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79%.
The trial was not designed and powered to demonstrate efficacy against severe disease in persons with comorbidities, in pregnancy, or in persons aged 60 years and above. Women were underrepresented in the trial. The median duration of follow-up available at the time of evidence review was 112 days.
Two other efficacy trials are under way but data are not yet available.
What’s the recommended dosage?
SAGE recommends the use of Sinopharm vaccine as 2 doses (0.5 ml) given intramuscularly.
SAGE recommends that a third, additional dose of the Sinopharm vaccine be offered to persons aged 60 and above as part of an extension of the primary series. Current data does not indicate the need for an additional dose in persons under 60 years of age.
SAGE recommends that severe and moderately immunocompromised persons should be offered an additional dose of vaccine. This is due to the fact that this group is less likely to respond adequately to vaccination following a standard primary vaccination series and are at higher risk of severe COVID-19 disease.
WHO recommends an interval of 3–4 weeks between the first and second dose of primary series. If the second dose is administered less than 3 weeks after the first, the dose does not need to be repeated. If administration of the second dose is delayed beyond 4 weeks, it should be given at the earliest possible opportunity. When administering an additional dose to over 60s, SAGE recommends countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting with the oldest age groups.
Is a booster dose recommended for this vaccine?
A booster dose may be considered 4 – 6 months after completion of the primary vaccination series, starting with the higher priority-use groups, in accordance with the WHO Prioritization Roadmap.
The benefits of booster vaccination are recognized following increasing evidence of waning vaccine effectiveness against mild and asymptomatic SARS-CoV-2 infection over time.
Either homologous (a different vaccine product to Sinopharm) or heterologous (a booster dose of Sinopharm) doses can be used. A study in Bahrain found that heterologous boosting resulted in a superior immune response compared to homologous boosting.
Can this vaccine be ‘mixed and matched’ with other vaccines?
SAGE accepts two heterologous doses of WHO EUL COVID-19 vaccines as a complete primary series.
To ensure equivalent or favourable immunogenicity or vaccine effectiveness either of the WHO EUL COVID-19 mRNA vaccines (Pfizer or Moderna) or the WHO EUL COVID-19 vectored vaccines (AstraZeneca Vaxzevria/COVISHIELD or Janssen) can be used as a second dose following a first dose with the Sinopharm vaccine dependent on product availability.
Does it prevent infection and transmission?
There is currently no substantive data available related to the impact of Sinopharm on transmission of SARS-CoV-2, the virus that causes COVID-19 disease.
In the meantime, WHO reminds of the need to maintain and strengthen public health measures that work: masking, physical distancing, handwashing, respiratory and cough hygiene, avoiding crowds and ensuring adequate ventilation.
Does it work against new variants of SARS-CoV-2 virus?
SAGE currently recommends using this vaccine, according to the WHO Prioritization Roadmap.
As new data becomes available, WHO will update recommendations accordingly. This vaccine has not yet been evaluated in the context of circulation of widespread variants of concern.
How does this vaccine compare to other vaccines already in use?
We cannot compare the vaccines head-to-head due to the different approaches taken in designing the respective studies, but overall, all of the vaccines that have achieved WHO Emergency Use Listing are highly effective in preventing severe disease and hospitalization due to COVID-19.
This webpage was updated on 10 June 2022 to update the latest guidance and ensure consistency of information and formatting.
|
|||||
6044
|
dbpedia
|
1
| 83
|
https://thediplomat.com/2021/06/chinas-covid-19-vaccine-rollout-surges-ahead/
|
en
|
China’s COVID-19 Vaccine Rollout Surges Ahead
|
[
"https://thediplomat.com/wp-content/themes/td_theme_v3/assets/logo/diplomat_logo_black.jpg",
"https://thediplomat.com/ads/magazine/cover/td-mag-s-1/issue_117_cover.jpg?v=1 138w, /ads/magazine/cover/td-mag-s-2/issue_117_cover.jpg?v=1 276w, /ads/magazine/cover/td-mag-m-1/issue_117_cover.jpg?v=1 219w, /ads/magazine/cover/td-mag-m-2/issue_117_cover.jpg?v=1 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-28-033041.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-28-033041.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-26-193248.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-26-193248.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-23-195813.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-23-195813.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-23-161856.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-23-161856.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-22-195933.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-22-195933.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2020/12/sizes/td-list-xs-1/thediplomat-2020-12-28-8.jpg 58w, https://thediplomat.com/wp-content/uploads/2020/12/sizes/td-list-xs-2/thediplomat-2020-12-28-8.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-20-014439.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-20-014439.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-19-200247.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-19-200247.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-16-192707.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-16-192707.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2021/03/sizes/td-list-xs-1/thediplomat-2021-03-04-5.jpg 58w, https://thediplomat.com/wp-content/uploads/2021/03/sizes/td-list-xs-2/thediplomat-2021-03-04-5.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-16-033156.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-16-033156.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-14-173957.jpeg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-14-173957.jpeg 116w",
"https://thediplomat.com/wp-content/uploads/2021/06/sizes/td-story-s-1/thediplomat-2021-06-02-9.jpg 300w, https://thediplomat.com/wp-content/uploads/2021/06/sizes/td-story-s-1/thediplomat-2021-06-02-9.jpg 300w, https://thediplomat.com/wp-content/uploads/2021/06/sizes/td-story-s-2/thediplomat-2021-06-02-9.jpg 600w, https://thediplomat.com/wp-content/uploads/2021/06/sizes/medium/thediplomat-2021-06-02-9.jpg 946w, https://thediplomat.com/wp-content/uploads/2021/06/sizes/medium_large/thediplomat-2021-06-02-9.jpg 1244w, https://thediplomat.com/wp-content/uploads/2021/06/sizes/large/thediplomat-2021-06-02-9.jpg 1568w",
"https://thediplomat.com/wp-content/uploads/2022/10/sizes/td-list-xs-1/thediplomat_2022-10-06-215423.jpg 58w, https://thediplomat.com/wp-content/uploads/2022/10/sizes/td-list-xs-2/thediplomat_2022-10-06-215423.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-1/thediplomat_2024-08-29-051649.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-xs-2/thediplomat_2024-08-29-051649.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/05/sizes/td-list-xs-1/thediplomat_2024-05-27-075735.jpg 58w, https://thediplomat.com/wp-content/uploads/2024/05/sizes/td-list-xs-2/thediplomat_2024-05-27-075735.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2022/06/sizes/td-list-xs-1/thediplomat_2022-06-08-071545.jpg 58w, https://thediplomat.com/wp-content/uploads/2022/06/sizes/td-list-xs-2/thediplomat_2022-06-08-071545.jpg 116w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-07-31-165450.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-07-31-165450.jpg 276w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-07-31-165432.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-07-31-165432.jpg 276w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-07-31-165505.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-07-31-165505.jpg 276w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-07-31-165435.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-07-31-165435.jpg 276w",
"https://thediplomat.com/wp-content/uploads/2020/11/sizes/thumbnail/thediplomat-2020-11-03-14.jpg 138w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-s-2/thediplomat-2020-11-03-14.jpg 276w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-m-1/thediplomat-2020-11-03-14.jpg 219w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-m-2/thediplomat-2020-11-03-14.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2020/11/sizes/thumbnail/thediplomat-2020-11-09-7.jpg 138w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-s-2/thediplomat-2020-11-09-7.jpg 276w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-m-1/thediplomat-2020-11-09-7.jpg 219w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-m-2/thediplomat-2020-11-09-7.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2020/11/sizes/thumbnail/thediplomat-2020-11-09-7.jpg 138w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-s-2/thediplomat-2020-11-09-7.jpg 276w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-m-1/thediplomat-2020-11-09-7.jpg 219w, https://thediplomat.com/wp-content/uploads/2020/11/sizes/td-list-m-2/thediplomat-2020-11-09-7.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2021/02/sizes/thumbnail/thediplomat-2021-02-19-6.jpg 138w, https://thediplomat.com/wp-content/uploads/2021/02/sizes/td-list-s-2/thediplomat-2021-02-19-6.jpg 276w, https://thediplomat.com/wp-content/uploads/2021/02/sizes/td-list-m-1/thediplomat-2021-02-19-6.jpg 219w, https://thediplomat.com/wp-content/uploads/2021/02/sizes/td-list-m-2/thediplomat-2021-02-19-6.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-22-151545.png 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-22-151545.png 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-22-151545.png 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-22-151545.png 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-21-142446.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-21-142446.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-21-142446.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-21-142446.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-19-101545.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-19-101545.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-19-101545.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-19-101545.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2021/03/sizes/thumbnail/thediplomat-2021-03-04-5.jpg 138w, https://thediplomat.com/wp-content/uploads/2021/03/sizes/td-list-s-2/thediplomat-2021-03-04-5.jpg 276w, https://thediplomat.com/wp-content/uploads/2021/03/sizes/td-list-m-1/thediplomat-2021-03-04-5.jpg 219w, https://thediplomat.com/wp-content/uploads/2021/03/sizes/td-list-m-2/thediplomat-2021-03-04-5.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-28-033041.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-28-033041.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-28-033041.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-28-033041.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-26-193248.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-26-193248.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-26-193248.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-26-193248.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-23-195813.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-23-195813.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-23-195813.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-23-195813.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-23-161856.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-23-161856.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-23-161856.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-23-161856.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2022/10/sizes/thumbnail/thediplomat_2022-10-06-215423.jpg 138w, https://thediplomat.com/wp-content/uploads/2022/10/sizes/td-list-s-2/thediplomat_2022-10-06-215423.jpg 276w, https://thediplomat.com/wp-content/uploads/2022/10/sizes/td-list-m-1/thediplomat_2022-10-06-215423.jpg 219w, https://thediplomat.com/wp-content/uploads/2022/10/sizes/td-list-m-2/thediplomat_2022-10-06-215423.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/08/sizes/thumbnail/thediplomat_2024-08-29-051649.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-s-2/thediplomat_2024-08-29-051649.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-1/thediplomat_2024-08-29-051649.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/08/sizes/td-list-m-2/thediplomat_2024-08-29-051649.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2024/05/sizes/thumbnail/thediplomat_2024-05-27-075735.jpg 138w, https://thediplomat.com/wp-content/uploads/2024/05/sizes/td-list-s-2/thediplomat_2024-05-27-075735.jpg 276w, https://thediplomat.com/wp-content/uploads/2024/05/sizes/td-list-m-1/thediplomat_2024-05-27-075735.jpg 219w, https://thediplomat.com/wp-content/uploads/2024/05/sizes/td-list-m-2/thediplomat_2024-05-27-075735.jpg 438w",
"https://thediplomat.com/wp-content/uploads/2022/06/sizes/thumbnail/thediplomat_2022-06-08-071545.jpg 138w, https://thediplomat.com/wp-content/uploads/2022/06/sizes/td-list-s-2/thediplomat_2022-06-08-071545.jpg 276w, https://thediplomat.com/wp-content/uploads/2022/06/sizes/td-list-m-1/thediplomat_2022-06-08-071545.jpg 219w, https://thediplomat.com/wp-content/uploads/2022/06/sizes/td-list-m-2/thediplomat_2022-06-08-071545.jpg 438w",
"https://thediplomat.com/ads/magazine/cover/td-mag-s-1/issue_117_cover.jpg?v=1 138w, /ads/magazine/cover/td-mag-s-2/issue_117_cover.jpg?v=1 276w, /ads/magazine/cover/td-mag-m-1/issue_117_cover.jpg?v=1 219w, /ads/magazine/cover/td-mag-m-2/issue_117_cover.jpg?v=1 438w"
] |
[] |
[] |
[
"Society",
"East Asia",
"China",
"China coronavirus",
"China COVID-19 vaccine",
"China Health Code app",
"COVID-19",
"Sinopharm",
"Sinovac"
] | null |
[
"Larry Mullin"
] |
2021-06-03T02:39:00+00:00
|
Despite some concerns and criticisms abroad, most Chinese (and expats) are eager to roll up their sleeves for the jab.
|
en
|
https://thediplomat.com/2021/06/chinas-covid-19-vaccine-rollout-surges-ahead/
|
A mere 15 minutes after his Sinovac jab at a Beijing stadium outfitted with vaccination stations on April 5, American expat Steven saw an inoculation status update on his jiankang bao, or “Health Kit,” a smartphone mini-app that has become ubiquitous in China throughout the COVID-19 pandemic. It was an efficient and technologically advanced process, according to Steven, who asked to only give his first name. He had eagerly queued up on one of the vaccine’s first days of availability for foreigners in China, well before the World Health Organization gave emergency approval to Sinopharm, the country’s other major vaccine, on May 7; Sinovac wasn’t given the WHO’s green light until June 2. One day before its WHO approval, a study in a Brazilian city determined the Sinovac vaccine is 95 percent effective in reducing COVID-19 deaths, according to a June 1 Chinese state media report, while Sinopharm was deemed “safe and effective” in a study published in the Journal of the American Medical Association late last month (though some critics still harbor doubts).
The WHO approval came after months of bad international press about Chinese vaccines. A few days after Steven’s inoculation, none other than Gao Fu, the director of the China Centers for Disease Control, was quoted as admitting that Chinese vaccines “don’t have very high protection rates,” before adding that officials are considering “whether we should use different vaccines from different technical lines for the immunization process.” He subsequently called that a misunderstanding, and said he was merely discussing methods to boost vaccine effectiveness “even further,” according to a DW article that went on to point out how Sinopharm and Sinovac are “more effective than some influenza vaccines” that have long been used, even though Western jabs like Pfizer and Moderna have higher efficacy levels against COVID-19. Chinese state media responded with an editorial titled: “Twisting Gao Fu’s remark shows spite against China’s COVID-19 vaccines.”
Some international experts spent months prior criticizing the efficacy rates of Chinese vaccines, while also criticizing Sinopharm and Sinovac for not releasing sufficient data. Adding to the furor was a September 2020 announcement from Sinopharm that it had inoculated hundreds of thousands of Chinese citizens before passing the final phase 3 clinical trials. This was described as “unsound public health practice” at the time by former University of Sydney global health security professor Adam Kamradt-Scott. He told Time magazine, “We have previous examples of where vaccines that have not gone through sufficient clinical trials have demonstrated adverse reactions with long-term health consequences.”
But Jennifer Huang Bouey was touting Chinese vaccines even during the rampant international criticism that followed a Brazilian study that put Sinovac’s efficacy at 50.38 percent, far short of its formerly announced 78 percent efficacy. At the time, Bouey, an epidemiologist and professor of global health at Georgetown University, said greater attention should be paid to the “endpoint outcomes” upon which vaccine efficacy is based.
In the case of Brazil’s phase 3 trial for Sinovac’s vaccine, Bouey said the drop from 78 percent to 50.38 could be attributed to the difference between preventing cases that are moderate to severe, versus those that are “very mild,” as the endpoint outcome. In her view, the results were therefore “not conflicting nor problematic. It is not a reason for questioning the vaccine’s efficacy to prevent moderate and severe cases of COVID-19.” She then pointed to the Pfizer vaccine’s steep dip to 29 percent efficacy when suspected cases, which are typically mild cases, were factored in. Referencing a blog post by Peter Doshi, editor of the peer-reviewed medical trade journal The BMJ, Bouey said that the Pfizer vaccine’s more than 90 percent efficacy was based on 170 symptomatic COVID-19 cases. Meanwhile, over 3,000 suspected and likely mild cases were not part of that calculation. She went on to note that the influenza vaccine that “we take every year” targets severe cases. Its efficacy? Typically a mere 40 percent.
Bouey added that with an understanding that the vaccines’ primary goal is “to reduce moderate and severe cases of COVID-19 safely, I’d say people and countries should take any vaccine they can get hold of, and keep social distancing practice until the majority of the population are vaccinated.”
That positive sentiment has been shared by a number of expats in China. Approximately 20 percent of foreigners in Beijing opted to be inoculated within their first week of eligibility, according to a survey by English language news site the Beijinger. As of May 8, that number shot up to 80 percent.
Some China expats who spoke to The Diplomat are encouraged that Sinovac and Sinopharm were tried and true inactivated vaccines. Employed for decades against polio, whopping cough, hepatitis A, and more, this traditional vaccine type works by exposing the immune system to the virus via killed viral particles, and is deemed safe because the shots are unable to infect recipients with the virus. The leading Western Moderna and Pfizer vaccines are a departure from that conventional method, using cutting edge mRNA technology. According to the U.S. Centers for Disease Control and Prevention, these vaccines help cells learn how to make proteins that produce antibodies, which defend the body against infection from the virus. The Oxford University-AstraZeneca vaccine, meanwhile, utilized a weakened genetically engineered virus that is the source of the common cold for chimpanzees.
Like those of Sinovac and Sinopharm, AstraZeneca’s vaccine can be easily stored at 2-8 degrees Celsius, as opposed to the more exacting -20 Celsius and -70 Celsius storage temperatures needed for Moderna and Pfizer, respectively. This less cumbersome refrigeration requirement has made Sinovac attractive to nations as varied as Indonesia, Brazil, and Chile. Meanwhile, Mexico and Hungary are among the countries using Sinopharm, according to a Chinese state media published list detailing the more than 60 countries that have authorized the use of Chinese vaccines.
In China, the Sinopharm vaccine became available for general use at the end of December 2020, after the company announced an efficacy rate of 79 percent in phase three trials, though it was criticized internationally for not offering further details. Sinovac followed suit in early February. By that time, China’s vaccination program, which has involved both of those vaccines, along with another candidate from Sinopharm, had administered more than 31 million doses, with a focus on those at higher risk of infection. A fourth candidate vaccine from CanSino was reportedly being used to inoculate Chinese military personnel.
Those Chinese vaccines had a head start on their Western counterparts thanks to the “uniqueness” of China’s regulatory market, according to Yiwu He, the chief innovation officer at the University of Hong Kong, who worked on his own COVID-19 vaccine candidate for the Chinese government. In the spring of 2020, officials established a “green channel” for approval of COVID-19 vaccines. This included five technical routes: inactivated vaccines (like the front-running Sinopharm and Sinovac vaccines), recombinant protein vaccines, adenoviral vector vaccines, attenuated influenza vaccines, and nucleic acid vaccines. “Once the government set up those five candidate areas, it began working with companies and universities on approvals,” said He. Chinese citizens didn’t doubt these briskly readied jabs, He added. That’s because China’s swift flattening of its pandemic curve, especially compared to spiking numbers in other locales, led “average people to think: ‘If the government can control the spreading of the virus well, then it can also do well developing a vaccine.’”
And yet, criticism has remained steady from a number of experts. University of Hong Kong virologist Jin Dong-Yan took issue with how little vaccine efficacy data was published in China. Prior to the WHO’s May 8 approval, he told The Diplomat that not only efficacy rates but also data transparency were important concerns. “The scientific community should push them and others to publish and share the real-world statistics and other results as soon as possible,” Jin said.
However, Julian Tang, a professor in the department of respiratory sciences at the University of Leicester in the U.K., said the matter’s thorny politics should be taken into consideration. He, by contrast, saw the Chinese government’s submission of its Sinopharm and Sinovac data to the WHO as a plus, before concluding: “Given the response of the West to China being the apparent origin of the COVID-19 pandemic, it does not surprise me that they may shy away from publishing their vaccine trial data or results in any Western journals.” He then pointed to Russia’s Sputnik V vaccine, the success of which made AstraZeneca look comparatively “overhyped,” in his view. That should give Western critics pause before finger wagging, Tang added.
Sinopharm’s rollout in the United Arab Emirates, meanwhile, was “encouraging,” according to Catherine Bennett, chair in epidemiology at Deakin University’s School of Health and Social Development. Prior to the WHO’s emergency approval, she told The Diplomat that the 50 percent drop in both cases and deaths once half of the population was vaccinated “suggests good safety and effectiveness” for Sinopharm jabs. She added: “Case numbers have plateaued as of late and we would hope to see the decline continue with that level of vaccine coverage as, with the efficacy reported to be 79 percent, we would hope to see signs it was interrupting transmission, not just protecting those vaccinated.” However, she said she would “feel more comfortable” once the WHO completed its review and decided whether or not to grant emergency approval, which it has since done for both Sinopharm and Sinovac’s vaccine candidates.
Such hesitancy wasn’t shared by a number of expats in China. Shanghai expat Sven said that he “immediately signed up” to receive Sinopharm once it became available. Negative international headlines about low efficacy rates didn’t faze him, especially because China is using inactivated vaccine processes that have “been around for decades, the same kind we received as children,” added Sven, who, like all vaccinated expats who spoke to The Diplomat, asked that only their first names be used. He sees vaccination as a civic duty that will hopefully raise the overall immunization totals. Meanwhile Sammy, an expat residing in the southern Chinese beach town of Sanya, cited more pragmatic and personal reasons for her vaccination, mainly a desire to visit home more freely after being separated from family since the beginning of the pandemic.
Enthusiasm was even higher among some Chinese citizens. In fact, hundreds of thousands of state officials and pharmaceutical executives were inoculated as early as last summer. Yang Bao Shan, a security guard at a shopping complex in Beijing’s Haidian district, had been vaccinated along with his colleagues back in February. “It’s really good that we are among the first in line,” he said at the time, adding: “Now, we can feel confident to be among the public. I think the government is handling this very well.”
That point was seconded by Tang, a driver for the ubiquitous Didi Chuxing ride sharing app. While driving throughout Beijing’s Chaoyang district on February 12, he sported a stylish black cloth face mask that complimented his dark aviator sunglasses, rather than the more widely used paper blue hospital masks. All the while, he gently reminded passengers to use their phones to scan the digital jiankang bao health QR code pasted to the back of his seat, to prove they were safe to board. Vaccines were made mandatory for Tang and all of his fellow Didi drivers on January 20. Tang said the jab “makes me safer, which is definitely good for the public.” Such comments from Tang are made all the more significant by the hefty 1 million RMB fine his employer received in January after a handful of Didi drivers tested positive for COVID-19. At a red light, Tang dug into his glove box to proudly show a card certifying his vaccination. He then declared: “Right now, China is the safest place to be during the pandemic.”
However, that was by no means the consensus among all Chinese citizens. Take Linda, the Chinese manager of a popular cocktail bar in Beijing’s bustling Sanlitun neighborhood, who only agreed to answer questions under her English name. She and neighboring food and beverage proprietors were given notice by officials in January that service industry workers would be among the first to be offered vaccines. But the then-newness of those vaccines, and a lack information about them, made Linda’s bar staff “a little bit worried,” she said, “so we didn’t do it” at the time. Meanwhile Mario, the owner and operator of a popular neighboring bar and grill (who answered questions under similar conditions as Linda) said officials warned him in January that all Sanlitun employees that handle frozen food would need to be vaccinated shortly after the lunar new year, or undergo weekly virus testing. While he was not yet certain that the vaccines were flawless, he was reassured that “it seems all good for everyone who has been vaccinated so far.”
Such lingering ambivalence, along with months of successful containment of the virus, undermined vaccination urgency for many Chinese citizens when the rollout for those jabs began in earnest this spring. That all changed, however, thanks to a COVID-19 resurgence in both Liaoning and Anhui provinces in May. While those cases remained in the low double digits, they were alarming enough to propel vaccination rates toward the lofty targets the government had set months earlier. A record high of 14 million doses were doled out on May 16, and the government’s goal to vaccinate half a billion of its population was reached a week later.
As more and more Chinese citizens queue up for Sinovac and Sinopharm jabs at home, the WHO’s emergency approval of both shots is changing the conversation abroad. Jin, the University of Hong Kong virologist who has been critical of Chinese vaccines in interviews with a number of outlets, admitted the emergency approval “helps to convince others of its efficacy and to justify its use in places where government and people still look up to the WHO, or where the WHO’s endorsement is still a big deal. It may also help the vaccination campaign back at home in China.” He also said widespread international usage of the vaccine has the potential to the flatten the curve of new cases, decrease deaths and hospitalizations, and grant greater access to vaccines for countries short on resources.
However, the efficacy rates and lack of transparent trial data are still matters of concern, in his view. “Approval from the WHO is not the ultimate goal but just the beginning of a new journey,” he said, before encouraging Chinese vaccine designers and manufacturers to enhance those products with dose adjustments, combinations with other vaccines, and perhaps conduct new trials for the development of improved jabs.
Bennett, meanwhile, said skeptics should bear in mind that “we have come to expect very highly efficacious vaccines, but the criteria for approving vaccines is based on safety and a much broader range of efficacy.” She went on to describe the potential of Sinopharm to slow the virus and bolster containment methods. “It’s another tool in the toolbox, not as sharp as others, but we need them all to fight this virus,” she said. “[It’s] better than nothing and buys a little time until other vaccines can be more widely distributed.”
|
||||||
6044
|
dbpedia
|
0
| 20
|
https://www.voanews.com/a/china-promotes-vaccines-around-the-world-but-critics-point-to-lower-efficacy-/6355437.html
|
en
|
China Promotes Vaccines Around the World, but Critics Point to Lower Efficacy
|
[
"https://ssc.voanews.com/b/ss/bbgprod,bbgentityvoa/1/G.4--NS/587448353?pageName=voa%3aeng%3aw%3aarticle%3achina%20promotes%20vaccines%20around%20the%20world%2c%20but%20critics%20point%20to%20lower%20efficacy%20&c6=china%20promotes%20vaccines%20around%20the%20world%2c%20but%20critics%20point%20to%20lower%20efficacy%20&v36=8.33.0.0.279&v6=D=c6&g=https%3a%2f%2fwww.voanews.com%2fa%2fchina-promotes-vaccines-around-the-world-but-critics-point-to-lower-efficacy-%2f6355437.html&c1=D=g&v1=D=g&events=event1,event52&c16=voa%20english&v16=D=c16&c5=s_covid-19-pandemic&v5=D=c5&ch=covid-19%20pandemic&c15=english&v15=D=c15&c4=article&v4=D=c4&c14=6355437&v14=D=c14&v20=no&c17=web&v17=D=c17&mcorgid=518abc7455e462b97f000101%40adobeorg&server=www.voanews.com&pageType=D=c4&ns=bbg&v29=D=server&v25=voa&v30=461&v105=D=User-Agent ",
"https://www.voanews.com/Content/responsive/img/player-spinner.png",
"https://www.voanews.com/Content/responsive/VOA/en-US/img/logo-compact.svg",
"https://www.voanews.com/Content/responsive/VOA/en-US/img/logo.svg",
"https://www.voanews.com/Content/responsive/VOA/en-US/img/logo-print.gif",
"https://www.voanews.com/Content/responsive/VOA/en-US/img/logo-print_color.png",
"https://gdb.voanews.com/f3ea4aa1-c422-428f-b4b9-659b145a2bc8_w250_r1_s.jpg",
"https://gdb.voanews.com/fa8d9e9d-008d-4dc8-89d1-84a2099574bf_w100_r1.jpg",
"https://gdb.voanews.com/fa8d9e9d-008d-4dc8-89d1-84a2099574bf_w33_r1.jpg",
"https://gdb.voanews.com/8a35ed38-4e39-418b-b195-76d109f50833_cx0_cy20_cw0_w100_r1.jpg",
"https://gdb.voanews.com/8a35ed38-4e39-418b-b195-76d109f50833_cx0_cy20_cw0_w33_r1.jpg",
"https://gdb.voanews.com/9b2a0bdb-47ab-468e-80d1-b9b3810b9ddb_w100_r1.jpg",
"https://gdb.voanews.com/9b2a0bdb-47ab-468e-80d1-b9b3810b9ddb_w33_r1.jpg",
"https://gdb.voanews.com/f1fb3836-7d52-4eb2-9a3f-b1743c59a1fa_cx0_cy8_cw0_w100_r1.jpg",
"https://gdb.voanews.com/f1fb3836-7d52-4eb2-9a3f-b1743c59a1fa_cx0_cy8_cw0_w33_r1.jpg"
] |
[] |
[] |
[
"East Asia",
"Science & Health",
"China News",
"COVID-19 Pandemic",
"vaccine",
"Sinovac"
] | null |
[
"Carol Pearson"
] |
2021-12-15T06:20:04+00:00
|
China’s vaccines: are they safe? Are they effective? What are their advantages?
|
en
|
/Content/responsive/VOA/img/webApp/favicon.svg
|
Voice of America
|
https://www.voanews.com/a/china-promotes-vaccines-around-the-world-but-critics-point-to-lower-efficacy-/6355437.html
|
COVID-19 was first discovered in China, which became the first country to produce a vaccine. Sinovac and Sinopharm are China’s leading vaccine makers, and both manufacture World Health Organization-approved COVID-19 vaccines.
What’s the difference between the two companies?
Sinovac is a privately owned company, while Sinopharm is government-run. Scientists at both companies use the same method to make both vaccines.
How are the vaccines made?
Dr. Andrea Cox, a professor at the Johns Hopkins University School of Medicine with a special interest in immunization, has provided expert advice to VOA about COVID-19 vaccines. Cox told VOA that scientists take a type of bacteria — or in this case, a virus — and inactivate or kill it. They then inject it into people. Because the virus is dead, it can’t infect anyone. Then, if a vaccinated person is exposed to the live virus, that person’s body recognizes it and fights it off.
Are these vaccines effective?
According to Cox, the Chinese vaccines are not as effective as the Moderna, Pfizer-BioNTech, AstraZeneca and Johnson & Johnson vaccines, so they aren’t the preferred jabs in countries that have access to the others. The Sinovac vaccine is about 50% effective, while Sinopharm’s effectiveness is higher, at 78%, WHO reported. Two doses are needed for both vaccines.
Vaccines are often mixed with an adjuvant, a harmless ingredient such as aluminum salts or a bubble of fat, to make them more effective. On its website, the Centers for Disease Control and Prevention says “aluminum is one of the most common metals found in nature and is present in air, food, and water,” so it’s not a foreign or dangerous ingredient, although anti-vax groups claim it is. For example, Sinovac uses aluminum hydroxide, an ingredient also used to treat an upset stomach. Sinopharm also uses an adjuvant in its vaccine.
Do the vaccines have advantages?
The Sinovac and Sinopharm vaccines have a major advantage over other COVID-19 vaccines: They are easy to store and need only normal refrigeration. That’s a huge plus in getting a COVID-19 vaccine to people in areas where there is little or no refrigeration.
“In an ideal world,” Cox said, “we wouldn’t need them. But at this point, we need a way to get the world vaccinated as rapidly and effectively as possible, and it may require a use of vaccines that we know are not as good but are better than not being vaccinated."
What will end the pandemic?
WHO says safe and effective vaccines are a game-changing tool, but for now and the foreseeable future, it recommends continued mask wearing, frequent hand-washing, good indoor ventilation, physical distancing, avoiding crowds and, above all, getting vaccinated when you can with whatever vaccine is available.
“Having the world’s best scientists — and I do really mean the world’s best scientists — thinking about how to make effective vaccines and deliver them to a global population is critical,” Cox said. “And the more data we get on these vaccines, the more we will be able to select out vaccines that do protect the largest number of the world’s population.”
As WHO says: “It’s not vaccines that will stop the pandemic, it’s vaccination.”
|
||||
6044
|
dbpedia
|
2
| 39
|
https://www.mitsubishicorp.com/jp/en/pr/archive/2009/html/0000008788.html
|
en
|
Mitsubishi Corporation - Press Room - 2009 - Comprehensive Strategic Alliance with Sinopharm Group and Investment in Beijing Huahong
|
[
"https://www.mitsubishicorp.com/jp/en/cmn/img/st.png",
"https://www.mitsubishicorp.com/jp/cmn/img/gh_btn_global.gif",
"https://www.mitsubishicorp.com/jp/cmn/img/menu_btn_global.png",
"https://www.mitsubishicorp.com/jp/en/pr/091015/img/0000008788_img1.jpg",
"https://www.mitsubishicorp.com/jp/cmn/img/btn_gotop.png"
] |
[] |
[] |
[
""
] | null |
[] | null |
en
|
/favicon.ico
|
Mitsubishi Corporation
|
https://www.mitsubishicorp.com/jp/en/pr/archive/2009/html/0000008788.html
|
Press Room
Comprehensive Strategic Alliance with Sinopharm Group and Investment in Beijing Huahong
Mitsubishi Corporation（Mitsubishi）, MEDIPAL HOLDINGS CORPORATION . （MEDIPAL）and major, Shanghai-based Chinese pharmaceutical distributor and whole-seller Sinopharm Group Co., Ltd. （Sinopharm Group）, have signed a memorandum for a comprehensive strategic alliance. To begin this alliance, Mitsubishi and MEDIPAL have purchased shares of Sinopharm Group Beijing HuaHong Co.,Ltd. （Huahong）from Sinopharm Group and Beijing ChangXinYiDa Investment Consulting Co., Ltd. (ChangXinYiDa). and undertaken an increased issuance of Huahong stock. Through this joint venture investment, Mitsubishi and MEDIPAL plan to make inroads into China’s pharmaceutical distribution and wholesales business.
１．Background
In September 2005, Mitsubishi and MEDIPAL signed a memorandum for a comprehensive strategic alliance in the healthcare business. The companies have since been jointly developing operational support for hospitals and prescription drug store chains in Japan. Envisioning further expansion in this domain and its profit base, the partners have been looking more and more seriously into future business development in the rapidly growing Chinese market.
Over the last five years, the Chinese pharmaceutical industry has continued to achieve double-digit growth, and is currently a four trillion yen market. With increasing deregulations enticing further foreign investment, this market is expected to grow even more from hereon. There has been some inefficiency, however, among many of the pharmaceutical distributors, and strong customer support, which is often taken for granted in Japan, is lacking. Distributors are being pressed to increase their management efficiency, better maintain their distribution functions, and generally improve the quality of their services.
Sinopharm Group is a major entity among China’s State-owned Assets Supervision and Administration Commission of the State Council (SASAC). It is the largest distributor in China and the only company capable of nationwide distribution. After numerous discussions, Mitsubishi, MEDIPAL and Sinopharm Group concluded that this alliance would allow them to marry their unique strengths for optimum development of the Chinese market. By investing in Huahong, and launching a joint venture in pharmaceutical distribution, Mitsubishi and MEDIPAL got the alliance off to a promising start. Huahong is a key subsidiary in Beijing, where pharmaceutical consumption is high.
２．Details
The main areas this alliance will cover are listed below. More in-depth discussions on each of these areas are planned via a project team, which is to be set up jointly by the three partners.
(1) Multi-Area Corporation of Pharmaceutical Distribution Business
(2) Pharmaceuticals and their constituents / Medical Care & Equipment Imports and Expansion of Sales.
(3) Joint Operation of Group Purchases, Deliveries and Management for Hospitals
(4) Development of Hospital Pharmaceutical Department Management
(5) Development of Prescription Pharmaceutical Chain Management
３．Investment in Huahong
１）Objective
Huahong is located in Beijing, where pharmaceutical consumption is the highest in China. The company began as a pharmaceutical distributor, and is expected to grow further from hereon. Mitsubishi and MEDIPAL have dispatched employees to the company to provide know-how in hospital management and internal operations based on their outsourcing business in Japan. This will set Huahong apart from the competition and help the company gain a larger market share in Beijing. For the time being marketing will be limited to Beijing; however, this may be expanded after discussions with Sinopharm Group. Furthermore, this investment will help strengthen the relationship with Sinopharm Group, facilitating greater access to sales channels throughout China. By utilizing Mitsubishi’s global sales network and MEDIPAL’s good relationship with Japanese Pharmaceutical Manufacturers, the partners should be able to expand these manufacturers’ business in the Chinese market.
２）Fundamental Scheme
Huahong is incorporated under Chinese law as a Limited Liability Company with a registered capital of 40,000,000RMB.
Sinopharm Group own 60% of Huahong, and ChangXinYiDa 40%.
Through this joint venture, Mitsubishi will acquire 9% interest in Huahong from Sinopharm Group and 16% interest from ChangXinYiDa, for a total of 25%. MEDIPAL will acquire 14% interest from ChangXinYiDa.
After completion of the stock transfer, Huahong’s capital will be increased. The increase in shares will be pro-rated between the four shareholders of Mitsubishi, MEDIPAL, Sinopharm Group, and ChangXinYiDa.
Huahong will then be re-registered as a Sino-Japan joint venture foreign company, with a capital of 80,000,000RMB.
＜Investment scheme＞
[Sinopharm Group Co., Ltd. Outline]
Operation
Pharmaceutical wholesales to hospitals and pharmacies, logistics and management of drugstores.
（Trade with 4,200 hospitals, approx.5,800 pharmacies,3,000 whole-sellers and 3,600 other medical institutes）
Group company of China National Pharmaceutical Group Corporation which is directly controlled by the State-owned Assets Supervision and Administration Commission of the State Council（SASAC）,China’s largest and only nationwide distributor and whole-seller.
Head office
Shanghai
History
Jointly established in January 2003, by China National Pharmaceutical Group Corporation and Fosun Pharmaceuticals (Group) Corporation.
Shareholders
Sinopharm Industrial Investment Co., Ltd. (96% *), China National Pharmaceutical Group Corporation (4%).
（*China National Pharmaceutical Group Corporation 51%, Fosun Pharmaceuticals (Group) Corporation 49%）
●China National Pharmaceutical Group Corporation
Established in 1951. SASAC controlled Pharmaceutical Manufacturing & Distribution company.
（Major distribution is handled by Sinopharm Group.）
●Fosun Pharmaceuticals (Group) Corporation
Private enterprise established in 1994, involved in bio-medical and pharmaceutical operations, and manufacturing of products for clinical trials. Established and developed by four individuals from Fudan University and IPO at Hongkong market in July 2007.
Chairman
She YuLin（China National Pharmaceutical Group Corporation CEO）
CEO
Fu MingZhong
Employee
11,123
Financials
Revenue 38.2 Billion RMB, profit after tax 818 Million RMB (end of 2008)
３）Outline of Huahong(after increasing capital)
（１）Co. Name
Sinopharm Medicine Holding Beijing Huahong Co., Ltd.
（２）Operation
Wholesales, import, export and sales of pharmaceuticals in China, medical equipment and group purchasing and supply management for hospitals.
（３）Place
Chongwen District, Beijing, China
（４）Representative
CEO：Hua WeiQiang
（５）Capital
80,000,000RMB〔approx.1.2 Billion Japanese yen〕
（６）# of employees
120
（７）Shareholders
Sinopharm Group：51％
ChangXinYiDa：10％
Mitsubishi：25％
MEDIPAL：14％
（８）Business
license period
30 years
（９）Fiscal year
January 1st to December 31st
（10）Established
April 29, 1998
（11）Launch date
End of October, 2009(Plan)
（12） Financials
（Fiscal Year 2008）
Revenues 1,053.38 Million RMB（15.8 Billion yen）
Net Profits 25.46 Million RMB（ 400 Million yen）
Total Assets 394.50 Million RMB（ 5.9 Billion yen）
* Figure of 〔 〕，calculated at 1 RMB ＝ 15 Japanese yen.
Inquiry Recipient
Mitsubishi Corporation
Telephone:+81-3-3210-2171 / Facsimile:+81-3-5252-7705
|
|||||
6044
|
dbpedia
|
0
| 77
|
https://asia.nikkei.com/Spotlight/Coronavirus/China-approves-first-domestic-COVID-vaccine-developed-by-Sinopharm
|
en
|
China approves first domestic COVID vaccine, developed by Sinopharm
|
[
"https://www.facebook.com/tr?id=1076130949081971&ev=PageView&noscript=1",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F9%2F5%2F4%2F7%2F31407459-1-eng-GB%2F2020-05-20T000000Z_995059873_RC2FSG91QI5M_RTRMADP_3_HEALTH-CORONAVIRUS-RUSSIA-VACCINE.JPG?width=693&height=390&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F8%2F6%2F1%2F6%2F31506168-3-eng-GB%2FCropped-16093131402020-12-30T071940Z_542993987_RC2JXK9JEREN_RTRMADP_3_HEALTH-CORONAVIRUS-BRITAIN-VACCINE.JPG?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F4%2F8%2F9%2F4%2F31164984-5-eng-GB%2FCropped-160775866720201212+vaccine.JPG?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F7%2F1%2F4%2F7%2F48037417-1-eng-GB%2Fphoto_SXM2024072500009469.jpg?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F1%2F5%2F5%2F2%2F47022551-1-eng-GB%2FIMG_0103.jpg?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F7%2F0%2F1%2F1%2F45681107-3-eng-GB%2FCropped-16843517632023-01-04T000000Z_920438820_RC2KJY9SDC8K_RTRMADP_3_HEALTH-CORONAVIRUS-CHINA.JPG?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://asia.nikkei.com/bundles/app/images/app-modal.png?ez"
] |
[] |
[] |
[
"China",
"approves",
"first",
"domestic",
"COVID",
"vaccine",
"",
"developed",
"Sinopharm"
] | null |
[
"CK TAN"
] |
2020-12-31T08:49:21+00:00
|
SHANGHAI -- China approved the country's first domestically made COVID-19 vaccine on Thursday, paving the way for mass inoculation and recognition ove
|
en
|
/apple-touch-icon-144x144.png?ez
|
Nikkei Asia
|
https://asia.nikkei.com/Spotlight/Coronavirus/China-approves-first-domestic-COVID-vaccine-developed-by-Sinopharm
|
SHANGHAI -- China approved the country's first domestically made COVID-19 vaccine on Thursday, paving the way for mass inoculation and recognition overseas.
Developed by the Beijing Biological Products Institute under China National Pharmaceutical Group, or Sinopharm, the vaccine showed 79.34% efficacy and a 99.52% antibody positive conversion rate in Phase 3 clinical trial results, the institute announced a day earlier.
|
||||
6044
|
dbpedia
|
2
| 81
|
https://www.thenationalnews.com/uae/2021/09/13/work-begins-on-sinopharm-vaccine-plant-in-serbia-in-tie-up-with-uae/
|
en
|
Work begins on Sinopharm vaccine plant in Serbia in tie-up with UAE
|
[
"https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/G64IQ6JKKZAWPBH5JVVOQZLFDU.jpg?smart=true&auth=4984205f0580af541dcf35f279ae8c1f09789d838a9522e1bbdc2a352d9aaf18&width=400&height=225",
"https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/https%3A%2F%2Fs3.amazonaws.com%2Farc-authors%2Fthenational%2F736ebb26-e270-44c5-96a2-80452d783888.png?smart=true&auth=6b2c4dc0614f332daaa4e848c41f090496fd16da3ccccaa940132372e6a74710&width=70&height=70",
"https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/3BV57UHMU5BJXDV3MM5MJTV4MU.jpg?smart=true&auth=e4e2705ee3418d09fe7a26f3e62f8edf9364ae54bb010b100c053053560d0c7d&width=200&height=200"
] |
[] |
[] |
[
""
] | null |
[
"Gillian Duncan"
] |
2021-09-13T00:00:00
|
Project is a partnership between Group42, Sinopharm CNBG, the Republic of Serbia and Hayat Biotech
|
en
|
/pf/resources/favicon.jpeg?d=771
|
The National
|
https://www.thenationalnews.com/uae/2021/09/13/work-begins-on-sinopharm-vaccine-plant-in-serbia-in-tie-up-with-uae/
|
The UAE Today
The latest news and analysis from the Emirates
|
||||
6044
|
dbpedia
|
1
| 17
|
https://asia.nikkei.com/Business/Biotechnology/China-s-Sinopharm-doubles-output-capacity-for-2020-vaccine-launch
|
en
|
China's Sinopharm doubles output capacity for 2020 vaccine launch
|
[
"https://www.facebook.com/tr?id=1076130949081971&ev=PageView&noscript=1",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F2%2F7%2F0%2F1%2F28061072-1-eng-GB%2FRTS3CIYD_2048x1152.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F1%2F2%2F1%2F7%2F27487121-3-eng-GB%2FCropped-1591289282RTX32OB6.JPG?width=693&height=390&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F3%2F2%2F4%2F3%2F27923423-1-eng-GB%2FRTS2GU51+%281%29.JPG?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F6%2F3%2F5%2F4%2F27894536-3-eng-GB%2FCropped-159306086020200625+36Kr+main.jpeg?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F0%2F3%2F7%2F6%2F44906730-4-eng-GB%2FCropped-1679512927-11-26T144415Z_1386840796_RC22JD9NXRA0_RTRMADP_3_GSK-RESULTS.JPG?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F7%2F8%2F1%2F9%2F40459187-5-eng-GB%2FCropped-1653059050photo_SXM2022052000009293.jpg?width=240&height=137&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms",
"https://asia.nikkei.com/bundles/app/images/placeholder.jpg?ez",
"https://asia.nikkei.com/bundles/app/images/app-modal.png?ez"
] |
[] |
[] |
[
"China's",
"Sinopharm",
"doubles",
"output",
"capacity",
"2020",
"vaccine",
"launch"
] | null |
[
"Staff"
] |
2020-07-03T17:19:30+00:00
|
DALIAN, China -- Chinese drugmaker Sinopharm has completed construction of a plant in Wuhan for mass production of a coronavirus vaccine candidate now
|
en
|
/apple-touch-icon-144x144.png?ez
|
Nikkei Asia
|
https://asia.nikkei.com/Business/Biotechnology/China-s-Sinopharm-doubles-output-capacity-for-2020-vaccine-launch
|
DALIAN, China -- Chinese drugmaker Sinopharm has completed construction of a plant in Wuhan for mass production of a coronavirus vaccine candidate now under development, doubling its capacity to more than 200 million doses a year
The state-backed company, known formally as China National Pharmaceutical Group, will be able to make 100 million doses a year at the site. The investment amount has not been disclosed. After the groundbreaking in March, construction took place quickly with support from the local government.
|
||||
6044
|
dbpedia
|
3
| 18
|
https://theconversation.com/sinopharm-covid-vaccine-the-world-needs-to-keep-using-it-even-if-its-less-effective-than-pfizer-162207
|
en
|
Sinopharm COVID vaccine: the world needs to keep using it, even if it’s less effective than Pfizer
|
[
"https://cdn.theconversation.com/static/tc/@theconversation/ui/dist/esm/logos/logo-en-b159aca2598f351db37072c75294e4c8.svg",
"https://cdn.theconversation.com/static/tc/@theconversation/ui/dist/esm/logos/logo-en-b159aca2598f351db37072c75294e4c8.svg",
"https://images.theconversation.com/files/406481/original/file-20210615-15-epel9k.jpg?ixlib=rb-4.1.0&rect=155%2C243%2C4511%2C2901&q=20&auto=format&w=320&fit=clip&dpr=2&usm=12&cs=strip",
"https://cdn.theconversation.com/avatars/94236/width170/image-20230517-27-e9af07.jpg",
"https://images.theconversation.com/files/406486/original/file-20210615-3832-10jtjzz.jpg?ixlib=rb-4.1.0&q=45&auto=format&w=754&fit=clip",
"https://images.theconversation.com/files/406485/original/file-20210615-23-1dysi8k.jpg?ixlib=rb-4.1.0&q=45&auto=format&w=754&fit=clip",
"https://jobs.theconversation.com/uploads/job/logo/338309932/Swinburne_University_of_Technology-logo-94B692951E-seeklogo.com.png",
"https://jobs.theconversation.com/uploads/job/logo/338155911/logo-1449792112.jpg",
"https://jobs.theconversation.com/uploads/job/logo/338287312/logo-1520549009.png",
"https://jobs.theconversation.com/uploads/job/logo/337873314/images.png",
"https://jobs.theconversation.com/uploads/job/logo/336998628/TC_rescaled_logo_for_Jobboard_copy_TRANSPARENT.png"
] |
[] |
[] |
[
""
] | null |
[
"Michael Head"
] |
2021-06-15T14:56:39+00:00
|
Infections have been reported in people vaccinated with the Sinopharm vaccine, but these aren’t necessarily unexpected.
|
en
|
The Conversation
|
https://theconversation.com/sinopharm-covid-vaccine-the-world-needs-to-keep-using-it-even-if-its-less-effective-than-pfizer-162207
|
In western countries, attention has understandably focused on which of the western-made COVID-19 vaccines people are likely to receive. But globally, these are far from the only products available. China, for instance, has developed multiple COVID-19 vaccines, and these are now being used to protect people both domestically and abroad.
One of these is the vaccine developed by Sinopharm, a Chinese state-owned company. It’s been authorised for use in over 50 countries, with tens of millions of doses having been given worldwide. Over 100 million doses have been ordered from outside China, the result being that the product forms a major part of vaccination programmes in many countries.
The World Health Organization (WHO) has issued an interim recommendation that the vaccine be used, stating that it’s sufficiently safe and effective. Yet COVID-19 cases have risen in some countries using the Sinopharm jab, and there have been reports of vaccinated people getting infected. With so many relying on the vaccine, is this a cause for alarm?
How it works
The Sinopharm jab is an inactivated vaccine, containing a killed coronavirus that cannot replicate. This is a different approach to the mRNA-based vaccines of Pfizer and Moderna and the viral-vectored platforms used by the Oxford/AstraZeneca, Sputnik V and Johnson & Johnson vaccines.
Using a whole, inactivated version of a virus to stimulate an immune response is tried and tested – historically many vaccines have used this approach. Examples include those for rabies and polio. Inactivated vaccines are easy to manufacture and are known for their safety, but tend to produce a weaker immune response compared to some other vaccine types.
The WHO initially reported that trials showed the vaccine to be 79% protective against both symptomatic disease and hospitalisation after two doses. Real-world evidence suggests protection against both symptomatic and severe COVID-19 could be higher still: possibly as high as 90%.
But the picture isn’t quite clear cut. With the Pfizer, Moderna and AstraZeneca vaccines, there’s lots of data on their performance. But with the Sinopharm vaccine, we don’t have as much performance data to look at, so we can’t be as certain of its efficacy, even if its numbers look good. The director of the Chinese Center for Disease Control and Prevention, Gao Fu, has also publicly said the Chinese-developed products needed improving.
There’s certainly a lack of data on how effective the Sinopharm vaccine is against variants of concern. Information available suggests it still works against the beta variant (B1351, first observed in South Africa), but may be less effective, though this was a small, lab-based study. Little is known about levels of protection against other variants. This gives some cause for concern.
Outbreaks should be expected
There have recently been outbreaks in a number of countries with relatively advanced vaccination programmes, including those that are and aren’t using the Sinopharm vaccine. Cases have risen in the UK, for example, as the delta variant has become dominant there. It isn’t using the Sinopharm vaccine.
However, increases in COVID-19 cases do appear to have been particularly apparent in countries using the Sinopharm jab. The Seychelles witnessed a notable spike, despite (at the time of reporting) over 60% of the country having had two doses. The initial vaccine used in the Seychelles was Sinopharm’s, along with additional use of AstraZeneca’s. It was reported that around one-third of new cases were in fully vaccinated people. Similar scenarios have been seen elsewhere, including in Chile, Bahrain and Uruguay.
There are several reasons why we might see new cases in fully vaccinated individuals. Firstly, none of the vaccines are 100% effective (and Sinopharm’s appears to probably be significantly less than that). Variants of concern can also lower protection. The immune response also takes a few weeks to fully develop. Some people may have been infected soon after their second dose.
What we have seen is that cases in vaccinated people are typically milder than in unvaccinated people, and that vaccines do appear to reduce transmission. Vaccines are, and will remain, the key tool that underpins the global route out of the pandemic. Therefore, we shouldn’t think of these events as “vaccine failures”, but as the impact of their limitations. These impacts may be more visible when using a less protective vaccine like Sinopharm’s compared to one such as Pfizer’s. This could explain why outbreaks have been more noticeable in countries using the Sinopharm vaccine widely.
Ultimately, if susceptible populations mix with infectious individuals, then there may be some onward transmission, no matter the vaccine.
A mixed solution
Countries are responding to outbreaks by scaling up and enhancing their existing rollouts, but also sometimes by offering booster doses of other vaccines. Bahrain and the United Arab Emirates have recommended an additional Sinopharm dose, or a single dose of Pfizer, around six months after someone has received two doses of Sinopharm. This will likely boost overall levels of protection, but is very much dependent upon countries having sufficient supply.
While vaccine demand outstrips supply and high-income nations hoard much of what is produced, the majority of the world remains unprotected and susceptible to COVID-19. Any further uncontrolled outbreaks, such as we have seen in India and other countries such as Nepal, not only risk overburdening fragile health systems in lower-income areas, but also facilitate further chances for new variants to emerge.
With this in mind, we should remember that the Sinopharm vaccine is a useful product. Other vaccines may well provide better protection – we’ll get a better sense of exactly how good the Sinopharm vaccine is as more data emerges – but China will undoubtedly continue to be able to supply many doses to the world. The Sinopharm jab will therefore be one of the tools that underpins the global response over the next 12-24 months.
|
|||||
6044
|
dbpedia
|
1
| 2
|
http://en.sinopharm.com/profile.html
|
en
|
Profile
|
[] |
[] |
[] |
[
""
] | null |
[] | null | null | |||||||||
6044
|
dbpedia
|
2
| 54
|
https://journals.lww.com/smj/fulltext/9900/characteristics_of_patients_who_received_sinopharm.67.aspx
|
en
|
Singapore Medical Journal
|
[
"https://cdn.wolterskluwer.io/wk-logos/1.0.x/favicon.png?rev=43",
"https://journals.lww.com/_layouts/15/images/spcommon.png?rev=43",
"https://images.journals.lww.com/smj/ArticleViewerPreview.00077293-990000000-00067.T1.jpeg",
"https://images.journals.lww.com/smj/ArticleViewerPreview.00077293-990000000-00067.T2.jpeg",
"https://images.journals.lww.com/smj/ArticleViewerPreview.00077293-990000000-00067.T3.jpeg",
"https://images.journals.lww.com/smj/ArticleViewerPreview.00077293-990000000-00067.F1.jpeg",
"https://images.journals.lww.com/smj/XLargeThumb.00077293-202408000-00000.CV.jpeg",
"https://journals.lww.com/_layouts/1033/IMAGES/OAKS.Journals/CAPrivacyPolicy.png"
] |
[] |
[] |
[
""
] | null |
[] | null |
An abstract is unavailable.
|
en
|
LWW
|
https://journals.lww.com/smj/fulltext/9900/characteristics_of_patients_who_received_sinopharm.67.aspx
|
INTRODUCTION
Most bodies of authority recognise messenger RNA (mRNA) vaccines as the most effective coronavirus disease 2019 (COVID-19) vaccines that have met safety standards.[1,2] Singapore, like many countries, encouraged its citizens and residents to receive mRNA vaccines for better protection. Despite the presence of significant evidence that mRNA vaccines reduce the severity of COVID-19 infection and prevent hospitalisation, mRNA vaccine hesitancy persisted due to low confidence and perceived side effects.[3-6] The safety of mRNA vaccines has been questioned due to the accelerated review processes used by authorities such as the US Food and Drug Administration and uncertainty about their long-term adverse events.[7] The public’s concerns were further exacerbated by reports of serious immediate side effects, including allergic reactions and anaphylaxis, myocarditis and pericarditis, and death.[8] However, to slow the infection rate and reduce the severity of COVID-19, vaccination programmes were the only practical and effective public health intervention available.
Singapore’s nationwide COVID-19 vaccination programme was the first in Asia and started on 30 December 2020. The Pfizer–BioNTech COVID-19 vaccine, an mRNA vaccine, was granted interim authorisation under the Pandemic Special Access Route (PSAR) by Singapore’s Health Sciences Authority on 14 December 2020, and authorisation of another mRNA vaccine, Moderna, followed on 3 February 2021. After 6 months, 36.8% of Singapore’s population had received two doses of COVID-19 vaccine and 58.1% had received only one dose.[9] It became apparent that providing access to non-mRNA COVID-19 vaccines listed on the Emergency Use Listing of the World Health Organization was necessary to address vaccine hesitancy among those with concerns and worries specifically related to the mRNA technology.
In June 2021, the Ministry of Health (MOH) allowed access to six COVID-19 vaccines under the Special Access Route (SAR) — a process to import and supply unregistered medicines and drugs to address unmet medical needs in special circumstances. Late in July, IHH Healthcare Singapore was among the first private healthcare groups in Singapore to obtain approval to import the inactivated Sinopharm BIBP vaccine (BBIBP-CorV), and its administration began on 30 August 2021, in the eighth month of the country’s nationwide vaccine campaign. By this time, 80% of the population had received two doses of COVID-19 vaccines and 83% had received one dose.[10]
This paper describes the sociodemographic profile of patients who received the Sinopharm BIBP vaccine in Singapore and their reasons for opting for an inactivated vaccine instead of an mRNA vaccine. These data can inform healthcare providers and policymakers when addressing vaccine hesitancy and concerns about mRNA vaccines.
METHODS
This cross-sectional study was conducted to explore the demographic characteristics of persons who presented to a three-doctor private general practice clinic in Singapore for vaccination with Sinopharm BIBP vaccine and to elucidate the underlying reasons for choosing this vaccine. Ethical approval was obtained from the institutional ethics committee (Parkway Independent Ethics Committee).
Patients who attended the clinic to be vaccinated with Sinopharm BIBP vaccine between 30 August 2021 and 30 October 2021 were invited to complete a questionnaire during their 15-min postvaccination observation period. Patients were informed that their participation was voluntary and would not impact their clinical care. The questionnaire was completed on a clinic desktop computer or on the patients’ smartphone via a QR code. Patients who had difficulty understanding the questionnaire items in English responded with the help of a translator.
The self-administered questionnaire included demographic details, respondents’ attitudes and beliefs regarding COVID-19 vaccines, and information-seeking behaviour. Our questionnaire adapted ten items measuring perceived susceptibility to COVID-19, vaccine benefit, vaccine risk, vaccine attitudes, information sourcing and fear of COVID-19 from a survey developed for a comparative study between Ireland and the UK on the causes of vaccination intentions.[11] This questionnaire was selected because it had been developed to specifically explore COVID-19 vaccine hesitancy, rather than generic vaccine hesitancy issues. Although the questions had not been validated for face, content or criterion validity, the questionnaire had undergone testing for scale reliability when it was developed.
Descriptive data analysis was conducted to identify the response distribution and sociodemographic differences. Chi-square analysis was used to identify significant relationships between sociodemographic characteristics and vaccine behaviour and intentions.
RESULTS
Of the 294 patients invited to participate, 212 (72.1%) agreed to complete the questionnaire. The majority of respondents were female (61.8%), aged between 30 and 59 years (64.2%), highly educated (61.2% with university or higher education) and Singapore residents (89.2%) [Table 1]. Almost all respondents (98.6%) reported not having been infected with COVID-19, and over 80% of the respondents were unvaccinated [Table 2].
Reasons for selecting Sinopharm
The most common reason for preferring an inactivated COVID-19 vaccine was concerns about the safety of mRNA vaccines (76.9%) [Table 3]. Other reasons included potential allergy to mRNA vaccines, need to get vaccinated with an inactivated vaccine for travel to China, booster after two doses of mRNA vaccines, recommended by a friend, relative or doctor, higher efficacy compared to CoronaVac, lack of access to mRNA vaccines and instructed by employer. Respondents were more likely to report that they would take Sinopharm if they were nonresidents of Singapore (χ2 (8) = 41.0, P < 0.001) or if they had a primary school educational level or lower (χ2 (24) = 64.0, P < 0.001).
Almost half of the respondents would not switch to mRNA vaccines in the future, 33% of the respondents were unsure and a minority (4.3%) would consider an mRNA vaccine [Table 3]. Respondents who were more likely to report a willingness to have an mRNA vaccine in the future had a primary school or lower educational level (χ2 (12) = 21.4, P = 0.045). Most respondents were aware that the Sinopharm vaccine was not as efficacious as an mRNA vaccine (95.8%) and that it was excluded from the National Vaccination Programme and the Vaccine Injury Financial Assistance Programme for COVID-19 Vaccination (VIFAP) (97.2%) [Table 3]. Respondents who were unaware that Sinopharm was not as effective as mRNA vaccines were 4.3 times more likely to be nonresidents of Singapore (χ2 (1) = 5.24, P = 0.022).
Information-seeking behaviour
Over half of the respondents reported actively seeking information on COVID-19 (61.3%). The main sources of information were traditional media (newspapers or TV) (56.6%) and, to a lesser extent, social media (31.1%), word of mouth (7.6%) and other sources (4.7%) [Table 3]. Further analysis indicated that respondents who were more likely to report that they received information about COVID-19 from word of mouth were nonresidents (χ2 (4) = 18.1, P = 0.001) and those with the lowest educational level (χ2 (12) = 22.8, P = 0.030).
Attitudes and beliefs about vaccines and COVID-19
One in four respondents (26.9%) thought other people were more likely to catch COVID-19 than themselves [Figure 1]; male respondents were significantly more likely to strongly agree with this view (χ2 (4) = 12.2, P = 0.016). The two items about vaccine benefits indicated that the majority of respondents believed that vaccines were the best measure to return to a prepandemic way of life (58.9%) and that their likelihood of contracting or suffering significantly from COVID-19 would be lessened if they were vaccinated (67.9%). Concerning vaccine risk, about a third of the respondents did not believe that vaccines in general were safe (30.6%) and a similar number disagreed (32.1%). The majority of respondents (60.4%) believed that if people in their environment were vaccinated, it would not be necessary for them to get vaccinated, a view that was expressed significantly more often in male respondents (χ2 (4) = 13.2, P = 0.010) and among nonresidents (χ2 (4) = 10.5, P = 0.033). Regarding the fear of COVID-19, 39.1% felt uncomfortable thinking about COVID-19 and 40.6% reported feeling nervous and anxious when watching the news and stories about COVID-19 on social media. But only a minority of respondents (6.6%) reported that their sleep was affected by worries about getting infected with COVID-19 [Figure 1]. Male respondents were more likely to strongly disagree with the statement that thinking about COVID-19 made them feel uncomfortable (χ2 (4) = 18.1, P = 0.001).
DISCUSSION
This study was conducted at a time when approximately 30% of the Singaporean population was not fully vaccinated.[12] We aimed to describe the characteristics of patients who sought the Sinopharm BIBP vaccine and their reasons for opting for an inactivated vaccine instead of an mRNA vaccine. In our study, most respondents were female, aged between 30 and 59 years, highly educated and residents of Singapore. In our sample, high levels of concern about mRNA technology and potential adverse events contributed to the reticence to use mRNA vaccines. This is a finding consistent with studies conducted in Australia and Japan,[13,14] which found the lowest uptake of COVID-19 vaccines in women, younger individuals and those with higher a level of education. A study of respondents from Bangladesh, India, Sri Lanka, Norway, the UK, Iran, Pakistan, Somalia, the United Arab Emirates, Australia, China, Japan, Malaysia, Singapore and Vietnam reported that respondents from Southeast Asia were more concerned about getting mRNA vaccines.[15] The authors reflected on the challenge of increasing the uptake of new mRNA vaccines despite clearly communicating their effective evaluation in clinical trials.
Responses to the questionnaire showed that most of the respondents were concerned about mRNA vaccine safety (76.9%) and a further 4.3% took the Sinopharm BIBP vaccine on the recommendations or instructions of their employer. All these respondents may be amenable to taking an mRNA vaccine in the future and are the target group for future public health interventions. In contrast, there were only 10.8% of respondents who did not have alternatives to the Sinopharm BIBP vaccine for medical reasons (e.g., potential allergy to mRNA vaccines [6.6%]), or due to the need to get vaccinated with an inactivated vaccine to obtain a visa to China (4.2%).
Approximately nine out of ten patients surveyed could potentially switch from non-mRNA to mRNA vaccines, so there is a strong justification to consider theories of health behaviour change and maintenance[15] and how mRNA vaccination uptake can be boosted at the four socioecological levels of influence: individual, relationship, community and societal.[16] At the individual level, interventions need to focus on education to address knowledge gaps or modify attitudes and beliefs. The health belief model is among the most commonly utilised theories of health behaviour and proposes several constructs that influence the ‘likelihood of taking action’. These are perceived susceptibility, perceived severity, perceived threat, cues to action, perceived benefits, perceived barriers and self-efficacy. The majority of respondents exhibited low perceived susceptibility but high perceived benefits (i.e., the resumption of the prepandemic way of life). Education should focus on raising risk perception through regular updating of COVID-19 cases in the community; providing cues to action by personalised reminders of the need for mRNA boosters; reducing perceived barriers with assistance such as subsidised transport to get to vaccination centres, and reassurance via frequent sharing of safety data. Most respondents were actively seeking information on COVID-19 via paper-based news or social media, so these media channels will reach over two-thirds of the target population. There were differences between males and females in their assessment of perceived susceptibility risk and attitudes to vaccine, with males feeling that the people around them were more likely to get infected by COVID-19. Male respondents also reported that they believed they would not need to be vaccinated if people in their environment were vaccinated, a view also echoed by respondents who were nonresidents of Singapore. This suggests that there may be benefit in exploring some gender-specific interventions.
In this context, the social marketing framework may be appropriate, combining social sciences and commercial marketing to change an individual’s behaviour for the benefit of society.[17] Social marketing uses four constructs: product, price, place and promotion. Product refers to benefits that the target audience will experience or expect from performing the target behaviour. These include increased protection from infection and reduced morbidity and mortality upon infection. For example, the MOH can mandate that individuals who opt for non-mRNA vaccines be counselled by the administering physician about the differing vaccine efficacies. Price refers to the cost of adopting the desired behaviour, and in this context, it includes cost of the vaccine, time spent to receive the vaccine, cost of transportation and side effects resulting in time-off from work. The Singapore government can regulate pricing of the Sinopharm BIBP vaccine at clinics to reduce its accessibility and affordability and to enhance the selection of mRNA vaccines for economic reasons. Place is the distribution channel or place of delivery. Promotion includes communication channels and activities to promote the benefits of the desired behaviour. Advocates can combine promotion and placement elements to maximise outreach to the target audience. They can utilise the mass media and spokespersons at schools, workplaces and healthcare institutions [Figure 1]. For example, the MOH can mandate that posters and pamphlets showing the location and opening hours of vaccination centres offering free mRNA vaccines be displayed in clinics administering the Sinopharm BIBP vaccine.
At the community level, influencers can be recruited to set social norms and influence behaviour. They can be individuals at home, workplace, faith-based organisations or healthcare institutions. For example, teachers and doctors can share data on the efficacy of different COVID-19 vaccines with students and patients, respectively. These are persons of authority and are responsible for encouraging and promoting mRNA vaccines by word of mouth. Studies show that when the messages come from community leaders — persons who are credible and trusted — there is better retention of long-term knowledge.[18] As indicated in our data, this may be a helpful strategy to engage nonresidents who are not likely to have sufficient knowledge (e.g., about the efficacy of different vaccines). Clear and assertive evidence-based recommendations from healthcare professionals such as doctors and nurses can also alleviate safety concerns and further enhance vaccine adoption.[19]
Finally, at the societal level, policies can be implemented to nudge individuals to adopt mRNA vaccines. As of 12 January 2022, the MOH has put in place some vaccine-differentiated measures. First, only medically ineligible persons qualify for free inactivated COVID-19 vaccines. Those without clinical contraindications are forced to pay for inactivated vaccines out of their own pocket. Second, persons who had received inactivated vaccines as their third vaccine dose are required to receive a booster dose 3 months after the third dose of the vaccine (compared to 5 months for those who took mRNA vaccines). Third, VIFAP is a goodwill financial assistance provided by the government only to those who experience serious side effects after receiving COVID-19 vaccines within the national programme. Better awareness of VIFAP may mitigate concerns about exorbitant medical bills due to an adverse event. Interventions to further promote mRNA vaccination might include subsidised travel and protected time off work.
This study is limited by being a single-centred study from a practice based in the central business district. Everyone attending for vaccination had the opportunity to complete the questionnaire, and the response rate was high for a community-based survey. Unfortunately, we do not have data on the nonresponders, making it impossible to assess response bias. We recognise that our findings may not be generalisable to all settings, including public housing estates, but it does provide a deeper understanding of vaccine intention in Singapore and can inform the promotion of vaccine uptake in the future.
In conclusion, with the extensive evidence demonstrating the superior efficacy of mRNA vaccines over inactivated COVID-19 vaccines, there is increasing pressure to improve community uptake. A better understanding of the characteristics of members of the public who avoided mRNA vaccination and the application of health behaviour theories, such as the Health Belief Model, will allow those leading public health and health education interventions to design and implement interventions tailored to facilitate successful behaviour change within the target audience.
Acknowledgement
We thank Dr Hoe Wan Sin and Dr Liew Su Lyn for helping to recruit patients for the study.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
|
|||||
6044
|
dbpedia
|
2
| 9
|
https://markets.ft.com/data/equities/tearsheet/summary%3Fs%3D1099:HKG
|
en
|
Error
|
[
"https://markets.ft.com/data/images/pulse"
] |
[] |
[] |
[
""
] | null |
[] | null |
en
|
//im.ft-static.com/m/icons/favicon.ico
| null |
The Markets Data site is currently unavailable.
It will be available again shortly, so please try again soon.
For help please visit help.ft.com.
We apologise for any inconvenience.
Error 500: Site unavailable
#CD76F758
|
||||||
6044
|
dbpedia
|
1
| 56
|
https://www.ft.com/content/99c7a9de-fc11-45ab-890b-f6733ccb4186
|
en
|
Subscribe to read
|
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
|
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
|
[
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_standard.svg?source=next-barrier-page&format=svg",
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_premium.svg?source=next-barrier-page&format=svg",
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_bundle.svg?source=next-barrier-page&format=svg",
"https://spoor-api.ft.com/px.gif?data=%7B%22category%22%3A%22page%22%2C%22action%22%3A%22view%22%2C%22system%22%3A%7B%22source%22%3A%22non-ctm%22%7D%2C%22context%22%3A%7B%22name%22%3A%22barrier-page%22%2C%22product%22%3A%22next%22%2C%22data%22%3A%7B%22source%22%3A%22%5BSOURCE%5D%22%7D%7D%7D"
] |
[] |
[] |
[
""
] | null |
[] | null |
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
| null |
Then €69 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.
|
|||||
6044
|
dbpedia
|
2
| 8
|
https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
|
en
|
WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
|
[
"https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue.svg?sfvrsn=aaed4f35_20",
"https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue.svg?sfvrsn=aaed4f35_20",
"https://www.who.int/images/default-source/fallback/maps/africa.png?sfvrsn=3204f957_18",
"https://www.who.int/images/default-source/fallback/maps/americas.png?sfvrsn=9efd6df3_18",
"https://www.who.int/images/default-source/fallback/maps/south-east-asia.png?sfvrsn=68e76dc2_16",
"https://www.who.int/images/default-source/fallback/maps/europe.png?sfvrsn=c7d5c5a5_18",
"https://www.who.int/images/default-source/fallback/maps/eastern-mediterranean.png?sfvrsn=71211e18_16",
"https://www.who.int/images/default-source/fallback/maps/western-pacific.png?sfvrsn=88cbdcd5_16",
"https://www.who.int/ResourcePackages/WHO/assets/dist/images/logos/en/h-logo-blue.svg",
"https://www.who.int/ResourcePackages/WHO/assets/dist/images/logos/en/h-logo-white.svg"
] |
[] |
[] |
[
""
] | null |
[] | null |
WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National
Biotec Group (CNBG). “The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for
Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines. The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements. The assessment is performed by the product evaluation group, composed by regulatory
experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions.In the case of the Sinopharm vaccine, the WHO assessment included on-site inspections of the production facility. The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor, a small sticker
on the vaccine vials that change color as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing
of three to four weeks. Vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined. Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group. Nevertheless, WHO is not recommending an upper age limit for the vaccine because preliminary data and supportive immunogenicity
data suggest the vaccine is likely to have a protective effect in older persons. There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations. WHO therefore recommends that
countries using the vaccine in older age groups conduct safety and effectiveness monitoring to make the recommendation more robust.WHO emergency use listing The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency, while
adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts and WHO
teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from
vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.WHO also listed the Pfizer/BioNTech vaccine for emergency use on 31 December 2020; two AstraZeneca/Oxford COVID-19 vaccines on 15 February 2021, produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India; and COVID-19 vaccine Ad26.COV2.S
developed by Janssen (Johnson & Johnson) on 12 March 2021.ListingsWHO has also listed the Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Janssen and Moderna vaccines for emergency use.See EUL listingsSAGESAGE is the principal advisory group to WHO for vaccines and immunization. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages
with other health interventions. SAGE is concerned not just with childhood vaccines and immunization, but all vaccine-preventable diseases.SAGE has issued recommendations on Pfizer
(8 January 2021), Moderna (25 January 2021), AstraZeneca (21 April 2021), and Janssen COVID (17 March 2021) vaccines, as well as issued a framework for access and population prioritization roadmap. SAGE and EUL are complementary but independent processes. The EUL process is centered on determining if a manufactured product is quality-assured, safe and effective. SAGE is policy oriented. Policy recommendations for a vaccine are only of value
to a vaccination campaign when the product has been listed or authorized for use. In the context of COVID-19 and due the pressing need for vaccines, the Secretariat of SAGE and the EUL team have been working in parallel to allow WHO EUL and policy recommendations, based on the available evidence, to be issued in a synchronized manner. The SAGE Interim Recommendations can be found at this location: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials
|
en
|
/favicon.ico
|
https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
|
WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”
WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements. The assessment is performed by the product evaluation group, composed by regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions.
In the case of the Sinopharm vaccine, the WHO assessment included on-site inspections of the production facility.
The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor, a small sticker on the vaccine vials that change color as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.
WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. Vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined.
Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group. Nevertheless, WHO is not recommending an upper age limit for the vaccine because preliminary data and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons. There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations. WHO therefore recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring to make the recommendation more robust.
WHO emergency use listing
The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency, while adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.
The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.
As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.
WHO also listed the Pfizer/BioNTech vaccine for emergency use on 31 December 2020; two AstraZeneca/Oxford COVID-19 vaccines on 15 February 2021, produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India; and COVID-19 vaccine Ad26.COV2.S developed by Janssen (Johnson & Johnson) on 12 March 2021.
Listings
WHO has also listed the Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Janssen and Moderna vaccines for emergency use.
See EUL listings
SAGE
SAGE is the principal advisory group to WHO for vaccines and immunization. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions. SAGE is concerned not just with childhood vaccines and immunization, but all vaccine-preventable diseases.
SAGE has issued recommendations on Pfizer (8 January 2021), Moderna (25 January 2021), AstraZeneca (21 April 2021), and Janssen COVID (17 March 2021) vaccines, as well as issued a framework for access and population prioritization roadmap.
SAGE and EUL are complementary but independent processes. The EUL process is centered on determining if a manufactured product is quality-assured, safe and effective. SAGE is policy oriented. Policy recommendations for a vaccine are only of value to a vaccination campaign when the product has been listed or authorized for use.
In the context of COVID-19 and due the pressing need for vaccines, the Secretariat of SAGE and the EUL team have been working in parallel to allow WHO EUL and policy recommendations, based on the available evidence, to be issued in a synchronized manner.
The SAGE Interim Recommendations can be found at this location: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials
|
|||||
6044
|
dbpedia
|
1
| 57
|
https://www.euractiv.com/section/china/news/hungary-reaches-deal-to-buy-chinas-sinopharm-vaccine/
|
en
|
Hungary reaches deal to buy China’s Sinopharm vaccine
|
[
"https://www.facebook.com/tr?id=307743630704587&ev=PageView&noscript=1",
"https://www.euractiv.com/wp-content/themes/euractiv/media/frontend/branding/logo_print.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/19.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/19.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/2.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/4.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/3.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/8.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/5.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/6.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/7.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/10.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/11.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/17.png",
"https://www.euractiv.com/wp-content/themes/euractiv/media/frontend/branding/loading.gif",
"https://www.euractiv.com/wp-content/themes/euractiv_com/logo2x.png",
"https://www.euractiv.com/wp-content/themes/euractiv/media/frontend/branding/loading.gif",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/19.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/19.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/2.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/4.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/3.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/8.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/5.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/6.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/7.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/10.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/11.png",
"https://www.euractiv.com/wp-content/themes/euractiv/hooks/network/flags/17.png",
"https://www.euractiv.com/wp-content/uploads/sites/2/2021/01/Sinovac-800x450.jpg",
"https://www.euractiv.com/wp-content/themes/euractiv_com/hooks/mods/Trust-Mark-400.webp",
"https://www.euractiv.com/wp-content/uploads/sites/2/2020/12/Sputnik-vaccine-cargo-800x600.jpg",
"https://www.euractiv.com/wp-content/uploads/sites/2/2021/01/File-photo-China-computer-screens-150x150.jpg"
] |
[] |
[] |
[
""
] | null |
[
"Georgi Gotev",
"Euractiv.com with",
"Viktor Orbán",
"coronavirus vaccine",
"Global Europe",
"Peter Szijjarto"
] |
2021-01-14T16:40:40
|
Hungary's government said it has reached a deal with China's Sinopharm to buy its coronavirus vaccine, the country's latest move to break away from Brussels as it tries to speed up inoculations to lift curbs on the economy.
|
en
|
https://www.euractiv.com/wp-content/themes/euractiv_com/favicon.ico
|
www.euractiv.com
|
https://www.euractiv.com/section/china/news/hungary-reaches-deal-to-buy-chinas-sinopharm-vaccine/
|
Hungary’s government said on Thursday (14 January) it has reached a deal with China’s Sinopharm to buy its coronavirus vaccine, the country’s latest move to break away from Brussels as it tries to speed up inoculations to lift curbs on the economy.
Hungary would be the first EU country to accept a Chinese vaccine if approved by Hungarian authorities. Under European Union rules it would have to give an ultra-fast emergency use approval, rather than waiting for the European drug regulator EMA to give the go-ahead for the Chinese vaccine.
Britain took a similar approach in December before it exited the bloc. It approved Pfizer Inc’s COVID-19 vaccine on 2 December, jumping ahead of the rest of the world in the race to begin a mass inoculation programme.
Hungary’s nationalist government has sharply criticised the EU for what it said were way too slow vaccine purchases and deliveries that now threatened an economic rebound.
Foreign Minister Péter Szijjártó said in a Facebook post on Thursday that due to the “scandalously” slow vaccine procurements of the European Commission, a fast rollout of vaccines could not happen early this year.
“If we look beyond the EU’s borders, we can see that in the US, in Britain and in Israel, people are vaccinated at warp speed,” Szijjártó said.
The government also passed a decree on Thursday allowing it to start procurements outside the EU’s centralised scheme.
Szijjártó’s spokesman told Reuters the approval process for the vaccine developed by Sinopharm’s Beijing-based affiliate, Beijing Institute of Biological Products Co., Ltd (BIBP), was already “underway”.
Beyond the supply bottlenecks, Hungarians are fairly sceptical about the new vaccines, with just about one in five people definitely planning to get a shot based on a late-December survey by the Central Statistics Office.
Prime Minister Viktor Orbán’s chief of staff Gergely Gulyas told a briefing on Thursday that vaccine shipments under the EU’s programme were arriving too slowly, with weekly shipments of less than 100,000 doses, and Hungary would continue talks with Russia and China about additional vaccine purchases.
“We have practically made an agreement with Sinopharm,” Gulyas said. “The first shipment could include up to one million doses.”
The timing of the Chinese shipment depends on how fast Hungarian health authorities authorize use of Sinopharm’s vaccine, which has been used to immunise some 20 million people, he added.
Gulyas said the second wave of the pandemic has peaked in Hungary and new infections have dropped but restrictions cannot be eased yet.
China approved the shot developed by Sinopharm’s BIBP in late December, its first COVID-19 vaccine for general public use.
No detailed efficacy data of the vaccine has been publicly released but BIBP has said the vaccine is 79.34% effective in preventing the disease based on interim data. Pakistan has already negotiated a supply deal for the vaccine.
The vaccine, along with another candidate developed by a Wuhan-based subsidiary of Sinopharm, is included in China’s emergency use programme launched in July, which targets limited groups of people facing high risk of virus exposure.
Since 11 November, all secondary schools have been closed in Hungary, as have hotels and restaurants except for takeaway meals, a 1900 GMT curfew has been in place, and gatherings have been banned.
Read more with Euractiv
|
||||
6044
|
dbpedia
|
1
| 3
|
https://en.wikipedia.org/wiki/Sinopharm_BIBP_COVID-19_vaccine
|
en
|
Sinopharm BIBP COVID
|
[
"https://en.wikipedia.org/static/images/icons/wikipedia.png",
"https://en.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-en.svg",
"https://en.wikipedia.org/static/images/mobile/copyright/wikipedia-tagline-en.svg",
"https://upload.wikimedia.org/wikipedia/en/thumb/1/1b/Semi-protection-shackle.svg/20px-Semi-protection-shackle.svg.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/2/24/Sinopharm_BBIBP-CorV_COVID-19_vaccine_vial_from_Nikli%2C_Bangladesh.jpg/220px-Sinopharm_BBIBP-CorV_COVID-19_vaccine_vial_from_Nikli%2C_Bangladesh.jpg",
"https://upload.wikimedia.org/wikipedia/commons/thumb/9/94/Coronavirus._SARS-CoV-2.png/110px-Coronavirus._SARS-CoV-2.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/4/4d/SARS-CoV-2_%28Wikimedia_colors%29.svg/15px-SARS-CoV-2_%28Wikimedia_colors%29.svg.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/2/2a/BBIBP-CorV_Vaccination_Certificate.jpg/220px-BBIBP-CorV_Vaccination_Certificate.jpg",
"https://upload.wikimedia.org/wikipedia/en/thumb/1/1d/Information_icon4.svg/40px-Information_icon4.svg.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/Scholia_logo.svg/40px-Scholia_logo.svg.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/8px-WHO_Rod.svg.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/2/2f/Sida-aids.png/19px-Sida-aids.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/4/4d/SARS-CoV-2_%28Wikimedia_colors%29.svg/18px-SARS-CoV-2_%28Wikimedia_colors%29.svg.png",
"https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?type=1x1",
"https://en.wikipedia.org/static/images/footer/wikimedia-button.svg",
"https://en.wikipedia.org/static/images/footer/poweredby_mediawiki.svg"
] |
[] |
[] |
[
""
] | null |
[
"Contributors to Wikimedia projects"
] |
2020-12-13T02:11:49+00:00
|
en
|
/static/apple-touch/wikipedia.png
|
https://en.wikipedia.org/wiki/Sinopharm_BIBP_COVID-19_vaccine
|
Vaccine against COVID-19
For other uses, see Sinopharm COVID-19 vaccine.
BBIBP-CorVVaccine descriptionTargetSARS-CoV-2Vaccine typeInactivatedClinical dataOther namesZhong'aikewei (Chinese: 众爱可维), Hayat-VaxRoutes of
administrationIntramuscularATC codeLegal statusLegal status
BR: Emergency use (COVAX)[1]
Full list of Sinopharm BIBP authorizations
IdentifiersCAS NumberDrugBank
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[2] the Sinopharm COVID-19 vaccine,[3] or BIBP vaccine,[3][4][5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products,[6] resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[7] BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19.[8][9] Its product name is SARS-CoV-2 Vaccine (Vero Cell),[10][11][12] not to be confused with the similar product name of CoronaVac.[13][14]
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[15] In December 2020, the UAE previously announced interim results showing 86% efficacy.[16]
While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. The BIBP vaccine could be transported and stored at normal refrigerated temperatures.[17]
The vaccine is being used in vaccination campaigns by certain countries in Asia,[18][19][20] Africa,[21][22][23] South America,[24][25][26] and Europe.[27][28][29] Sinopharm expects to produce one billion doses of the vaccine in 2021.[30] By May, Sinopharm had supplied 200 million doses.[31]
On 7 May 2021, the World Health Organization approved the BIBP vaccine for use in COVAX.[32][33] Sinopharm has signed purchase agreements for 170 million doses from COVAX.[34]
The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.
Medical uses
The vaccine is given by intramuscular injection into the deltoid muscle. The initial course consists of two doses, and there is no evidence that a third booster dose is needed. The World Health Organization (WHO) recommends an interval of 3 to 4 weeks between doses.[35]
Effectiveness
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval.[36] Effectiveness is generally expected to slowly decrease over time.[37]
Real-world test-negative analysis in Bahrain (based on 14 days post 2nd dose) indicated a vaccine effectiveness of 90% (95% CI, 88– 91%) for adults aged 18–59, and 91% ( ) for those 60 year old or older.[38] While confident in its overall efficacy, WHO experts expressed very low confidence in their current ability to determine the safety of the BIBP vaccine for people with comorbidities, pregnant women, and the elderly as they were under-represented in the studies.[39]
In April 2021, a study by the Abu Dhabi Public Health Centre found the vaccine was 93% effective in preventing hospitalization and 95% effective against admission to intensive care. The study found no deaths related to COVID-19 in patients who received both doses. It was unknown how many people were included in the research.[40]
On 1 July, the Ministry of Health of Argentina reported the vaccine reduced deaths by 62% after the first dose and by 84% after the second dose.[41]
On 22 July, Peru's National Institute of Health reported the vaccine reduced deaths by 94% after analyzing data from 361,000 people.[42]
On 13 August, a study with 400,000 health workers in Peru from February to June 2021, during a wave mostly caused by the Lambda and Gamma variants, found a vaccine effectiveness of 50% ( ) against infection and 94% ( ) against death after two doses. With a single dose, the effectiveness was 17% ( ) against infections and 46% ( ) against death.[43][44]
On 24 August, preliminary results from a non-randomized study of one million people in Bahrain, of whom 569,054 received the BIBP vaccine, found that the vaccine continued to reduce infection, hospitalization, and death when the Delta variant became dominant, though not as effectively as Pfizer–BioNTech, Oxford–AstraZeneca and Sputnik V.[45]
Initial effectiveness by variant Doses Severity of illness Delta Alpha 1 Symptomatic Not reported Not reported Hospitalization Not reported Not reported 2 Asymptomatic Not reported 69% ( )[A] Symptomatic Not reported Not reported Hospitalization Not reported Not reported Death Not reported 88% ( )[A]
Efficacy
In December 2020, UAE's Ministry of Health and Prevention previously announced interim analysis showing the vaccine to have a 86% efficacy against COVID-19 infection and nearly 100% efficacy in preventing moderate and severe cases.[47]
On 7 May 2021, the World Health Organization reported a vaccine efficacy of 79% (95% CI, 66– 88%) against symptomatic disease and 79% ( ) against hospitalization.[35]
In 26 May, peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed the vaccine 74% ( ) effective against cases including asymptomatic and symptomatic infections, 78% (95% CI, 65– 86%) effective against symptomatic cases, and nearly 100% against severe cases (0 cases in vaccinated group, 2 cases in placebo group). 12,726 people received the vaccine and 12,737 people received the placebo in these trials.[15]
As of 1 July, six of the 71 COVID-19 deaths in Seychelles were among the fully vaccinated people. Only one of the six was fully vaccinated by the BIBP vaccine, the remaining five had been fully vaccinated by Covishield, which was mainly reserved for people aged 60 years or more.[48]
Variants
In February, lab studies of twelve serum samples taken from recipients of BBBP-CorV and ZF2001 retained neutralizing activity against the Beta variant although with weaker activity than against the original virus.[49] For the BIBP vaccine, geometric mean titers declined by 1.6-fold, from 110.9 to 70.9, which was less than antisera from mRNA vaccine recipients with a 6-folds decrease.[50] Preliminary clinical data from Novavax and Johnson & Johnson also showed they were less effective in preventing COVID-19 in South Africa, where the new variant is widespread.[49]
In June, a pre-print study with 282 recipients of the vaccine in Sri Lanka showed that:
95% seroconverted following 2 doses, a similar rate seen in natural infection, with significantly lower seroconversion for >60 year-olds (93%) compared to 20-39 year-olds (99%)
81% had ACE2 receptor blocking antibodies capable of naturalizing the virus at 6 weeks, with the antibody titres at a level also similar to natural infection
the antibody levels against Delta and Beta were at similar levels seen in natural infection, although much lower against Alpha
there was a 1.38-fold reduction in antibody titres against Delta compared to the original strain, in contrast with 10-fold reduction against Beta
the vaccine also induced T cell and memory B cell responses,[51][52] although at lower magnitudes than some other vaccines[53]
Manufacturing
As an inactivated vaccine like CoronaVac and Covaxin, the BIBP vaccine uses a more traditional technology[8] that is similar to the inactivated polio vaccine. Initially, a sample of SARS-CoV-2 strain 19nCoV-CDC-Tan-HB02 (HB02) from China capable of rapid multiplication was chosen.[54] Then, it was used to grow large quantities of the virus using vero cells. From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with the adjuvant aluminium hydroxide.[9][38]
Sinopharm's Chairman Yang Xioyun has said the company could produce one billion doses in 2021.[30]
In March 2021, Sinopharm and Abu Dhabi G42 announced plans to produce up to 200 million doses annually in the UAE at a new plant to become operational in 2021. The vaccine will be branded Hayat-Vax.[55]
In December 2020, Egypt announced an agreement between Sinopharm and Egypt's VACSERA for the vaccine to be manufactured locally.[56]
In March 2021, Serbia announced plans to produce 24 million doses of the BIBP vaccine annually starting in October.[57]
In April 2021, Bangladesh approved local production of the BIBP vaccine.[58]
In July 2021, Morocco's Société Thérapeutique Marocaine announced it would produce 5 million doses a month.[59]
In November 2021, Sinopharm announced that it will build a sterile bottling plant in Singapore to enhance the distribution of the vaccine.[60]
History
Clinical trials
Main article: COVID-19 vaccine
Phases I and II
In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BIBP)[2] and the Wuhan Institute of Biological Products (WIBP).[61] Both vaccines are chemically inactivated whole virus vaccines for COVID-19.
On 15 October, the Beijing Institute of Biological Products published results of its Phase I (192 adults) and Phase II (448 adults) clinical studies for the BIBP vaccine, showing it to be safe and well-tolerated at all tested doses in two age groups. Antibodies were elicited against SARS-CoV-2 in all vaccine recipients on day 42. These trials included individuals older than 60.[2]
The vaccine may have characteristics favorable for vaccinating people in the developing world. While mRNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of +90%, mRNA vaccines present distribution challenges for some nations, as some may require deep-freeze facilities and trucks. By contrast, the BIBP vaccine can be transported and stored at normal refrigeration temperatures.[17] While Pfizer and Moderna are among developers relying on novel mRNA technology, manufacturers have decades of experience with the inactivated virus technology Sinopharm is using.[17]
Phase III
In July 2020, Sinopharm began trials with 31,000 volunteers in the UAE in collaboration with G42 Healthcare, an Abu Dhabi-based company.[62] In June 2021, Sinopharm began Phase III trials for children and adolescents aged 3–17 with 1,800 volunteers.[63]
In September 2020, Sinopharm began trials in Casablanca and Rabat on 600 people.[64][65] In September, Egypt started trials with 6,000 people.[66]
In August, Sinopharm began trials in Bahrain with 6,000 people,[67] later increased to 7,700 people.[68] Also in August, Jordan began trials with 500 people.[69][70]
In September, Peru began trials with 6,000 people[71] which later expanded to 12,000 people.[72] On 26 January, a volunteer in the placebo group of the trials had died from COVID-19 related pneumonia.[73]
In September, Argentina began trials with 3,000 people.[74]
In Pakistan, University of Karachi conducted a trial with 3,000 volunteers.[75]
Authorizations
In China, Sinopharm obtained an EUA in July 2020.[76] On 30 December 2020, China's National Medical Products Administration approved the BIBP vaccine for general use.[18] In July 2021, China approved the EUA for children and adolescents aged 3–17.[77]
In September 2020, UAE approved for emergency use authorization.[78] In December 2020, UAE approved for full authorization.[79] In August 2021, UAE approved the EUA for children and adolescents aged 3–17.[80]
On 3 November 2020, Bahrain granted emergency use authorization for frontline workers.[68] In December 2020, Bahrain approved the vaccine.[81]
On 7 May 2021, the World Health Organization added the vaccine to the list of vaccines authorized for emergency use for COVID-19 Vaccines Global Access (COVAX).[32][33]
In May 2021, Zambia approved use of the vaccine.[82]
In June 2021, Philippines approved the BIBP vaccine for emergency use.[83]
On 5 May 2021, EMA's human medicines committee (CHMP) has started a rolling review of the vaccine. The EU applicant for this medicine is the Italian company Life'On S.r.l.[84]
Society and culture
Economics
By May, Sinopharm had supplied 200 million doses across all countries.[31] In July, Sinopharm signed advanced purchase agreements with GAVI to supply COVAX 60 million doses in the third quarter of 2021 and up to a total of 170 million doses by the first half of 2022.[85][34]
Asia
On 10 June, Afghanistan received a donation of 700,000 doses of the BIBP vaccine from China.[86]
In July, Armenia approved the purchase of doses of the BIBP vaccine.[87]
In April 2021, Bangladesh approved emergency use[88] and had received 7 million doses by August. The country will purchase 60 million doses.[89]
In February 2021, Brunei received the first batch of the vaccine donated by China,[90] which has been approved for emergency use.[91]
In February 2021, Cambodia granted emergency use authorization[92] and started the vaccination campaign on 10 February.[93] By July the country had received 5.2 million doses.[94]
In April 2021, Indonesia approved emergency use.[95] In May, a donation of 500,000 doses from the UAE arrived.[96] By July, 7.5 million out of 15 million doses had arrived for a private vaccination program called "Gotong Royong", where companies could arrange a free COVID-19 vaccine rollout for their employees.[97]
In February 2021, Iran approved emergency use[98] and received 650,000 doses by 15 April of the same year, including 400,000 dose donation from Red Cross Society of China.[99] Spokesperson of the Food and Drug Administration (Iran): What is offered and consumed from Sinopharm vaccine in Iran is its main platform and is licensed for emergency use by the World Health Organization.[100]
In January 2021, Iraq approved emergency use.[101] On 2 March, the first 50,000 dose arrived as a donation from China, with the Health Ministry indicating intention to purchase further 2 million doses.[102]
In January 2021, Jordan approved emergency use,[103] By July 1.37 million people had received their first dose and 833,000 people had received their second.[104]
In April 2021, Kazakhstan approved emergency use of the vaccine,[105] for which it had ordered 1 million doses.[106]
In March 2021, Kyrgyzstan received a donation of 150,000 doses from China[107] and began vaccinations on 29 March.[108] The country later purchased 1.25 million doses which arrived in August.[109]
In January 2021, Laos began vaccinating healthcare workers in Vientiane[110] and received another 300,000 doses in early February.[111]
In April 2021, Lebanon received a donation of 90,000 doses from China[112][113] after granting emergency use authorization on 2 March.[114]
In February 2021, Macau received the first 100,000 doses of 400,000 doses.[115]
In March 2021, Maldives granted emergency approval for use.[116] 100,000 doses were received on 25 March out of a total of 200,000 Chinese-donated doses.[117]
By May 2021, Mongolia had received 4 million doses, with 300,000 doses as a donation from China.[118] On 10 March, Governor of Ulaanbaatar D. Sumiyabazar and Deputy Prime Minister S. Amarsaikhan received the first doses.[119]
In February 2021, Nepal approved the vaccine for emergency use.[120] On 12 July, AP reported that China had donated 1.8 million doses, and was selling 4 million doses to Nepal.[121]
In January 2021, Pakistan approved the vaccine for emergency use[122] and began a vaccination campaign on 2 February.[20] The country has purchased up to 23 million doses[123] and received 6 million doses by July, including 1 million doses as a donation from China.[124]
In March 2021, Palestine received 100,000 doses donated by China.[125]
In April 2021, Philippines president Rodrigo Duterte received the vaccine after the food and drug regulator approved compassionate use of 10,000 doses for his security team.[126]
In July 2021, Singapore began importing the vaccine under the Special Access Route framework.[127]
In April 2021, Syria received 150,000 dose donated by China.[128]
In March 2021, Sri Lanka approved emergency use.[129] The country ordered 14 million doses on top of 1.1 million doses previously donated by China.[130]
In April 2021, Turkmenistan began vaccinating school teachers and medical personnel with the Sinopharm vaccine.[131]
On 14 September 2020, the United Arab Emirates approved the vaccine for front-line workers following interim Phase III trials.[62] In December, the country registered the BIBP vaccine after it reviewed the results of the interim analysis.[47] In March, a small number of people who have reduced immunity against diseases, chronic illnesses, or belong to high-risk groups have been given a third booster dose.[132] In May, due to concerns about effectiveness, Bahrain planned to give a third booster dose to some groups at risk, and the United Arab Emirates extended its third booster dose to anyone who had received the second dose more than six months ago.[133]
In June 2021, Thailand received one million doses.[134][135]
In June 2021, Vietnam received a donation of 500,000 doses from China[136] and later licensed importing of 5 million more doses.[137]
On 11 August 2021 Philippines received 100,000 doses from United Arab Emirates, also will received 1,000,000 doses from China on 21 August.[138]
Africa
In February, Algeria received a donation of 200,000 doses from China.[139]
In March, Angola received a donation of 200,000 doses from China.[140]
In April, Cameroon took delivery of 200,000 donated doses from China.[141][142]
In January, Egypt approved use of the vaccine[143] and had purchased 20 million doses, of which 1.5 million had arrived by April.[144] President Abdel Fattah el-Sisi announced a vaccination campaign starting 24 January.[21]
In March, Ethiopia received a donation of 300,000 doses from China.[145]
In February, Equatorial Guinea received a Chinese donation of 100,000 doses which arrived on 10 February. The country began vaccinations on 15 February.[146]
In March, Gabon received a Chinese donation of 100,000 doses which was the second vaccine approved for use in the country.[147]
In May, Kenya announced plans to buy the vaccine.[148]
In August, Libya received 2 million doses of the vaccine.[149]
Morocco has ordered 40.5 million doses, of which 8.5 million had been delivered by May.[150] Morocco had granted emergency use approval on 23 January.[151]
In March, Mauritania received a donation of 50,000 doses from China[152] and started its vaccination campaign on 26 March.[153]
In April, Mauritius received a donation of 100,000 doses from China and ordered an additional 500,000 doses.[154][155]
In February, Mozambique received a donation of 200,000 doses from China[156] and planned to start vaccinations on 8 March.[157]
In March, Namibia received a donation of 100,000 doses from China and announced the start of vaccinations in the Khomas and Erongo regions.[158][159]
In March, Niger received a donation of 400,000 doses from China and began vaccinations on 27 March.[160]
In February, Senegal received 200,000 doses that it purchased[161] and began vaccinating health workers on 22 February.[162]
In February, Sierra Leone received a donation of 200,000 doses from China.[163] It was approved for emergency use and vaccinations began on 15 March.[164]
In January, Seychelles began administering vaccinations with 50,000 doses it had received as a gift from the UAE.[165][166]
In April, Somalia received a donation of 200,000 doses from China[167] and started vaccinations with the vaccine on 14 April.[168][169]
In March, Sudan received a donation of 250,000 doses from China.[170][171]
In March, Republic of the Congo received 100,000 Chinese-donated doses with vaccinations prioritizing the medically vulnerable and those over 50.[172]
In February, Zimbabwe purchased 600,000 doses on top of 200,000 doses donated by China,[173] and started vaccinations on 18 February.[23] Zimbabwe purchased an additional 1.2 million doses.[174]
Europe
In February, Belarus received a donation of 100,000 doses from China[175] and began using the vaccine on 15 March.[29]
In July, Bosnia and Herzegovina ordered 500,000 doses.[176]
In May, Georgia began vaccinations with the BIBP vaccine[177] and received 1 million doses by July.[178]
In January, Hungary became first member of the European Union to approve the BIBP vaccine, signing a deal for 5 million doses.[179] Prime Minister Viktor Orbán was vaccinated with the BIBP vaccine on 28 February.[180] 5.2 million doses were delivered to Hungary by May, fulfilling the contract.[181]
In March, Moldova received 2,000 doses donated by the UAE[182] which will be used to vaccinate doctors starting on 22 March.[183]
In May, Montenegro received 200,000 doses, which was used to launch the vaccination campaign starting 4 May.[184]
In April, North Macedonia received the first 200,000 of 800,000 doses which arrived from Serbia[185] which was used in the vaccination campaign starting 4 May.[186]
On 19 January, Serbia started vaccinations with the BIBP vaccine and was the first country in Europe to approve the vaccine. By April, Serbia has received 2.5 million doses. In March, Serbia had signed an agreement for an additional 2 million doses.[187]
North America
In February, the Dominican Republic ordered 768,000 doses of the BIBP vaccine.[188]
In March, Dominica received 20,000 donated doses of the BIBP vaccine from China which it began using in its vaccination campaign on 4 March.[189][190]
In March, Mexico announced it would order 12 million doses of the BIBP vaccine pending approval by its health regulator,[191] which was granted in August.[192]
In May, Trinidad and Tobago received a donation of 100,000 doses from China. Another 200,000 and 800,000 doses were purchased and arrived 14 June and 13 July, respectively; bringing total doses of the BIBP vaccine received to 1.1 million.[193]
In April, Barbados announced it would receive 30,000 doses of Chinese donated the BIBP vaccine, according to Prime Minister Mia Mottley.[194]
Oceania
In April, Solomon Islands received a donation of 50,000 doses from China.[195]
In May, Papua New Guinea approved use of 200,000 Chinese donated doses,[196] which arrived on 1 July.[197]
South America
In February, Argentina authorized emergency use of the BIBP vaccine.[198] Eligibility was expanded to include people older than 60 on 25 March.[24] By 4 June million doses had arrived and 6 million more were ordered.[199]
In February, Bolivia started its vaccination campaign with the BIBP vaccine.[26] In June, Bolivia purchased 6 million doses in addition to 2.7 million doses it had already received.[200]
In March, Guyana received a donation of 20,000 doses from China[201] and later purchased another 100,000 doses. Vaccinations started with elderly and healthcare workers.[202]
In January, Peru purchased 38 million doses of the BIBP vaccine.[203] Peru granted emergency approval on 27 January[204] and started vaccinations on 9 February.[25]
In March, Venezuela granted approval for the vaccine[205] and received a donation of 500,000 doses from China on 2 March.[206]
Controversies
See also: Vacunagate
In February 2021, it was revealed that former Peruvian President Martín Vizcarra and other senior politicians were vaccinated in November 2020 before the vaccines were made available to health professionals and the public. They were vaccinated with extra doses that were brought in for the Phase III trials being conducted by Cayetano Heredia University in Lima with 12,000 volunteers.[207][72]
In May 2021, Philippine President Rodrigo Duterte apologized for taking the BIBP vaccine which was not approved at the time. In response, Duterte said China should in the future only send CoronaVac, a separate vaccine which was approved in the Philippines at the time. Duterte said he only got the vaccine under a compassionate use clause, on recommendation from his doctor to get vaccinated.[208] Later in June, the BIBP vaccine was approved for emergency use.[83]
References
|
||||||
6044
|
dbpedia
|
2
| 55
|
http://www.spicgz.com/en/About/
|
en
|
å½è¯ï¼å¹¿å·ï¼å½é å»è¯å«çæéå ¬å¸
|
[
"http://www.spicgz.com/UploadFile/CoolSite/2019-8/2019821142129484.png",
"http://www.spicgz.com/UploadFile/Soft/2018-2/2018226162710857.jpg",
"http://www.spicgz.com/UploadFile/upi/image/20180226/20180226134457705770.jpg",
"http://www.spicgz.com/UploadFile/CoolSite/2017-4/20174220508720.png"
] |
[] |
[] |
[
"About Us"
] | null |
[] | null |
About Us
| null |
Sinopharm International Guangzhou Ltd. was founded in 1993. It is a wholly-owned subsidiary of China National Pharmaceutical Group Corporation (Sinopharm) and an important member of Sinopharm Group. The company is located in Guangzhou CBD Central Business District, with Pearl River New City, Free Trade Zone and Taojin district and its own property and office space 24,000 square meters, net assets of nearly 200 million yuan.
The company upholds the core concept of "Caring for Life and Attending to Health" and closely follows the "Medical" and "Medicine" double-loop strategies. The Company has formed a total of three core business segments: Medical Devices, Health and Wellness 3C Products Import and Export Trade and Agency Sales, Public hospital equipment and supplies "two votes" professional services, internal hospital market-oriented projects and the integration of blood purification chain project. At the same time also carry out bonded warehousing services and own property leasing business. After 24 years of development, the company currently has customers in more than 100 countries around the world. Every year, China wins the bid of dozens of large-scale public hospitals in China and the blood purification chain project has been steadily promoted.
China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the Stateowned Assets Supervision and Administration Commission (SASAC) of the State Council. Sinopharm owns 1,700 subsidiaries and 8 listed companies, with operating revenue of more than 700 billion yuan. In 2022, Sinopharm ranked 80th in Fortune Global 500 and 1st among global pharmaceutical companies. China International Medical and Health Corporation is the "medical platform" and "internationalized platform" of Sinopharm. It has 50 medical institutions and more than 10,000 beds.
|
|||||||
6044
|
dbpedia
|
3
| 19
|
https://www.cnbc.com/2020/12/09/chinas-covid-vaccine-from-sinopharm-is-86percent-effective-uae-says-.html
|
en
|
China's Covid vaccine from Sinopharm is 86% effective, UAE says
|
[
"https://static-redesign.cnbcfm.com/dist/7821ea3cb72f88388591.svg",
"https://static-redesign.cnbcfm.com/dist/2469ed0a9a4cafdf055e.svg",
"https://static-redesign.cnbcfm.com/dist/2469ed0a9a4cafdf055e.svg",
"https://image.cnbcfm.com/api/v1/image/105390270-1533915418989natashaturak2.jpg?v=1533915460&w=60&h=60&ffmt=webp",
"https://image.cnbcfm.com/api/v1/image/106807771-16074335942020-12-08t090448z_722051655_rc2xik975sm5_rtrmadp_0_health-coronavirus-britain-rollout.jpeg?v=1607433629&w=750&h=422&vtcrop=y",
"https://static-redesign.cnbcfm.com/dist/7821ea3cb72f88388591.svg",
"https://static-redesign.cnbcfm.com/dist/17269f1b6083fd5f61be.svg",
"https://static-redesign.cnbcfm.com/dist/09c161b9810767a7849e.svg"
] |
[] |
[] |
[
"Dubai",
"United Arab Emirates",
"Health care industry",
"Pharmaceuticals",
"Biotech and Pharmaceuticals",
"Emerging markets",
"business news"
] | null |
[
"Natasha Turak",
"www.facebook.com"
] |
2020-12-09T00:00:00
|
The announcement was thin on details, however, and did not mention any side effects experienced by patients.
|
en
|
https://sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/favicon.ico
|
CNBC
|
https://www.cnbc.com/2020/12/09/chinas-covid-vaccine-from-sinopharm-is-86percent-effective-uae-says-.html
|
DUBAI, United Arab Emirates — Human trials of a Chinese vaccine in the United Arab Emirates have yielded positive results, the UAE's national health authorities said Wednesday, citing an 86% efficacy rate.
The figure was announced by the UAE Ministry of Health via state news agency WAM, detailing an "interim analysis" conducted by Sinopharm's China National Biotec Group (CNBG). The Gulf state of 10 million began Phase 3 human trials of the experimental vaccine in July, and in September approved its emergency use for health workers.
"The registration of this vaccine is a decision in response to the application from Sinopharm CNBG. The announcement is a significant vote of confidence by the UAE's health authorities in the safety and efficacy of this vaccine," the health ministry said Wednesday, without elaborating on what "registration" meant. The vaccine itself was developed by CNBG's Beijing Institute of Biological Product.
The Phase 3 trials included 31,000 volunteers across 125 nationalities, the ministry said, highlighting the UAE's diverse and large expatriate population — comprising roughly 90% of the country's total population — as an advantage in carrying out human tests. The volunteers, between the ages of 18 and 60, took two doses of the vaccine over 28 days.
The announcement was thin on details, however; it did not elaborate on the parameters of the trials like how many patients were given the vaccine dosage versus placebos, and did not mention any side effects experienced by patients.
After citing the 86% efficacy figure, the ministry said: "The analysis also shows the vaccine to have 99 percent seroconversion rate of neutralising antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease." Seroconversion is the process by which an antibody becomes identifiable in a patient's blood.
It added that "the analysis shows no serious safety concerns."
It is unclear how the 86% efficacy figure was calculated. CNBC has reached out to Sinopharm for comment.
Dubai ruler Sheikh Mohammed bin Rashid al Maktoum in early November reported that he received the trial vaccine, shortly after the UAE's Minister of Foreign Affairs Sheikh Abdullah bin Zayed al Nahyan received it, both tweeting images of themselves being vaccinated and praising the work of the medical workers behind the effort.
|
||||
6044
|
dbpedia
|
2
| 43
|
https://www.mediaoffice.ae/en/news/2021/Jan/30-01/DHA-to-start-using-sinopharm-starting-sunday
|
en
|
DHA to begin administering Sinopharm COVID-19 vaccine
|
http://www.mediaoffice.ae/-/media/2015/dhaahq.jpg
|
http://www.mediaoffice.ae/-/media/2015/dhaahq.jpg
|
[
"https://www.mediaoffice.ae/-/media/feature/navigation/logo/god-logo/god-logo1.png",
"https://www.mediaoffice.ae/-/media/feature/navigation/logo/logo.png",
"https://www.mediaoffice.ae/-/media/news-banner/newsbanner.jpg",
"https://www.mediaoffice.ae/-/media/2015/dhaahq.jpg?h=2551&iar=0&w=3705&hash=258A5ACE646EB3A6A4476DCE9C1B207D",
"https://www.mediaoffice.ae/-/media/2024/august/28-08/10/gdmo1-p02-28-08-24.jpg?cx=0&cy=0&cw=370&ch=223&hash=B238B38A08E53B0579BD4770ACAF6E82",
"https://www.mediaoffice.ae/-/media/2024/july/29-07/03/01-29072024-hisham.jpg?cx=0&cy=0&cw=370&ch=223&hash=0172F5DB4D5056654361A76531054912",
"https://www.mediaoffice.ae/-/media/2024/august/29-08/01/dmcc-and-the-bogota-chamber-of-commerce-sign-mou.jpeg?cx=0&cy=0&cw=370&ch=223&hash=DD6C62EDAF0D5A5396BDBD9BFD2A01F5",
"https://www.mediaoffice.ae/-/media/feature/navigation/logo/logo.png",
"https://www.mediaoffice.ae/-/media/feature/navigation/footer/government-logo/udotae/dubai-logo.png",
"https://www.mediaoffice.ae/-/media/feature/navigation/footer/government-logo/udotae.png",
"https://www.mediaoffice.ae/assets/svgs/logo.svg",
"https://www.mediaoffice.ae/assets/svgs/rotate.gif"
] |
[] |
[] |
[
""
] | null |
[
"Traffic Digital"
] |
2021-01-30T00:00:00
|
en
|
/favicon.ico
|
Government of Dubai Media Office
|
http://www.mediaoffice.ae/en/news/2021/jan/30-01/dha-to-start-using-sinopharm-starting-sunday
|
The Dubai Health Authority (DHA) today announced that it will begin providing the Sinopharm COVID-19 vaccine to Emirati citizens and Dubai residents who are aged 60 and above, starting 31 January, 2021.
The move is in line with the DHA’s keenness to provide the public with an opportunity to select between various types of vaccines available in the emirate.
The Sinopharm vaccine will be available at Nad Al Hamr Health Centre, Al Twar Health Centre and Al Mankhool Health Centre, the Authority said.
“Providing the Sinopharm vaccine is part of the DHA’s keenness to ensure the availability of COVID-19 vaccination services to all segments of the community, especially the older age groups who are considered to be among the high-risk categories. In the first phase of the launch of the vaccine, the DHA’s Contact Centre will reach out to those who already have pre-registered appointments for vaccination.” said Dr Farida Al Khaja, CEO of DHA’s Clinical Support Services and Nursing Sector and Chairperson of the COVID-19 Vaccination Steering Committee.
Dr Al Khaja added that the Sinopharm COVID-19 vaccine will be available to other segments of the population in future phases.
The health authority reiterated the importance of continuing to adhere to precautionary measures and leading a healthy lifestyle even after taking the vaccine.
|
|||
6044
|
dbpedia
|
1
| 41
|
https://www.livemint.com/news/world/who-approves-china-s-sinopharm-covid-19-vaccine-11620403533298.html
|
en
|
WHO approves China’s Sinopharm Covid vaccine for emergency use
|
[
"https://sb.scorecardresearch.com/p?c1=2&c2=6035286&cv=3.6.0&cj=1",
"https://www.livemint.com/lm-img/img/static/search.png",
"https://www.livemint.com/lm-img/img/static/ico-e-paper-web.png",
"https://images.livemint.com/img/2021/05/07/600x338/2021-05-07T155827Z_557004033_RC23BN9GXX7Y_RTRMADP_3_HEALTH-CORONAVIRUS-WHO-CHINA-SINOPHARM_1620403557144_1620403578132.JPG",
"https://www.livemint.com/lm-img/img/static/value-up.png"
] |
[] |
[] |
[
"Vaccine",
"Covid-19 vaccine",
"UN health",
"Countries",
"Pfizer-BioNTech",
"Moderna",
"JohnSon and Johnson"
] | null |
[
"Staff"
] |
2021-05-07T21:39:26+05:30
|
The UN health agency signed off on the two-dose vaccine, which is already being deployed in dozens of countries around the world.The move could help Beijing step up its vaccine diplomacy amid the surge in coronavirus vaccines in several countries
|
en
|
mint
|
https://www.livemint.com/news/world/who-approves-china-s-sinopharm-covid-19-vaccine-11620403533298.html
|
In a big relief for China, the World Health Organization (WHO) on Friday finally approved the Sinopharm Covid-19 vaccine for emergency use -- the first Chinese jab to receive the WHO's green light.
The move could help Beijing step up its vaccine diplomacy amid the surge in coronavirus vaccines in several countries.
China has approved about five of its Covid-19 vaccines for emergency use and especially using Sinopharm and Sinovac vaccines for both at home and abroad.
The UN health agency signed off on the two-dose vaccine, which is already being deployed in dozens of countries around the world.
China was eagerly awaiting the global health body’s nod for it to aggressively push the vaccine among different countries.
"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," WHO chief Tedros Adhanom Ghebreyesus told a news conference.
"The Strategic Advisory Group of Experts on Immunisation, or SAGE, has also reviewed the available data, and recommends the vaccine for adults 18 years and older, with a two-dose schedule."
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).
The two-jab vaccine is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings, the WHO press release said.
An emergency use listing by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution, especially those states without an international-standard regulator of their own.
It also opens the door for the jabs to enter the Covax global vaccine-sharing scheme, which aims to provide equitable access to doses around the world and particularly in poorer countries.
The Sinopharm vaccine is already in use in 42 territories around the world, fourth behind AstraZeneca (166), Pfizer-BioNTech (94) and Moderna (46), according to an AFP tally.
Besides China, it is being used in Algeria, Cameroon, Egypt, Hungary, Iraq, Iran, Pakistan, Peru, the United Arab Emirates, Serbia and Seychelles, among others.
A clutch of other vaccines are on the road towards WHO emergency use listing, including a second Sinopharm product being made in Wuhan -- the city where coronavirus was first detected.
A decision is expected within days on Sinovac, a second Chinese-made vaccine already being used in 22 countries.
The WHO has already given emergency use listing to the vaccines being made by Pfizer-BioNTech, Moderna, Johnson and Johnson, and the AstraZeneca jab being produced at separate sites in India and in South Korea.
Russia's Sputnik V vaccine is the next furthest ahead in the process.
|
|||||
6044
|
dbpedia
|
0
| 76
|
https://www.dw.com/en/coronavirus-how-effective-are-the-chinese-vaccines/a-56370802
|
en
|
Coronavirus: How effective are the Chinese vaccines? – DW – 02
|
[
"https://static.dw.com/image/56102131_600.jpg 78w, https://static.dw.com/image/56102131_601.jpg 201w, https://static.dw.com/image/56102131_602.jpg 379w, https://static.dw.com/image/56102131_603.jpg 545w, https://static.dw.com/image/56102131_604.jpg 767w, https://static.dw.com/image/56102131_605.jpg 1199w"
] |
[] |
[] |
[
""
] | null |
[
"Fabian Schmidt"
] |
2021-01-28T15:52:05.299000+00:00
|
Some countries have already approved vaccines from China or are currently participating in trials. But how effective and safe are the vaccines?
|
en
|
/images/icons/favicon-16x16.png
|
dw.com
|
https://www.dw.com/en/coronavirus-how-effective-are-the-chinese-vaccines/a-56370802
|
Three vaccines are currently far along in development in China. They are the vaccines from the companies Sinopharm, Sinovac Biotech and CanSino.
Only partial data on the efficacy of the vaccines has been released from their respective phase II and III trials. Sinopharm was the first company to officially announce data at the turn of 2020.
The situation is also still unclear with regard to approval of the vaccines. More than a million people have already been vaccinated with Sinopharm's vaccine, but this was done either as part of studies or with emergency approval.
Vaccine nationalism — the other way around
Meanwhile, correspondents in China for Germany's public broadcaster ARD and the daily newspaper FAZ report on a campaign currently underway in Chinese state media questioning the efficacy and safety of vaccines approved in Western countries.
One accusation is that Western media are concealing the dangers of BioNTech-Pfizer's vaccine. A prominent presenter on the state-controlled broadcaster joined in these accusations on Twitter.
Paradoxically, China is actually procuring vaccines from BioNTech-Pfizer via the company Fosun Pharma. There are many indications that the Chinese government is using this media campaign to deflect criticism over the lack of transparency about its own vaccine manufacturers, possibly because its own development is not delivering the desired results.
The data on vaccines from China so far tend to indicate somewhat lower efficacy than their Western competitors. Here is an overview of the vaccines, where they are already being used, and what is known about their efficacy.
Sinopharm
The vaccine called Vero is based on an inactivated virus. The company Sinopharm developed it in collaboration with the Wuhan Institute of Virology and the Institute of Biological Products. Such vaccines — also called inactivated vaccines — have been tried and tested for decades. For example, they are successfully used against diphtheria, hepatitis B, polio, whooping cough and tetanus.
Phase III trials for Vero have been conducted in 10 countries worldwide, including the United Arab Emirates, Bahrain, Peru, Morocco, Argentina, Jordan and Pakistan. Test in Serbia were planned, but not implemented. One reason for the research outside the People's Republic is that in China, case numbers dropped so sharply in the summer due to the strict lockdown that it was difficult to obtain any meaningful data at all.
So far, Vero is the only Chinese vaccine for which the manufacturer has published official data. On December 29, 2020, Sinopharm reported 79% efficacy in an interim evaluation. The vaccine was licensed in China one day later.
Data from other countries does not present a consistent picture — the Emirates confirmed even higher efficacy in their study: 86%.
The authorities there were even quicker to approve the vaccine than the Chinese. The vaccine was allowed to be administered from the beginning of December. Serbia also approved the vaccine in January.
Things were less promising in Peru. Authorities there halted clinical trials in December after one patient suffered paralysis in his arms as a result of vaccination.
Sinovac Biotech
The vaccine, called CoronaVac, is also based on inactivated viruses. It has been tested in various phase III trials since the summer, including in Brazil (which approved the vaccine on January 19), Indonesia, Bangladesh and Turkey. The manufacturer has not released official figures on the efficacy of the CoronaVac vaccine, but evaluations by the Brazilian collaborators suggest an efficacy of up to 78%. Indonesian health authorities report an efficacy of about 65%.
Although this means that the vaccine is not as effective as the mRNA vaccines approved for use in Europe and the US, it does reach and exceed values that are common for influenza vaccines. Some of these are only 30-60% effective.
Potentially interested countries like Malaysia and Singapore are still hesitant. Thailand plans to introduce the vaccine despite its moderate efficacy. In China, the vaccine has received emergency approval.
Sinovac hopes to increase efficacy by prolonging the interval between doses. However, further studies are needed before this can happen. Prolonging the time between the first vaccination and the booster shot also increases the risk of mutations occurring.
CanSino Biologics
The vaccine called Ad5-nCoV or Convidecia, which the company CanSino Biologics developed together with the Beijing Institute of Biotechnology, is a vector virus vaccine based on an adenovirus type 5.
This means that a harmless transport virus brings non-replicable surface proteins of the SARS-CoV-2 pathogen to the cells and triggers the immune reaction there. In terms of its mode of action, the vaccine is comparable to the British-Swedish vaccine developed by AstraZeneca and the University of Oxford.
Phase III trials have started in Pakistan, Russia, Mexico and Chile. A study is also planned in Saudi Arabia.
In Canada, however, a trial was cancelled because China had not delivered the vaccine doses as agreed to its partner, the Canadian Center for Vaccinology in Halifax. It is possible that one reason for the failure of the envisaged collaboration is a diplomatic dispute between the People's Republic and Canada, which remains unresolved. However, none of the partners involved have commented on the matter.
In China, the vaccine has been administered to military personnel since June 2020. The manufacturer has not yet released efficacy data.
This article has been updated on February 1, 2021
|
||||
6044
|
dbpedia
|
3
| 23
|
https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html
|
en
|
Serbia Becomes First European Nation To Use China's Sinopharm Vaccine
|
[
"https://ssc.rferl.org/b/ss/bbgprod,bbgentityrferl/1/G.4--NS/1173707255?pageName=rfe%3aeng%3aw%3aarticle%3aserbia%20becomes%20first%20european%20nation%20to%20use%20china%27s%20sinopharm%20vaccine&c6=serbia%20becomes%20first%20european%20nation%20to%20use%20china%27s%20sinopharm%20vaccine&v36=8.33.0.0.342&v6=D=c6&g=https%3a%2f%2fwww.rferl.org%2fa%2fserbia-covid-vaccine-china-sinopharm%2f31053091.html&c1=D=g&v1=D=g&events=event1,event52&c16=rferl%20english&v16=D=c16&c5=serbia&v5=D=c5&ch=serbia&c15=english&v15=D=c15&c4=article&v4=D=c4&c14=31053091&v14=D=c14&v20=no&c17=web&v17=D=c17&mcorgid=518abc7455e462b97f000101%40adobeorg&server=www.rferl.org&pageType=D=c4&ns=bbg&v29=D=server&v25=rfe&v30=420&v105=D=User-Agent ",
"https://www.rferl.org/Content/responsive/img/player-spinner.png",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo-compact.svg",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo.svg",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo-print.gif",
"https://www.rferl.org/Content/responsive/RFE/en-US/img/logo-print_color.png",
"https://gdb.rferl.org/3da039d2-7098-4df2-b547-b197e38a55ac_w250_r1_s.jpg",
"https://gdb.rferl.org/01000000-0a00-0242-88ae-08dc16a2f407_w100_r5.png",
"https://gdb.rferl.org/01000000-0a00-0242-88ae-08dc16a2f407_w66_r5.png",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w100_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w33_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-d2c5-08dcbb9f1d5c_w100_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-d2c5-08dcbb9f1d5c_w33_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-3b22-08dcabbc41f5_w100_r1.jpg",
"https://gdb.rferl.org/01000000-0aff-0242-3b22-08dcabbc41f5_w33_r1.jpg",
"https://gdb.rferl.org/f22a3e38-3380-4e2c-a344-32fb631c77a9_cx0_cy6_cw0_w100_r1.jpg",
"https://gdb.rferl.org/f22a3e38-3380-4e2c-a344-32fb631c77a9_cx0_cy6_cw0_w33_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-7053-08dcbbb11a7a_cx15_cy29_cw80_w100_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-7053-08dcbbb11a7a_cx15_cy29_cw80_w33_r1.jpg",
"https://gdb.rferl.org/f8bbd50a-a99f-4564-937f-e63ae931bdc7_w50_r5.jpg",
"https://gdb.rferl.org/f8bbd50a-a99f-4564-937f-e63ae931bdc7_w50_r5.jpg",
"https://gdb.rferl.org/f8bbd50a-a99f-4564-937f-e63ae931bdc7_w50_r5.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w100_r1.jpg",
"https://gdb.rferl.org/01000000-c0a8-0242-36f0-08dcbd38b47a_w33_r1.jpg"
] |
[] |
[] |
[
"News",
"Serbia"
] | null |
[
"RFE/RL"
] |
2021-01-20T00:46:52+00:00
|
Serbia became the first European country to begin a mass inoculation campaign using China’s Sinopharm COVID-19 vaccine, with health officials and hundreds of uniformed soldiers lining up to get their jabs in the capital, Belgrade.
|
en
|
/Content/responsive/RFE/img/webApp/favicon.svg
|
RadioFreeEurope/RadioLiberty
|
https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html
|
Serbia became the first European country to begin a mass inoculation campaign using China’s Sinopharm COVID-19 vaccine, with health officials and hundreds of uniformed soldiers lining up to get their jabs in the capital, Belgrade.
"It is the only way to return to normal life," Health Minister Zlatibor Loncar said on January 19 as he became the first person to receive the vaccine in an event broadcast live on state television.
"These are all very safe vaccines," Loncar said from Belgrade’s virology institute.
Meanwhile, at an exhibition hall in the capital, hundreds of soldiers in camouflage uniforms bared their arms to receive their shots from dozens of nurses.
Defense Minister Nebojsa Stefanovic said that he and more than 700 members of the military had been vaccinated with the Chinese-made vaccine.
The Sinopharm vaccine has become a source of controversy in many Western countries.
China approved the shot developed by Sinopharm's BIBP late last year. No detailed efficacy data has been released, but BIBP has said the vaccine is 79 percent effective based on interim data.
That number is below the efficacy rates of around 95 percent reported by Western-made vaccines, such as those produced by Pfizer/BioNTech or Moderna.
Serbia, which last week received 1 million doses of the Sinopharm vaccine, has close ties with Beijing, and Chinese companies have invested billions of euros in the Western Balkan country of 7 million people.
"I have been inoculated with the Chinese vaccine, which we completely trust.... I've said I will get the same vaccine as our troops," defense chief Stefanovic told reporters.
Serbia, which also has close ties to Russia, began using the Sputnik-V vaccine on January 6, with top officials getting the first jabs to boost public trust in the shot.
Russians are also being inoculated with the Sputnik-V vaccine after it was approved by Moscow in August 2020 despite a lack of large-scale clinical trials and perceived shortcomings in data to support its safety and efficacy.
Serbia and Belarus are the only European countries using the Russian vaccine, which does not have the approval of the European Medicines Agency or the World Health Organization.
Serbia launched its coronavirus vaccination program using the Pfizer-BioNTech vaccine in December 2020 when Prime Minister Ana Brnabic received the shot, which alongside the Moderna vaccine has been approved for use in the EU and North America.
But with supplies of the Pfizer-BioNTech limited for now, Serbia is seeking to diversify its sourcing of vaccines.
Serbian President Aleksandar Vucic over the weekend said the country expects to get another 250,000 doses of the Sputnik-V vaccine and 20,000 doses of the Pfizer-BioNTech vaccine in the coming days.
Vucic on January 19 said vaccinations will be administered at some 300 locations in Serbia's biggest cities. He added that he will receive his dose this weekend.
Serbia is vaccinating essential workers such as police officers, teachers, and soldiers after it last month began to treat the elderly in care homes and medical workers.
Serbia has recorded 3,771 deaths from COVID-19 and 347,111 overall cases.
In the Western Balkan region, vaccinations have begun in Serbia and Albania, but Bosnia-Herzegovina, Kosovo, Montenegro, and North Macedonia have not yet received vaccine supplies.
|
||||
6044
|
dbpedia
|
0
| 21
|
https://news.un.org/en/story/2021/05/1091542
|
en
|
WHO approves Chinese COVID-19 vaccine for emergency use
|
[
"https://news.un.org/en/themes/custom/un3/un3_base/images/logos/UN_logo_en.svg",
"https://global.unitednations.entermediadb.net/assets/mediadb/services/module/asset/downloads/preset/Libraries/Production+Library/06-04-2021-Unsplash-COVID-19-vaccine.jpg/image1170x530cropped.jpg",
"https://global.unitednations.entermediadb.net/assets/mediadb/services/module/asset/downloads/preset/Libraries/Production+Library/25-03-2021_Unsplash_DPRK.jpg/image100x100cropped.jpg",
"https://global.unitednations.entermediadb.net/assets/mediadb/services/module/asset/downloads/preset/Libraries/Production+Library/27-03-21_vaccines_consignment_India.jpg/image100x100cropped.jpg",
"https://global.unitednations.entermediadb.net/assets/mediadb/services/module/asset/downloads/preset/Libraries/Production+Library/25-03-2020-Lu+Xiang+5.jpg/image100x100cropped.jpg",
"https://global.unitednations.entermediadb.net/assets/mediadb/services/module/asset/downloads/preset/Libraries/Production+Library/07-04-2021-PAHO-Colombia-vaccine-02.jpg/image350x235cropped.jpg"
] |
[] |
[] |
[
""
] | null |
[] |
2021-05-07T16:33:00-04:00
|
A COVID-19 vaccine produced in China has been given the green light for global rollout, potentially paving the way for its use in underserved countries, the World Health Organization (WHO) announced on Friday. |
|
en
|
/en/themes/custom/un_base_theme/favicon.ico
|
UN News
|
https://news.un.org/en/story/2021/05/1091542
|
The UN agency has approved the Sinopharm vaccine for emergency use, which is a prerequisite for inclusion in the global vaccine solidarity initiative, COVAX.
The vaccine is easy to store, making it suitable for locations with limited resources, and proved 79 per cent effective in clinical trials.
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk”, said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products.
“We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”
A vaccine first
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).
It is the first vaccine to carry a vaccine vial monitor. The vials have a small sticker that changes colour as the vaccine is exposed to heat, so health workers know whether it can be safely used.
The vaccine is recommended for adults 18 and older, with a two-dose schedule spaced over a period of three to four weeks.
Although few people over 60 participated in the clinical trials, WHO did not recommend an upper age limit for use as data suggests the vaccine is likely to have a protective effect in older persons.
Safely expediting vaccines
WHO emergency use listing (EUL) allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
The EUL process assesses the suitability of new medicines, vaccines and diagnostics during public health emergencies.
The goal is to make them available as rapidly as possible, while maintaining strict criteria of safety, efficacy and quality.
The Sinopharm vaccine is the sixth to receive the EUL approval. The others are by Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Janssen (Johnson & Johnson) and Moderna.
|
||||
6044
|
dbpedia
|
3
| 74
|
https://www.bmj.com/content/373/bmj.n912/rr-0
|
en
|
China's COVID-19 vaccine: not just about efficacy and price, but also its access in 2021; beware of discrimination by vaccine origin
|
[
"https://googleads.g.doubleclick.net/pagead/viewthroughconversion/973817434/?value=0&guid=ON&script=0"
] |
[] |
[] |
[
""
] | null |
[] | null |
en
|
”/sites/default/themes/bmj/the_bmj/img/icon.png”/
|
The BMJ
|
https://www.bmj.com/content/373/bmj.n912/rr-0
|
Dear Editors
As we discovered from various sources, the cost of COVID-19 vaccine varies significantly and does not necessarily equate to reported efficacy/effectiveness.
This article cited sources which place the sale price per dose of Sinopharm's vaccine as between $19-$36 ($30 in China), which contrasts with the reported prices of other vaccines used in the EU and the US (Ref 1).
Specifically Oxford-AstraZeneca vaccine is reported to be under $6 (as low as $2.15), while the vaccines from Moderna and Pfizer are generally sub $20 range per dose.
Russia's Sputnik V costs under $10 per dose according to the deal made with the African Union (Ref 2).
Johnson & Johnson/Janssen's vaccine also costs under $10 per dose, but unlike all other vaccines mentioned here so far, only requires a single dose rather than 2 doses.
Hence not withstanding the uncertainty about reported efficacy of Sinopharm vaccines and potential discounts afforded to sponsoring countries (EU.UK/US) who financially supported vaccine development by pharmaceutical companies, the pricing of Sinopharm vaccine is higher than expected.
If there is any immediate advantages for using Sinopharm vaccine, it is its availability to various third-world countries, particularly those in the the African Union. At least 223 million doses of Sinopharm vaccine have been reported to be already distributed worldwide (including 120 million in China), compared to 92 million doses of vaccine doses in EU (from various companies - Ref 3) whereas the US saw 238 million doses being distributed (ref 4).
It is evident that the inequity in geographic access (according to manufacturing sites) and advanced orders placed months ahead by various countries, compounded by export restrictions placed by countries where vaccine factories are located, pretty much dictated the availability of vaccines in 2021. There is some allegations that the Chinese government may be using vaccine diplomacy (Ref 5) to advocate or coerce their agenda to various developing countries, but frankly the antics of vaccine export restriction/delay from the EU, US and India leaves very little room for the China-skeptics to provide a viable alternate solution.
I foresee some dangers in such skewed distribution of vaccine. Some media reporting has already reflected the trend whereby vaccines from China and Russia, due to the lack of information, are being hinted at or even denigrated as second-class even though these products do fulfill WHO's guidelines of 50% efficacy threshold for vaccine against COVID-19 (Ref 6).
As the world starts to open for international travel toward the end of 2021, there may be much potential for vaccine casteism by various countries, to discriminate those vaccinated with products from China and Russia. As I pointed out, vaccine access in less-developed countries is not merely due to vaccine prices (Sinopharm vaccine in fact costs significantly more than others) but also relative availability for distribution.
There are dangers that discrimination by vaccine origin may not be due to local government border policies; airlines may also impose requirements upon passengers wanting to travel between continents to deny boarding to avoid potential penalties from local authorities at some destinations. As 'immunity passport' becomes a political hot potato within the UK and the US, I seriously doubt foreign citizen arrivals to these countries will be immune from similar controversy.
The WHO and the UN would need to pre-emptively address potential member country nationalism by vaccine origin.
|
|||||
6044
|
dbpedia
|
3
| 1
|
https://en.wikipedia.org/wiki/Sinopharm_(company)
|
en
|
Sinopharm (company)
|
[
"https://en.wikipedia.org/static/images/icons/wikipedia.png",
"https://en.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-en.svg",
"https://en.wikipedia.org/static/images/mobile/copyright/wikipedia-tagline-en.svg",
"https://upload.wikimedia.org/wikipedia/en/b/b2/China_National_Pharmaceutical_Group_Corporation.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/1/14/Sinopharm_Building_%2820230206145912%29.jpg/220px-Sinopharm_Building_%2820230206145912%29.jpg",
"https://upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png",
"https://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png",
"https://upload.wikimedia.org/wikipedia/commons/thumb/f/fa/Flag_of_the_People%27s_Republic_of_China.svg/23px-Flag_of_the_People%27s_Republic_of_China.svg.png",
"https://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png",
"https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?type=1x1",
"https://en.wikipedia.org/static/images/footer/wikimedia-button.svg",
"https://en.wikipedia.org/static/images/footer/poweredby_mediawiki.svg"
] |
[] |
[] |
[
""
] | null |
[
"Contributors to Wikimedia projects"
] |
2009-09-20T00:49:45+00:00
|
en
|
/static/apple-touch/wikipedia.png
|
https://en.wikipedia.org/wiki/Sinopharm_(company)
|
Chinese state-owned enterprise
This article is about the pharmaceutical company. For the COVID-19 vaccine that it developed, see Sinopharm BIBP COVID-19 vaccine.
For other uses, see Sinopharm (disambiguation).
"Sinopharm" redirects here. Not to be confused with Sinovac Biotech.
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine [zh] (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.),[5] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[6]
Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.[7]
History
[edit]
Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).[citation needed]
Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[8]
Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.[9]
COVID-19 vaccines
[edit]
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[10] the Sinopharm COVID-19 vaccine,[11] or BIBP vaccine,[11][12][13] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[14] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.[15]
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[16] In December 2020, the UAE previously announced interim results showing 86% efficacy.[17] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[18]
BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[19][20][21] Africa,[22][23][24] South America,[25][26][27] and Europe.[28][29][30] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[31] On 7 May 2021, the World Health Organization approved the vaccine for emergency use[32] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.[33]
The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.[citation needed]
See also
[edit]
CanSino Biologics
Sinovac
References
[edit]
|
||||||
6044
|
dbpedia
|
1
| 82
|
https://www.parkwayshenton.com.sg/health-plus/article/sinopharm-COVID-19-vaccine-efficacy
|
en
|
19 Vaccine: 5 Things to Know
|
https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcL2M4XC8zOTQwM1wvODQyOGU3YmU4Y2RhYTVkODI2Y2FmOGY2MTYxYTY5ZjYtMTY1ODMwODA2My5qcGcifQ:ihh-healthcare-berhad:MV3IK4q2T1xB7G6oFsnrphqCkOWZOcwwRk1ICazplGc?width={width}
|
https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcL2M4XC8zOTQwM1wvODQyOGU3YmU4Y2RhYTVkODI2Y2FmOGY2MTYxYTY5ZjYtMTY1ODMwODA2My5qcGcifQ:ihh-healthcare-berhad:MV3IK4q2T1xB7G6oFsnrphqCkOWZOcwwRk1ICazplGc?width={width}
|
[
"https://www.parkwayshenton.com.sg/images/default-source/default-album/logo.png?sfvrsn=217f77b1_1",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcL2M4XC8zOTQwM1wvODQyOGU3YmU4Y2RhYTVkODI2Y2FmOGY2MTYxYTY5ZjYtMTY1ODMwODA2My5qcGcifQ:ihh-healthcare-berhad:MV3IK4q2T1xB7G6oFsnrphqCkOWZOcwwRk1ICazplGc?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9maWxlXC8yTEh5ellKNjEzMUJOajNYRmJFeC5qcGcifQ:ihh-healthcare-berhad:P0E2E1Pz5TgLSgHK5GK9PpXgmkIWbJmNbc-DDPdm1TU?width=70&height=88&crop=fp&fp=0.5,0.5&fp_zoom=1&format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1leHBsb3JlciJ9LCJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvYTNcLzM5NDA1XC9jOTFlOGVhYTIwY2NmNzk3ZTkzNTQxYjY5MGI2MTlmMS0xNjU4MzA4MDYzLmpwZyJ9:ihh-healthcare-berhad:6OsHs2ZxMwMg4p8spOP-4LifCsM8hWJFfBCNCGEKFzQ?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1leHBsb3JlciJ9LCJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvODNcLzM5NDA0XC9iMTNjOWViNmY0NGQ4ODM0YTkyM2Y5MWE3MGZkMGI4YS0xNjU4MzA4MDYzLmpwZyJ9:ihh-healthcare-berhad:Oaw42i_hM1bjZ2n5CYzLlN8eC1kJbGywe5kcJeeYL5g?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvYTFcLzM4MTU1XC83NTUyYWMzMmJmODYxNTUzYjE0Zjk4YzY0MGEwZmE1YS0xNjU4MzAxMDMwLmpwZyJ9:ihh-healthcare-berhad:Gv9tXsglsIuEkvhK_mEWJbvoXXSZ91BzyriS5GpUcGs?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvNTlcLzM4NjcwXC9iZmZkOWNjZjFhMzY1OTZlNTVkMTEwYzBmN2RhNmI1MS0xNjU4MzAyNzA5LmpwZyJ9:ihh-healthcare-berhad:-EBMbHCwPxq_E1uWJfOrr0_vBmXAVUaNn5dRndBu04Y?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcL2JkXC8zODE5NVwvMzVmMDU0YTMyMDA2NmI2NjIyYjZhZDJiYTkzNmU0MzYtMTY1ODMwMTAzMC5qcGcifQ:ihh-healthcare-berhad:PhcoYzu6DxVcfr-mnm8Dxtnm22INMiPQCHETNzO2Hf8?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcLzI5XC8zNzA0NFwvMzM3NmM3YzRkYjNiYzU2MDEwNWVhNjE3NzdmMjdkZDUtMTY1ODI5ODk1Ny5qcGcifQ:ihh-healthcare-berhad:5X_TNqxc96quM-tZR4MPTXtQHUXDF7IjoVDRMeARvzM?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcLzU3XC8zODU3M1wvYWQ4YzA2MTg0ZDQ2MzJkMjA3MTEzMWJmNzYwNDY2YzUtMTY1ODMwMjcwOS5qcGcifQ:ihh-healthcare-berhad:l8yrzuZ9u-kxRM9UxyXuitaHIu3t-l-bLwKk4YPLkHw?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcL2E0XC8zNzAxNFwvZGIzOTVlNjFjMmFiNjFmN2ZkYTA0YTY4NThkYmE3OWYtMTY1ODI5Nzg0MS5qcGcifQ:ihh-healthcare-berhad:yLbC9zmraOdkuivdvoZB9ncio0iHNBp7RJMW5-kGau0?format=webp",
"https://www.parkwayshenton.com.sg/ResourcePackages/PS/assets/dist/images/arrowright_saffron.png",
"https://www.parkwayshenton.com.sg/ResourcePackages/PS/assets/dist/images/arrowleft_saffron.png",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9maWxlXC9GU2ZYZVNpdEVGYmphakpNZTZlOC5wbmcifQ:ihh-healthcare-berhad:Q4axKCNI8-ge7V8nWS-hO-G-dYeRlVhYj4yMoRadTQ0?format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvNDBcLzMzODY4XC9kNWUwOTkyNzQ4NTZkYjUxNjFmNTI2Mzc3ODc0MDQ4MC0xNjQ2OTI0OTAwLnBuZyJ9:ihh-healthcare-berhad:M-8QtQYE0G-SzRw80ZpIx-4kQ1Ot5cgy_JE2CJwfqMY?width={width}&format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvNGFcLzMzNjE1XC82YWIwMDFlZmIwMjRmNmVlODBmMmFlOThmNzMxYTAxYy0xNjQ2OTI0MzgzLnBuZyJ9:ihh-healthcare-berhad:n8zS3TXCRsABWHqfxzpwN4D0AIJ8vpeMhi27R8VWhfI?width={width}&format=webp"
] |
[] |
[] |
[
""
] | null |
[
"Edwin Chng Aik Chen"
] | null |
Is the Sinopharm BBIBP-CorV vaccine safe and effective? How does it compare with Sinovac, Modern and Pfizer-BioNTech/Cominarty vaccines? Dr Edwin Chng, medical director at Parkway Shenton, One Raffles Quay shares more.
|
en
|
/ResourcePackages/PS/assets/dist/images/favicon.ico
|
PS
|
https://www.parkwayshenton.com.sg/health-plus/article/sinopharm-COVID-19-vaccine-efficacy
|
1. The Sinopharm vaccine is the first China-made vaccine to be approved by the World Health Organisation (WHO)
The Sinopharm COVID-19 vaccine, BBIBP-CorV was approved for use by the China’s National Medical Products Administration in December 2020 and gained WHO’s approval for emergency use in May 2021.
The vaccine was developed by the Beijing Bio-Institute of Biological Products (BBIBP) and is the first China-made COVID-19 vaccine approved by the WHO for emergency use. It is also the first approved COVID-19 vaccine developed by a non-Western country. Sinovac’s vaccine, the CoronaVac, is the second.
To date, more than a billion doses of the Sinopharm BBIBP-CorV have been administered. The vaccine has also been approved for use in over 50 countries around the world. It is currently undergoing Phase 3 trials in Middle Eastern countries such as Egypt and the United Arab Emirates (UAE), and South American countries like Argentina and Peru.
The BBIBP-CorV is a two-dose vaccine, with a recommended gap of 3 weeks between the doses. Similar to the Sinovac vaccine, it is recommended for individuals aged 18 years and older who have no history of anaphylaxis to any component of the vaccine. Further research is needed to demonstrate its efficacy against severe COVID-19 disease in persons with other diseases, pregnant women and individuals aged above 60 years old. However, no upper age limit has been set for the vaccine as it is likely to have a protective effect in older adults and is unlikely to differ in safety for both older and younger adults.
2. Both the Sinopharm BBIBP-CorV and Sinovac’s CoronaVac vaccines are inactivated vaccines
Unlike the Pfizer-BioNTech/Cominarty and Moderna vaccines which use mRNA technology, the Chinese-made vaccines are inactivated vaccines which use killed COVID-19 viral particles. In these vaccines, the surface spike protein of the virus particle is kept intact to trigger the body’s immune system to develop antibodies to protect against the live COVID-19 virus in the event that the person is infected.
Inactivated vaccines are a tried-and-tested form of vaccine technology which is used in other well-established vaccines, such as the flu and hepatitis B vaccines.
3. Sinopharm’s efficacy: How it compares with the Sinovac CoronaVac and Pfizer-BioNTech/Cominarty COVID-19 vaccines
Sinopharm’s COVID-19 vaccine proved 79% effective in preventing symptomatic infection in the multi-country Phase 3 trial. This is compared to 51% for Sinovac’s and 95% for the Pfizer-BioNTech/Cominarty COVID-19 vaccine.
More studies are required to prove the BBIBP-CorV’s efficacy against COVID-19 variants.
4. Most reported side-effects of the Sinopharm vaccine were mild to moderate
The most common side-effects of the Sinopharm vaccine are pain at the injection site, headache, and fatigue. However, 2 serious side effects may possibly be linked to the vaccine – serious nausea, and acute disseminated encephalomyelities, a neurological disorder involving inflammation of the brain and spinal cord.
5. It has much easier storage requirements compared to the mRNA vaccines
Due to the fragility of the mRNA molecule, mRNA vaccines need to be stored in sub-zero temperatures in the long-term. In comparison, both the Sinopharm and Sinopharm vaccines can be stored at a refrigerator temperature of 2 – 8 degree Celsius. This makes shipment and storage of these vaccines less costly and highly suitable for countries with low resources. The Sinopharm vaccine is also the first vaccine that will carry a vaccine vial monitor, which is a sticker that changes colour when the vaccine is exposed to heat. This allows for closer monitoring of whether the vaccine is safe to use.
Register your interest for the Sinopharm vaccine
If you have yet to be vaccinated against COVID-19, it is important for you to receive a COVID-19 vaccine as soon as you can to protect yourself against developing severe COVID-19 infection. The benefits of receiving approved COVID-19 vaccines outweigh the risks.
|
||
6044
|
dbpedia
|
0
| 37
|
https://www.ft.com/content/f3f4052b-2582-4602-a0ba-63d672e7490a
|
en
|
Subscribe to read
|
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
|
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
|
[
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_standard.svg?source=next-barrier-page&format=svg",
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_premium.svg?source=next-barrier-page&format=svg",
"https://www.ft.com/__origami/service/image/v2/images/raw/https://barrier-page-components.s3.eu-west-1.amazonaws.com/assets/icons/primary_product_icon_bundle.svg?source=next-barrier-page&format=svg",
"https://spoor-api.ft.com/px.gif?data=%7B%22category%22%3A%22page%22%2C%22action%22%3A%22view%22%2C%22system%22%3A%7B%22source%22%3A%22non-ctm%22%7D%2C%22context%22%3A%7B%22name%22%3A%22barrier-page%22%2C%22product%22%3A%22next%22%2C%22data%22%3A%7B%22source%22%3A%22%5BSOURCE%5D%22%7D%7D%7D"
] |
[] |
[] |
[
""
] | null |
[] | null |
https://www.ft.com/__origami/service/image/v2/images/raw/ftlogo-v1%3Abrand-ft-logo-square-coloured?source=update-logos&format=svg
| null |
Try unlimited access
Only €1 for 4 weeks
Then €69 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.
Why the FT?
See why over a million readers pay to read the Financial Times.
|
|||||
6044
|
dbpedia
|
1
| 94
|
https://www.independent.co.uk/news/who-panel-oks-emergency-use-of-chinas-sinopharm-vaccine-who-china-geneva-unicef-americas-b1843912.html
|
en
|
WHO panel OKs emergency use of China’s Sinopharm vaccine
|
[
"https://www.independent.co.uk/img/logo-white-out.svg",
"https://static.independent.co.uk/static-assets/images/newsletter/breaking-news/breaking-news-thumb.png",
"https://www.independent.co.uk/img/icons/google.svg"
] |
[] |
[] |
[
"WHO",
"China",
"Geneva",
"UNICEF",
"Americas",
"Beijing",
"Covid",
"Chinese",
"AP"
] | null |
[
"Via news wire"
] |
2021-05-07T15:58:25+00:00
|
The World Health Organization has given its authorization for emergency use of a COVID-19 vaccine manufactured by China’s Sinopharm
|
en
|
/img/shortcut-icons/favicon.ico
|
The Independent
|
https://www.independent.co.uk/news/who-panel-oks-emergency-use-of-chinas-sinopharm-vaccine-who-china-geneva-unicef-americas-b1843912.html
|
The World Health Organization on Friday gave its authorization for emergency use of a COVID-19 vaccine manufactured by China s Sinopharm, potentially paving the way for millions of the doses to reach needy countries through a U.N.-backed program rolling out coronavirus vaccines.
The decision by a WHO technical advisory group opens the possibility that the Sinopharm vaccine could be included into the U.N.-backed COVAX program in coming weeks or months, and distributed through UNICEF and WHO’s regional office in the Americas
Sinopharm has released very little data publicly, aside from efficacy numbers for its two vaccine shots – one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.
The Beijing shot is one that was considered by WHO for the emergency use listing.
“This afternoon, WHO gave emergency use listing to sign off on Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality,” WHO Director-General Tedros Adhahom Ghebreysus said. “This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine.”
A separate group advising the U.N. agency on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” of the vaccine's efficacy in people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.
THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.
GENEVA (AP) — A key World Health Organization panel was set to decide Friday whether to authorize emergency of a Chinese-made COVID-19 vaccine, a WHO spokesperson said, potentially paving the way for millions of doses to reach needy countries through a U.N.-backed program.
The review by a technical advisory group could open the possibility of the Sinopharm vaccine being included in the U.N.-backed COVAX program in the coming weeks or months, and distributed through WHO’s regional office for the Americas and the U.N. children's agency UNICEF.
WHO spokesman Christian Lindmeier said a decision was expected later Friday.
Apart from efficacy information, Sinopharm has released very little public data about its two vaccines - one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.
The Beijing shot is one that WHO is considering for an emergency use listing.
A separate group advising the U.N. agency on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” of vaccine's efficacy in people 60 and over. It expressed “very low confidence” in the available data about potentially serious side effects in that age group.
|
||||
6044
|
dbpedia
|
3
| 62
|
https://u.ae/en/information-and-services/justice-safety-and-the-law/handling-the-covid-19-outbreak/vaccines-against-covid-19-in-the-uae/sinopharm-covid-19-vaccine
|
en
|
The Official Portal of the UAE Government
|
https://u.ae/assets/images/favicon.ico
|
https://u.ae/assets/images/favicon.ico
|
[
"https://u.ae/assets/images/government-ae-logo-english.png",
"https://u.ae/assets/images/UAEPASS_Sign_in_Btn_Outline_Pill_Active.png",
"https://u.ae/assets/images/government-ae-logo-english.png",
"https://u.ae/assets/images/TDRALogo.png",
"https://u.ae/assets/images/UAEPASS_Sign_in_Btn_Outline_Pill_Active.png",
"https://u.ae/assets/images/accessibility.svg",
"https://u.ae/assets/images/U-1.svg"
] |
[] |
[] |
[
"Sinopharm",
"COVID-19",
"vaccine"
] | null |
[] | null |
On 9 December 2020, Ministry of Health and Prevention (MOHAP) announced that it had officially registered 'Sinopharm vaccine’ for use on eligible individuals against the COVID-19 infection. Sinopharm vaccine is available in all public healthcare centres across the country. In Abu Dhabi, you do not need an appointment to take the vaccine. Just call Abu Dhabi Healthcare Company (SEHA) on the toll free number 800-50 to know the locations of SEHA-affiliated COVID-19 vaccine facilities.
|
en
|
/assets/images/favicon.ico
| null |
On 9 December 2020, Ministry of Health and Prevention (MOHAP) announced that it had officially registered the ‘Beijing Institute of Biological Products’ inactivated vaccine’, known as the ‘Sinopharm' vaccine which was developed jointly with Sinopharm - CNBG (China National Biotec Group).
A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79 per cent against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79 per cent.
Who can get the vaccine?
Priority is given to citizens and residents above the age of 18, particularly, the elderly and those suffering from chronic diseases.
Sinopharm vaccine requires two doses. The first dose is taken following an assessment of the patient’s health and the second dose is taken after a period averaging between 21 to 28 days.
Where can I get the Sinopharm vaccine?
Sinopharm vaccine is available throughout the UAE.
Refer to the list of COVID-19 vaccination centres in:
Urdu (PDF, 3.26 MB)
Filipino (PDF, 2.05 MB)
Mandarin (1.80 MB).
The vaccine is also available at SEHA's drive-through centres and the following locations:
Abu Dhabi Cruise Terminal, Abu Dhabi City - from 7 am to 10 pm
Al Ain Convention Center, Al Ain City - from 7 am to 10 pm
Dubai Parks & Resort, Dubai - from 9 am to 5 pm
Madinat Zayed Wedding Hall, Al Dhafra - from 8 am to 7:30 pm.
Find more information on SEHA’s website.
View the list of DHA vaccination centres in Dubai.
The vaccine is also available at several private hospitals across the UAE, free of charge.
Earlier, in September 2020, the UAE authorised the emergency use of the Sinopharm vaccine for frontline workers, as they are the most at risk of getting COVID-19. The Sinopharm vaccine was used in the UAE’s ‘4Humanity’ campaign, which hosted the first global clinical Phase-III of an inactivated vaccine to combat COVID-19 back in July 2020.
Contact MoHaP for queries and appointments.
|
|||
6044
|
dbpedia
|
0
| 60
|
https://healthpolicy-watch.news/are-chinese-vaccines-underperforming-a-dearth-of-real-life-studies-on-covid-vaccine-performance-leaves-question-unanswered/
|
en
|
Are Chinese COVID Vaccines Underperforming? A Dearth Of Real
|
[
"https://i0.wp.com/healthpolicy-watch.news/wp-content/uploads/2020/08/HPW-Logo-Full.png?fit=1099%2C206&ssl=1",
"https://healthpolicy-watch.news/wp-content/themes/hpw2018/images/header-twitter.svg",
"https://healthpolicy-watch.news/wp-content/themes/hpw2018/images/header-facebook.svg",
"https://www.paypal.com/en_CH/i/scr/pixel.gif",
"https://healthpolicy-watch.news/wp-content/themes/hpw2018/images/header-twitter.svg",
"https://healthpolicy-watch.news/wp-content/themes/hpw2018/images/header-facebook.svg",
"https://www.paypal.com/en_CH/i/scr/pixel.gif",
"https://healthpolicy-watch.news/wp-content/uploads/2021/05/Screenshot-2021-05-10-at-17.29.29-300x181.png",
"https://healthpolicy-watch.news/wp-content/uploads/2021/06/sino-284x300.jpg",
"https://healthpolicy-watch.news/wp-content/uploads/2021/03/Screenshot-2021-03-26-at-18.55.17-300x201.png",
"https://healthpolicy-watch.news/wp-content/uploads/2021/04/Vaccination-counter-in-PIMS-300x180.jpeg",
"https://healthpolicy-watch.news/wp-content/uploads/2021/06/sino_map-300x170.jpg",
"https://www.paypal.com/en_CH/i/scr/pixel.gif",
"https://www.paypal.com/en_CH/i/scr/pixel.gif",
"https://www.paypal.com/en_CH/i/scr/pixel.gif",
"https://healthpolicy-watch.news/wp-content/uploads/2020/12/Wellcome_logo_Black.jpg",
"https://healthpolicy-watch.news/wp-content/uploads/2020/12/geneva.png",
"https://www.loro.ch/themes/logo.svg"
] |
[
"https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01..latest&pickerSort=desc&pickerMetric=new_cases_smoothed_per_million&hideControls=true&Metric=People+vaccinated&Interval=7-day+rolling+average&Relative+to+Population=true&Align+outbreaks=false&country=IND~URY~COL~BRA~ARG~IDN~CHL~USA~ISR",
"https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01..latest&pickerSort=desc&pickerMetric=new_cases_smoothed_per_million&hideControls=true&Metric=Confirmed+cases&Interval=7-day+rolling+average&Relative+to+Population=true&Align+outbreaks=false&country=IND~URY~COL~BRA~ARG~IDN~CHL~USA~ISR"
] |
[] |
[
""
] | null |
[
"Svĕt Lustig Vijay",
"www.facebook.com"
] |
2021-06-18T23:23:39+02:00
|
From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold
|
en
|
https://healthpolicy-watch.news/wp-content/themes/hpw2018/images/favicon.ico
|
Health Policy Watch
|
https://healthpolicy-watch.news/are-chinese-vaccines-underperforming-a-dearth-of-real-life-studies-on-covid-vaccine-performance-leaves-question-unanswered/
|
From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2.
At the same time, it is too early to draw any conclusions, cautioned WHO’s Chief Scientist, Soumya Swaminathan on Friday – because there is a dearth of well-designed, real-life studies on the massive COVID vaccine rollout underway at either global or national levels.
“We need more data, again from well designed studies on the efficacy of the different vaccines that are in use in different countries against the different variants,” said Swaminathan, speaking at a biweekly WHO press conference on Friday.
She was responding to growing concerns that rapidly advancing vaccination drives are not necessarily leading to the hoped-for sharp reductions in new infections, hospitalizations, and deaths – possibly because some vaccines, including the Sinopharm and Sinovac vaccines from China, are weaker than other frontrunners like Pfizer, Moderna, AstraZeneca, or even Russia’s Sputnik V.
Said Swaminathan, WHO has “actually compiled and provided on its website different study designs, to see what happens when people have one dose of the vaccine, two doses of the vaccine”.
Such studies would compare COVID illness among those who get vaccines – as compared to those who do not, as the vaccines are rolled out.
However, the overwhelming focus of WHO so far, has been getting any approved vaccines to low- and middle-income countries. Comparing how well different vaccine formulations are working once they arrive and get into peoples’ arms has received little attention from the global health agency so far.
Spate of COVID Surges In Countries Dependent on Sinovac & Sinopharm
Against that background, a spate of recent COVID surges in Latin American and Asian countries that have relied heavily on either the Chinese Sinovac or the Sinopharm vaccines are prompting more questions about the efficacy of those vaccines, in particular.
This includes recent reports that over 350 Indonesian healthcare workers who were vaccinated with Sinovac, were reinfected with COVID in mid-June – although only a dozen of those required hospitalization.
The Seychelles has seen a significant recent surge of COVID-19 despite almost 70% of the population having been vaccinated, mostly with the Sinopharm vaccine. Of those who were infected, a third reportedly received both shots – but none of them died, according to the country’s health minister.
Chile is another country that has scientists scratching their heads. Initially lauded for quickly vaccinating 62% of the population with at least one jab and almost 50% with both jabs, the country went into lockdown last week to contain an outbreak that is triggering 70,000 new cases a day – a caseload that is on par with the heights of the first wave seen last year.
About 87% of the vaccines administered in Chile were procured from Sinovac in a deal that is to include procurement of some 60 million doses over three years – making Chile among the largest buyers of Chinese vaccines in Latin America, along with Brazil and Mexico.
Together, Latin America and the Asia-Pacific region have bought up some 80% of the 759 million doses of Chinese vaccines sold until now. Most of those doses, about 511 million, were sold by Sinovac, with Sinopharm’s vaccine accounting for the bulk of the remainder of sales so far.
Vaccine Efficacy Ratings For Sinovac And Sinopharm
According to the WHO, which recently granted both vaccines “Emergency Use Listings”, Sinovac’s vaccine efficacy stands at 51% against symptomatic disease and 100% against severe disease, while Sinopharm’s efficacy seems to fare slightly better, at 79% against mild and hospitalized disease.
But that data fails to include efficacy estimates for older people, one of the main COVID risk groups, as too few took part in large-scale clinical trials.
The WHO EUL’s for those two vaccines were unique in that unlike the Pfizer, AstraZeneca, Moderna, and Jonhson & Johonson vaccines that it had also approved, neither had undergone review and approval by a strict national or regional regulatory authority such as the US Food and Drug Administration or the European Medicines Agency. Nor have Phase 3 results of the Sinopharm and Sinovac trials been published in a peer-reviewed medical journal.
More to the point, post-approval, any large-scale tracking of the efficacy of the Sinovac and Sinopharm vaccine rollouts by WHO or national authorities seems to be missing.
In contrast, rollouts of other vaccines have seen careful monitoring and assessment by the regulatory agencies of the US, UK, Europe, as well as independent researchers. The massive Israeli rollout of Pfizer’s vaccine by countries, for instance, saw the detailed reporting of data on illness, hospitalizations, and among hundreds of thousands of people who were vaccinated as compared to similar groups of people who had not received their jabs.
The massive tracking of outcomes, including peer reviewed publication of results, helped boost confidence in the mRNA vaccines. But outside of developed countries, such tracking appears to be much weaker – or non-existent.
One exception is a report by the Uruguayan government this week on a study of some 800,000 people who received two Sinovac vaccine shots – representing some 35% of the population.
The study, which so far has not been published in a peer-reviewed journal, concluded that deaths among people immunized with the Sinovac vaccine had been cut by 95%, intensive care admissions by 92% and infections by 61%.
At the same time, Uruguay has also recently seen one of the largest COVID spikes in the world – with over 766 cases per million on 17 June, as compared to 50 per million in India and just 36 in the United States on the same day.
Complex Factors At Work
The lack of hard data on the efficacy of different vaccines being used in large scale rollouts has left WHO – as well as other health experts – to respond anecdotally.
For instance, with regards to the reinfection of Indonesian health workers with COVID-19, WHO Senior Advisor to the Director-General Bruce Alyward noted that this is not necessarily unexpected, especially during intense periods of community transmission.
“There are reports of people who received Sinovac [who] caught the disease, the health care workers,” Aylward acknowledged, referring to the Indonesian reinfection case.
“But that does not mean failure of the vaccine because as you know, vaccines are not going to protect everybody who receives them,” he explained. “The vaccine efficacy estimate [for Sinovac] is between 50% to 76%…it’s not unexpected in areas where everyone gets a vaccine as we get intense transmission, there will be some [COVID] cases in people who are vaccinated.”
Although Sinovac’s weaker efficacy rating may have contributed to Chile’s current outbreak, Ian Jones, Professor of Virology at the University of Reading in the UK, contended that the nation’s complacency also has a role to play:
“In Chile, it seems clear that there was a sense of success after only part of the population had been immunised with the inactivated vaccine,” he told Health Policy Watch:
“That led to a false sense of security as the single dose only provided about 55% protection and, in addition, many people remained unvaccinated and naive. The opening up allowed ample mixing and the case rate took off again – even if those vaccinated were protected from severe infection.”
Antoine Flahault, Director of the Global Health Institute at the University of Geneva, added that we should also “keep in mind that these Latin American countries are entering their cold season”, which favors the spread of respiratory viruses like SARS-CoV-2.
WHO’s Swaminathan has also cautioned that more documentation is needed to shed light on whether people who are vaccinated still contract milder, or more severe forms of the disease, and to what extent.
“If there’s a lot of community transmission there will be more infection among health workers, but are they getting ill, are they needing to be hospitalised and what’s the proportion between the vaccinated, unvaccinated and those with a single dose and complete doses?” said Swaminathan.
“I think we have to be very careful about suggesting there’s evidence that a vaccine is failing because there certainly isn’t the evidence to suggest that at this point.”
Data On Vaccine Efficacy Against Variants “Limited” To “Very Limited”
WHO’s Weekly Epidemiological Update from 8 June acknowledged that the evidence around vaccine efficacy against variants remains “limited” to “very limited” – adding that the vaccines still are “likely” to confer some degree of protection against COVID-19 disease.
Those variants of concern include Alpha, first discovered in the UK, Beta (South Africa), Gamma (Brazil), and Delta (India). All of those have now been identified in the Latin American context, notably in Chile and Brazil.
The Epidemiological update from early June cites a number of studies suggesting that the Beta and Gamma variants, in particular, appear to lead to “minimal-to-modest” reductions in neutralization capacity of Sinopharm and Sinovac vaccines; although the alpha variant appears to lead to “no/minimal loss” in neutralization capacity in both cases.
Experts have meanwhile warned that studies of vaccine performance against new variants are limited mainly to small populations or laboratory analyses of the so-called “neutralizing antibodies” found in blood samples – as compared to real-life epidemiological surveys.
WHO has also highlighted that all vaccines, including the most efficacious mRNA vaccines, perform less well against new variants. It cites, as an example, one study from Qatar, which found the Pfizer vaccine to be less effective against symptomatic diseases against Alpha and Beta variants – although not necessarily for hospitalizations and deaths.
On the other hand, studies from Israel, where some 53% of the population was vaccinated with the Pfizer mRNA vaccine, have confirmed the high protection the mRNA vaccines appear to confer against the alpha variant, at least.
Weak Chinese Vaccines Could Deal COVAX & Latin America Big Blow
If the two Chinese vaccines turn out to perform poorly in real-life contexts, it could deal the vaccine-thirsty COVAX facility a large blow.
The Facility, led by Gavi, the Vaccine Alliance and WHO plans to seal deals with Sinopharm and Sinovac on large-scale procurement of the vaccines for developing countries – in the wake of WHO’s recent decision to grant both vaccines an Emergency Use Listing.
If more problems emerge, it also would be particularly unfortunate for Latin America, which is currently seeing higher rates of COVID transmission than most regions in the world – including India.
Latin America has so far procured 289 million of the 759 million doses of Chinese vaccines produced so far. As such, it is the second largest regional buyer of Chinese vaccines after the Asian Pacific region, according to the China Vaccine Tracker – a joint initiative by the Beijing-based Bridge Consulting and New York-based Global Health Strategies.
‘Literally Everyone Needs to be Vaccinated’
Even if the Chinese vaccines are efficacious against severe disease and death, they may be less effective in halting transmission of SARS-CoV-2.
That could explain some of the spikes being seen now in Latin America, Beate Kampmann, Director of The Vaccine Centre at the London School of Hygiene and Tropical Medicine, told Health Policy Watch.
She added, however, that “the only way to be certain is to conduct nasal carriage studies of Sars-CoV2 to show if viral load remains high/virus present in vaccinated people” – adding that no such studies have been done for the Sinopharm and Sinovac vaccines. In contrast, multiple studies undertaken on Pfizer as well as AstraZeneca vaccines have shown they significantly cut SARS-CoV-2 transmission.
If this is indeed the case, then a much larger proportion of the population will have to be vaccinated with the Chinese vaccines to really curb local transmissions, she warned.
“As far as transmission is concerned, these [Chinese] vaccines are not going to be helpful unless literally everyone is vaccinated,” said Kampmann. “And even then, the virus would still circulate and subsequent cohorts need to be protected via vaccination as well.”
-Elaine Ruth Fletcher contributed to this story.
Image Credits: Twitter – Chinese Ambassador to Zimbabwe, Bridge Consulting, Rahul Basharat Rajput.
Combat the infodemic in health information and support health policy reporting from the global South. Our growing network of journalists in Africa, Asia, Geneva and New York connect the dots between regional realities and the big global debates, with evidence-based, open access news and analysis. To make a personal or organisational contribution click here on PayPal.
|
||||
6044
|
dbpedia
|
2
| 79
|
https://www.parkwayeast.com.sg/tests-treatments/covid-19-vaccines
|
en
|
COVID-19 Vaccines: Types & Side Effects
|
https://www.parkwayeast.com.sg/ResourcePackages/PEH/assets/dist/images/favicon.ico
|
https://www.parkwayeast.com.sg/ResourcePackages/PEH/assets/dist/images/favicon.ico
|
[
"https://www.parkwayeast.com.sg/ResourcePackages/PEH/assets/dist/images/logo.png",
"https://www.parkwayeast.com.sg/ResourcePackages/PEH/assets/dist/images/arrow-down-black.svg",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJjbGllbnQtZGszOHhmd2NldmZ5cXJ2biJ9LCJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9maWxlXC9yNUtyNFpRUHZBaTNSbzF1RWRyUi5wbmcifQ:ihh-healthcare-berhad:UeFEXLWOpaDSsZWPkecgwLjNfXttYQKSVMeEcr1KSYY?sf_dm_key=IBfFnHhRDvZ_fsjGFnh98IUWt_52sjg0S7g9KiLSD0E1&format=png",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJjbGllbnQtZGszOHhmd2NldmZ5cXJ2biJ9LCJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9maWxlXC93dW9iZWJ6Y3ZWTHdFZG9ubWV4OC5wbmcifQ:ihh-healthcare-berhad:5R_oh5MPvoQ36bLxSekeESQGkvdBexRzakikXkiYitA?sf_dm_key=Dkd9UFGzo0JZ_BcXiV2Z7CnRV3qZky0aierbhwFCDAY1&format=png",
"https://www.parkwayeast.com.sg/ResourcePackages/PEH/assets/dist/images/search.png",
"https://www.parkwayeast.com.sg/ResourcePackages/PEH/assets/dist/images/logo.png",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJjbGllbnQtZGszOHhmd2NldmZ5cXJ2biJ9LCJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9maWxlXC92NE5TNVNtenhMWlNFY2ZkNlBYZy5wbmcifQ:ihh-healthcare-berhad:k84YhpRXsi59DhTaxLJSA6tRQVtYv60aJkGeaarX3fM?sf_dm_key=BHVQwh1KF5rwXWGhwxwMT0iCh0Us7l1AukRNyCHazjo1&format=png",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJjbGllbnQtZGszOHhmd2NldmZ5cXJ2biJ9LCJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9maWxlXC8ycmdISkFUeUVYZ1RKZVpua1cxNC5wbmcifQ:ihh-healthcare-berhad:ZxAaBlFViTwAEdWhFaPWW-_at2AsZHNb2XOupwmdugM?sf_dm_key=EXFPPfF0jd4DmqfcuMiP2C1A02LJCMSn7gLAATg8IMc1&format=png",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvZmlsZVwvS1VTc2FaajdYSDdFOW0xRFIzUFUuanBnIn0:ihh-healthcare-berhad:xmuQLoVoxN5b92__rN36VuUy1Wpqpj6qrKBDKeCpMT4?width={width}",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcL2M4XC8zOTQwM1wvODQyOGU3YmU4Y2RhYTVkODI2Y2FmOGY2MTYxYTY5ZjYtMTY1ODMwODA2My5qcGcifQ:ihh-healthcare-berhad:MV3IK4q2T1xB7G6oFsnrphqCkOWZOcwwRk1ICazplGc?width={width}",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcLzI0XC8zODk1NlwvMTliNmUzYjM4Njk1OTcxM2UyOWU4NGRlZWQ2MjBkMDgtMTY1ODMwMjcwOS5qcGcifQ:ihh-healthcare-berhad:glPQPtrRwg9Sx2Ffx3yg7rrMdA-fITAXSaOlSsOJluY?width={width}",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcLzQ3XC8zNzc0OVwvNTNmMDIzZWRjOTNiNTgyODc0NTBkOWIwYjk4MTZhZWQtMTY1ODMwMDAwOS5qcGcifQ:ihh-healthcare-berhad:nFonoYDAy1RvhBbBs53QziY0tcWZWLmE2UbJav9diK0?width={width}",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcL2M5XC8zNzc2NlwvODBmY2FmZDYyNWNjZGNlYjJjMjk0OTA5MTFmMjQ3YmQtMTY1ODMwMDAwOS5qcGcifQ:ihh-healthcare-berhad:7D06ZgUMbpBDXIu1ZBXPQ284cWy5iRBUa4hGswNOo8c?width={width}",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJvYXV0aCI6eyJjbGllbnRfaWQiOiJmcm9udGlmeS1maW5kZXIifSwicGF0aCI6ImloaC1oZWFsdGhjYXJlLWJlcmhhZFwvYWNjb3VudHNcL2MzXC80MDAwNjI0XC9wcm9qZWN0c1wvMjA5XC9hc3NldHNcLzk2XC8zNzc4NlwvMDYxYTY1ZDIzNDNlZWIwNmYxZjhmMGZhMTQ2MTdjZmMtMTY1ODMwMDAwOS5qcGcifQ:ihh-healthcare-berhad:zUCC6vy1tluTbeAs68hGzFVx7Mtrnyb0UTn42c17I1M?width={width}",
"https://www.parkwayeast.com.sg/images/default-source/default-album/myhealth360-logo.png?sfvrsn=c3aa8f37_1",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvNDBcLzMzODY4XC9kNWUwOTkyNzQ4NTZkYjUxNjFmNTI2Mzc3ODc0MDQ4MC0xNjQ2OTI0OTAwLnBuZyJ9:ihh-healthcare-berhad:M-8QtQYE0G-SzRw80ZpIx-4kQ1Ot5cgy_JE2CJwfqMY?width={width}&format=webp",
"https://cdn-assets-eu.frontify.com/s3/frontify-enterprise-files-eu/eyJwYXRoIjoiaWhoLWhlYWx0aGNhcmUtYmVyaGFkXC9hY2NvdW50c1wvYzNcLzQwMDA2MjRcL3Byb2plY3RzXC8yMDlcL2Fzc2V0c1wvNGFcLzMzNjE1XC82YWIwMDFlZmIwMjRmNmVlODBmMmFlOThmNzMxYTAxYy0xNjQ2OTI0MzgzLnBuZyJ9:ihh-healthcare-berhad:n8zS3TXCRsABWHqfxzpwN4D0AIJ8vpeMhi27R8VWhfI?width={width}&format=webp"
] |
[] |
[] |
[
""
] | null |
[] | null |
Learn how different types of COVID-19 vaccines protect against severe illness, and their common side effects, at Parkway East Hospital.
|
en
|
/ResourcePackages/PEH/assets/dist/images/favicon.ico
|
PEH
|
https://www.parkwayeast.com.sg/tests-treatments/covid-19-vaccines
|
A: The Sinopharm COVID-19 vaccine (BBIBP-CorV) is the first China-made vaccine to be approved by the World Health Organisation (WHO). It was approved in December 2020.
The Sinopharm vaccine is an inactivated vaccine, a tried-and-tested form of vaccine technology used in other well-established vaccines, such as the flu and hepatitis B vaccines.
The Sinopharm vaccine provides an alternative for people in Singapore who have previously been found unsuitable to receive the mRNA options. This includes those who have taken a dose of Pfizer or Moderna vaccine and had an allergic reaction.
How does the Sinopharm vaccine work?
The Sinopharm vaccine uses weakened or inactive viral particles to stimulate our body to produce antibodies that will help neutralise the COVID-19 virus.
A: The number of doses you need depends on whether you have had a COVID-19 infection and your vaccination history.
If you are unsure of how many doses you need for the Sinopharm vaccine, please book an appointment for 1 dose first and consult our doctors for further advice.
If you have not been infected by COVID-19 before
You may need 1 – 3 doses, depending on your vaccination history and primary vaccination series:
No previous COVID-19 vaccine
You should take 3 doses, based on the following dosing schedule:
Dose 1: Day 0
Dose 2: 21 days after dose 1
Dose 3: 90 days after dose 2
1 dose of Sinopharm, Sinovac or Pfizer
You should take 2 doses, based on the following dosing schedule:
Dose 1: 21 days after the previous dose was taken
Dose 2: 90 days after dose 1
1 dose of Moderna
You should take 2 doses, based on the following dosing schedule:
Dose 1: 28 days after the previous dose was taken
Dose 2: 90 days after dose 1
2 doses of Sinopharm
You should take 1 dose 90 days after the last dose was taken.
2 doses of mRNA vaccine (Pfizer or Moderna)
You should take 1 dose 5 – 6 months after the last dose was taken.
Any other vaccine (e.g. AstraZeneca, Janssen), regardless of the number of doses
You should take 2 doses, based on the following dosing schedule:
Dose 1: 28 days after other vaccine
Dose 2: 21 days after dose 1
If you have recovered from a COVID-19 infection before
You do not need a Sinopharm booster dose if:
You had 2 doses of the Pfizer or Moderna vaccines before your infection.
You had 1 dose of Pfizer or Moderna and 1 dose of Sinopharm (regardless of the order taken) before your infection.
You had any other vaccines (e.g. AstraZeneca, Janssen) before your infection.
If you do not meet the criteria above, you may need 1 – 2 doses, depending on your history of vaccination, infection and recovery:
No previous COVID-19 vaccine, followed by infection and recovery
You should take 2 doses based on the following schedule:
Dose 1: 90 days from date of infection (Positive PCR result)
Dose 2: 21 days after dose 1
1 dose of Sinopharm, Sinovac or Pfizer, followed by infection and recovery
You should take 2 doses based on the following schedule:
Dose 1: 90 days from date of infection (Positive PCR result)
Dose 2: 21 days after dose 1
2 doses of Sinopharm or Sinovac, followed by infection and recovery
You should take 1 dose 90 days from your date of infection (Positive PCR result).
Note: These dosages are recommended guidelines and are subject to changes at any time as more data becomes available.
|
||
6044
|
dbpedia
|
3
| 35
|
https://www.clinicaltrialsarena.com/news/sinopharm-covid-vaccine-uae-trial/
|
en
|
China’s Sinopharm launches Phase III trial of Covid-19 vaccine in UAE
|
[
"https://www.facebook.com/tr?id=1175064750058523&ev=PageView&noscript=1",
"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/06/CTA.png",
"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/07/Abu-Dhabi.jpg",
"https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png",
"https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png",
"https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png",
"https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/images/newsletter-new.svg",
"https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png",
"https://pr-fr-json-b2b-gdm-figaro1.pantheonsite.io/pharmaceutical-technology/wp-content/themes/goodlife-wp-B2B/assets/img/report.png",
"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/Ascentage-shutterstock_2371567861-1024x599.jpg",
"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/shutterstock_2414094791.jpg",
"https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/images/icons/catfish-icon.svg",
"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/06/ClinicalTrialsArena_footer.png",
"https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/linkedin_icon_w.svg",
"https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/twitter_icon_w.svg",
"https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/facebook_icon_w.svg",
"https://www.clinicaltrialsarena.com/code/wp-content/themes/goodlife-wp-B2B/assets/images/verdict-logo-w.png",
"https://analytics.twitter.com/i/adsct?txn_id=ocdmp&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0",
"https://t.co/i/adsct?txn_id=ocdmp&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0"
] |
[] |
[] |
[
""
] | null |
[
"Divya Tirumalaraju"
] |
2020-07-17T06:29:28+00:00
|
China-based pharmaceutical company Sinopharm has initiated a Phase III clinical trial to assess its Covid-19 vaccine candidate in Abu Dhabi, UAE.
|
en
|
Clinical Trials Arena
|
https://www.clinicaltrialsarena.com/news/sinopharm-covid-vaccine-uae-trial/
|
China-based pharmaceutical company Sinopharm has initiated a Phase III clinical trial to assess its Covid-19 vaccine candidate in Abu Dhabi, UAE.
The candidate is said to be the world’s first inactivated vaccine to enter a Phase III trial.
This trial is being conducted by Sinopharm’s China National Biotec Group (CNBG) in alliance with the Abu Dhabi Government and Abu Dhabi-based artificial intelligence company G42 Healthcare.
Health practitioners from Abu Dhabi Health Services (SEHA) will manage the trial. A mobile clinic is also being operated to ensure easy access to participants.
Sinopharm selected UAE for the Phase III trials as the nation houses more than 200 nationalities, noted G42.
Sinopharm CNBG Biological products president Jingjin Zhu said: “The United Arab Emirates is a nation of innovation and tolerance, that is home to individuals from every part of the world and ethnic background.
“We will work closely with our partner to complete this clinical trial successfully, and make this vaccine available to the people in need worldwide.”
The UAE has authorised the participation of up to 15,000 volunteers in the trials. G42 and SEHA intend to enrol at least 5,000 volunteers aged 18 to 60 years in the first stage.
Abu Dhabi Department of Health (DoH) chairman Sheikh Abdullah bin Mohammed Al Hamed and DoH acting undersecretary Dr Jamal Alkaabi have volunteered to take part in the trial.
G42 Healthcare CEO Ashish Koshy said: “Using our AI solutions, super-computer, advanced diagnostics solutions for Covid-19, G42 Healthcare is uniquely postured to conduct these trials. G42 Healthcare will be responsible for running clinical operations for this trial.
“We will be leveraging our group’s technical and our own business capabilities to: compute, correlate and provide fast and synthesized insights by deploying multiple AI models on the data generated during the trials to accelerate the much awaiting results.”
|
|||||
6044
|
dbpedia
|
3
| 42
|
https://www.cnn.com/2020/12/30/asia/china-sinopharm-vaccine-efficacy-intl-hnk/index.html
|
en
|
China approves Sinopharm Covid-19 vaccine, promises free shots for all citizens
|
[
"https://media.cnn.com/api/v1/images/stellar/prod/200717084450-nector-gan-headshot.jpg?c=16x9&q=h_270,w_480,c_fill/c_thumb,g_face,w_100,h_100",
"https://media.cnn.com/api/v1/images/stellar/prod/201230204643-sinopharm-vaccine-efficacy-china-wang-lklv-ctw-vpx-00000918.png?q=x_539,y_125,h_621,w_1104,c_crop/w_1280",
"https://media.cnn.com/api/v1/images/stellar/prod/201119222957-sinopharm-0320-restricted.jpg?q=x_2,y_83,h_898,w_1596,c_crop/h_144,w_256",
"https://media.cnn.com/api/v1/images/stellar/prod/201201225939-shenzhen-airport-ethiopian-airlines.jpeg?q=x_2,y_82,h_898,w_1596,c_crop/h_144,w_256"
] |
[] |
[] |
[
"asia",
"business and industry sectors",
"business",
"economy and trade",
"china",
"communicable disease control",
"continents and regions",
"coronavirus",
"diseases and disorders",
"drug efficacy",
"drug safety",
"efficacy and availability",
"east asia",
"health and medical",
"infectious diseases",
"life forms",
"microscopic life",
"pharmaceuticals",
"public health",
"respiratory diseases",
"vaccination and immunization",
"viruses",
"medical fields and specialties",
"medical research",
"clinical trials"
] | null |
[
"Nectar Gan"
] |
2020-12-30T00:00:00
|
China approved its first homegrown coronavirus vaccine for general public use on Thursday, with officials promising to provide the general public with free inoculations.
|
en
|
/media/sites/cnn/apple-touch-icon.png
|
CNN
|
https://www.cnn.com/2020/12/30/asia/china-sinopharm-vaccine-efficacy-intl-hnk/index.html
|
China approved its first homegrown coronavirus vaccine for general public use on Thursday, with officials promising to provide the general public with free inoculations.
The approval comes a day after its manufacturer, state-owned pharmaceutical giant Sinopharm, said the vaccine is 79.34% effective, citing interim analysis of Phase 3 clinical trials.
Though no detailed efficacy data for the vaccine has been released, the decision to grant approval underscores claims made by Chinese officials in recent weeks over the safety and effectiveness of the country’s domestically produced vaccine candidates.
China is aiming to inoculate 50 million people with domestic Covid-19 vaccines ahead of February’s Lunar New Year celebrations. It has also drastically scaled up its vaccine emergency use program in recent weeks.
Zeng Yixin, vice-minister of China’s National Health Commission, said at a news conference Thursday that the Sinopharm vaccine will be provided free of charge to Chinese citizens.
“Vaccine is a public good by its nature, and the price may vary based on the scale of use, but an important premise is that it will be provided to the public for free,” Zeng said.
Since December 15, more than 3 million vaccine doses have been administered to “key groups,” Zeng said. That’s on top of the 1.5 million doses administered to “high-risk groups” by the end of November, he added.
Among those inoculated, fewer than 0.1% developed a light fever, and about two people per million developed “relative serious adverse reactions” such as allergies, according to Zeng.
The next step is to inoculate vulnerable groups such as the elderly and people with underlying diseases, before vaccinating the general population, Zeng said, without offering more details on how the vaccines will be provided for free.
A Sinopharm company executive said Thursday the vaccine’s Phase 3 trials covered more than 60,000 people, while detailed data will be released later and published in scientific journals at home and abroad.
An official with China’s drug regulator said the vaccine’s clinical trials are still ongoing, and its manufacturer will be required to submit follow-up data to authorities.
The Sinopharm vaccine is less effective than those developed by Pfizer-BioNTech and Moderna, which have an efficacy rate of about 95%. Russia says its Sputnik V vaccine is 91% effective.
And the vaccine’s efficacy rate of 79% is lower than the 86% announced by the United Arab Emirates for the same vaccine on December 9. The UAE based its results on an interim analysis of late-stage clinical trials conducted there from July. It has since approved the vaccine for public use.
The Sinopharm vaccine has a higher efficacy rate than the one developed by the UK’s Oxford University and AstraZeneca, which averaged 70%. On Wednesday, the UK became the first country to approve that vaccine for public distribution.
A step closer to massive rollout
Sinopharm’s results were announced weeks after its global competitors. And with a lack of details, it remains unclear whether the information provided will be enough to dispel skepticism over the quality of Chinese vaccines.
Nevertheless, the announcement could still pave the way for the vaccine’s large-scale rollout both within China and globally.
China is ready to send hundreds of millions of doses to countries that have conducted last-stage trials for its leading vaccine candidates. Chinese leaders have also promised a growing list of developing countries priority access.
Beijing is using the global campaign as a soft power tool, analysts say, to try to repair any damage to its image from its early mishandling of the coronavirus pandemic.
Aside from the approved Sinopharm vaccine, China has four coronavirus candidates which have reached Phase 3 clinical trials – the last and most important step of testing before regulatory approval is sought. Having largely eliminated the spread of coronavirus inside its borders, Chinese drugmakers had to look abroad for places to test the efficacy of their vaccines. Together, they have rolled out Phase 3 trials in at least 16 countries.
Sinopharm’s two vaccine candidates, including the one approved in China, have rolled out Phase 3 trials in 10 countries, mostly in the Middle East and South America.
Sinopharm chairman Liu Jingzhen said last month that dozens of countries have requested to buy the company’s vaccines. He did not name the countries or elaborate on the amount of doses they proposed, but he said CNBG was capable of producing more than a billion doses in 2021.
Compared with Pfizer and Moderna, Sinopharm’s vaccines do not require freezing temperatures for storage, making transport and distribution much easier – especially in developing countries that lack cold storage capacities.
Correction: An earlier version of this story misstated the number of "relative serious adverse reactions" to Chinese vaccine candidates. It is about two people per million among those inoculated.
|
||||
6044
|
dbpedia
|
2
| 4
|
https://www.forbes.com/companies/sinopharm-group/
|
en
|
Company Overview & News
|
https://www.forbes.com/no-pic/
|
https://www.forbes.com/no-pic/
|
[
"https://imageio.forbes.com/i-forbesimg/media/lists/people/no-pic_416x416.jpg?format=jpg&height=87&width=87",
"https://imageio.forbes.com/i-forbesimg/media/lists/people/no-pic_416x416.jpg?format=jpg&height=87&width=87",
"https://imageio.forbes.com/specials-images/imageserve/5d7ff48522254b000712f6c8/0x0.jpg?format=jpg&crop=416,416,x0,y0,safe&height=87&width=87"
] |
[] |
[] |
[
"Sinopharm Group"
] | null |
[
"Erik Kain Senior Contributor",
"Ime Ekpo Contributor",
"Jon McGowan Contributor",
"Trent Reinsmith Contributor",
"David Axe Forbes Staff",
"Hank Tucker Forbes Staff",
"Tim Casey Senior Contributor",
"Zinnia Lee Forbes Staff",
"John Perrotto Senior Contributor",
"Tom Sanderson Senior Contributor"
] | null |
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic
|
en
|
Forbes
|
https://www.forbes.com/companies/sinopharm-group/
|
Powerade Signs Carson Beck And Other College Players To NIL Deals
This college football season, Powerade has signed NIL deals with Georgia quarterback Carson Beck, LSU quarterback Garrett Nussmeier and other players.
Casino Magnate Lawrence Ho’s Second SPAC Raises $150 Million, Eyes Merger With AI Company
Black Spade Acquisition II, formed by Ho’s Hong Kong-based family office, plans to acquire a company in entertainment, lifestyle or technology that benefits from AI.
No Surprise That Russell Wilson Wins Steelers’ Starting QB Job
As expected, Russell Wilson prevailed in the Pittsburgh Steelers' starting quarterback competition over Justin Fields.
Real Madrid Versus Las Palmas Line Up: Two Changes From Ancelotti
Real Madrid head coach Carlo Ancelotti will make two changes to his starting line up when Los Blancos face Las Palmas away in La Liga on Thursday.
Nvidia Leads After-Market Slump In Chip Stocks Despite Posting Record Revenues
Despite beating forecasts in its second-quarter earnings report, Nvidia’s future projections failed to meet some of the loftier expectations by analysts.
How Anand Ekarshi, Ajith Joy Explored Morality In ‘Aattam’
In an exclusive interview, Indian filmmakers Anand Ekarshi and Ajith Joy talk about the journey of their national Film Award-winning movie 'Aattam'.
Surgeon General Proclaims Today’s Stressed Parents Need Mental Health Support Which Luckily Generative AI Stands Ready To Fulfill
Surgeon General advisory on the stresses of parenthood and mental health impacts is vital. I'd like to point out that generative AI can help parents. Here's the scoop.
The Basics Of Film Screen Credits
This article discusses the basics of film screen credits.
Northern Lights Update: These States Could Get Another Chance At Viewing Aurora Borealis
Chances to see the natural phenomenon have remained somewhat consistent since late July amid an increase in solar activity.
‘The Rings Of Power’ Season 2 Debuts To Truly Shocking Review Scores On Rotten Tomatoes
The Rings Of Power is anything but Fresh.
Today’s ‘Wordle’ #1167 Hints, Clues And Answer For Thursday, August 29th
Looking for help with today's New York Times Wordle? Here are hints, clues and commentary to help you solve today's Wordle and sharpen your guessing game.
How Kelly Rowland And Pepsi Are Reviving Community In Restaurants
Kelly Rowland is utilizing her celebrity to boost the visibility of flourishing local restaurants, in partnership with Pepsi.
Swiss Government Rejects Court’s Ruling Linking Climate Change And Human Rights
On August 28, the Swiss Federal Council voted to reject a landmark ruling that protection from climate change is a human right, while complying with the Court's order.
Undefeated UFC Welterweight Wants First Shot At Champ Belal Muhammad
Shavkat Rakhmonov wants to be the first fighter to face recently crowned UFC welterweight champion Belal Muhammad for his title.
If Ukraine’s Invasion Of Russia’s Kursk Oblast Was A Diversion, It Has Failed
Russian troops continue to march on Pokrovsk.
|
|||
6044
|
dbpedia
|
2
| 59
|
https://theprofesional.com/index.php/tpmj/article/view/7116/5023
|
en
|
View of Prevalence and predictors for adverse effects of Sinopharm and Sinovac COVID
|
[] |
[] |
[] |
[
""
] | null |
[] | null |
en
| null | ||||||||
6044
|
dbpedia
|
0
| 56
|
https://www.scmp.com/topics/sinopharm
|
en
|
Sinopharm: Latest News and Updates
|
[
"https://cdn.i-scmp.com/sites/default/files/styles/300x300/public/d8/topics/2024/08/21/Sinopharm_600x600.jpg?itok=U9Zz1V2h",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2024/02/22/e6527e37-cd95-44fc-b9c9-16b8b56712bf_126cb206.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2023/01/20/e751448b-0e18-4f5c-9129-d5835ed74452_aad713d7.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2022/02/23/917a3501-c9be-4415-8af6-5522ab430066_24e0ec0e.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2022/01/05/9ea0ae1e-7934-401e-b45e-bc596f7105d4_e0f97d7c.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2021/12/20/35e30765-cdd6-4c21-b37d-65813746ff34_4d6659a7.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/09/17/58386f50-1787-11ec-ab69-f2bfe93835cf_image_hires_165847.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/08/26/e57fba10-057d-11ec-a83e-ec0670db1017_image_hires_075759.jpeg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/05/28/c9531632-bebc-11eb-9b2e-758b3029e26f_image_hires_153934.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/05/13/dc0380c4-b2fe-11eb-93b7-03206dd91175_image_hires_042523.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/05/08/e0181666-af48-11eb-9c9f-63ba12e765d1_image_hires_180430.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2021/03/23/54fd05e1-2eb3-4347-8db5-2bbc9de8d271_d590c3ea.jpg",
"https://cdn.i-scmp.com/sites/default/files/d8/images/methode/2021/03/17/cd4b5f5c-8734-11eb-b55b-f690abcc0fed_image_hires_233054.jpg",
"https://cdn.i-scmp.com/sites/default/files/styles/300x300/public/d8/topics/2024/08/21/Sinopharm_600x600.jpg?itok=U9Zz1V2h",
"https://assets-v2.i-scmp.com/production/_next/static/media/wheel-on-gray.af4a55f9.gif"
] |
[] |
[] |
[
"Sinopharm"
] | null |
[] |
2024-02-22T01:36:21+00:00
|
Sinopharm is a joint venture between state-owned China National Pharmaceutical Group and privately run Fosun Pharmaceutical. The company is the largest wholesaler and retailer of pharmaceuticals and medical devices in China. It produced the first Chinese vaccine against Covid-19.
|
en
|
https://assets-v2.i-scmp.com/production/favicon.ico
|
South China Morning Post
|
https://www.scmp.com/topics/sinopharm
|
Experimental jab is similar to more effective foreign vaccines and is designed to target the Omicron variant.
Sun Yat-sen University research, which has not been peer-reviewed, suggests immune response cannot be endlessly boosted and there will be a ‘turning point’ after repeated vaccination.
The jab shows significantly weaker neutralising activity against the variant than against an older strain, researchers say.
It is being developed to provide protection against Delta and Beta strains, and clinical trials of a booster shot are also under way, CNBG vice-president says.
Interim phase 3 results suggest two products have efficacy above 70 per cent for symptomatic cases but there is little data on elderly and vulnerable groups.
The green light given to Sinopharm comes more than four months after the WHO handed out its first emergency use listing for a Covid-19 vaccine to US pharmaceutical company Pfizer and German company BioNTech.
Elsewhere, Taiwan will form its first travel bubble of the pandemic with the tiny Pacific nation of Palau, and Japan is to lift a state of emergency in the Tokyo area.
|
||||
6044
|
dbpedia
|
3
| 54
|
https://www.forbes.com/companies/sinopharm-group/
|
en
|
Company Overview & News
|
https://www.forbes.com/no-pic/
|
https://www.forbes.com/no-pic/
|
[
"https://imageio.forbes.com/i-forbesimg/media/lists/people/no-pic_416x416.jpg?format=jpg&height=87&width=87",
"https://imageio.forbes.com/i-forbesimg/media/lists/people/no-pic_416x416.jpg?format=jpg&height=87&width=87",
"https://imageio.forbes.com/specials-images/imageserve/5d7ff48522254b000712f6c8/0x0.jpg?format=jpg&crop=416,416,x0,y0,safe&height=87&width=87"
] |
[] |
[] |
[
"Sinopharm Group"
] | null |
[
"Nick Crain Contributor",
"John Tamny Contributor",
"Dana Feldman Senior Contributor",
"Simon Thompson Contributor",
"Hank Tucker Forbes Staff",
"Tom Sanderson Senior Contributor",
"Tim Lammers Contributor",
"Christine McDaniel Contributor",
"Marc Berman Senior Contributor",
"John Perrotto Senior Contributor"
] | null |
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic
|
en
|
Forbes
|
https://www.forbes.com/companies/sinopharm-group/
|
FC Barcelona Predicted Line Up Versus Valencia In La Liga Opener
This is FC Barcelona's predicted starting line up for its La Liga season opener against Valencia at the Mestalla on Saturday.
Mark Wahlberg On Becoming ‘The Jersey James Bond’ For ‘The Union’
“The Union” star Mark Wahlberg discusses his work with Halle Berry in the new Netflix movie and what inspired his character.
Trade Doesn’t Require A Bunch Of Free-Market-Loving Capitalists
We don’t need everyone to become free-market-loving capitalists. We just need a recommitment to a few agreeable core principles.
Remembering Peter Marshall: Friends And Colleagues Pay Tribute
Friends and colleagues of "Hollywood Squares" host Peter Marshall are speaking out following his death on Thursday.
Steelers Ready To Let Russell Wilson Cook In Second Preseason Game
Nine-time Pro Bowl quarterback Russell Wilson will see his first preseason action for the Pittsburgh Steelers on Saturday after being signed as a free agent in March.
Today’s ‘Wordle’ #1154 Hints, Clues And Answer For Friday, August 16th
Looking for help with today's New York Times Wordle? Here are hints, clues and commentary to help you solve today's Wordle and sharpen your guessing game.
Back Surgery Brings Christian Yelich’s Season To An Unfortunate End
If the Brewers are to make a deep playoff run this Fall, they'll have to do it without All-Star outfielder Christian Yelich who's season came to an end Thursday.
UFC 305 Fighter’s Stark Physical Changes Draw Attention On Media Day
UFC 305 fighter and New Zealand native Dan Hooker shocked the media when he posed for his fight week images in Australia.
Harris Will Propose $25,000 In Down Payment Aid For First-Time Homebuyers As Part Of Economic Agenda
Harris’ economic platform, set to be unveiled Friday, also includes measures to tackle high grocery prices.
Trump Says He Is ‘Entitled To Personal Attacks’ Against Harris Despite Republican Calls To Cease Insults
Trump told reporters he did not have a lot of respect for Vice President Kamala Harris or her intelligence while defending personal attacks against her.
Breaking Down OKC Thunder’s Schedule For 2024-25 Campaign
What does the Oklahoma City Thunder's schedule look like for the 2024-25 season?
J.P. Morgan and Starbucks Remind Us CEOs Are Vastly Underpaid
Through CEO failures we see just how much uncaptured value the great CEOs bring.
Costume Designer Marylin Fitoussi On Fashion Must Haves In ‘Emily In Paris’
"At some point, it became about being free and fearless,” said Marylin Fitoussi in an interview pegged to Season 4 of Netflix's 'Emily In Paris.'
Elizabeth Banks Spotlights The Ugly Side Of Beauty In ‘Skincare’
"The woman I play is aging, like me, in an industry that really values the new," explains the actress who plays a famed aesthetician on the verge of losing everything.
|
|||
6044
|
dbpedia
|
2
| 18
|
https://hayatbiotech.com/abu-dhabi-launches-new-covid-19-vaccine-plant-with-chinas-sinopharm/
|
en
|
19 vaccine plant with China's Sinopharm
|
[
"https://hayatbiotech.com/wp-content/themes/hayat-biotech/img/logo.gif",
"https://hayatbiotech.com/wp-content/themes/hayat-biotech/img/logo-main-white.png",
"https://hayatbiotech.com/wp-content/uploads/2022/05/IMage02.jpg",
"https://hayatbiotech.com/wp-content/themes/hayat-biotech/img/footer-logo.svg"
] |
[] |
[] |
[
""
] | null |
[
"@dmin_hayat",
"Lisa Barrington"
] |
2022-05-25T17:25:07+04:00
|
A new factory in Abu Dhabi will manufacture a COVID-19 vaccine from Sinopharm.
|
en
|
Hayat Biotech
|
https://hayatbiotech.com/abu-dhabi-launches-new-covid-19-vaccine-plant-with-chinas-sinopharm/
|
DUBAI (Reuters) -A new factory in Abu Dhabi will start manufacturing a COVID-19 vaccine from Chinese pharmaceutical giant Sinopharm later this year under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42 (G42).
The project is an expansion of Chinese diplomacy in the Gulf region and helps the United Arab Emirates’ quest to diversify its economy away from hydrocarbon production.
The plant, which is being built in the Khalifa Industrial Zone of Abu Dhabi (KIZAD), will have a production capacity of 200 million doses a year with three filling lines and five automated packaging lines, a statement from the joint venture said on Monday.
The vaccine will be called Hayat-Vax when manufactured in the UAE, but is the same inactivated vaccine from the Beijing Institute of Biological Product (BiBP), a unit of Sinopharm’s China National Biotec Group (CNBG), that the UAE approved for general use in December.
As part of the joint venture, interim production of Hayat-Vax has already begun in the emirate of Ras al-Khaimah under a deal between G42 and Gulf Pharmaceutical Industries PSC, the statement said.
That interim production line has an initial capacity of 2 million doses per month and no details were given about how long production will continue there.
The UAE, through G42, hosted Phase III clinical trials of the Sinopharm vaccine from July, which later expanded to other countries in the region including Bahrain. The UAE approved the vaccine for frontline workers in September before making it available to the general public in December.
G42 has previously said it has distribution and manufacturing agreements with Sinopharm and hopes to provide the UAE and other states in the region with the vaccine.
The deal was launched during a two-day visit to the UAE by Chinese Foreign Minister Wang Yi which ended on Sunday.
The joint venture also includes a purpose-built research and development hub for life sciences, biotechnology and vaccine production in KIZAD.
“Our joint venture is also actively looking to bring our capabilities to new markets around the world,” G42 CEO Peng Xiao said.
The UAE has said its trials showed the vaccine has 86% efficacy, while Sinopharm reports 79.34% efficacy based on interim results.
Some people in the UAE failed to develop sufficient antibodies after a second dose of the Sinopharm vaccine and were given a third dose, the UAE health ministry said this month. It said the number was “minimal” compared to the number of vaccines administered.
On Sunday, a Sinopharm executive said the company will need to assess results from overseas Phase III clinical trials to decide whether its two-shot vaccine should be followed by a booster shot.
“Thanks to the close collaboration with the UAE, Sinopharm’s vaccine has been now administered to millions of people in the country, the region, and the world,” Sinopharm Chairman Liu Jingzhen said at a virtual launch also attended by UAE Foreign Affairs Minister Sheikh Abdullah bin Zayed Al Nahyan.
|
|||||
6044
|
dbpedia
|
0
| 6
|
https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
|
en
|
The Sinopharm COVID-19 vaccine: What you need to know
|
[
"https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue.svg?sfvrsn=aaed4f35_20",
"https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue.svg?sfvrsn=aaed4f35_20",
"https://www.who.int/images/default-source/fallback/maps/africa.png?sfvrsn=3204f957_18",
"https://www.who.int/images/default-source/fallback/maps/americas.png?sfvrsn=9efd6df3_18",
"https://www.who.int/images/default-source/fallback/maps/south-east-asia.png?sfvrsn=68e76dc2_16",
"https://www.who.int/images/default-source/fallback/maps/europe.png?sfvrsn=c7d5c5a5_18",
"https://www.who.int/images/default-source/fallback/maps/eastern-mediterranean.png?sfvrsn=71211e18_16",
"https://www.who.int/images/default-source/fallback/maps/western-pacific.png?sfvrsn=88cbdcd5_16",
"https://www.who.int/ResourcePackages/WHO/assets/dist/images/logos/en/h-logo-blue.svg",
"https://www.who.int/ResourcePackages/WHO/assets/dist/images/logos/en/h-logo-white.svg"
] |
[] |
[] |
[
""
] | null |
[] | null |
The WHO Strategic Advisory Group of Experts (SAGE) on Immunization has issued Interim recommendations for the use of the inactivated COVID-19 vaccine BIBP developed by Sinopharm/China National Pharmaceutical Group.
|
en
|
/favicon.ico
|
https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
|
Updated on 10 June 2022, pursuant to revised interim recommendations.
The WHO Strategic Advisory Group of Experts (SAGE) has issued interim recommendations for the use of the Sinopharm vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance document here.
Here is what you need to know.
Who can be vaccinated?
The vaccine is safe and effective for all individuals aged 18 and above. In line with the WHO Prioritization Roadmap and the WHO Values Framework, older adults, health workers and immunocompromised persons should be prioritised.
The Sinopharm vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to delay vaccination for 3 months following the infection.
Should pregnant and breastfeeding women be vaccinated?
The available data on the COVID-19 vaccine Sinopharm in pregnant women are insufficient to assess either vaccine efficacy or vaccine-associated risks in pregnancy. However, this vaccine is an inactivated vaccine with an adjuvant that is routinely used in many other vaccines with a documented good safety profile, including in pregnant women. The effectiveness of the COVID-19 vaccine Sinopharm in pregnant women is therefore expected to be comparable to that observed in non-pregnant women of similar age.
In the interim, WHO recommends the use of the COVID-19 vaccine Sinopharm in pregnant women when the benefits of vaccination to the pregnant woman outweigh the potential risks. To help pregnant women make this assessment, they should be provided with information about the risks of COVID-19 in pregnancy; the likely benefits of vaccination in the local epidemiological context; and the current limitations of safety data in pregnant women. WHO does not recommend pregnancy testing prior to vaccination. WHO does not recommend delaying pregnancy or considering terminating pregnancy because of vaccination.
Vaccine effectiveness is expected to be similar in breastfeeding women as in other adults. WHO recommends the use of the COVID-19 vaccine Sinopharm in breastfeeding women as in other adults. WHO does not recommend discontinuing breastfeeding after vaccination.
Who is the vaccine not recommended for?
Individuals with a history of anaphylaxis to any component of the vaccine should not take it.
Anyone with a body temperature over 38.5ºC should postpone vaccination until they no longer have a fever.
Is it safe?
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.
Safety data are limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared to younger age groups can be anticipated, countries considering using this vaccine in persons older than 60 years should maintain active safety monitoring.
How efficacious is the vaccine?
A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79%.
The trial was not designed and powered to demonstrate efficacy against severe disease in persons with comorbidities, in pregnancy, or in persons aged 60 years and above. Women were underrepresented in the trial. The median duration of follow-up available at the time of evidence review was 112 days.
Two other efficacy trials are under way but data are not yet available.
What’s the recommended dosage?
SAGE recommends the use of Sinopharm vaccine as 2 doses (0.5 ml) given intramuscularly.
SAGE recommends that a third, additional dose of the Sinopharm vaccine be offered to persons aged 60 and above as part of an extension of the primary series. Current data does not indicate the need for an additional dose in persons under 60 years of age.
SAGE recommends that severe and moderately immunocompromised persons should be offered an additional dose of vaccine. This is due to the fact that this group is less likely to respond adequately to vaccination following a standard primary vaccination series and are at higher risk of severe COVID-19 disease.
WHO recommends an interval of 3–4 weeks between the first and second dose of primary series. If the second dose is administered less than 3 weeks after the first, the dose does not need to be repeated. If administration of the second dose is delayed beyond 4 weeks, it should be given at the earliest possible opportunity. When administering an additional dose to over 60s, SAGE recommends countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting with the oldest age groups.
Is a booster dose recommended for this vaccine?
A booster dose may be considered 4 – 6 months after completion of the primary vaccination series, starting with the higher priority-use groups, in accordance with the WHO Prioritization Roadmap.
The benefits of booster vaccination are recognized following increasing evidence of waning vaccine effectiveness against mild and asymptomatic SARS-CoV-2 infection over time.
Either homologous (a different vaccine product to Sinopharm) or heterologous (a booster dose of Sinopharm) doses can be used. A study in Bahrain found that heterologous boosting resulted in a superior immune response compared to homologous boosting.
Can this vaccine be ‘mixed and matched’ with other vaccines?
SAGE accepts two heterologous doses of WHO EUL COVID-19 vaccines as a complete primary series.
To ensure equivalent or favourable immunogenicity or vaccine effectiveness either of the WHO EUL COVID-19 mRNA vaccines (Pfizer or Moderna) or the WHO EUL COVID-19 vectored vaccines (AstraZeneca Vaxzevria/COVISHIELD or Janssen) can be used as a second dose following a first dose with the Sinopharm vaccine dependent on product availability.
Does it prevent infection and transmission?
There is currently no substantive data available related to the impact of Sinopharm on transmission of SARS-CoV-2, the virus that causes COVID-19 disease.
In the meantime, WHO reminds of the need to maintain and strengthen public health measures that work: masking, physical distancing, handwashing, respiratory and cough hygiene, avoiding crowds and ensuring adequate ventilation.
Does it work against new variants of SARS-CoV-2 virus?
SAGE currently recommends using this vaccine, according to the WHO Prioritization Roadmap.
As new data becomes available, WHO will update recommendations accordingly. This vaccine has not yet been evaluated in the context of circulation of widespread variants of concern.
How does this vaccine compare to other vaccines already in use?
We cannot compare the vaccines head-to-head due to the different approaches taken in designing the respective studies, but overall, all of the vaccines that have achieved WHO Emergency Use Listing are highly effective in preventing severe disease and hospitalization due to COVID-19.
This webpage was updated on 10 June 2022 to update the latest guidance and ensure consistency of information and formatting.
|
|||||
6044
|
dbpedia
|
2
| 63
|
https://www.lemonde.fr/en/europe/article/2022/11/18/from-miracle-to-mirage-serbia-s-vaccine-factories_6004810_143.html
|
en
|
From miracle to mirage: Serbia's vaccine factories
|
[
"https://img.lemde.fr/2024/08/14/0/0/8256/5504/360/0/95/0/9afe813_1723647894080-gettyimages-2165576128.jpg 2x",
"https://img.lemde.fr/2024/08/14/0/150/1620/1080/360/0/95/0/2bca53b_1723633225033-sei-quence-03-00-04-53-22-still002.jpg 2x",
"https://img.lemde.fr/2024/08/14/0/0/5400/3600/360/0/95/0/04f5d50_5419355-01-06.jpg 2x",
"https://img.lemde.fr/2024/08/11/0/0/5650/3766/360/0/95/0/6b6bbff_1723388965935-lgeai-ceremonie-jo-26-07-12.jpg 2x",
"https://img.lemde.fr/2024/08/14/0/0/5959/3972/360/0/95/0/9913370_5418522-01-06.jpg 2x",
"https://img.lemde.fr/2024/08/01/1/0/5098/3398/360/0/95/0/25e47ba_1722525629428-000-33lv4re.jpg 2x",
"https://img.lemde.fr/2024/08/14/110/0/5269/3512/360/0/95/0/1ea220e_1723649541787-000-1g08vo.jpg 2x",
"https://img.lemde.fr/2023/02/02/0/0/5568/3712/360/0/95/0/ba63325_1675355378834-000-9n647d.jpg 2x",
"https://img.lemde.fr/2024/08/14/78/0/5500/3666/360/0/95/0/97e35e4_1723652007957-2024-06-22t044541z-1642699159-rc23g8a3kav9-rtrmadp-3-india-bangladesh.JPG 2x",
"https://img.lemde.fr/2024/08/12/1/0/4456/2970/360/0/95/0/fa1ed69_1723474549956-000-34q823c.jpg 2x",
"https://img.lemde.fr/2024/08/14/1/0/4132/2754/360/0/95/0/d17c11c_1723650946515-2024-05-02t142737z-226733322-rc2ei7a6f0ne-rtrmadp-3-russia-putin.JPG 2x",
"https://img.lemde.fr/2024/07/27/0/0/7843/5228/360/0/95/0/f9ce647_1722103668256-dsc09769.jpg 2x",
"https://img.lemde.fr/2024/07/16/587/0/3350/2233/360/0/95/0/a50539a_40f1f406d4284d04afdb346fb4f00a22-0-f23230b4be6c492a9e118d4dd28bc670.jpg 2x",
"https://img.lemde.fr/2024/06/18/0/0/6000/4000/360/0/95/0/023e3a1_2024-06-18t083238z-178761460-rc22b8a9i1mh-rtrmadp-3-france-election.JPG 2x",
"https://img.lemde.fr/2024/06/11/0/44/991/661/360/0/95/0/0e5091b_1718115980940-en-eu-results-00-02-04-01.png 2x",
"https://img.lemde.fr/2024/03/01/7/0/2948/1965/360/0/95/0/314d623_1709304069259-000-arp1469936.jpg 2x",
"https://img.lemde.fr/2017/08/16/40/0/3846/2564/360/0/95/0/dc43992_3135-6o2z3l.oeh9p5jyvi.jpg 2x",
"https://img.lemde.fr/2024/08/11/0/291/5604/3736/360/0/95/0/ad31e61_1723396808166-119071.jpg 2x",
"https://img.lemde.fr/2024/07/18/0/0/6000/4000/360/0/95/0/edc483d_2024-07-18t191222z-969165384-rc2vx8artlaa-rtrmadp-3-france-politics.JPG 2x",
"https://img.lemde.fr/2024/08/05/0/0/5808/3872/360/0/95/0/6e9b674_5318659-01-06.jpg 2x",
"https://img.lemde.fr/2024/07/03/1/0/3210/2140/360/0/95/0/cecfa04_1720012009584-pns-747121420.jpg 2x",
"https://img.lemde.fr/2024/07/31/0/0/1920/1280/360/0/95/0/4511cd6_1722433286774-469c7f7-1722427714648-appel-resto.png 2x",
"https://img.lemde.fr/2024/08/05/0/0/1999/1333/360/0/95/0/719acda_1722895732025-d52a9053-dxo.jpg 2x",
"https://img.lemde.fr/2024/07/05/4422/0/5504/3669/360/0/95/0/1e1ee64_1720170979205-bios-2556174.jpg 2x",
"https://img.lemde.fr/2022/11/11/168/0/4032/2688/664/0/75/0/fdbbe9e_1668161976839-img-6086.jpg",
"https://img.lemde.fr/2022/11/11/168/0/4032/2688/664/0/75/0/fdbbe9e_1668161976839-img-6086.jpg"
] |
[] |
[] |
[
""
] | null |
[
"Jean-Baptiste Chastand"
] |
2022-11-18T00:00:00
|
Launched with much fanfare, production of Covid-19 vaccines never got off the ground, a foregone conclusion given a lack of European markets and Serbian vaccine scepticism.
|
en
|
/en/bucket/assets/9abde188d173336fab13ba96d22acb5c316be9a8/img/logos/favicon.ico
|
Le Monde.fr
|
https://www.lemonde.fr/en/europe/article/2022/11/18/from-miracle-to-mirage-serbia-s-vaccine-factories_6004810_143.html
|
LETTER FROM CENTRAL EUROPE
In front of the brand new factory, which shows no sign of activity, three flags – Chinese, Emirati and Serbian – are in tatters, due as much to the effects of passing time as to the weather. "Don't take a picture of them, we'll replace them soon," said the security guard, the only sign of life in the empty parking lot of this Chinese vaccine factory, located a few kilometres from Belgrade airport in Serbia. The government-built road gleams immaculately, but the only perceptible traffic in the vicinity is that of landing planes.
Slated to open in March 2022, this plant was to be the first in Europe to produce Sinopharm, the Chinese vaccine against Covid-19. But on Tuesday, November 8, it still seems a long way from being able to manufacture "40 million annual doses" and employ "180 people," as promised by the Serbian president at the time of the construction site's launch in September 2021.
When President Aleksandar Vučić came to break ground on the project, he brought with him the Chinese ambassador to Serbia as well as representatives of Hayat Biotech – an Emirati company and Sinopharm joint venture – promising to open the plant six months later.
Read more Subscribers only European Union approves Sanofi's Covid-19 vaccine
"A regional miracle," boasted Mr. Vučić, a former nationalist who has dominated the political landscape of this Balkan country since 2014 by skillfully playing to various international geopolitical interests, all the while insisting that he wishes to join the European Union (EU) as soon as possible.
During the pandemic, he massively imported Chinese Sinopharm and Russian Sputnik V vaccines, ignoring European scientific reticence. This ensured him a certain popularity in his country, which has maintained, ever since the Yugoslav wars, a mistrust of anything from the West. In his enthusiasm, he then promised to produce the two vaccines on Serbian territory, but this "miracle" seems to have turned into a mirage with the decline of the epidemic and the scientific victory of Western vaccines.
'I don't think it's for vaccines'
The state-owned national vaccine production institute Torlak, a glorious legacy of the Yugoslav period, was selected to bottle Sputnik V and had begun this work in June 2021, again on the watch of Mr. Vučić. "The humanity shown by Russia to Serbia is an indication of the quality of political relations between our countries. Dear Vladimir Vladimirovich [Putin], it is a great honor and privilege for me to launch the production of the Russian-Serbian vaccine with you," the president declared in front of the cameras, tugging on the Serbs' historical pro-Russian cord.
|
||||
6044
|
dbpedia
|
0
| 95
|
https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/
|
en
|
Sinopharm: COVID-19 vaccine production figures 2022
|
[
"https://cdn.statcdn.com/Study/160000/162257-standard.png",
"https://cdn.statcdn.com/Statistic/1190000/1194939-blank-100.png",
"https://cdn.statcdn.com/Statistic/1195000/1196142-blank-100.png",
"https://cdn.statcdn.com/Statistic/1190000/1194934-blank-100.png",
"https://cdn.statcdn.com/Statistic/1275000/1279024-blank-100.png",
"https://cdn.statcdn.com/static/img/modalEmployeeGroup.png",
"https://cdn.statcdn.com/static/icons/blank.gif",
"https://cdn.statcdn.com/Topic/9385.jpg",
"https://cdn.statcdn.com/Topic/5898.jpg",
"https://cdn.statcdn.com/Topic/5001.jpg",
"https://cdn.statcdn.com/Topic/5305.jpg",
"https://cdn.statcdn.com/Topic/5994.jpg"
] |
[] |
[] |
[
""
] | null |
[
"Wenyi Zhang"
] | null |
By the end of January, the Beijing Institute of Biological Products Co.
|
en
|
Statista
|
https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/
|
Number of COVID-19 vaccine doses produced by Sinopharm BIBP 2021-2022
Published by
Cumulative number of COVID-19 vaccine doses manufactured by Sinopharm BIBP between April 2021 and January 2022 (in millions)
CharacteristicVaccine doses in millions------------------
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
Immediate access to all statistics
Incl. source references
Download as PDF, XLS, PNG and PPT
Already have an account? Login
Source
Show detailed source information?
Register for free
Already a member?
Log in
Sources
Use Ask Statista Research Service
Release date
February 2022
More information
Region
China
Survey time period
April 2021 to January 2022
Supplementary notes
Beijing Institute of Biological Products Co. Ltd. (BIBP) is a subsidiary of Sinopharm, producing one of the two types of Sinopharm's COVID-19 vaccines.
Data for months prior to December 2021 come from previous reports.
Citation formats
|
|||||
6044
|
dbpedia
|
3
| 97
|
https://www.arise.tv/who-approves-emergency-use-of-chinas-sinopharm-covid-vaccine/
|
en
|
WHO Approves Emergency Use of China’s Sinopharm Covid Vaccine
|
[
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/en.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/ar.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/zh-CN.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/nl.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/en.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/fr.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/de.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/it.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/pt.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/ru.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/es.png",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2021/05/Sinopharm-COVID-Vaccine.jpeg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Nigerias-Dassault-Falcon-7X-and-Airbus-30.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/ES.jpeg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Sgt-Korbein-Schultz-.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/06/Tinubu-Approves.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Zeekr-Unveils-Fastest-Charging-EV-Battery-Overtakes-Tesla-and-BYD.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Russia-Declares-State-of-Emergency-in-Belgorod-Amid-Intensified-Ukrainian-Incursion.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Linda-Thomas-Greenfield.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Google-Unveils-New-Pixel-Smartphones-With-Deeper-AI-Integrations.jpeg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/seized-presidential-aircraft-in-France-and-Switzerland.jpeg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/06/Edward-Buba-1.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Presidential-jets-and-Bayo-Onanuga.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Nigeria-Equatorial-Guinea-Sign-Gulf-of-Guinea-Gas-Pipeline-Agreement.jpeg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Shehu-Sani-VID.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/Tinubu-Administration-Launches-Zero-Duty-Policy-On-Basic-Food-Imports-Effective-August-15.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2023/09/SEGUN-AJAYI-KADIR.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2024/08/tinubu.jpg",
"https://global.ariseplay.com/amg/www.arise.tv/uploads/2023/01/arise-news-logo.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/ar.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/zh-CN.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/nl.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/en.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/fr.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/de.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/it.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/pt.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/ru.png",
"https://www.arise.tv/wp-content/plugins/gtranslate/flags/24/es.png"
] |
[] |
[] |
[
""
] | null |
[
"AriseNews",
"Gideon Arinze",
"Nneoma Udensi",
"Chioma Kalu",
"Enome Boluwatife",
"Ikechukwu Aleke",
"Deji Elumoye",
"Nancy Mbamalu"
] |
2021-05-07T20:20:11+00:00
|
The World Health Organization has approved the emergency use of a Covid-19 vaccine manufactured by China’s Sinopharm. Friday’s decision by a WHO technical advisory group, a first for a Chinese
|
en
|
Arise News
|
https://www.arise.tv/who-approves-emergency-use-of-chinas-sinopharm-covid-vaccine/
|
The World Health Organization has approved the emergency use of a Covid-19 vaccine manufactured by China’s Sinopharm.
Friday’s decision by a WHO technical advisory group, a first for a Chinese vaccine, opens the possibility that Sinopharm’s offering could be included in the United Nations-backed COVAX programme in coming weeks or months, and distributed through United Nations children’s agency UNICEF and WHO’s Americas regional office.
Aside from efficacy numbers, the Chinese manufacturer has released very little public data about its two vaccines – one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.
The Beijing-made Sinopharm shot is one the WHO advisory group considered for the emergency use listing.
“This afternoon, WHO gave emergency use listing to sign off on Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality,” WHO Director-General Tedros Adhahom Ghebreyesus said.
The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorisation from the UN health agency.
“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.
Sinopharm has not published its late-stage test results in scientific journals, so the WHO requested a breakdown of its data, which come mostly from the United Arab Emirates.
A summary posted online by WHO suggests the vaccine is about 78 percent effective, with the caveat that all but a few hundred of the study volunteers were younger than 60.
Gavi, the Vaccine Alliance, which co-runs COVAX, welcomed WHO’s approval of emergency use.
“This means the world has yet another safe and effective tool in the fight against this pandemic,” the alliance said.
Follow us on:
|
|||||
6044
|
dbpedia
|
3
| 78
|
http://www.xinhuanet.com/english/2021-04/30/c_139916901.htm
|
en
|
Indonesia approves emergency use of China's Sinopharm COVID-19 vaccine - Xinhua
|
[
"http://www.xinhuanet.com/english/2020new/images/downArrow.png",
"http://www.xinhuanet.com/english/2020new/images/downArrow.png",
"http://www.newsimg.cn/english/20170321/images/banner.png",
"http://www.newsimg.cn/english/20170321/images/menu.png",
"http://www.newsimg.cn/english/20170321/images/close.png",
"http://www.xinhuanet.com/english/20161108new/images/logo.jpg",
"http://webd.home.news.cn/1.gif?z=1&_wdxid=010020070750000000000000011100001399169011"
] |
[
" "
] |
[] |
[
""
] | null |
[] |
2021-04-30T00:00:00
| null |
JAKARTA, April 30 (Xinhua) -- Indonesia's food and drug authority BPOM has issued an emergency use authorization (EUA) for the COVID-19 vaccine produced by Chinese pharmaceutical company Sinopharm, an official source said on Friday.
Chief of BPOM Penny Lukito made the announcement, saying the issuance of the EUA was based on the third phase of clinical trials in the United Arab Emirates and other countries.
Indonesia would use the Sinopharm vaccine for a mutual vaccination scheme locally known as "Gotong Royong", where companies or legal entities can arrange the COVID-19 vaccine rollout for their employees for free, to help the country achieve herd immunity faster.
Previously, Indonesia had approved the emergency use for three other brands of COVID-19 vaccines, namely the CoronaVac produced by the Chinese company Sinovac, the COVID-19 vaccine produced by the state-company PT Bio Farma in collaboration with Sinovac, and the AstraZeneca vaccine. Enditem
|
||||||||
6044
|
dbpedia
|
3
| 81
|
https://www.cbc.ca/news/world/who-approves-china-sinopharm-covid-vaccine-1.6017958
|
en
|
WHO panel approves emergency use of China's Sinopharm vaccine
|
[
"https://www.cbc.ca/a/images/nojsimg.gif",
"https://i.cbc.ca/1.6018112.1620406417!/cpImage/httpImage/image.jpg_gen/derivatives/16x9_780/virus-outbreak-china.jpg",
"https://i.cbc.ca/1.6018091.1620405672!/fileImage/httpImage/image.JPG_gen/derivatives/original_300/health-coronavirus-china-vaccine.JPG 300w,https://i.cbc.ca/1.6018091.1620405672!/fileImage/httpImage/image.JPG_gen/derivatives/original_460/health-coronavirus-china-vaccine.JPG 460w,https://i.cbc.ca/1.6018091.1620405672!/fileImage/httpImage/image.JPG_gen/derivatives/original_620/health-coronavirus-china-vaccine.JPG 620w,https://i.cbc.ca/1.6018091.1620405672!/fileImage/httpImage/image.JPG_gen/derivatives/original_780/health-coronavirus-china-vaccine.JPG 780w,https://i.cbc.ca/1.6018091.1620405672!/fileImage/httpImage/image.JPG_gen/derivatives/original_1180/health-coronavirus-china-vaccine.JPG 1180w",
"https://i.cbc.ca/ais/1.6014232,1717198914663/full/max/0/default.jpg?im=Crop%2Crect%3D%280%2C0%2C1920%2C1080%29%3BResize%3D%28620%29",
"https://i.cbc.ca/1.6018087.1620405608!/fileImage/httpImage/image.jpg_gen/derivatives/original_300/virus-outbreak-pakistan.jpg 300w,https://i.cbc.ca/1.6018087.1620405608!/fileImage/httpImage/image.jpg_gen/derivatives/original_460/virus-outbreak-pakistan.jpg 460w,https://i.cbc.ca/1.6018087.1620405608!/fileImage/httpImage/image.jpg_gen/derivatives/original_620/virus-outbreak-pakistan.jpg 620w,https://i.cbc.ca/1.6018087.1620405608!/fileImage/httpImage/image.jpg_gen/derivatives/original_780/virus-outbreak-pakistan.jpg 780w,https://i.cbc.ca/1.6018087.1620405608!/fileImage/httpImage/image.jpg_gen/derivatives/original_1180/virus-outbreak-pakistan.jpg 1180w",
"https://subscriptions.cbc.ca/newsletter_static/images/1584038567869-coronavirus-brief.png",
"https://www.cbc.ca/a/assets/open-in-new.svg",
"https://www.cbc.ca/a/assets/logo_cbc-radio-canada.svg"
] |
[] |
[] |
[
""
] | null |
[
"The Associated Press"
] |
2021-05-07T17:10:00+00:00
|
The World Health Organization gave emergency use authorization Friday to a COVID-19 vaccine manufactured by China's Sinopharm, potentially paving the way for millions of the doses to reach needy countries through a UN-backed program rolling out coronavirus vaccines.
|
en
|
/a/apple-touch-icon.png
|
CBC
|
https://www.cbc.ca/news/world/who-approves-china-sinopharm-covid-vaccine-1.6017958
|
The World Health Organization gave emergency use authorization Friday to a COVID-19 vaccine manufactured by China's Sinopharm, potentially paving the way for millions of the doses to reach needy countries through a UN-backed program rolling out coronavirus vaccines.
The decision by a WHO technical advisory group, a first for a Chinese vaccine, opens the possibility that Sinopharm's offering could be included in the UN-backed COVAX program in coming weeks or months and distributed through UN children's agency UNICEF and WHO's Americas regional office.
Aside from efficacy numbers, the Chinese manufacturer has released very little public data about its two vaccines — one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.
The Beijing shot, which has already been exported to some countries, is one the WHO advisory group considered for the emergency use listing.
"This afternoon, WHO gave emergency use listing to sign off on Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," WHO director general Tedros Adhahom Ghebreysus said.
The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the UN health agency.
"This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine," Tedros said at a Geneva news conference.
Up to 79% effectiveness
Previously, a separate group advising WHO on vaccines said it was "very confident" the Sinopharm vaccine protects people ages 18 to 59. The group said it had a "low level of confidence" in the vaccine's efficacy for people 60 and over. Its members said they had "very low confidence" in the available data about serious side-effects in that age group.
Sinopharm hasn't published its late-stage test results in scientific journals, so the WHO requested a breakdown of its data, which come mostly from the United Arab Emirates.
"[We] came to the conclusion that there is enough evidence of safety and the capacity of the vaccine to prevent severe disease or symptomatic and hospitalized cases up to 79 per cent," said Dr. Alejandro Cravioto, who heads the WHO advisory group on immunizations. "The information we have for people over 60 is still very scarce."
"There is no reason to think that the vaccine would behave differently in this older age group," he added.
Arnaud Didierlaurent, a professor at the University of Geneva's medical school who chairs the advisory group, said it had requested additional studies from Sinopharm, and that there would be "continuous evaluation" of the vaccine.
"In fact, the work does not stop after the listing," he said.
'Another safe and effective tool'
Gavi, the Vaccine Alliance, which co-runs COVAX, welcomed WHO's emergency approval.
"This means the world has yet another safe and effective tool in the fight against this pandemic," the alliance said. The public-private partnership said it was in discussions with several manufacturers, including Sinopharm, "to expand and diversify the portfolio further and secure access to additional doses" for countries in the COVAX program.
COVAX aims to send vaccines for free to 92 lower-income countries and to help another 99 countries and territories procure them. It was not immediately clear when the Sinopharm vaccine might be made available to the COVAX portfolio.
The program, which has already distributed over 54 million doses of COVID-19 vaccines but faces limited supplies from Western countries and India, has been working hard to strike deals as part of its goal to procure two billion doses by the end of the year.
WATCH | WHO urges global COVID-19 vaccine equity:
Limited public data
Suerie Moon, co-director of the Global Health Program at Geneva's Graduate Institute, said WHO's decision on the Sinopharm COVID-19 vaccine and other Chinese vaccines will "carry a lot of weight" because of limited information publicly available about them.
"The decision is also sure to be scrutinized all around for any whiff of political bias, and no doubt the committee members were very well aware of this," she said, noting that the decision could also be a boon for developing countries.
"If there is a greenlight, these vaccines could boost the thin stream of supplies that has been channelled through COVAX to date," she said, as the program has been hit hard by export bans limiting vaccine supply from India. India has kept those doses amid a surge of cases at home.
Moon also said if Chinese suppliers start channeling large volumes, "this would signal a step-change in their participation in global vaccine markets." Before the pandemic, India was a well-integrated player in the global health vaccine supply system, but China was not, she said.
WHO's decision on Sinopharm, months in the making, was particularly complex because the vaccine has not faced the high-level scrutiny of a rigorous medicines regulator like those in Europe and the U.S.
The WHO panel relied frequently on those Western agencies' findings when it came to vaccines that it has already approved emergency use.
Many officials in countries without such regulatory structures rely on WHO's emergency use listings to authorize vaccine rollouts for their populations.
'Inactivated' vaccines
Hundreds of millions of Chinese vaccines have already been delivered to dozens of countries around the world through bilateral deals as many scrambled to secure supplies after rich countries had reserved the vast majority of supplies from Western pharmaceutical makers.
While China has five shots in use, the majority of its exports abroad come from two companies: Sinopharm and Sinovac. A decision on Sinovac is expected next week, WHO said.
The Chinese vaccines are "inactivated" vaccines, made with killed coronavirus. Most other COVID-19 vaccines being used around the world, particularly in the West, are made with newer technologies that instead target the "spike" protein that coats the surface of the coronavirus.
The WHO, in what it called a first, said the vaccine would come a small sticker on the vaccine vials that changes colour as it is exposed to heat, which will inform health workers about whether the vaccine can be safely used.
Sinopharm said last month that over 100 million doses of its two vaccines have been used across the world.
Sinovac, by comparison, has shared more data. Last month, a study published by a team of scientists in Brazil confirmed a previously reported efficacy rate of over 50 per cent. A real-world study in Chile last month found an efficacy rate of 67 per cent.
|
||||
6044
|
dbpedia
|
1
| 98
|
https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/amid-oxford-snag-chinese-vaccines-in-spotlight/1967894
|
en
|
Amid Oxford snag, Chinese vaccines in spotlight
|
[
"https://cdnassets.aa.com.tr/assets/newVersion/images/logo.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/logo.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/logo.png",
"https://cdnuploads.aa.com.tr/uploads/Contents/2020/09/09/thumbs_b_c_94ac60face15ec5d4a592c957b88e199.jpg?v=154143",
"https://cdnassets.aa.com.tr/assets/newVersion/images/bip.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/analiz.png",
"https://cdnuploads.aa.com.tr/uploads/Contents/2024/08/28/thumbs_m_c_6059f90a2d2409a9a45f746148be078c.jpg?v=141326",
"https://cdnuploads.aa.com.tr/uploads/Contents/2024/08/27/thumbs_m_c_e7959017d9f0f1d28b7747f3c4694618.jpg?v=223309",
"https://cdnuploads.aa.com.tr/uploads/Contents/2024/08/27/thumbs_m_c_0d2db206ba0ca2dfca32fd6b9289c65c.jpg?v=184246",
"https://cdnuploads.aa.com.tr/uploads/Contents/2024/08/27/thumbs_m_c_5c01797a9905ab9e447493746b169bce.jpg?v=151216",
"https://cdnuploads.aa.com.tr/uploads/Contents/2024/08/27/thumbs_m_c_4882712adc3b7b3366c7526571a097d7.jpg?v=144203",
"https://cdnuploads.aa.com.tr/uploads/Contents/2024/08/27/thumbs_m_c_20721274058bef1087b23577f3ca6e56.jpg?v=133409",
"https://cdnassets.aa.com.tr/assets/newVersion/images/footerlogo-notype.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/facebook.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/x_twitter.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/youtube.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/instagram.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/googleplay.png",
"https://cdnassets.aa.com.tr/assets/newVersion/images/appstore.png"
] |
[] |
[] |
[
"China",
"Coronavirus",
"COVID-19",
"COVID-19 vaccine",
"Oxford University",
"SinoPharm",
"vaccine",
"Anadolu Ajansı"
] | null |
[] | null |
3 Chinese companies unveil COVID-19 vaccines that are in final stage of clinical trials - Anadolu Ajansı
|
https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/amid-oxford-snag-chinese-vaccines-in-spotlight/1967894
|
ANKARA
With the Oxford vaccine trials in seemingly choppy waters, at least three Chinese companies have unveiled their COVID-19 vaccines.
China National Biotec Group (CNBG) and Sinovac Biotech displayed their vaccines at the China International Fair for Trade in Services (CIFTIS) in the capital Beijing.
At least 22,000 companies and institutions from 148 countries and regions took part in this year’s online and offline CIFTIS, China’s Commerce Ministry said on Wednesday.
According to its chief executive officer Yin Weidong, Sinovac is testing its vaccine candidate CoronaVac in Brazil, Indonesia, Turkey, Bangladesh, and some other countries, Shanghai-based East Day news website reported.
“The pace of research is fast in Brazil,” Yin said, adding that the vaccine is in the third and last phase of clinical trials.
He said the company plans to offer the vaccine to 9,000 volunteers and hopes to have results “by the end of the year.”
Around 50,000 have been involved in clinical trials of CNBG’s coronavirus vaccine in the UAE, Bahrain, Peru, Morocco, and Argentina, which have entered the last phase.
CNBG has set up biosecurity production facilities at the company’s research institutes in Beijing and Wuhan, which are expected to produce 300 million doses a year.
The third Chinese company to present a vaccine is Sinopharm, a state-owned pharmaceutical firm.
The company said it tested the vaccine on its own employees, claiming that those immunized then traveled overseas and did not contract the virus.
Sinopharm currently has two vaccines in the third phase of clinical trials.
“If one is optimistic, the vaccines could be launched by the end of the year,” Zhou Song, general counsel of Sinopharm, was quoted as saying in a report by the New York Times, which was sourced from the same Shanghai-based news website.
Multiple firms and countries are racing to develop an effective vaccine as the global COVID-19 fatalities are now nearing 900,000.
One of the most promising vaccine candidates has been developed by researchers at the Oxford University and pharmaceutical company AstraZeneca.
However, final clinical trials of the vaccine in the UK have been suspended after a participant had an adverse reaction.
“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee,” a spokeswoman for AstraZeneca said.
|
|||||||
6044
|
dbpedia
|
2
| 22
|
https://apnews.com/article/europe-middle-east-business-science-health-4b770731d5995e3bb49a1d8ec63febbd
|
en
|
Study: Chinese COVID shot may offer elderly poor protection
|
https://dims.apnews.com/dims4/default/cafe9c7/2147483647/strip/true/crop/3000x1688+0+156/resize/1440x810!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg
|
https://dims.apnews.com/dims4/default/cafe9c7/2147483647/strip/true/crop/3000x1688+0+156/resize/1440x810!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg
|
[
"https://assets.apnews.com/fa/ba/9258a7114f5ba5c7202aaa1bdd66/aplogo.svg",
"https://dims.apnews.com/dims4/default/94c503b/2147483647/strip/true/crop/640x236+0+0/resize/320x118!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc3%2F4c%2F65482a7b452db66043542c093eaf%2Fpromo-2x.png 1x,https://dims.apnews.com/dims4/default/6e4b276/2147483647/strip/true/crop/640x236+0+0/resize/640x236!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc3%2F4c%2F65482a7b452db66043542c093eaf%2Fpromo-2x.png 2x",
"https://dims.apnews.com/dims4/default/6094c65/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/aa46f0c/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/36bf4cc/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/d10bffb/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/6094c65/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/aa46f0c/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F7f5b1f562521420390cf0664a6686890%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/36bf4cc/2147483647/strip/true/crop/3000x2000+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 1x,https://dims.apnews.com/dims4/default/d10bffb/2147483647/strip/true/crop/3000x2000+0+0/resize/1198x798!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F3084b6eeeb734aeab24b1581e8fcc4eb%2F3000.jpeg 2x",
"https://dims.apnews.com/dims4/default/6fae603/2147483647/strip/true/crop/500x500+0+0/resize/100x100!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F66%2F1d%2F54d056f94e5e80755dde33a1d45c%2Frsz-img-20220211-093250-edit-justin-spike.jpg",
"https://dims.apnews.com/dims4/default/bc1ddbf/2147483647/strip/true/crop/2851x1534+0+0/resize/240x129!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F22%2F25%2F9576fafb4e768552fed602a60238%2Fap-pri-wordmarktagline-rgb-dbg.png 1x,https://dims.apnews.com/dims4/default/84565e0/2147483647/strip/true/crop/2851x1534+0+0/resize/480x258!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F22%2F25%2F9576fafb4e768552fed602a60238%2Fap-pri-wordmarktagline-rgb-dbg.png 2x",
"https://sb.scorecardresearch.com/p?c1=2&c2=3005041&cv=4.4.0&cj=1"
] |
[] |
[] |
[
"General news",
"COVID-19",
"Middle East",
"Europe",
"Budapest",
"Beijing",
"Hungary",
"Asia Pacific",
"Health",
"Science",
"Business",
"World News"
] | null |
[
"JUSTIN SPIKE",
"Huizhong Wu",
"Hungary. twitter mailto",
"apnews.com",
"justin-spike"
] |
2021-07-23T08:15:40+00:00
|
A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly.
|
en
|
/apple-touch-icon.png
|
AP News
|
https://apnews.com/article/europe-middle-east-business-science-health-4b770731d5995e3bb49a1d8ec63febbd
|
BUDAPEST, Hungary (AP) — A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.
A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.
The study by two Hungarian researchers was posted online this week but not yet reviewed by other scientists. Three outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm’s Beijing Institute of Biological Products.
“This is very, very worrying that these people, who are high-risk, have a poor antibody response,” said Jin Dong-yan, a Hong Kong University virologist who was not affiliated with the study.
Antibody levels are not a direct measure of how protected a person is from COVID-19, but there is growing evidence that they are a good proxy. One expert cautioned that the choice of test kits could have limited the accuracy of the measurements.
Still, the study’s findings have value and are the first public, scientific attempt to analyze the effect of the Sinopharm vaccine in the elderly, said Wang Chenguang, a former professor at Peking Union Medical College and an immunology expert.
China’s National Health Commission declined to comment on the study, saying it would only respond to studies by governments or major research institutions.
This is not the first time questions have been raised about the efficacy of the vaccine, which was given a greenlight by the World Health Organization in May and is being used in more than 50 countries, many of which seized upon it when other vaccines were tough to come by.
A spokesperson for the WHO said Wednesday that its experts “are aware of the study and continue to look at all available evidence.” The agency’s advisers raised questions months ago about whether it provided protection in people 60 and over, but when it was OK’d a WHO expert said that there was no reason to think it would work differently in the elderly.
The vaccine is one of two similar shots developed by Sinopharm. The state-owned Chinese company’s research showed that almost all the participants in final-stage clinical trials were under 60 — and its own researchers said there was insufficient evidence to say whether the vaccines work in the elderly. Overall, the Beijing Institute vaccine was found to be 78% effective.
In Hungary, concern about the shots led many to seek out private antibody tests. Eventually the capital city of Budapest offered free testing to elderly residents as part a bid to ratchet up pressure on the government to conduct its own wider survey and provide booster shots to those who need them.
After initially rebuffing calls for a government response to efficacy concerns — including from the antibody study’s authors Balazs Sarkadi and Tamas Ferenci — Prime Minster Viktor Orban finally acquiesced last week in the face of growing public anger. He announced that the government would provide its citizens with an optional third shot.
His office said, though, that all vaccines authorized by Hungary are effective.
The United Arab Emirates and Bahrain both announced in May that they, too, would offer a third dose of Sinopharm amid concerns about an insufficient antibody response. Bahrain recommended that people over 50 and some other vulnerable people receive Pfizer-BioNTech’s vaccine as their booster regardless of whether they got Sinopharm initially.
CNBG, the Sinopharm subsidiary that oversees the Beijing Institute, has said a third dose is not part of the company’s clinical guidance.
It’s not clear how many doses of the Beijing Institute Sinopharm vaccine have been exported. Overall, China exported 500 million vaccines doses in the first half of the year, and the company is one of country’s two major COVID vaccine makers, along with privately owned Sinovac.
The Global Alliance for Vaccines and Immunization recently ordered 550 million doses from the two companies for the U.N.-backed COVAX program.
Both Sinopharm vaccines are also in wide use in China, including in the elderly. The country’s National Health Commission said in April that the shots provide some protection, even though it acknowledged that early stages of clinical trials of Sinopharm’s vaccines and two others found fewer antibodies in people 60 and over.
In Budapest, Beata Englohner became concerned for her 76-year-old mother after hearing that people who had been vaccinated with Sinopharm were shown to have no antibodies.
Englohner started a Facebook group to press the government to address the issue. She is cautiously optimistic now that Hungary will offer a third dose.
“We’re very glad that we achieved our aim and that we were heard,” she said. “Though we’re a bit afraid that we’ll receive what we already got before.”
___
Wu reported from Taipei, Taiwan.
|
||
6044
|
dbpedia
|
0
| 83
|
https://www.rafflesmedicalgroup.com/covid-19/vaccines/sinopharm/
|
en
|
COVID-19 Vaccines - Sinopharm
|
[
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2023/05/raffles-medical-group-logo-2023.svg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2020/07/logo-raffles-medical.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid-sinovac-icon-deadvirus.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid-sinovac-icon-deadvirus.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/icon-chemical.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/icon-chemical.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/icon-normaltemp.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/icon-normaltemp.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid-sinovac-icon-adult.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid-sinovac-icon-adult.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid-icon-2doses-34weeks.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid-icon-2doses-34weeks.png",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid19-sinovac-howdiagram.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid19-sinovac-howdiagram.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid19-sinovac-howdiagram-mb.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/2021/06/covid19-sinovac-howdiagram-mb.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/header-covid-vac-safe-720x405-landscape-c0ce7c15edf003cc53c4ba7cc49add07-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/header-covid-vac-safe-720x405-landscape-c0ce7c15edf003cc53c4ba7cc49add07-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid19-sinovac-mrna-difference-article-720x405-landscape-eabf94949a44c80b4f25069314f7f843-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid19-sinovac-mrna-difference-article-720x405-landscape-eabf94949a44c80b4f25069314f7f843-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid19-sinovac-5myths-article-720x405-landscape-820b1d3eeab48b61eca3b9a391c241e0-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid19-sinovac-5myths-article-720x405-landscape-820b1d3eeab48b61eca3b9a391c241e0-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/header-vaccine-101-720x405-landscape-4e27d6fab3a3969f3478b0407cb4705d-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/header-vaccine-101-720x405-landscape-4e27d6fab3a3969f3478b0407cb4705d-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid-19-variants-720x405-landscape-e04d5c46993c6501e1622813ce96474c-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid-19-variants-720x405-landscape-e04d5c46993c6501e1622813ce96474c-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid-19-older-people-720x405-landscape-867efc35ec49cda4c5ec66b3106ae78c-.jpg",
"https://www.rafflesmedicalgroup.com/wp-content/uploads/bb-plugin/cache/covid-19-older-people-720x405-landscape-867efc35ec49cda4c5ec66b3106ae78c-.jpg"
] |
[] |
[] |
[
""
] | null |
[] |
2021-06-29T03:36:07+00:00
|
Sinopharm vaccine uses a traditional method of inactivated virus to protect against COVID-19 and is developed by the Beijing Bio-Institute of Biological Products Co Ltd.
|
en
|
Raffles Medical Group
|
https://www.rafflesmedicalgroup.com/covid-19/vaccines/sinopharm/
|
Sinopharm COVID-19 Vaccine
What you need to know about Sinopharm vaccine
Single-dose vaccine
Double-dose vaccine
On this page:
What's different about Sinopharm vaccine?
Who is eligible for the Sinopharm vaccine?
How does Sinopharm vaccine work?
How effective is Sinopharm?
How safe is Sinopharm?
Register your interest in Sinopharm vaccine
Frequently Asked Questions about Sinopharm vaccine
What’s different about the Sinopharm vaccine?
It uses inactivated virus to fight against COVID-19
Sinopharm uses a traditional and widely known method of inactivated virus to protect against COVID-19.
The virus is inactivated through chemical treatment
Beta-propiolactone is the chemical that binds to the SARS-CoV-2 virus’ genetic material and inactivates it, preventing it from replicating and causing COVID-19.
It is stored at normal fridge temperatures
Like the traditional flu vaccination, Sinopharm can be stored at normal refrigerator temperatures.
Who is eligible for taking Sinopharm?
Individuals aged 18 years and older, with no history of anaphylaxis.
Individuals with a history of anaphylaxis or any form of severe allergic reactions to medication/food/vaccination should not be administered with the vaccine.
Individuals with a body temperature over 38.5ºC should postpone vaccination until the fever subsides.
What is the recommended dosage for administration?
According to WHO, the recommendation is two-dose with an interval of 3-4 weeks between first and second dose.
How does Sinopharm vaccine work?
Similar to Sinovac, Sinopharm vaccine is a vaccine that uses inactivated COVID-19 virus to teach your immune system to make antibodies against COVID-19, creating an immune response to COVID-19.
When introduced to your body, your immune system will make antibodies against the coronavirus, attaching to viral proteins. As the vaccine uses a dead or inactivated virus, the vaccine can be safely injected into the arm without causing the individual to develop COVID-19.
Once the vaccine is in your system, some of the inactivated viruses will be absorbed by a type of immune cell called the anti-gen presenting cell. This type of cell will then display some of the fragments of inactivated virus on its surface, then known as a helper T cell. If the fragment fits onto the surface protein of the cell, it then can be activated and gets other immune cells to also respond to the vaccine.
When you are vaccinated with Sinopharm, your body’s immune system can respond to an infection of live coronaviruses by producing antibodies to block the virus.
How effective is Sinopharm?
Efficacy rate of 75% against symptomatic COVID-19 infection and an efficacy of 75% against hospitalisation.
How safe is Sinopharm?
SAGE (Strategic Advisory Group of Experts) from WHO has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.
The most commonly reported side effects in this trial were fever and pain at the injection site. Based on the data from clinical trials, the most common side effects recorded were:
headaches
fatigue
injection site reactions
These side effects were mild to moderate, and similar to those of other authorized vaccines against COVID-19.
Register your interest for Sinopharm COVID-19 vaccine
FAQs: Frequently asked questions about Sinopharm COVID-19 vaccine
After a thorough review by SAGE, WHO assessed the vaccine efficacy for Sinopharm is up to 75 percent.
On 7 May 7 2021, WHO approved the Sinopharm COVID-19 vaccine for emergency use, allowing the vaccine to be distributed globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.
Due to the small number of participants above 60 years of age, there is limited data on the safety of the vaccines for this age group. While there are no salient differences in the safety profile of the vaccine in older adults compared to the younger age groups, persons aged 60 and above that are considering Sinopharm should seek medical advice and be actively monitored.
The COVID-19 Sinopharm vaccine triggers the immune system to produce a response to the inactivated version of the COVID-19 virus. MRNA vaccines work by injecting the COVID-19 genetic code into the body, triggering the production of viral proteins that trains the immune system to defend against the virus.
WHO recommends the Sinopharm vaccine for people aged 18 years and above. Those who have had COVID-19 in the past are eligible for vaccination post six months after COVID-19 infection. Lactating women are eligible to be administered with the Sinopharm vaccine, and able to continue breastfeeding post-vaccination.
Individuals with a history of anaphylaxis or any form of severe allergic reactions to medication/food/vaccination should not be administered with the vaccine.
Individuals with a body temperature over 38.5ºC should postpone vaccination until the fever subsides.
Based on the data from clinical trials, the common side effects are headaches, fatigue and fever. These reported side effects were mild to moderate, like the other approved COVID-19 vaccines.
All the vaccines approved by WHO Emergency Use Listing are highly effective in preventing severe disease and hospitalization due to COVID-19.
Under the special access route (SAR), Raffles Medical Group has received approval to import the Sinopharm vaccines. You may register your interest, and you will be notified on next steps once the vaccine is available. Do note that registration of interest does not guarantee access to vaccines as it is subjected to availability and prevailing criteria.
Two doses are required with an interval of 3-4 weeks between first and second dose.
In case of any clarifications, seek advice from your medical doctor to assess your suitability. You may visit one of our clinics to do so or send in an enquiry.
Footnotes & references:
The Sinopharm COVID-19 vaccine: What you need to know
Sinopharm COVID-19 vaccine: Should you worry about the side effects?
|
|||||
6044
|
dbpedia
|
2
| 75
|
https://www.pharmacompass.com/contact-details-sinopharm-weiqida-pharmaceutical-co-ltd
|
en
|
Sinopharm Weiqida Pharmaceutical Co Ltd
|
[
"https://www.pharmacompass.com/image/others/loader-TV.gif",
"https://www.pharmacompass.com/image/flap/abbvie-corp-adgif-27965.gif",
"https://www.pharmacompass.com/image/flap/abbvie-corp-ad-w33-mob-headergif-39012.gif",
"https://www.pharmacompass.com/image/pc-logo-star-orange-gradient-blue-bg-final-100x100.png",
"https://www.pharmacompass.com/image/vb/menu-dropdown-white.png",
"https://www.pharmacompass.com/image/vb/MP-Icon-100x100.png",
"https://www.pharmacompass.com/image/vb/post-enquiry-icon-100x100.png",
"https://www.pharmacompass.com/image/pc-logo-star-orange-gradient-blue-bg-final-100x100.png",
"https://www.pharmacompass.com/image/vb/menu-dropdown-white.png",
"https://www.pharmacompass.com/image/ASK_US_Button.gif",
"https://www.pharmacompass.com/image/icons/MP-Icon.png",
"https://www.pharmacompass.com/image/pc-logo-star-orange-gradient-blue-bg-final-100x100.png",
"https://www.pharmacompass.com/image/vb/VB-Icon-Shadow-Ver2.png",
"https://www.pharmacompass.com/image/vb/menu-dropdown-white.png",
"https://www.pharmacompass.com/image/pc-blue-orange-logo-star-200x200.png",
"https://www.pharmacompass.com/image/vb/menu-dropdown-white.png",
"https://www.pharmacompass.com/image/vb/envelope_access.png",
"https://www.pharmacompass.com/image/button-icons/Google-Map-1.png",
"https://www.pharmacompass.com/image/button-icons/Email-cnt.png",
"https://www.pharmacompass.com/image/country/globe-blue.png",
"https://www.pharmacompass.com/image/country/address-blue.png",
"https://www.pharmacompass.com/image/country/phone-blue.png",
"https://www.pharmacompass.com/image/vb/website.png",
"https://www.pharmacompass.com/image/country/linkedin-blue.png",
"https://www.pharmacompass.com/image/country/twitter-blue.png",
"https://www.pharmacompass.com/image/vb/route-100.png",
"https://www.pharmacompass.com/image/banner/inke-sa-m-39725.png",
"https://www.pharmacompass.com/image/linkedin_ln.png",
"https://www.pharmacompass.com/image/message icon.png"
] |
[] |
[] |
[
"Sinopharm Weiqida Pharmaceutical Co Ltd Contact details"
] | null |
[] | null |
Get Contact Details of Sinopharm Weiqida Pharmaceutical Co Ltd at Pharmacompass.com.
|
en
|
https://www.pharmacompass.com/image/favicon.ico
|
PharmaCompass.com
|
https://www.pharmacompass.com/contact-details-sinopharm-weiqida-pharmaceutical-co-ltd
|
Room 303-1, Zhuoming Mansion, Building 1, No. 6, South Jianhua Road, Chaoy...
|
||||
3536
|
dbpedia
|
2
| 7
|
https://d23.com/list-of-disney-films/
|
en
|
List of Disney Films
|
[
"https://d23.com/app/themes/d23/assets/dist/images/weblogo1.png",
"https://d23.com/app/uploads/2023/12/2024-D23-Logo_Horizontal_Stacked-Tagline_BLK_500_00.png",
"https://d23.com/app/uploads/2023/12/2024-D23-Logo-Lockup_Logomark-02_500_00.png",
"https://d23.com/app/uploads/2022/05/1180w-600h_A_Z_Hero_2.jpg",
"https://d23.com/app/uploads/2021/12/D23_Home_DisneyPlusButton_Composite.jpg",
"https://d23.com/app/uploads/2021/12/D23_Home_SWButton_Composite.jpg",
"https://d23.com/app/uploads/2021/12/D23_Home_MarvelButton_Composite.jpg",
"https://d23.com/app/uploads/2021/12/D23_Home_PixarButton_Composite.jpg",
"https://d23.com/app/uploads/2021/12/D23_Home_ParksButton_Composite.jpg",
"https://d23.com/app/uploads/2021/12/D23_Home_DisneyPrincessesButton_Composite.jpg",
"https://d23.com/app/plugins/bb-plugin/img/pixel.png",
"https://d23.com/app/uploads/2022/05/1180w-600h_disney_a_z_yondu_00.jpg",
"https://d23.com/app/uploads/2022/05/1180w-600h_disney_a_z_tron_00.jpg",
"https://d23.com/app/uploads/2016/06/1180-x-600-062116_Rocketeer_BillyCampbell.jpg",
"https://d23.com/app/uploads/2022/05/1180w-600h_disney_a_z_toy_story_1_00.jpg",
"https://d23.com/app/uploads/2022/05/1180w-600h_disney_a_z_pirates_00.jpg",
"https://d23.com/app/uploads/2022/05/1180w-600h_disney_a_z_up_00.jpg",
"https://d23.com/app/uploads/2022/05/1180w-600h_disney_a_z_star_wars_the_force_awakens_00.jpg",
"https://d23.com/app/uploads/2022/05/1180w-600h_disney_a_z_avengers_endgame_00.jpg",
"https://d23.com/app/uploads/2022/02/D23_2024_FanFare_Email_Footer_1180x664_update_0731.jpg",
"https://d23.com/app/uploads/2021/12/AppleAppStore.png",
"https://d23.com/app/uploads/2021/12/GooglePlay.png",
"https://d23.com/app/uploads/2022/02/1180h_664w_2024_Collector_Set_00.jpg",
"https://d23.com/app/uploads/2023/12/2024-D23-Logo_Horizontal_Stacked-Tagline_BLK_500_00.png",
"https://d23.com/app/uploads/2023/12/2024-D23-Logo-Lockup_Logomark-02_500_00.png"
] |
[] |
[] |
[
""
] | null |
[] |
2013-04-24T08:15:29+00:00
|
D23 presents a list of all the Disney films from A-Z, including titles from Marvel, Pixar, Disney Animation, Touchstone, and more!
|
en
|
D23
|
https://d23.com/list-of-disney-films/
|
712. 2015: Star Wars: The Force Awakens (Lucasfilm) (PG-13)
713. 2016: The Finest Hours (PG-13)
714. 2016: Zootopia (PG)
715. 2016: The Jungle Book (PG)
716. 2016: Captain America: Civil War (Marvel) (PG-13)
717. 2016: Alice Through the Looking Glass (PG)
718. 2016: Finding Dory (PG)
719. 2016: The BFG (PG)
720. 2016: Pete’s Dragon (PG)
721. 2016: The Light Between Oceans (PG-13)
722. 2016: Queen of Katwe (PG)
723. 2016: Doctor Strange (Marvel) (PG-13)
724. 2016: Moana (PG)
725. 2016: Rogue One: A Star Wars Story (Lucasfilm) (PG-13)
726. 2017: Dangal (Disney India)
727. 2017: Beauty and the Beast (PG)
728. 2017: Born in China (Disneynature) (G)
729. 2017: Guardians of the Galaxy, Vol. 2 (Marvel) (PG-13)
730. 2017: Pirates of the Caribbean: Dead Men Tell No Tales (PG-13)
731. 2017: Cars 3 (Pixar) (G)
732. 2017: Jagga Jasoos (Disney India)
733. 2017: Posledny bogatyr (The Last Warrior) (NR)
734. 2017: Thor: Ragnarok (Marvel) (PG-13)
735. 2017: Coco (Pixar) (PG)
736. 2017: Star Wars: The Last Jedi (Lucasfilm) (PG-13)
737. 2018: Black Panther (Marvel) (PG-13)
738. 2018: A Wrinkle in Time (PG)
739. 2018: Avengers: Infinity War (Marvel) (PG-13)
740. 2018: Solo: A Star Wars Story (Lucasfilm) (PG-13)
741. 2018: Incredibles 2 (Pixar) (PG)
742. 2018: Ant-Man and The Wasp (Marvel) (PG_13)
743. 2018: Christopher Robin (PG)
744. 2018: The Nutcracker and the Four Realms (PG)
745. 2018: Ralph Breaks the Internet (PG)
746. 2018: Mary Poppins Returns (PG)
747. 2019: Captain Marvel (Marvel) (PG-13)
748. 2019: Dumbo (PG)
749. 2019: Penguins (Disneynature) (G)
750. 2019: Avengers: Endgame (Marvel) (PG-13)
751. 2019: Aladdin (PG)
752. 2019: Toy Story 4 (Pixar) (G)
753. 2019: The Lion King (PG)
754. 2019: Maleficent: Mistress of Evil (PG)
755. 2019: Lady and the Tramp (PG) [Disney+]
756. 2019: Noelle (G) [Disney+]
757. 2019: Frozen 2 (PG)
758. 2019: Star Wars: The Rise of Skywalker (PG-13)
759. 2019: Togo (PG) [Disney+]
760. 2020: Timmy Failure: Mistakes Were Made (PG) [Disney+]
761. 2020: Onward (Pixar) (PG)
762. 2020: Stargirl (PG) [Disney+]
763. 2020: Dolphin Reef (Disneynature) (G) [Disney+]
764. 2020: Elephant (Disneynature) (G) [Disney+]
765. 2020: Artemis Fowl (PG) [Disney+]
766. 2020: Hamilton (PG-13) [Disney+]
767. 2020: Magic Camp (PG) [Disney+]
768. 2020: The One and Only Ivan (PG) [Disney+]
769. 2020: Mulan (PG-13) [Disney+]
770. 2020: Godmothered (PG) [Disney+]
771. 2020: Safety (PG) [Disney+]
772. 2020: Soul (Pixar) (PG) [Disney+]
773. 2021: Posledny bogatyr: Koren’ zla (The Last Warrior: Root of Evil) (NR)
774. 2021: Flora & Ulysses (PG) [Disney+]
775. 2021: Raya and the Last Dragon (PG) [Theatrical & Disney+]
776. 2021: Cruella (PG-13) [Theatrical & Disney+]
777. 2021: Luca (Pixar) (PG) [Theatrical & Disney+]
778. 2021: Black Widow (Marvel) (PG-13) [Theatrical & Disney+]
779. 2021: Jungle Cruise (PG-13) [Theatrical & Disney+]
780. 2021: Shang-Chi and the Legend of the Ten Rings (Marvel) (PG-13)
781. 2021: Eternals (Marvel) (PG-13)
782. 2021: Encanto (PG)
783. 2021: Diary of a Wimpy Kid (20th Century Animation) (PG) [Disney+]
784. 2021: Posledny bogatyr: Poslannik t’my (The Last Warrior: A Messenger of Darkness) (NR)
785. 2022: The Ice Age Adventures of Buck Wild (20th Century Animation) (PG) [Disney+]
786. 2022: The Beatles: Get Back – The Rooftop Concert (PG-13)
787. 2022: Turning Red (Pixar) (PG) [Disney+]
788. 2022: Cheaper by the Dozen (20th Century Studios) (PG) [Disney+]
789. 2022: Better Nate Than Ever (PG) [Disney+]
790. 2022: Polar Bear (Disneynature) (PG) [Disney+]
791. 2022: Doctor Strange in the Multiverse of Madness (Marvel) (PG-13)
792. 2022: Chip ’n Dale: Rescue Rangers (PG) [Disney+]
793. 2022: Hollywood Stargirl (PG) [Disney+]
794. 2022: Lightyear (Pixar) (PG)
795. 2022: Rise (PG) [Disney+]
796. 2022: Thor: Love and Thunder (Marvel) (PG-13)
797. 2022: Mija (PG-13)
798. 2022: Pinocchio (PG) [Disney+]
799. 2022: Hocus Pocus 2 (PG) [Disney+]
800. 2022: Black Panther: Wakanda Forever (Marvel) (PG-13)
801. 2022: Strange World (PG)
802. 2022: Disenchanted (PG) [Disney+]
803. 2022: Diary of a Wimpy Kid: Rodrick Rules (PG) [Disney+]
804. 2022: Night at the Museum: Kahmunrah Rises Again (PG) [Disney+]
805. 2023: Ant-Man and the Wasp: Quantumania (Marvel) (PG-13)
806. 2023: Chang Can Dunk (PG) [Disney+]
807. 2023: Peter Pan & Wendy (PG) [Disney+]
808. 2023: Guardians of the Galaxy Vol. 3 (Marvel) (PG-13)
809. 2023: Crater (PG) [Disney+]
810. 2023: The Little Mermaid (PG)
811. 2023: Elemental (Pixar) (PG)
812. 2023: World’s Best (PG) [Disney+]
813. 2023: Indiana Jones and the Dial of Destiny (Lucasfilm) (PG-13)
814. 2023: Haunted Mansion (PG-13)
815. 2023: The Marvels (Marvel) (PG-13)
816. 2023: Dashing Through the Snow (PG) [Disney+]
817. 2023: Wish (PG)
818. 2023: Diary of a Wimpy Kid Christmas: Cabin Fever (PG) [Disney+]
|
|||||
3536
|
dbpedia
|
1
| 19
|
https://www.thesun.co.uk/tvandshowbiz/5805003/stephen-hawking-movies-eddie-redmayne-benedict-cumberbatch-played-the-physicist/
|
en
|
Actors who've played Stephen Hawking - from Eddie Redmayne to Benedict Cumberbatch
|
[
"https://www.thesun.co.uk/wp-content/themes/thesun/images/sunmasthead.svg",
"https://www.thesun.co.uk/wp-content/themes/thesun/images/sunmasthead_mobile.svg",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/rb-composite-hawkings.jpg?w=620",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict0003920587101.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392089762-e1521026828175.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/nintchdbpict000392140000.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/bbt-11.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-1.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/sh-2.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/fu.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=335 335w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=480 480w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=620 620w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=670 670w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=960 960w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=1240 1240w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=1005 1005w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=1440 1440w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=1860 1860w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=1340 1340w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=1920 1920w, https://www.thesun.co.uk/wp-content/uploads/2018/03/lb.jpg?w=2480 2480w",
"https://www.thesun.co.uk/wp-content/uploads/2024/01/VP-CASE-FILE-EPSTEIN-v2_COMP-1.jpg?strip=all&w=300&h=192&crop=1",
"https://www.thesun.co.uk/wp-content/uploads/2021/09/ACP-1709-COMP-HAWKING.jpg?strip=all&w=300&h=192&crop=1",
"https://www.thesun.co.uk/wp-content/uploads/2021/03/dk-comp-page21hawking-v2.jpg?strip=all&w=300&h=192&crop=1",
"https://www.thesun.co.uk/wp-content/uploads/2020/04/NINTCHDBPICT000472145091-e1587762536198.jpg?crop=0px%2C337px%2C2133px%2C1421px&resize=300%2C192",
"https://www.thesun.co.uk/wp-content/uploads/2024/08/TM-12-08-Graziano-Kym_COMP.jpg?strip=all&w=150&h=100&crop=1",
"https://www.thesun.co.uk/wp-content/uploads/2024/08/dk-12-08-piers-morgan-harry-meghan-v2-comp_6cb46f.png?strip=all&w=150&h=100&crop=1",
"https://www.thesun.co.uk/wp-content/uploads/2024/08/newspress-collage-e1yi83zwn-1723480246275.jpg?1723483807&strip=all&w=150&h=100&crop=1",
"https://www.thesun.co.uk/wp-content/uploads/2024/08/KH_12_08_GRAHAM_THORPE-v2.jpg?strip=all&w=150&h=100&crop=1"
] |
[] |
[] |
[
"Stephen Hawking",
"movies",
"films",
"Eddie Redmayne",
"Benedict Cumberbatch",
"The Theory of Everything"
] | null |
[
"Joanne Kavanagh",
"www.facebook.com"
] |
2018-06-15T10:00:36+01:00
|
PROFESSOR Stephen Hawking may have been a science genius but he was also featured in many films and TV shows - either with someone playing him or as a
|
en
|
The Sun
|
https://www.thesun.co.uk/tvandshowbiz/5805003/stephen-hawking-movies-eddie-redmayne-benedict-cumberbatch-played-the-physicist/
|
PROFESSOR Stephen Hawking may have been a science genius but he was also featured in many films and TV shows - either with someone playing him or as a cameo.
We take a look at the times when the late physicist was portrayed in the movies...
Who has played Stephen Hawking in a film?
Eddie Redmayne
Eddie Redmayne played Professor Hawking in the 2014 biographical romantic drama The Theory of Everything.
His performance received universal acclaim and Eddie was awarded an Oscar, Golden Globe and Bafta Award for Best Actor.
The film explores Hawking's relationship with his first wife Jane, his ALS diagnosis and his ambitious study of time.
Hawking said of the film: "Unfortunately, Eddie [Redmayne] did not inherit my good looks."
Benedict Cumberbatch
In 2004, a then little known Benedict Cumberbatch played Hawking in the 90-minute made-for-television movie Hawking, which ran on the BBC.
Just like The Theory of Everything, Hawking sees the budding cosmologist meet his future wife, Jane Wilde, at a party.
But unlike Eddie's portrayal, which follows Hawking's degeneration of muscle function to the point that he's unable to use his own voice, Benedict plays Hawking while he was still very much able to walk and talk.
The actor was nominated for a Bafta TV Best Actor Award in 2005.
What TV shows did Stephen Hawking appear in?
Professor Hawking became known for his funny cameos in numerous hit shows:
The Big Bang Theory
The sit-com made for him - a flat full of science geeks who worship his work.
Professor Hawking played himself, stunning chief science geek Sheldon, played by Jim Parsons, and his pals Leonard, Raj and Howard.
Hilarious scenes include the boys doing creepy impressions of his robot voice.
He appeared in seven episodes and sang Happy Birthday to Sheldon over Skype.
The Simpsons
Game for a laugh, Professor Hawking lent his voice to FOUR episodes of the legendary animated sitcom, The Simpsons.
In our favourite, the great man came to Springfield to warn them their vision of utopia would never pan out.
Star Trek: The Next Generation
Hawking popped up in the season six finale of Next Generation, where he played poker against Albert Einstein and Isaac Newton as holograms.
The professor is a famous Trekkie, and his book A Brief History of Time was adapted into a documentary by Leonard Nimoy, aka, Spock.
Futurama
Stephen popped up in season two of the futuristic cartoon Futurama.
He joins the Vice Presidential Action Rangers, led by Al Gore, who aim to protect the space-time continuum.
He later wound up as a floating head in a jar in the Futurama movie.
Little Britain
The theoretical physicist popped up for a Comic Relief cameo in Little Britain.
He was being pushed along by over-eager carer Lou, as he teaches him how to say "quack" like a duck.
Stephen showed off his comic timing, providing droll comebacks to everyone who came over to patronise him.
In the end, annoyed by everyone talking down to him, Hawking turns into a giant rocket-launching transformer robot.
|
|||||
3536
|
dbpedia
|
1
| 35
|
https://tellyvisions.org/article/british-actors-you-should-know-eddie-redmayne
|
en
|
British Actors You Should Know: Eddie Redmayne
|
[
"https://tellyvisions.org/themes/custom/telly_visions/logo.svg",
"https://tellyvisions.org/themes/custom/telly_visions/images/weta-logo-small.svg",
"https://tellyvisions.org/themes/custom/telly_visions/logo.svg",
"https://tellyvisions.org/themes/custom/telly_visions/images/weta-logo-small.svg",
"https://tellyvisions.org/sites/default/files/eddieredmayneashawking.jpg",
"https://tellyvisions.org/sites/default/files/styles/1_1__80x80/public/14516504_1089898581107233_6612206257875994885_n.jpg?itok=aNbgEWz2 1x",
"https://tellyvisions.org/themes/custom/telly_visions/images/weta-passport.svg",
"https://tellyvisions.org/themes/custom/telly_visions/images/weta-logo-reversed.svg",
"https://tellyvisions.org/themes/custom/telly_visions/images/tellyvisions-logo.svg"
] |
[
"/media/oembed?url=https%3A//www.youtube.com/watch%3Fv%3DNeHDZODFKNw&max_width=0&max_height=0&hash=7CZUNlY66Z9Aiqs246vMEoMmSmLrvTMnxrFBQTWdnSs",
"/media/oembed?url=https%3A//www.youtube.com/watch%3Fv%3DYdYp1olDJeU&max_width=0&max_height=0&hash=Re1SfHAj8MVbjUHNsgkT7ygFojeZR2yTFFRoyH-o8e8",
"/media/oembed?url=https%3A//www.youtube.com/watch%3Fv%3DNNXw2ZjvEdU&max_width=0&max_height=0&hash=gFrMnbN44-7YMvFi0tYjgUxynmthfLgJM-mPmVtgYPw"
] |
[] |
[
""
] | null |
[
"Carmen Croghan",
"Lacy Baugher"
] |
2014-11-28T20:26:28-05:00
|
The major film festivals have taken place and now Hollywood is releasing the trailers for its 2015 Oscar contenders. If you pay attention to that sort of thing, you may well have heard the buzz around our latest featured actor – Eddie Redmayne. He’s receiving accolades for his performance as Stephen Hawking in The Theory of Everything. The film follows the life of the world famous scientist from his days as a student at Oxford through his devastating ALS diagnosis and out the other side to the triumph of his career and his determination to outlive the dire predictions of his doctors. He does all this with the love and full support of his fiancé, and later, wife, Jane (Felicity Jones) by his side. (Curious about The Theory of Everything? Watch the trailer.) Long before this breakout lead role, however, young Mr. Redmayne had been getting noticed for his acting skills on both sides of the pond. He’s won the Olivier and the Tony for his supporting role in the play Red as well as other theatre and film award nominations. So if you’re not familiar with this talented performer, here are just a few examples of Eddie’s past television and film work which you can view, in most cases, tonight if the mood strikes you.
|
en
|
/themes/custom/telly_visions/favicons/apple-touch-icon.png
|
Telly Visions
|
https://tellyvisions.org/article/british-actors-you-should-know-eddie-redmayne
|
The major film festivals have taken place and now Hollywood is releasing the trailers for its 2015 Oscar contenders. If you pay attention to that sort of thing, you may well have heard the buzz around our latest featured actor – Eddie Redmayne.
He’s receiving accolades for his performance as Stephen Hawking in The Theory of Everything. The film follows the life of the world famous scientist from his days as a student at Oxford through his devastating ALS diagnosis and out the other side to the triumph of his career and his determination to outlive the dire predictions of his doctors. He does all this with the love and full support of his fiancé, and later, wife, Jane (Felicity Jones) by his side.
(Curious about The Theory of Everything? Watch the trailer.)
Long before this breakout lead role, however, young Mr. Redmayne had been getting noticed for his acting skills on both sides of the pond. He’s won the Olivier and the Tony for his supporting role in the play Red as well as other theatre and film award nominations. So if you’re not familiar with this talented performer, here are just a few examples of Eddie’s past television and film work which you can view, in most cases, tonight if the mood strikes you.
My Week with Marilyn. Based on the true story of Marilyn Monroe’s (Michelle Williams) visit to England to film The Prince and the Showgirl, My Week with Marilyn features Redmayne as Colin Cooper, an aspiring film maker who talks his way into a job helping director Laurence Olivier (Kenneth Branagh)with various duties on the set.
His main tasks include making arrangements for Monroe’s stay and getting her from place to place. Surrounded by her acting coach and other hangers on, Oliver soon tires of Marilyn’s less than professional behavior and constant delays. Only Colin’s new friendship seems to be able to get Marilyn through the difficult production.
The Pillars of the Earth. Pillars of the Earth is a mini-series based on Ken Follet’s very long historical fiction novel of the same name. The story centers around the formidable process of building a cathedral against the turbulent backdrop of 12th century England. Redmayne plays Jack Jackson, a talented stonemason whose passion for building a beautiful cathedral is surpassed only by his forbidden love for the Lady Aliena (Haley Atwell).
This mini-series is only available through the Netflix DVD option or to purchase through Amazon Instant Video at this time.
Les Miserables. Considering the dialogue of the entire film is sung rather than spoken, the star-studded cast of 2012’s Les Miserables included more than a few unexpected casting choices. Eddie Redmayne was one of those surprises when he got the nod to play Marius, the student revolutionary who must choose between his newfound love Cosette (Amanda Seyfried) and his comrades at the barricades. Apparently when he attended Eton College Redmayne was trained as a chorister; however, his Les Mis role required months of special vocal training to prepare for moving live performances like this one.
[This video is no longer available.]
Les Miserables can be streamed on Amazon Instant Video.
Birdsong. Some of you may have seen the two-part series Birdsong when it aired on PBS in 2012. This WWI drama finds Redmayne in the trenches as Lieutenant Stephen Wraysford, a man still grieving over the end of an affair with his true love, a married woman named Isabelle (Clemence Poesy). In times of war, the future is uncertain and circumstances are extraordinary so if you like your romances full of tragic events and tinged with a ray of hope, then Redmayne’s silent heartbreak may be for you.
Tess of D’Urbervilles. In this adaptation of the Thomas Hardy classic Tess of the D’Urbervilles, Eddie portrays Angel Clare, an aspiring farmer and son of a parson. When he meets new milkmaid Tess (Gemma Arterton), they are immediately smitten with one another. Unfortunately our heroine hides a shaming secret that will eventually have to come out (as secrets inevitably do) and change both of their lives forever.
[This video is no longer available.]
This mini-series can be streamed on Hulu Plus and Amazon Prime.
Hick. And finally, there comes a time when every British actor worth his salt must take on the challenge of an American accent, preferably Southern-ish. Hick is the film where Eddie Redmayne did just that. The total opposite of his usual sensitive characters, this drunken violent drifter (coincidentally named Eddie) crosses paths with a thirteen year old runaway called Luli (Chloe Grace Moretz). Surely nothing good comes of this situation.
[This video is no longer available.]
Stream Hick on Netflix and judge Redmayne’s accent and intense performance for yourself.
So who’s got The Theory of Everything on your must-see movie list? What’s your favorite Eddie Redmayne performance? And if I’ve neglected to include a notable role, please let us know in the comments!
|
||||
3536
|
dbpedia
|
2
| 60
|
https://stephenfollows.com/how-many-films-are-released-each-year/
|
en
|
How many films are released each year?
|
[
"https://stephenfollows.com/wp-content/uploads/2024/01/Stephen_Follows_24_500-1-e1705919404323.png",
"https://stephenfollows.com/wp-content/uploads/2017/08/Films-released-01@025x.png",
"https://stephenfollows.com/wp-content/uploads/2017/08/How-many-films-are-released-in-US-cinemas-900x497.png",
"https://stephenfollows.com/wp-content/uploads/2017/08/Number-of-studio-and-non-studio-films-released-in-US-cinemas-900x490.png",
"https://stephenfollows.com/wp-content/uploads/2017/08/How-many-films-are-released-in-UK-cinemas-900x494.png",
"https://stephenfollows.com/wp-content/uploads/2017/08/How-many-films-are-released-in-UK-and-US-900x524.png",
"https://stephenfollows.com/wp-content/uploads/2017/08/Percentage-of-the-UK-cinema-box-office-going-to-major-releases-900x484.png",
"https://stephenfollows.com/wp-content/uploads/2021/06/shre-more-round.svg",
"https://stephenfollows.com/wp-content/uploads/2021/07/211-gender-inequality-in-the-uk-film-industry-768x461.jpg",
"https://stephenfollows.com/wp-content/uploads/2021/07/156-are-films-with-public-funding-any-good-768x461.jpg",
"https://stephenfollows.com/wp-content/uploads/2021/07/172-thoughts-from-the-industry-on-the-decline-in-uk-production-768x461.jpg",
"https://stephenfollows.com/wp-content/uploads/2023/03/authoredbyaipodcastherosmall-768x768.jpg",
"https://stephenfollows.com/wp-content/uploads/2023/02/hero-1-768x768.jpg",
"https://stephenfollows.com/wp-content/uploads/2024/08/Which-nations-rate-drug-content-in-movies-most-harshly-300x180.png",
"https://stephenfollows.com/wp-content/uploads/2024/07/Which-countries-care-most-about-violence-in-movies-300x180.png",
"https://stephenfollows.com/wp-content/uploads/2000/06/What-percentage-of-movies-are-written-by-women-over-40-300x180.png",
"https://stephenfollows.com/wp-content/uploads/2024/06/Which-countries-care-most-about-sex-in-movies-300x180.png",
"https://stephenfollows.com/wp-content/uploads/2021/06/1516545040336-1-1-1.png",
"https://stephenfollows.com/wp-content/uploads/2021/06/clapperboard-1-1.svg",
"https://stephenfollows.com/wp-content/uploads/2021/06/1516545040336-1-1-1.png",
"https://stephenfollows.com/wp-content/uploads/2024/01/Stephen_Follows_24_500-1-e1705919404323.png",
"https://stephenfollows.com/wp-content/uploads/2021/06/Original-1-1.svg",
"https://stephenfollows.com/wp-content/uploads/2021/06/Original-2-1.svg",
"https://stephenfollows.com/wp-content/uploads/2021/06/Original-3.svg"
] |
[] |
[] |
[
""
] | null |
[
"Stephen Follows"
] |
2017-08-14T00:01:03+00:00
|
In an unusual moment of synchronicity this week, three unconnected people have contacted me to ask how many films are released in cinemas each year. Each had different reasons for asking but all were working from the same basic hypothesis - that the number is increasing. In the past, I have looked at the number of...
|
en
|
Stephen Follows
|
https://stephenfollows.com/how-many-films-are-released-each-year/
|
In an unusual moment of synchronicity this week, three unconnected people have contacted me to ask how many films are released in cinemas each year. Each had different reasons for asking but all were working from the same basic hypothesis – that the number is increasing.
In the past, I have looked at the number of feature films made (both in the UK and worldwide) but today we’re going to focus on the number of feature films released in cinemas to the paying public. This doesn’t include film festivals, private screenings or other types of content in cinemas, such as broadcasts of opera or theatre productions.
The first thing to note is that there is no one simple answer. Firstly, we need to consider that each country will have its own unique market for movies and so the number of films released in the UK will differ from that of the US. Secondly, there is no one company or body which possesses every piece of data required to report a completely accurate figure. Each company involved in collecting movie data will have its own methods, criteria and biases. Finally, the biggest films are intensively studied, but smaller, independent films can be overlooked, especially if they are released in a small number of cinemas and for a short space of time.
With those warnings in place, let’s look at what numbers are being reported.
How many films are released in US theatres?
We’ll start in the US, where the number of films released has increased massively. In 2016, there were 736 films released in US cinemas; twice the number in 2000.
Let’s break that down into a little more detail. Using data from The Numbers, we can split these numbers into two groups – films by one of the six major Hollywood studios (i.e. Warners, Disney, Fox, Paramount, Sony and Universal) which have a wide release (i.e. in at least 1,000 cinemas) versus all other films.
This shows us that the large growth in film releases has not come from the big Hollywood movies we hear so much about. In fact, they’ve dropped slightly. In 2006 there were 128 such “wide Studio releases” and just 93 in 2016 (a 27% reduction).
How many films are released in UK cinemas?
We see a similar pattern in the UK, with the number of films released in UK cinemas more than doubling between 2000 and 2016. Last year a staggering 821 movies released in UK cinemas – an average of almost sixteen per week. This means that if you saw a new movie every morning and every afternoon on every single day of the year, you would still miss 91 new movies.
Why is this happening?
Is this huge growth being caused by an increase in supply or demand? In other words, is the root cause an increased number of movies being pushed into cinemas, or are cinema-goers demanding ever more movies?
If we compare the change in supply (i.e. movie releases) with the change in demand (i.e. cinema admissions) we can see that it’s very much supply driven. Whilst the number of movies released between 2000 and 2016 doubled, admissions have been fairly flat – both in the US and in the UK.
Technological changes mean that movies are easier and cheaper to make and distribute. In addition, shifts in the industry mean that films spend far less long in cinemas before moving on to other platforms, such as DVD and Video On Demand.
Even the UK’s film public body has called this growth “ridiculous“. In 2014, the head of the BFI’s Film Fund, Ben Roberts, said:
There are too many films being released. That number is ridiculous, and the fact it keeps going up is not sustainable. There’s just too much stuff out there. A real challenge for us is to make sure that films stay on screen for long enough… It’s too much for the market to bear. Financially, it doesn’t make as much sense.
Does the increase in releases mean more money for independent filmmakers?
We’ve already seen how the number of major Hollywood releases is not increasing, meaning that the growth in releases must be due to a greater number of independent films receiving a theatrical release. This could be viewed as a positive change for artists and independents, as they get a greater-than-ever chance to get their film seen and to earn some of that box office income.
However, the data reveals that the studios have managed to keep control of the majority of the cinema market. Over the past ten years, 74% of all the money collected at the UK box office has gone to the top 50 grossing films.
Related articles
If you want to read more about trends in the film industry, then here are a few articles you may want to check out:
Six ways the film business is changing
The state of the UK film industry
Notes
The UK data for today’s article came from the Film Distributors Association, comScore and the BFI; the US data came via the MPAA, The Numbers and Box Office Mojo.
We need to be a little careful about relying on data from the pre-internet age as it has a higher chance of being incomplete than data captured contemporaneously. For example, Box Office Mojo launched in 1999 so all data from that year would have been added in 1999 or later.
Epilogue
A big thank you to Erin, Steve, and Franklin (via Michael), whose questions led to today’s article. To be honest, I thought I had covered the topic already but it turns out that I had only addressed the topic in passing in amongst other articles. I’ve been doing this for so long that I often forget what I have covered. Twice last month I had an idea for a topic, Googled it and found that I had already looked into it. I worry that this is early senility, but it’s a comfort to think I’ll soon forget I have it.
|
|||||
3536
|
dbpedia
|
1
| 62
|
https://kids.kiddle.co/Benedict_Cumberbatch
|
en
|
Benedict Cumberbatch facts for kids
|
[
"https://kids.kiddle.co/images/wk/kids-robot.svg",
"https://kids.kiddle.co/images/wk/kids-search-engine.svg",
"https://kids.kiddle.co/images/thumb/6/6e/BCumberbatch_Comic-Con_2019.jpg/300px-BCumberbatch_Comic-Con_2019.jpg",
"https://kids.kiddle.co/images/thumb/c/cb/Benedict_Cumberbatch_2008.jpg/230px-Benedict_Cumberbatch_2008.jpg",
"https://kids.kiddle.co/images/thumb/c/cd/Benedict_Cumberbatch_filming_Sherlock_cropped.jpg/230px-Benedict_Cumberbatch_filming_Sherlock_cropped.jpg",
"https://kids.kiddle.co/images/thumb/7/75/Benedict_Cumberbatch_2011.jpg/230px-Benedict_Cumberbatch_2011.jpg",
"https://kids.kiddle.co/images/thumb/e/e0/Benedict_Cumberbatch_on_the_set_of_Doctor_Strange_2_%28cropped%29.jpg/230px-Benedict_Cumberbatch_on_the_set_of_Doctor_Strange_2_%28cropped%29.jpg",
"https://kids.kiddle.co/images/thumb/5/53/The_Children%27s_Monologues_cast_%282010%29.jpg/300px-The_Children%27s_Monologues_cast_%282010%29.jpg",
"https://kids.kiddle.co/images/thumb/e/ef/Benedict_Cumberbatch_figure_at_Madame_Tussauds_London.jpg/230px-Benedict_Cumberbatch_figure_at_Madame_Tussauds_London.jpg",
"https://kids.kiddle.co/images/thumb/7/72/Sophie_Hunter_and_Benedict_Cumberbatch_July_2015.jpg/230px-Sophie_Hunter_and_Benedict_Cumberbatch_July_2015.jpg",
"https://kids.kiddle.co/images/thumb/5/5f/Kids_robot.svg/60px-Kids_robot.svg.png",
"https://kids.kiddle.co/images/wk/kids-search-engine.svg"
] |
[] |
[] |
[
""
] | null |
[] | null |
Learn Benedict Cumberbatch facts for kids
|
en
|
/images/wk/favicon-16x16.png
|
https://kids.kiddle.co/Benedict_Cumberbatch
|
Benedict Timothy Carlton Cumberbatch, CBE (born 19 July 1976) is an English actor. Known for his work on screen and stage, he has received various accolades, including a British Academy Television Award, a Primetime Emmy Award and a Laurence Olivier Award. He has also been nominated for two Academy Awards, two British Academy Film Awards and four Golden Globe Awards. In 2014, Time magazine named him one of the 100 most influential people in the world, and in 2015, he was appointed a CBE at Buckingham Palace for services to the performing arts and to charity.
Cumberbatch studied drama at the Victoria University of Manchester and obtained a Master of Arts in classical acting at the London Academy of Music and Dramatic Art. He began acting in Shakespearean theatre productions before making his West End debut in Richard Eyre's revival of Hedda Gabler in 2005. Since then, he has starred in Royal National Theatre productions of After the Dance (2010) and Frankenstein (2011), winning the Laurence Olivier Award for Best Actor for the latter. In 2015, he played the title role in Hamlet at the Barbican Theatre.
Cumberbatch's television work includes his performance as Stephen Hawking in the television film Hawking (2004). He gained greater recognition for playing Sherlock Holmes in the BBC series Sherlock from 2010 to 2017, for which he won a Primetime Emmy Award for Outstanding Lead Actor in a Miniseries or a Movie. For playing the title role in the miniseries Patrick Melrose (2018), he won the British Academy Television Award for Best Actor.
In films, Cumberbatch has played Khan in Star Trek Into Darkness (2013), and has appeared in the historical dramas Amazing Grace (2006), 12 Years a Slave (2013), 1917 (2019) and The Courier (2020). He received critical acclaim and nominations for the Academy Award for Best Actor for his performances as Alan Turing in The Imitation Game (2014) and as a volatile rancher in The Power of the Dog (2021). From 2012 to 2014, through voice and motion capture, Cumberbatch played Smaug and Sauron in The Hobbit film series. Since 2016, he has played Dr. Stephen Strange in the Marvel Cinematic Universe, including the films Doctor Strange (2016) and Doctor Strange in the Multiverse of Madness (2022).
Early life and education
Antecedents and family tree
In 1728, Benedict Cumberbatch's 7th-great-grandfather, Abraham Cumberbatch of Saint Andrew, Barbados (died 1753), acquired properties on the island of Barbados in the West Indies, which used enslaved people for labour. St Nicholas Abbey was owned by Cumberbatch's ancestors for at least two hundred years.
These properties were passed down through the generations to Benedict's great-great-great-grandfather, Abraham Parry Cumberbatch (died 1840 in Hellingly, Sussex). He was an absentee landlord of two estates, Cleland and Lammings, for which he received £5388 as slave compensation (via the Slave Compensation Act 1837, four years after the Slavery Abolition Act 1833 had abolished slavery). The Cleland plantation enslaved 250 people, and was the main source of the Cumberbatch family's considerable wealth at the time; they were one of the richest families in Britain.
There has been media speculation that the Barbados National Task Force on Reparations, which, as part of the wider Caribbean's CARICOM Reparations Commission, is as of January 2023 seeking reparations from wealthy British MP Richard Drax for his ancestors' involvement in slavery, might also consider seeking reparations from families such as the Cumberbatches. Benedict Cumberbatch has said that by the time of his birth, most of the money had run out, and he grew up "definitely middle class", or upper middle class. The Drax family still owns a large estate in Barbados, and Richard Drax is said to be worth at least £150 million.
Abraham Parry Cumberbatch's son (Benedict's great-great-grandfather) Robert William Cumberbatch, was a British consul in Turkey and the Russian Empire. His great-grandfather, Henry Alfred Cumberbatch, was also a diplomat who served as consul in Turkey and Lebanon, and his grandfather, Henry Carlton Cumberbatch, was a submarine officer of both World Wars, and a prominent figure of London high society.
Cumberbatch is third cousin 16 times removed of King Richard III, whom he portrayed in The Hollow Crown. He attended Richard III's 2015 reburial and read a poem.
Birth family and schooling
Benedict Timothy Carlton Cumberbatch was born on 19 July 1976 at Queen Charlotte's and Chelsea Hospital in the London district of Hammersmith, to actors Timothy Carlton (born Timothy Carlton Congdon Cumberbatch) and Wanda Ventham. He grew up in the borough of Kensington and Chelsea. He has a half-sister, Tracy Peacock, from his mother's first marriage.
Cumberbatch attended boarding schools from the age of eight, attending Brambletye, a prep school near East Grinstead, West Sussex.
He undertook secondary schooling as an arts scholar at Harrow School. He was a member of the Rattigan Society, Harrow's principal club for the dramatic arts, which was named after Old Harrovian and playwright Sir Terence Rattigan. He was involved in numerous Shakespearean works at school and made his acting debut as Titania, Queen of the Fairies, in A Midsummer Night's Dream when he was 12. His first leading role was as Eliza Doolittle in Bernard Shaw's Pygmalion, in a production by the Head of Classics, James Morwood, who observed that Cumberbatch "acted everyone else off the stage". Cumberbatch's drama teacher, Martin Tyrell, called him "the best schoolboy actor" he had ever worked with. Despite his abilities, Cumberbatch's drama teacher at Harrow warned him against a career in acting, calling it a "tough business".
Tertiary education
After leaving Harrow, Cumberbatch took a gap year to volunteer as an English teacher at a Tibetan monastery in Darjeeling, India.
He then attended the Victoria University of Manchester, where he studied drama.
He continued his training as an actor at the London Academy of Music and Dramatic Art (LAMDA), graduating with an MA in classical acting. In January 2018, Cumberbatch succeeded Timothy West as president of LAMDA.
Performing arts career
See also: List of Benedict Cumberbatch performances
Theatre
Since 2001, Cumberbatch has had major roles in a dozen classic plays at the Regent's Park Open Air, Almeida, Royal Court and Royal National Theatres. He was nominated for an Olivier Award for Best Performance in a Supporting Role for his role as George Tesman in Hedda Gabler, which he performed at the Almeida Theatre on 16 March 2005 and at the Duke of York's Theatre when it transferred to the West End on 19 May 2005. This transfer marked his first West End appearance.
In June 2010, Cumberbatch led the revival of Sir Terence Rattigan's After the Dance directed by Thea Sharrock at the Royal National Theatre. He played 1920s aristocrat David Scott-Fowler to commercial and critical success. The play won four Olivier Awards including Best Revival. He acted in Danny Boyle's The Children's Monologues, a theatrical charity event at London's Old Vic Theatre on 14 November 2010 which was produced by Dramatic Need.
In February 2011, Cumberbatch began playing, on alternate nights, both Victor Frankenstein and his creature, opposite Jonny Lee Miller, in Boyle's stage production of Mary Shelley's Frankenstein at the Royal National Theatre. Frankenstein was broadcast to cinemas as a part of National Theatre Live in March 2011.
Cumberbatch achieved the "Triple Crown of London Theatre" in 2011 when he received the Olivier Award, Evening Standard Award and Critics' Circle Theatre Award for his performance in Frankenstein.
Cumberbatch was a part of a cast featuring members of the Royal National Theatre Company in 50 Years on Stage, the Royal National Theatre's landmark event for its 50th anniversary on 2 November 2013. He played Rosencrantz in a selected scene from Sir Tom Stoppard's play Rosencrantz and Guildenstern Are Dead. The show was directed by Sir Nicholas Hytner and was broadcast on BBC Two and in cinemas worldwide as a part of National Theatre Live.
Cumberbatch returned to theatre to play Shakespeare's Hamlet at London's Barbican Theatre. The production was directed by Lyndsey Turner and produced by Sonia Friedman, which started its 12-week run in August 2015. The performance, co-starring Sian Brooke, was broadcast by the National Theatre Company by satellite internationally as Hamlet in Rehearsal. He earned his third Laurence Olivier Awards nomination for the role.
Television
Cumberbatch's early television roles include two separate guest roles in Heartbeat (2000, 2004), Freddy in Tipping the Velvet (2002), Edward Hand in Cambridge Spies (2003) and Rory in the ITV comedy drama series Fortysomething (2003). He also featured in Spooks and Silent Witness. In 2004, he landed his first main part in television as Stephen Hawking in Hawking. He was nominated for the BAFTA TV Award for Best Actor and won the Golden Nymph for Television Films – Best Performance by an Actor. He later provided Hawking's voice in the first episode of the television series Curiosity. He also appeared in the BBC miniseries Dunkirk as Lieutenant Jimmy Langley.
In 2005, Cumberbatch portrayed protagonist Edmund Talbot in the miniseries To the Ends of the Earth, based on Sir William Golding's trilogy; during filming he said he experienced a terrifying carjacking in South Africa, managing to escape. He made brief appearances in the comedy sketch show Broken News and the Channel 4 sitcom Nathan Barley in 2005 and featured alongside Tom Hardy in the television adaptation of Stuart: A Life Backwards, which aired on the BBC in September 2007.
In 2008, Cumberbatch played the lead character in the BBC miniseries drama The Last Enemy, earning a Satellite Award nomination for Best Actor in a Miniseries or TV Film. In 2009, he appeared in Agatha Christie's Miss Marple: Murder Is Easy as Luke Fitzwilliam. He played Bernard in the TV adaptation of Small Island, earning him a nomination for BAFTA Television Award for Best Supporting Actor. Cumberbatch featured in Michael Dobbs' play, The Turning Point, which aired as one of a series of TV plays broadcast live on Sky Arts. The play depicted an October 1938 meeting between Soviet spy Guy Burgess, then a young man working for the BBC, and Winston Churchill. Cumberbatch portrayed Burgess; Churchill was played by Matthew Marsh, who had played a supporting role in Hawking. He narrated the 6-part series South Pacific (US title: Wild Pacific), which aired from May to June 2009 on BBC 2.
In 2010, Cumberbatch portrayed Vincent van Gogh in Van Gogh: Painted with Words. The Daily Telegraph called his performance "[a] treat ... vividly bringing Van Gogh to impassioned, blue-eyed life." In the same year, Cumberbatch began playing Sherlock Holmes in the joint BBC/PBS television series Sherlock, to critical acclaim. The second series began on New Year's Day 2012 in the United Kingdom and was broadcast on PBS in the United States in May 2012. The third series aired on PBS over a period of three weeks in January to February 2014. Cumberbatch won an Emmy as Outstanding Lead Actor in a Miniseries or a Movie for the third episode of the third series of the show entitled His Last Vow. Cumberbatch has one of the most aggressive fanbases to date, part of the 'Big Three' fandoms on the social media site Tumblr, called SuperWhoLock. In April 2015, Cumberbatch was nominated for his sixth British Academy Television Award for Best Leading Actor for the third series of the Sherlock. In 2016, he was once again nominated for an Emmy as Outstanding Lead Actor in a Miniseries or a Movie, this time for Sherlock: The Abominable Bride.
In 2012, he led the BBC and HBO co-produced miniseries Parade's End with Rebecca Hall. An adaptation of the tetralogy of novels of the same name by Ford Madox Ford, it was filmed as five episodes, directed by Susanna White and adapted by Sir Tom Stoppard. His performance earned Cumberbatch his second Emmy Award nomination for Best Actor in Miniseries or TV Movie. In February 2014, Cumberbatch appeared with Sesame Street characters Murray and Count von Count for PBS. In 2016, Cumberbatch portrayed Richard III in Shakespeare's play of the same name, as part of the second series of films for The Hollow Crown, which aired in both Britain and the United States. Cumberbatch has also been a brand ambassador for Dunlop and Jaguar luxury cars since 2014.
Cumberbatch starred in Patrick Melrose, a miniseries adaptation of the Edward St Aubyn novels, which began airing on Showtime on 12 May 2018. In 2019 Cumberbatch appeared as British political strategist Dominic Cummings (who served as the campaign director of Vote Leave, the official campaign in favour of the UK leaving the European Union) in HBO and Channel 4's television film Brexit: The Uncivil War.
Film
In 2006, Cumberbatch played late 18th/early 19th century British parliamentarian William Pitt the Younger in Amazing Grace, a role that garnered him a nomination for the London Film Critics Circle "British Breakthrough Acting Award". In Atonement (2007), Cumberbatch played what The Guardian called one of his "small parts in big films", and came to the attention of Sue Vertue and Stephen Moffat, who would later cast him in Sherlock. In 2008 he had a supporting role in The Other Boleyn Girl, and the next year he appeared in the Charles Darwin biographical film Creation as Darwin's friend Joseph Hooker. In 2010, he appeared in The Whistleblower as well as Four Lions. He portrayed Peter Guillam, George Smiley's right-hand man, in the 2011 adaptation of the John le Carré novel Tinker Tailor Soldier Spy. The film was directed by Tomas Alfredson and featured Gary Oldman and Colin Firth. Cumberbatch played Major Jamie Stewart in Steven Spielberg's War Horse in 2011.
In 2012, Cumberbatch provided the voice and motion-capture for both Smaug the Dragon and the Necromancer in An Unexpected Journey, the first instalment of The Hobbit series based on the novel of the same name by J. R. R. Tolkien. He reprised his roles as Smaug and the Necromancer for The Desolation of Smaug (2013) and The Battle of the Five Armies (2014). For the motion-capture aspect of the films, he used a suit and facial markers to highlight the dragon's expressions and movements.
In 2013, Cumberbatch appeared in J. J. Abrams' sequel, Star Trek Into Darkness, as Khan, the film's antagonist. Three of the four films he featured in during the second half of 2013 premiered at the Toronto International Film Festival: The Fifth Estate, in which he played WikiLeaks founder Julian Assange, 12 Years a Slave, in which he played William Prince Ford, a slave owner, and August: Osage County, in which he played Charles Aiken. For the official soundtrack of the latter film, he recorded a song titled "Can't Keep it Inside".
Cumberbatch had a voice role in DreamWorks Animation's feature film Penguins of Madagascar, which was released in November 2014. He then starred in the historical drama The Imitation Game as British cryptographer Alan Turing, also released in November 2014. The role earned him nominations for the Golden Globe, BAFTA, SAG, and Academy Award for Best Actor. In May 2014, he joined the cast of the film Black Mass opposite Johnny Depp which was distributed by Warner Bros. Pictures.
Cumberbatch starred as Doctor Strange in both the eponymous film released in November 2016, in Avengers: Infinity War in April 2018, and in Avengers: Endgame in April 2019. His depiction of Strange also appeared in Spider-Man: No Way Home (2021) and in Doctor Strange in the Multiverse of Madness (2022). He starred as electricity titan Thomas Edison in the film The Current War in September 2017. In 2018, Cumberbatch voiced the title character in the film The Grinch, and provided the voice and did performance capture for the tiger Shere Khan in Mowgli: Legend of the Jungle, Netflix's film adaptation of Rudyard Kipling's The Jungle Book, starring alongside Christian Bale and Cate Blanchett. In 2019, he appeared briefly as British Colonel Mackenzie in Sam Mendes' World War I film 1917.
In 2021, Cumberbatch starred in the drama The Power of the Dog, written and directed by Jane Campion. His performance in the film was acclaimed, and he received nominations for the Academy Award, British Academy Film Award, Screen Actors Guild Award, and Golden Globe Award for Best Actor. The same year Cumberbatch played Louis Wain, an eccentric English artist known for drawing anthropomorphized large-eyed cats, in The Electrical Life of Louis Wain.
Cumberbatch will star as the titular character in Wes Anderson's The Wonderful Story of Henry Sugar (2023), a film adaptation of a short story by Roald Dahl. He will appear opposite Ralph Fiennes, Dev Patel and Ben Kingsley.
Radio
Cumberbatch has repeatedly expressed his affection for radio and has done numerous productions for the BBC. Among his best-known radio work is the adaptation of John Mortimer's novel Rumpole and the Penge Bungalow Murders in 2009. He played Young Rumpole, and went on to play the part in nine more adaptations of Mortimer's works. Between 2008 and 2014, he played Captain Martin Crieff in the BBC Radio 4's sitcom Cabin Pressure, alongside Stephanie Cole, John Finnemore, and Roger Allam. He then went on to play the Angel Islington in the 2013 BBC Radio 4 adaptation of Neil Gaiman's Neverwhere. In the same year, he led the BBC Radio 3 adaptation of Michael Frayn's play Copenhagen wherein he played theoretical physicist Werner Heisenberg.
For the 70th anniversary of the Normandy landings, on 6 June 2014 Cumberbatch read the original BBC radio bulletins from June 1944 for BBC Radio 4.
Narration
Cumberbatch has narrated numerous documentaries for the National Geographic and Discovery channels. He has also read for several audiobooks, including Casanova, The Tempest, The Making of Music, Death in a White Tie, Artists in Crime, Tom and Viv, and Sherlock Holmes: The Rediscovered Railway Mysteries and Other Stories. He has done voice-overs for several commercials, including for major names Jaguar, Sony, Pimms, and Google+, performing the Seven Ages of Man monologue. For the 2012 London Olympics, he featured in a short film on the history of London, which began the BBC coverage of the opening ceremony. He made appearances for two Cheltenham Festivals, in July 2012 for Music when he read World War I poetry and prose accompanied by piano pieces and in October 2012 for Literature when he discussed Sherlock and Parade's End at The Centaur. In 2012, he lent his voice to a four-part, spoken-word track titled "Flat of Angles" for Late Night Tales based on a story written by author and poet Simon Cleary, the final instalment of which was released on 9 May 2014.
In 2012, he provided the voice of Dante Alighieri in the documentary Girlfriend in a Coma. In 2013, Cumberbatch narrated the documentary film Jerusalem about the ancient city. It was distributed by National Geographic Cinema Ventures in IMAX 3D theatres worldwide. The same year, he appeared as a special guest in a recording of Gordon Getty's opera Usher House, where he voiced the role of "the visitor", recorded and released by PENTATONE.
He narrated the documentary Cristiano Ronaldo: The World at His Feet about the Portuguese footballer for Vimeo and Vision Films in 2014. In August 2014, he recorded the first ever unabridged audiobook of William Golding's 1964 novel, The Spire, for Canongate Books.
Music
On 28 September 2016, Cumberbatch appeared on stage with Pink Floyd member David Gilmour during one of the musician's shows in London held at the Royal Albert Hall. He sang lead vocals on the song "Comfortably Numb", singing the verse sections originally sung by Roger Waters.
Impressionist
Adept at impersonating others, Cumberbatch was referred to as the "New King of Celebrity Impressionists" by Vulture magazine. He has imitated celebrities on a number of chat shows, such as The Graham Norton Show on the BBC, The Tonight Show Starring Jimmy Fallon on NBC, and in general interviews on channels such as MTV. His impersonations include Alan Rickman, Sean Connery, Jack Nicholson, Tom Hiddleston, Michael Caine, Christopher Walken, Tom Holland, Bane, John Malkovich, Matthew McConaughey, Taylor Swift and Chewbacca.
Production company
Cumberbatch, Adam Ackland, writer-director Patrick Monroe, action coordinator Ben Dillon, and production manager Adam Selves launched a production company, SunnyMarch Ltd., in late 2013.
Their first project under the company's banner was the £87,000 crowd-funded short film Little Favour, written and directed by Monroe with Cumberbatch in the lead role. The 30-minute action-thriller became internationally available on iTunes on 5 November 2013. In 2022 filming began on The End We Start From, an adaptation of the Megan Hunter novel of the same name, the rights to which the company had acquired in 2017.
Other activities
Charity
Cumberbatch is an ambassador for The Prince's Trust. He is a supporter and patron of organisations focused on using the arts to help disadvantaged young people including Odd Arts, Anno's Africa and Dramatic Need. Since portraying Stephen Hawking in 2004, he has been an ambassador, and in 2015 patron, for the Motor Neurone Disease Association and in 2014 did the Ice Bucket Challenge for the organisation. He also set up a recovery fund for the benefit of Amyotrophic Lateral Sclerosis Association. Cumberbatch has donated artworks for charities and fundraisers including the Willow Foundation, and Thomas Coram Foundation for Children.
Together with Prince Philip, Cumberbatch presented 85 young people with the Duke of Edinburgh's Award at St James's Palace on 19 March 2014. "Our ambition is to extend this opportunity to hundreds of thousands across the UK", Cumberbatch said on behalf of the youth awards programme.
In May 2014, he joined Prince William and Ralph Lauren at Windsor Castle for a cancer awareness and fundraising gala for the benefit of the Royal Marsden NHS Foundation Trust. Cumberbatch stated, "Cancer isn't a disease that needs much awareness, but it does need continued funding for research." In September 2014, he participated in a video campaign for Stand Up To Cancer. Cumberbatch posed for photographer Jason Bell for an exhibition at Pall Mall, London from 16 to 20 September 2014 to mark 10 years of the "Give Up Clothes For Good" charity campaign, which has raised £17 million for Cancer Research UK. In 2014, Cumberbatch publicly backed "Hacked Off" and its campaign for UK press self-regulation by "safeguarding the press from political interference while also giving vital protection to the vulnerable." In late 2014, Cumberbatch designed a Sherlock Holmes-themed Paddington Bear statue, one of fifty located around London prior to the release of the film Paddington, which was auctioned to raise funds for the National Society for the Prevention of Cruelty to Children (NSPCC).
Cumberbatch is a founding member of the "Save Soho" campaign which aims "to protect and nurture iconic music and performing arts venues in Soho." In an open letter published in The Guardian on 31 January 2015, Cumberbatch, amongst others, asked for pardons of all gay and bisexual men who were convicted under the same now-defunct "indecency" laws as Alan Turing was (whom Cumberbatch portrayed in The Imitation Game).
In September 2015, Cumberbatch condemned the UK government's response to the migrant crisis in a speech to theatregoers during a curtain call at a performance of Hamlet, for which he stars. He also fronted a video campaign to help the charity Save The Children in its mission to aid young Syrian refugees. He was one of the signatories of an open letter, published in The Guardian, criticising the government for its actions regarding the refugee problem. He also gave nightly speeches after his curtain call as Hamlet at the Barbican in London, asking for donations to help Syrian refugees. At the end of the run, the audience contributed more than £150,000 for Save the Children. He faced criticism for not taking in refugees himself, responding "I do have a house, but it's empty, it's gutted, there's no electricity or water, so that wouldn't work, and I have a baby in my flat, there are no spare rooms". In 2017 he told The Big Issue "I understand why some might think I should be housing people instead of complaining about a government not doing it. But I was trying to raise awareness that we can do more as a society [...] But we raised money for children in need. So I don't regret doing it for a second, and I will do it again, even if it does put me in the firing line".
In May 2020, Cumberbatch was among the ten celebrities who read an instalment of Roald Dahl's children's fantasy novel James and the Giant Peach. The audio-visual readings were published by Oscar-winning director Taika Waititi in aid of the global-non profit charity Partners In Health, co-founded by Dahl's daughter Ophelia, which had been fighting COVID-19 in vulnerable areas.
Politics
In 2003, Cumberbatch joined the Stop the War Coalition protest in London against the Iraq War. He addressed activists in a 2010 protest sponsored by the Trade Union Congress in Westminster on the suggested risks to the arts due to spending cuts expected in the Spending Review. In 2013, he protested against what he perceived were civil liberties violations by the UK government.
Cumberbatch is a supporter of LGBT+ rights and in July 2013 officiated at the same-sex marriage of friends. Through this ordination he officiated the wedding of Robert Rinder, best known as Judge Rinder and his partner Seth Cummings. For International Women's Day 2014, he was a signatory of Amnesty International's letter to the Prime Minister David Cameron for women's rights in Afghanistan. Cumberbatch identifies as a feminist.
In 2016, Cumberbatch was one of over 280 figures from the arts world who backed a vote for the United Kingdom to stay in the European Union with regard to the June 2016 referendum on that issue.
Awards and honours
Main article: List of awards and nominations received by Benedict Cumberbatch
Cumberbatch was appointed a CBE in the 2015 Birthday Honours for services to the performing arts and to charity. He received the honour from the Queen at an investiture ceremony at Buckingham Palace on 10 November 2015.
In February 2016, Cumberbatch was appointed visiting fellow at Lady Margaret Hall, Oxford University.
Public image and other recognition
Cumberbatch achieved international recognition with the first series of Sherlock in 2010. He has since been called "The Thinking Woman's Crumpet" and has been listed among most attractive celebrities by Empire and People.
Tatler listed Cumberbatch in the "Most Eligible Bachelors in the United Kingdom" in 2012. In the same year, Cumberbatch described a cyberstalking incident in which he discovered that someone had been live-tweeting his movements in his London home. Coming to terms with it, he said, it is "an ongoing process. To think that somebody knew everything I'd done in a day and told the rest of the world in real time!" His photograph taken at the Garrick Club by Derry Moore, 12th Earl of Drogheda was the cover of Moore's 2012 book An English Room.
In 2013, Cumberbatch was ranked fifth in the Tatler's "Most Fascinating People in Britain" list, higher than the Duchess of Cambridge and just below Queen Elizabeth II. Entertainment Weekly identified Cumberbatch as one of the "50 Coolest and Most Creative Entertainers" in Hollywood. He has also appeared on the covers of GQ, Time and The Hollywood Reporter's "New A-list" issue.
In 2014, Cumberbatch was included in The Sunday Times "100 Makers of the 21st Century", cited as this generation's Laurence Olivier." Film critic Roger Friedman stated that "Cumberbatch may be the closest thing to a real descendant of Sir Laurence Olivier." GQ identified him as one of the "100 Most Connected Men" in the UK in 2014. In the same year, Country Life magazine labelled him as one of its "Gentlemen of the Year".
In April 2014, Cumberbatch was regarded as a British cultural icon, with young adults from abroad naming him among a group of people whom they most associated with UK culture, which included William Shakespeare, Queen Elizabeth II, David Beckham, J. K. Rowling, The Beatles, Charlie Chaplin, Elton John and Adele. The same month, Time magazine included him in its annual Time 100 as one of the Most Influential People in the World. Cumberbatch was the inspiration and focus of the play Benedict Cumberbatch Must Die which, despite its title, was a "love letter" and portrait of the fan obsession surrounding the actor. It premiered in June 2014 at BATS Theatre in New Zealand. The Tennessee Aquarium named one of its otters "Benny" in reference to Cumberbatch's first name after a naming contest on the zoo's website.
A wax figure of Cumberbatch has been on display at Madame Tussauds London since October 2014. In 2015, he was named one of GQ's 50 best dressed British men. In 2018, PETA declared Cumberbatch and director Ava DuVernay to be the Most Beautiful Vegan Celebs of 2018.
Personal life
While in KwaZulu-Natal, South Africa, in 2005, Cumberbatch and two friends (Theo and Denise Black) were abducted, after bursting a tyre, and held at gunpoint by a group of locals. Eventually their abductors drove them into unsettled territory and set them free without explanation. Cumberbatch said of the incident: "It taught me that you come into this world as you leave it, on your own. It's made me want to live a life less ordinary." Before the burst tyre, they had been listening to "How to Disappear Completely" by Radiohead. Following this experience, whenever Cumberbatch hears the song it "reminds [him] of a sense of reality ... [and] a reason for hope".
He subscribes to Buddhist philosophy and has expressed affinity for meditation and mindfulness.
Cumberbatch was in a twelve-year-long relationship with actress Olivia Poulet, from his time at Manchester University until 2010.
Cumberbatch is married to English theatre and opera director Sophie Hunter. Their engagement was announced in the "Forthcoming Marriages" section of The Times on 5 November 2014, after a seventeen-year friendship. On 14 February 2015, the couple married at the 12th-century Church of St. Peter and St. Paul in Mottistone on the Isle of Wight followed by a reception at Mottistone Manor. They have three sons.
See also
|
|||||
3536
|
dbpedia
|
2
| 37
|
https://www.moviemaker.com/one-way-or-another-why-i-released-my-film-for-free-on-youtube/
|
en
|
One Way or Another: Why I Released My Film for Free on YouTube
|
[
"https://www.moviemaker.com/cdn-cgi/image/quality=80,format=auto,onerror=redirect,metadata=none/wp-content/uploads/2023/01/mm_site_logo-2.svg",
"https://www.moviemaker.com/cdn-cgi/image/width=300,height=194,fit=crop,quality=80,format=auto,onerror=redirect,metadata=none/wp-content/uploads/image4.jpeg",
"https://www.moviemaker.com/wp-content/uploads/image5.jpeg"
] |
[
"https://www.youtube.com/embed/6wI4VrLNy98"
] |
[] |
[
""
] | null |
[
"Naama Kates"
] |
2015-08-17T09:31:25-07:00
|
Releasing our film by just posting it to YouTube, which does not promote any sales or require any legal documentation, is an extremely innocuous way to release a film.
|
en
|
MovieMaker
|
https://www.moviemaker.com/one-way-or-another-why-i-released-my-film-for-free-on-youtube/
|
Within the independent film world, prestige is the name of the game.
It’s all about where you premiere, who represents you, what kind of release you have. (Theatrical, limited, wide? Oh my!) There is an almost superstitious belief that the entire course of your film’s life is determined by what is really just the beginning… and if you blow it, you’re damaged goods.
Yet it’s not that simple anymore. On-demand streaming platforms provide an endless array of options to get your film out to the world, and one doesn’t necessarily preclude the others. Many indies find their home, and possibly even their distributor, long after their premiere. In fact my very first feature, Nothing Sacred, just landed one this year—and it was shot when I was a (very green) 19-year-old, in 2006, nearly a decade ago!
The 10 Commandments of Chloe is an understated, smart little film about overcoming yourself, directed by Princeton Holt and starring myself as Chloe. The film was also co-written and co-produced by Princeton and me, and the story of its creation and its journey into the world of indie film is some parts dream-come-true, some parts cautionary-tale—and, just like Chloe’s story in the film itself, its last scene should really be interpreted as a happy ending.
Chloe was made on a wing and a prayer, planned over phone conversations between Princeton and me from across the country, and cast and shot in less than a week in Nashville, Tennessee. The talent we found there and the dozens of happy accidents were nothing short of miraculous; for a no-budget film with hardly any pre-production or a concrete script, it ended up winning nine awards and having a serendipitous premiere at Calgary International Film Festival, where it was a Discovery Award Nominee. The late 2013 premiere was followed by a nice U.S. festival run, where it scooped up some more awards and notability.
During that festival run, we got some interest from a well-known, reputable distribution/production company that offered to step in and back the release of a new, slightly altered cut of the film. They would provide the music licensing rights, and give it a post/FX cleanup job done by an Academy Award-nominated in-house team.
I asked our film’s new (and very prominent) attorney: Did it matter that the film had already shown in places around the U.S. and, in fact around the world? Or that we had, at one point, briefly put it out online? The lawyer waved away the question like it was fruit fly: “That’s not a problem. I think you should just play [the existing version] down as much as possible; we’re not talking about millions of sales here.” He then regaled us with tales of other well-known indie film reincarnations that had made minor changes to deftly avoid the “premiere” rule.
No, we weren’t talking millions of anything. Maybe a hundred views during a two-week period in mid-2013. We’d gotten a handful of rejections and were just burnt out—before the premiere, after dozens of festival submissions, but before any bites—so we’d decided to put the film up on our production company’s website. We didn’t promote much, because neither of us were sure it was the right move, and shortly thereafter we got our first jury prize (Best Actress at IndieFest) and took it down.
Apparently, it was OK with our distributor. So we stopped the presses: held off any further showings, write-ups or release plans for the original cut. Instead, we worked with the company to re-edit the film and sort out the music placements for the new release. Then we waited for the rest of the magic to happen…
… Now, nearly a year later, we’re still waiting for that magic to happen. Though we understand the nature of being a small fish in a big pond (I’ve experienced this as an actress in talent agencies, and certainly in my music career), and still hold out some hope for the delivery of the new cut, we want what we’ve always wanted—for our “stunning” film to just be out there.The situation with the distributor is tough: We’re still in touch, but I only receive updates every month or two. What started with a flood has slowed to a trickle. When we first began talking they were very enthusiastic, communicating weekly and sometimes daily; they held impressive screenings to discuss suggestions for the new cut and title, and almost immediately took care of the music licenses. We spoke at length about the right festival for the premiere. It was all very exciting.
Then, as last summer turned to fall, responses became increasingly sparse. It seemed that there was always a queue of “bigger” projects on their plates. First it was because of Sundance, after which, we were told, they’d have “plenty of time,” but Sundance consumed an entire season, and was immediately followed by Tribeca, and so on. To be fair, they merged with another company and relocated during that time, and for a big distributor, a relatively small investment can easily go out of sight, out of mind. But it’s heartbreaking, the letdown. Being “low-priority.”
This past spring, during the revisions, negotiations, and seemingly endless waiting process of re-releasing Chloe, I was at artist residency in Finland when I felt the urge to tell another story. I had a budget available from artist grants and so made the psychological thriller/romance Sorceress, my second feature behind the scenes and my first at the helm.
With the rough cut already 80 percent completed, I started a crowdfunding campaign for Sorceress—which was when Princeton suggested releasing Chloe for free online, and using it in the campaign. “Why not use your last film to help finance your new one,” he asked, “instead of just letting it sit on our hard drives?” Which led to the idea of putting it on YouTube.
We’re in an era where being “signed to a major” hasn’t meant much in a long time. The advent of BitTorrent and VOD streaming services have not just changed the players, or the rules, they’ve changed the game entirely. The beauty of “releasing” or “publishing” for free is that it is something of a loophole—despite certain perceptions associated with it, there are no sticky legal issues to deal with, such as intellectual property laws or licensing fees, and it does not preclude an eventual home with a traditional distributor.
Of course, the traditional theatrical distribution route is certainly a best-case scenario, if you can make it work for you. With Sorceress, for example, which has a wider scope and an international market, I think that the festival circuit, the sales rep, and all that goes with it, will be appropriate. But with Chloe in limbo, our digital release feels right, especially with the purpose of moving the next project forward. It feels like we’re taking back a little control of our own destiny, independently.
We have not broken off ties with our distributor; nor have we broken a contract—the version they have, the virginal (hitherto-unseen, not even by Princeton or myself) Chloe, is, indeed, a different film. The ending is different, after a minor edit that implies a dramatically different resolution. The structure is completely different; the original film is composed of 10 chapters, or “commandments,” which indirectly pertain to the subsequent scenes. We ditched ’em in the new cut, in favor of a different motif. The rest of the revisions are basically cosmetic, but there are quite a few. Long story short, it’s not the same film. We haven’t broken any rules. Because just as recently as a month ago I received a communication about one of the music licenses going through, part of me believes that our distributor will eventually finish whatever remains to be finished, and get it onto HBO, or something… but more of me believes it will just grow old on a shelf in their post-facilities warehouse.
Releasing our film by just posting it to YouTube, which does not promote any sales or require any legal documentation, is an extremely innocuous way to release a film. Streaming for free on a private website is equally devoid of legal hassles and intellectual property issues, and may be preferable to some people. It depends on your priorities.This part, for us, isn’t about prestige. Our film got its stamp of approval and credibility in the festival circuit, through its many awards and great reviews. Without a top-notch distributor behind us (and now, not next year or the following), there isn’t really an attainable level of prestige so lofty that it will drastically affect our audience… Hopefully that will happen ultimately, so that it can reach millions of people, but until then it will most likely be good old-fashioned word-of-mouth. And it just needs a place, any place, where someone can tell their friend to check it out.Included among the myriad self-distribution options that do not require a registered copyright:
streaming on the official movie website, under the appropriate domain name, which probably has the most prestigious and professional appearance
VHX and Vimeo on Demand, which allow price-setting and do have some quality-control and criteria for inclusion
finally, YouTube, the opposite extreme, where clips of people tripping reign supreme, and which can be kind of low-brow
And ironically, of all the above options, YouTube is the most accessible. Yes, YouTube, with its island of servers, with its app pre-installed on every mobile device and SmartTV, with its trillions of talking-cat videos, is some very efficient code. It rarely stutters or stops; it supports HD; it doesn’t require a ton of add-ons. If you’re not depending on your platform to typify or promote your film (and hopefully you’re not!), then choose one you can depend on to stream your video properly and consistently.
So, to go along with the campaign for Sorceress, we’ve decided to release The 10 Commandments of Chloe, the original version (which garnered all those prizes!), back out into the world (on YouTube below, or on Vimeo here). Consider your own situation carefully when you’ve finished all the work of pre-production, filming, post, and possibly even a festival run. Weigh your options and the costs and benefits of each. If the traditional route is open to you, and you have momentum, then run with it. But more important, usually, is exposure. So remember to follow your intuition, that your body of work is important, and of no use to anyone if it’s tucked away in a drawer. Three cheers for self-starters and art that cannot be stopped. MM
|
|||||
3536
|
dbpedia
|
2
| 21
|
https://www.bbc.com/culture/article/20160819-the-21st-centurys-100-greatest-films
|
en
|
The 21st Century’s 100 greatest films
|
[
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160xn/p0454cv4.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240xn/p0454cv4.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320xn/p0454cv4.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480xn/p0454cv4.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640xn/p0454cv4.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800xn/p0454cv4.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024xn/p0454cv4.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376xn/p0454cv4.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920xn/p0454cv4.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jj1w6n.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jj1w6n.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jj1w6n.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jj1w6n.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jj1w6n.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jj1w6n.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jj1w6n.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jj1w6n.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jj1w6n.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jh7q4n.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jh7q4n.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jh7q4n.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jh7q4n.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jh7q4n.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jh7q4n.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jh7q4n.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jh7q4n.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jh7q4n.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jhkgr5.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jhkgr5.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jhkgr5.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jhkgr5.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jhkgr5.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jhkgr5.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jhkgr5.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jhkgr5.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jhkgr5.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jhdj56.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jhdj56.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jhdj56.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jhdj56.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jhdj56.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jhdj56.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jhdj56.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jhdj56.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jhdj56.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jhbwpw.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jhbwpw.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jhbwpw.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jhbwpw.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jhbwpw.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jhbwpw.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jhbwpw.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jhbwpw.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jhbwpw.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jh3rxr.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jh3rxr.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jh3rxr.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jh3rxr.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jh3rxr.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jh3rxr.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jh3rxr.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jh3rxr.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jh3rxr.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jgv54f.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jgv54f.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jgv54f.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jgv54f.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jgv54f.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jgv54f.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jgv54f.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jgv54f.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jgv54f.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0ck00fw.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0ck00fw.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0ck00fw.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0ck00fw.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0ck00fw.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0ck00fw.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0ck00fw.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0ck00fw.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0ck00fw.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jgjkrd.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jgjkrd.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jgjkrd.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jgjkrd.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jgjkrd.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jgjkrd.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jgjkrd.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jgjkrd.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jgjkrd.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jffbnb.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jffbnb.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jffbnb.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jffbnb.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jffbnb.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jffbnb.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jffbnb.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jffbnb.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jffbnb.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jhy6cw.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jhy6cw.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jhy6cw.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jhy6cw.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jhy6cw.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jhy6cw.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jhy6cw.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jhy6cw.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jhy6cw.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jfrc8h.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jfrc8h.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jfrc8h.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jfrc8h.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jfrc8h.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jfrc8h.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jfrc8h.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jfrc8h.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jfrc8h.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jfpzp9.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jfpzp9.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jfpzp9.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jfpzp9.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jfpzp9.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jfpzp9.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jfpzp9.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jfpzp9.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jfpzp9.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jf8x8m.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jf8x8m.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jf8x8m.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jf8x8m.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jf8x8m.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jf8x8m.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jf8x8m.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jf8x8m.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jf8x8m.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jcjlmd.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jcjlmd.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jcjlmd.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jcjlmd.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jcjlmd.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jcjlmd.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jcjlmd.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jcjlmd.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jcjlmd.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jcg2rq.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jcg2rq.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jcg2rq.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jcg2rq.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jcg2rq.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jcg2rq.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jcg2rq.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jcg2rq.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jcg2rq.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jcbcgg.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jcbcgg.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jcbcgg.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jcbcgg.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jcbcgg.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jcbcgg.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jcbcgg.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jcbcgg.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jcbcgg.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jdl9hb.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jdl9hb.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jdl9hb.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jdl9hb.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jdl9hb.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jdl9hb.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jdl9hb.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jdl9hb.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jdl9hb.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jdrwf5.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jdrwf5.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jdrwf5.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jdrwf5.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jdrwf5.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jdrwf5.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jdrwf5.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jdrwf5.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jdrwf5.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p0jcb32s.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p0jcb32s.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p0jcb32s.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p0jcb32s.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p0jcb32s.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p0jcb32s.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p0jcb32s.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p0jcb32s.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p0jcb32s.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p091hm6t.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p091hm6t.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p091hm6t.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p091hm6t.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p091hm6t.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p091hm6t.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p091hm6t.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p091hm6t.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p091hm6t.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p08qjvsh.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p08qjvsh.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p08qjvsh.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p08qjvsh.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p08qjvsh.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p08qjvsh.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p08qjvsh.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p08qjvsh.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p08qjvsh.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p08myfhw.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p08myfhw.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p08myfhw.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p08myfhw.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p08myfhw.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p08myfhw.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p08myfhw.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p08myfhw.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p08myfhw.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p08gsl10.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p08gsl10.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p08gsl10.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p08gsl10.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p08gsl10.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p08gsl10.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p08gsl10.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p08gsl10.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p08gsl10.jpg.webp 1920w",
"https://www.bbc.com/bbcx/grey-placeholder.png",
"https://ichef.bbci.co.uk/images/ic/160x90/p08g549m.jpg.webp 160w,https://ichef.bbci.co.uk/images/ic/240x135/p08g549m.jpg.webp 240w,https://ichef.bbci.co.uk/images/ic/320x180/p08g549m.jpg.webp 320w,https://ichef.bbci.co.uk/images/ic/480x270/p08g549m.jpg.webp 480w,https://ichef.bbci.co.uk/images/ic/640x360/p08g549m.jpg.webp 640w,https://ichef.bbci.co.uk/images/ic/800x450/p08g549m.jpg.webp 800w,https://ichef.bbci.co.uk/images/ic/1024x576/p08g549m.jpg.webp 1024w,https://ichef.bbci.co.uk/images/ic/1376x774/p08g549m.jpg.webp 1376w,https://ichef.bbci.co.uk/images/ic/1920x1080/p08g549m.jpg.webp 1920w"
] |
[] |
[] |
[
""
] | null |
[] |
2016-08-23T01:53:17+00:00
|
The best that cinema has had to offer since 2000 as picked by 177 film critics from around the world.
|
en
|
/bbcx/apple-touch-icon.png
|
https://www.bbc.com/culture/article/20160819-the-21st-centurys-100-greatest-films
|
The best that cinema has had to offer since 2000 as picked by 177 film critics from around the world.
“They don’t make ‘em like they used to.”
How often have we all heard that resigned expression? How often have we said it ourselves? ‘The death of cinema’ is debated in university film studies programs worldwide. Critics lament the loss of 'small movies' in favour of superhero spectacles. Box-office analysts look for signs of an industry on the brink. Studio executives fear that video-on-demand may destroy the idea of going to the cinema more than broadcast and cable TV ever did.
And what can we really call a new classic? What in recent vintage can hold its own on the big screen with the likes of The Searchers, The Godfather, The Rules of the Game, Seven Samurai or Citizen Kane? Some film journalists even think the movie star is a thing of the past.
Perhaps the fault lies not in our movie stars, but in ourselves. If you can’t find masterpieces amid the blockbuster flotsam, you simply aren’t looking hard enough. Film-making today, whether massively expensive or made with tiny budgets, shot on celluloid or video, is thriving artistically as much as it ever has. But today you’ll find greater diversity in the kinds of films being made, if not in the people who are making them. That’s why we, the editors of BBC Culture, decided to commission a poll of critics to determine the 100 greatest films of the 21st Century. Last year, we asked critics to name the greatest American films of all time, and we were surprised that only six films made since 2000 made the top 100. Is there a feeling that time sanctifies a classic? Perhaps. But this time, we wanted to prove that this century has given us films that will stand the test of time, that you will continue to think about and argue about if only you give them a chance and watch them.
For our poll to determine the 100 greatest American films, we surveyed 62 film critics from around the world. This time, we received responses from 177 – from every continent except Antarctica. Some are newspaper or magazine reviewers, others write primarily for websites; academics and cinema curators are well-represented too. For the purposes of this poll we have decided that a list of the greatest films of the 21st Century should include the year 2000, even though we recognise that there was no ‘Year Zero’ and that 2001 is mathematically the start of the century. Not only did we all celebrate the turn of the millennium on 31 December 1999, but the year 2000 was a landmark in global cinema, and, in particular, saw the emergence of new classics from Asia like nothing we had ever seen before.
We believe that the new classics on this list are destined to become old classics. Whether or not that happens is ultimately up to you, the moviegoers. But one thing is certain: cinema isn’t dying, it’s evolving.
100. Toni Erdmann (Maren Ade, 2016)
100. Requiem for a Dream (Darren Aronofsky, 2000)
100. Carlos (Olivier Assayas, 2010)
99. The Gleaners and I (Agnès Varda, 2000)
98. Ten (Abbas Kiarostami, 2002)
97. White Material (Claire Denis, 2009)
96. Finding Nemo (Andrew Stanton, 2003)
95. Moonrise Kingdom (Wes Anderson, 2012)
94. Let the Right One In (Tomas Alfredson, 2008)
93. Ratatouille (Brad Bird, 2007)
92. The Assassination of Jesse James by the Coward Robert Ford (Andrew Dominik, 2007)
91. The Secret in Their Eyes (Juan José Campanella, 2009)
90. The Pianist (Roman Polanski, 2002)
89. The Headless Woman (Lucrecia Martel, 2008)
88. Spotlight (Tom McCarthy, 2015)
87. Amélie (Jean-Pierre Jeunet, 2001)
86. Far From Heaven (Todd Haynes, 2002)
85. A Prophet (Jacques Audiard, 2009)
84. Her (Spike Jonze, 2013)
83. A.I. Artificial Intelligence (Steven Spielberg, 2001)
82. A Serious Man (Joel and Ethan Coen, 2009)
81. Shame (Steve McQueen, 2011)
80. The Return (Andrey Zvyagintsev, 2003)
79. Almost Famous (Cameron Crowe, 2000)
78. The Wolf of Wall Street (Martin Scorsese, 2013)
77. The Diving Bell and the Butterfly (Julian Schnabel, 2007)
76. Dogville (Lars von Trier, 2003)
75. Inherent Vice (Paul Thomas Anderson, 2014)
74. Spring Breakers (Harmony Korine, 2012)
73. Before Sunset (Richard Linklater, 2004)
72. Only Lovers Left Alive (Jim Jarmusch, 2013)
71. Tabu (Miguel Gomes, 2012)
70. Stories We Tell (Sarah Polley, 2012)
69. Carol (Todd Haynes, 2015)
68. The Royal Tenenbaums (Wes Anderson, 2001)
67. The Hurt Locker (Kathryn Bigelow, 2008)
66. Spring, Summer, Fall, Winter…and Spring (Kim Ki-duk, 2003)
65. Fish Tank (Andrea Arnold, 2009)
64. The Great Beauty (Paolo Sorrentino, 2013)
63. The Turin Horse (Béla Tarr and Ágnes Hranitzky, 2011)
62. Inglourious Basterds (Quentin Tarantino, 2009)
61. Under the Skin (Jonathan Glazer, 2013)
60. Syndromes and a Century (Apichatpong Weerasethakul, 2006)
59. A History of Violence (David Cronenberg, 2005)
58. Moolaadé (Ousmane Sembène, 2004)
57. Zero Dark Thirty (Kathryn Bigelow, 2012)
56. Werckmeister Harmonies (Béla Tarr, director; Ágnes Hranitzky, co-director, 2000)
55. Ida (Paweł Pawlikowski, 2013)
54. Once Upon a Time in Anatolia (Nuri Bilge Ceylan, 2011)
53. Moulin Rouge! (Baz Luhrmann, 2001)
52. Tropical Malady (Apichatpong Weerasethakul, 2004)
51. Inception (Christopher Nolan, 2010)
50. The Assassin (Hou Hsiao-hsien, 2015)
49. Goodbye to Language (Jean-Luc Godard, 2014)
48. Brooklyn (John Crowley, 2015)
47. Leviathan (Andrey Zvyagintsev, 2014)
46. Certified Copy (Abbas Kiarostami, 2010)
45. Blue Is the Warmest Color (Abdellatif Kechiche, 2013)
44. 12 Years a Slave (Steve McQueen, 2013)
43. Melancholia (Lars von Trier, 2011)
42. Amour (Michael Haneke, 2012)
41. Inside Out (Pete Docter, 2015)
40. Brokeback Mountain (Ang Lee, 2005)
39. The New World (Terrence Malick, 2005)
38. City of God (Fernando Meirelles and Kátia Lund, 2002)
37. Uncle Boonmee Who Can Recall His Past Lives (Apichatpong Weerasethakul, 2010)
36. Timbuktu (Abderrahmane Sissako, 2014)
35. Crouching Tiger, Hidden Dragon (Ang Lee, 2000)
34. Son of Saul (László Nemes, 2015)
33. The Dark Knight (Christopher Nolan, 2008)
32. The Lives of Others (Florian Henckel von Donnersmarck, 2006)
31. Margaret (Kenneth Lonergan, 2011)
30. Oldboy (Park Chan-wook, 2003)
29. WALL-E (Andrew Stanton, 2008)
28. Talk to Her (Pedro Almodóvar, 2002)
27. The Social Network (David Fincher, 2010)
26. 25th Hour (Spike Lee, 2002)
25. Memento (Christopher Nolan, 2000)
24. The Master (Paul Thomas Anderson, 2012)
23. Caché (Michael Haneke, 2005)
22. Lost in Translation (Sofia Coppola, 2003)
21. The Grand Budapest Hotel (Wes Anderson, 2014)
20. Synecdoche, New York (Charlie Kaufman, 2008)
19. Mad Max: Fury Road (George Miller, 2015)
18. The White Ribbon (Michael Haneke, 2009)
17. Pan's Labyrinth (Guillermo Del Toro, 2006)
16. Holy Motors (Leos Carax, 2012)
15. 4 Months, 3 Weeks and 2 Days (Cristian Mungiu, 2007)
14. The Act of Killing (Joshua Oppenheimer, 2012)
13. Children of Men (Alfonso Cuarón, 2006)
12. Zodiac (David Fincher, 2007)
11. Inside Llewyn Davis (Joel and Ethan Coen, 2013)
10. No Country for Old Men (Joel and Ethan Coen, 2007)
9. A Separation (Asghar Farhadi, 2011)
8. Yi Yi: A One and a Two (Edward Yang, 2000)
7. The Tree of Life (Terrence Malick, 2011)
6. Eternal Sunshine of the Spotless Mind (Michel Gondry, 2004)
5. Boyhood (Richard Linklater, 2014)
4. Spirited Away (Hayao Miyazaki, 2001)
3. There Will Be Blood (Paul Thomas Anderson, 2007)
2. In the Mood for Love (Wong Kar-wai, 2000)
1. Mulholland Drive (David Lynch, 2001)
More on BBC Culture’s 100 greatest films of the 21st Century:
Surprising facts from the 100 greatest films of the 21st Century list
The full list of critics who participated – and how they voted
What the critics had to say about the top 25
Why Mulholland Drive is number one
Are we living in a golden age of film?
How many of these films have you seen? Let us know with the hashtag #FilmsOfTheCentury on Facebook orTwitter.
And if you liked this story, sign up for the weekly bbc.com features newsletter, called “If You Only Read 6 Things This Week”. A handpicked selection of stories from BBC Future, Earth, Culture, Capital, Travel and Autos, delivered to your inbox every Friday.
|
|||||
3536
|
dbpedia
|
1
| 23
|
https://landofbooks.org/2015/02/10/book-to-movie-adaptation-the-theory-of-everything/
|
en
|
BOOK TO MOVIE ADAPTATION: THE THEORY OF EVERYTHING
|
[
"https://landofbooks.org/wp-content/uploads/2015/02/music-e1423506940315.jpg?w=604",
"https://landofbooks.org/wp-content/uploads/2015/02/traveling_cover.jpg?w=604",
"https://landofbooks.org/wp-content/uploads/2015/02/eddie.jpg?w=604&h=366",
"https://landofbooks.org/wp-content/uploads/2015/02/eddie_stpehen-e1423506920910.jpg?w=604&h=341",
"https://2.gravatar.com/avatar/e0d93dccb457569eccedbe2fb188ab0c2107acffd1a7f440d9bd768bbdb3ce15?s=60&d=identicon&r=G",
"https://s2.wp.com/i/logo/wpcom-gray-white.png",
"https://s2.wp.com/i/logo/wpcom-gray-white.png",
"https://pixel.wp.com/b.gif?v=noscript"
] |
[
"https://www.youtube.com/embed/Salz7uGp72c?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en&autohide=2&wmode=transparent"
] |
[] |
[
""
] | null |
[
"Ognian Georgiev"
] |
2015-02-10T00:00:00
|
If the main character of your book has more friends and fans than enemies, you must be aware of what you are writing. Jane Wilde Hawking experienced the hard way. She wrote a memoir about her life with well known cosmologist Stephen Hawking, called Music to Move the Stars: A Life with Stephen. The book…
|
en
|
https://s1.wp.com/i/favicon.ico
|
Land Of Books
|
https://landofbooks.org/2015/02/10/book-to-movie-adaptation-the-theory-of-everything/
|
If the main character of your book has more friends and fans than enemies, you must be aware of what you are writing. Jane Wilde Hawking experienced the hard way. She wrote a memoir about her life with well known cosmologist Stephen Hawking, called Music to Move the Stars: A Life with Stephen. The book was published in 1999. Soon the critics and fans of the scientist ripped apart the author. Poor Jane was described as selfish for pointing to the world how despotic the handicapped Stephen Hawking, who is suffering from Lou Gehrig’s disease, was.
During the publishing of Music to Move the Stars, Stephen and Jane had been already divorced and had remarried to another partners. Their relation wasn’t very good, but in time everything changed. Same as former Mrs Hawking’s reminiscences from her years spent together with the so called ”Puppeteer” from the first book. In fact the memoir was released four years after the scientist had remarried to his second wife Elaine.
In 2008 the new version found its place in the bookstores. It was named Traveling to Infinity: My life with Stephen. Did you notice the difference in the second title? “A life” versus “My life”. The brightening of the genius’s portrait was visible. It’s strange how Jane’s point of view was changed. Now the famous cosmologist became a hero. A man who fought his way against all odds. Take a look few sentences above when Hawking remarried. The updated book was published two years after he gave a divorce to his second wife Elaine. Tell me about the power of female jealousy.
Both books never became bestsellers despite the fact that Hawking is at the Top 10 of the most famous scientist in our planet. Traveling to Infinity is far more popular and received better reviews. Mainly because of the motion picture The Theory of Everything, who was billed as book adaptation. The publishers changed the second title to The True Story Behind The Theory of Everything. Smart move!
What is the truth of real Stephen Hawking, we will never know. An amazing personality and a very strong woman right next to him are shown as characters in the huge movie hit.
New Zealand’s novelist and scriptwriter Anthony McCarten was the driving force behind the creation of The Theory of Everything. He had been inspired by Stephen Hawking book A Brief History of Time (more than 5 million copies sold) and later read the remake of Jane’s memoire. The producer Lisa Bruce needed three years to convince Hawking’s first wife to approve the project. Academy award director for documentary Man on Wire James Marsh took the charge of the filming.
The casting was very successful. The producers hit the bull’s eye with Eddie Redmayne, who portrayed perfectly Stephen Hawking. Felicity Jones did great job taking the skin of Jane. The cosmologist and his former wife helped as much as they can for the reality of the movie. Stephen Hawking was so happy of the final result that he agreed his real life computer voice to be used in the movie.
The critics were writing mostly positive reviews. IMDB’s rating is very high – 7.8. Rotten Tomatoes’ score averaged 7.3, while Metacritic put 72 out of 100 points. My girlfriend cries sometimes on movies, but during The Theory of Everything I counted at least three times when her tears started to fall.
Eddie Redmayne already won Golden Globe for best leading male role. He is huge favorite of the bookies for Oscar. The Theory of Everything received additional four more nominations for Academy Awards.
The movie was released worldwide on November 26. With a budget of $15 millions currently the box office is booming with $91 million. Good job, guys!
Check out personally the difference between the first and second book here:
Music to Move the Stars: A Life with Stephen
Traveling to Infinity: My life with Stephen
|
||||
3536
|
dbpedia
|
2
| 56
|
https://www.coachella.com/
|
en
|
Coachella Valley Music and Arts Festival
|
[
"https://media-prd.coachella.com/content/coachella-2024/icon-close.svg",
"https://media-prd.coachella.com/content/coachella-2024/icon-search.svg",
"https://media-prd.coachella.com/content/coachella-2024/icon-close.svg",
"https://media.web.aegpresents.com/content/coachella-2023/logo-coachella.svg",
"https://media.web.aegpresents.com/content/coachella-2023/icon-chevron-left-sm.svg",
"https://media.web.aegpresents.com/content/coachella-2023/icon-close-nav.svg",
"https://media-prd.coachella.com/content/background_images/452/EZncdEdp4jXDCfXeijtTqI77RS3BFOhRuqg2bmqn.png",
"https://media-prd.coachella.com/content/background_images/452/gUW8z5YsgnkVjNqc4orfeQrA1bxkIqQgnZQJfVq7.png",
"https://media-prd.coachella.com/content/background_images/452/d6WX2eZHwXHgJTr6PIfhrBRdxhFCVFQAlGqveZvu.png",
"https://media-prd.coachella.com/content/background_images/452/EmEAaC5CVHb5UmgfVgsgSg0nMCpDHbaEjGC6s2r7.png",
"https://media-prd.coachella.com/content/coachella-2024/icon-close.svg",
"https://media.web.aegpresents.com/content/coachella-2023/logo-coachella.svg",
"https://media-prd.coachella.com/content/coachella-2024/nav-bg-blue.png",
"https://media-prd.coachella.com/content/coachella-2024/nav-bg-red.png",
"https://media-prd.coachella.com/content/coachella-2024/nav-bg-green.png",
"https://media-prd.coachella.com/content/coachella-2024/nav-bg-pink.png",
"https://media-prd.coachella.com/content/coachella-2024/nav-bg-purp.png",
"https://media.web.aegpresents.com/content/coachella-2023/icon-search.svg",
"https://media-prd.coachella.com/content/",
"https://media-prd.coachella.com/content/background_images/452/EZncdEdp4jXDCfXeijtTqI77RS3BFOhRuqg2bmqn.png",
"https://media-prd.coachella.com/content/background_images/452/gUW8z5YsgnkVjNqc4orfeQrA1bxkIqQgnZQJfVq7.png",
"https://media-prd.coachella.com/content/background_images/452/d6WX2eZHwXHgJTr6PIfhrBRdxhFCVFQAlGqveZvu.png",
"https://media-prd.coachella.com/content/background_images/452/EmEAaC5CVHb5UmgfVgsgSg0nMCpDHbaEjGC6s2r7.png",
"https://media-prd.coachella.com/content/",
"https://media-prd.coachella.com/content/coachella-2024/blob-hero-green-2.png",
"https://media-prd.coachella.com/content/coachella-2024/blob-hero-blue-2.png",
"https://media-prd.coachella.com/content/vertical_card_images/452/cmc89xcDrNwg0RA5wdnXjZOTiPvRTdhc8SS0SI6G.png",
"https://media-prd.coachella.com/content/news_card_images/452/vDkh9KmYlTnbaye96HpijG0OIBL5QE2rxoN9CQLY.png",
"https://media-prd.coachella.com/content/coachella-2024/blob-grid-1.png",
"https://media-prd.coachella.com/content/news_card_images/452/HLmMpLIK88cWn1JEfBe4BpLFHcA48S6V1XncMY3y.png",
"https://media-prd.coachella.com/content/coachella-2024/blob-grid-2.png",
"https://media-prd.coachella.com/content/news_card_images/452/4d0J2hW7XfsSFxEAhpvQQ76IUbi9xuXF4TYxz0pt.png",
"https://media-prd.coachella.com/content/coachella-2024/blob-grid-3.png",
"https://media-prd.coachella.com/content/news_card_images/452/Pd2HlIiKYKKCiEc3xYKTHcCKbn5Ka0OC46CDvknA.png",
"https://media-prd.coachella.com/content/coachella-2024/blob-grid-4.png",
"https://media-prd.coachella.com/content/news_card_images/452/ymiXIjxnccdKvD2Q6P3O5ETjPDdgpHl9m5sPCSA2.png",
"https://media-prd.coachella.com/content/coachella-2024/blob-grid-5.png",
"https://media-prd.coachella.com/content/news_card_images/452/SCkPiJRUpn9MGr40MkOjI7QAkTrj9SH313Cyq1fQ.png",
"https://media-prd.coachella.com/content/coachella-2024/blob-grid-6.png",
"https://media-prd.coachella.com/content/coachella-2024/icon-arrow-backtotop.svg",
"https://media-prd.coachella.com/templates/template10/svgs/coachella-logo.svg",
"https://media-prd.coachella.com/templates/template10/svgs/goldenvoice-logo.svg",
"https://media-prd.coachella.com/content/coachella-2024/footer-background-mobile.png"
] |
[] |
[] |
[
""
] | null |
[] | null |
APR 12-14 & 19-21, 2024
| null |
Our most popular overnight option. Build an oasis for you & your crew.
Choose Preferred Car Camping for a guaranteed spot in the lot closest to the venue entrance.
|
|||||||
3536
|
dbpedia
|
1
| 0
|
https://www.imdb.com/title/tt2980516/
|
en
|
Die Entdeckung der Unendlichkeit (2014)
|
[
"https://fls-na.amazon.com/1/batch/1/OP/A1EVAM02EL8SFB:138-9144508-1181900:7C5B6BS9G94SQ16BR2X7$uedata=s:%2Fuedata%2Fuedata%3Fstaticb%26id%3D7C5B6BS9G94SQ16BR2X7:0",
"https://m.media-amazon.com/images/M/MV5BMjBkOWQyMjMtNjJmOC00M2VjLTk5Y2UtMjJiYmQ5YmEwNzVhXkEyXkFqcGdeQXVyMTYzMDM0NTU@._V1_QL75_UX190_CR0,2,190,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BNTg1MzIyODg1OV5BMl5BanBnXkFtZTgwMjYwNTU4MjE@._V1_QL75_UX500_CR0,47,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BNTg1MzIyODg1OV5BMl5BanBnXkFtZTgwMjYwNTU4MjE@._V1_QL75_UX500_CR0,47,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjI3OTk5Mzg3MF5BMl5BanBnXkFtZTgwMzIxNjkzMjE@._V1_QL75_UX500_CR0,47,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BMDRjNTg2MzAtYjgwYS00MjM2LTgwMDMtODU4MWU4NDdmMjQxXkEyXkFqcGdeQTNwaW5nZXN0._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BNDhiMGQ0OGYtMTNiMC00N2Q1LTkxMDItNWQxYzliN2Q0YjI1XkEyXkFqcGdeQWFsZWxvZw@@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjMxOTQwMTExN15BMl5BanBnXkFtZTgwNjczNjI5MzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjIxNjQ2MDE4MV5BMl5BanBnXkFtZTgwMDM3OTYxMzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjE3ODQyNjQ4M15BMl5BanBnXkFtZTgwODk2OTYxMzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjAxOTU3MDEzNl5BMl5BanBnXkFtZTgwMjk2OTYxMzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BNTE1MDE1MTI1M15BMl5BanBnXkFtZTgwNDA3OTYxMzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BODI1MDU5MTcyN15BMl5BanBnXkFtZTgwNDYyMDYxMzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BOTI0NTc4MDcyNV5BMl5BanBnXkFtZTgwMzE0NjExMzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BNjkwNTEwMjk0NF5BMl5BanBnXkFtZTgwNjkyNjExMzE@._V1_QL75_UX500_CR0,0,500,281_.jpg",
"https://m.media-amazon.com/images/M/MV5BNDQzNTE4MDA0MV5BMl5BanBnXkFtZTgwMzQ1ODQ0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTk5MzU4NzkxNF5BMl5BanBnXkFtZTgwMTk4ODE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjI3MjAxMDM4OV5BMl5BanBnXkFtZTgwMDY3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTUyMDE0NjgwM15BMl5BanBnXkFtZTgwODU3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTQ5MjY4Mjk5OF5BMl5BanBnXkFtZTgwOTU3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjI3MDkwNTIxMl5BMl5BanBnXkFtZTgwMzU3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTUzODczNzMyM15BMl5BanBnXkFtZTgwNjU3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BNTE3ODA2NjY1NF5BMl5BanBnXkFtZTgwMDU3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTU1ODY1NDU2MV5BMl5BanBnXkFtZTgwMjU3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTcyODgzMTA3NF5BMl5BanBnXkFtZTgwNTQ3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjMyMDY0MzQ5NF5BMl5BanBnXkFtZTgwNjQ3MDE0MzE@._V1_QL75_UY140_CR36,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTgyMDM1MzMxNF5BMl5BanBnXkFtZTgwNzQ3MDE0MzE@._V1_QL75_UY140_CR40,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTU0MjEyNzQyM15BMl5BanBnXkFtZTcwMTc4ODUxOQ@@._V1_QL75_UX140_CR0,12,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjA0MTIwMzIyN15BMl5BanBnXkFtZTgwNDEyMzg1NDE@._V1_QL75_UX140_CR0,13,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BOTk0MjViYTUtNmI0OS00OTU1LTllMTktMzQyZGY0ZDdkZmJhXkEyXkFqcGdeQXVyMTkxNjUyNQ@@._V1_QL75_UY140_CR35,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjE2OTkyOTkzMl5BMl5BanBnXkFtZTcwODYxMTUwOA@@._V1_QL75_UX140_CR0,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTQ1Nzk2NjQxMV5BMl5BanBnXkFtZTcwNTgyMDIyOQ@@._V1_QL75_UX140_CR0,12,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BNTA3MjM4NTE0NV5BMl5BanBnXkFtZTcwOTU1OTY4NQ@@._V1_QL75_UX140_CR0,12,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BY2U5MzM0M2QtMDIzNi00OTM0LTg0M2EtM2NiNDcwOTA0OTI3XkEyXkFqcGdeQXVyMzM1NjkxNA@@._V1_QL75_UX140_CR0,3,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BOTU2NjIyZDQtYzNkOS00ODE4LWI0Y2UtMTU5YTE1YjQ5NDlkXkEyXkFqcGdeQXVyOTAxNjIwMjU@._V1_QL75_UY140_CR53,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjAwNzc5MjE0N15BMl5BanBnXkFtZTcwMzUyNTMzNw@@._V1_QL75_UX140_CR0,6,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjAyOTEzOTg2M15BMl5BanBnXkFtZTYwNTU3MTQ1._V1_QL75_UX140_CR0,9,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BMjQxOTEwNzA3NV5BMl5BanBnXkFtZTgwMTQ3Njg5NzM@._V1_QL75_UY140_CR35,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BYzE4OGY1NjctYzZkZS00NDZjLWFhMWMtZTY4M2QzZDI1MDRmXkEyXkFqcGdeQXVyNjUxMjc1OTM@._V1_QL75_UX140_CR0,0,140,140_.jpg",
"https://m.media-amazon.com/images/M/MV5BNzFlOTE2YjEtNWU4Zi00ZWUzLWIwZGUtMGRjZjdmN2UxZWM3XkEyXkFqcGdeQXVyMTYzMDM0NTU@._V1_QL75_UX140_CR0,1,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTA2NDc3Njg5NDVeQTJeQWpwZ15BbWU4MDc1NDcxNTUz._V1_QL75_UX140_CR0,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BNWYzNjU3YzItZDI1Ni00NzE3LWJkODAtNmJlYTAzOGQ3NTFlXkEyXkFqcGdeQXVyMTA4NjE0NjEy._V1_QL75_UY207_CR3,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BYTFkZDYwY2QtZDg3Ni00ZTRkLTg4ZTMtYjM4Y2ZlZTkzNTdkXkEyXkFqcGdeQXVyMTYzMDM0NTU@._V1_QL75_UX140_CR0,1,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BOGUyZDUxZjEtMmIzMC00MzlmLTg4MGItZWJmMzBhZjE0Mjc1XkEyXkFqcGdeQXVyMTMxODk2OTU@._V1_QL75_UX140_CR0,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BZDFiNDIzZjktNzhmYS00NTIwLTgxYzEtM2U1ZTQ1MmNkYzZiXkEyXkFqcGdeQXVyMTYzMDM0NTU@._V1_QL75_UY207_CR3,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BNTE3ZWRmOWUtMjE4MC00YjVmLWJjYWYtMjZjNmE2N2NlMGQwXkEyXkFqcGdeQXVyMTYzMDM0NTU@._V1_QL75_UY207_CR3,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BNTg2OTY2ODg5OF5BMl5BanBnXkFtZTcwODM5MTYxOA@@._V1_QL75_UX140_CR0,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BZjdiY2NjYzUtM2FkYS00YWQwLTg5ZmEtYTU1ODU1NTk3YzEyXkEyXkFqcGdeQXVyODc0OTEyNDU@._V1_QL75_UY207_CR3,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BMTYwMTA4MzgyNF5BMl5BanBnXkFtZTgwMjEyMjE0MDE@._V1_QL75_UX140_CR0,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BYTcyNGRmMzYtNjc1NC00MDRkLTlmMzAtOTY4Yjk4NTY5YzM1XkEyXkFqcGdeQXVyNDk3NzU2MTQ@._V1_QL75_UY207_CR3,0,140,207_.jpg",
"https://m.media-amazon.com/images/M/MV5BNDg3NmI3MzUtOWI0Mi00NDZmLWFjOWEtZGJmNzkzNWM2YzgxXkEyXkFqcGdeQXVyNjkwOTQ4MDE@._V1_QL75_UX140_CR0,0,140,207_.jpg",
"https://m.media-amazon.com/images/G/01/IMDb/Mobile/DesktopQRCode-png.png",
"https://fls-na.amazon.com/1/batch/1/OP/A1EVAM02EL8SFB:138-9144508-1181900:7C5B6BS9G94SQ16BR2X7$uedata=s:%2Fuedata%2Fuedata%3Fnoscript%26id%3D7C5B6BS9G94SQ16BR2X7:0"
] |
[] |
[] |
[
"Reviews",
"Showtimes",
"DVDs",
"Photos",
"User Ratings",
"Synopsis",
"Trailers",
"Credits"
] | null |
[] |
2014-12-25T00:00:00
|
Die Entdeckung der Unendlichkeit: Directed by James Marsh. With Eddie Redmayne, Felicity Jones, Tom Prior, Sophie Perry. Stephen Hawking gets unprecedented success in the field of physics despite being diagnosed with motor neuron disease at the age of 21. He defeats awful odds as his first wife Jane aids him loyally.
|
en
|
IMDb
|
https://www.imdb.com/title/tt2980516/
|
One might think that this movie would be about esoteric theories that are beyond the capacity for most people.
You would be so wrong!
This was probably the best love story I have ever seen. I was on the edge of my seat watching Jane Hawking (Felicity Jones) as she did more and more amazing acts of love for Stephan Hawking (Eddie Redmayne). I cannot imagine anyone that fits the definition of love more than she did.
Redmayne was brilliant as Hawking.
Anthony McCarten took Jane Hawing's book and wrote a screenplay that was a thrill to watch.
|
|||||
3536
|
dbpedia
|
2
| 40
|
https://ew.com/article/2013/08/19/remember-me-ending-still-not-over/
|
en
|
I'm Still Not Over ... The twist ending of 'Remember Me'
|
[
"https://ew.com/thmb/zCPjS_ja72PEWrL06uPMERtadnw=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/remember-me-ccf9188d5a9542b18d96ff967d950a61.jpg",
"https://ew.com/thmb/zCPjS_ja72PEWrL06uPMERtadnw=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/remember-me-ccf9188d5a9542b18d96ff967d950a61.jpg",
"https://ew.com/thmb/Po35JYm7qikXKbNYZcfW_RmEB3Y=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/mccain-073024-423af5d53a344bb194ece69e98e291eb.jpg",
"https://ew.com/thmb/Po35JYm7qikXKbNYZcfW_RmEB3Y=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/mccain-073024-423af5d53a344bb194ece69e98e291eb.jpg",
"https://ew.com/thmb/vVql8I_woqe4-qEdV2--QIuds4k=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/trap-movie-080124-1-698c51d11cdf4bfc9dd0da933da006a3.jpg",
"https://ew.com/thmb/vVql8I_woqe4-qEdV2--QIuds4k=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/trap-movie-080124-1-698c51d11cdf4bfc9dd0da933da006a3.jpg",
"https://ew.com/thmb/SW9PHC54iIeT0ThRo1RJaqlG8TQ=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Yellowstone-1883-and-1923-tout-080824-63978c78043a4c749c4928c2dc8dbd60.jpg",
"https://ew.com/thmb/SW9PHC54iIeT0ThRo1RJaqlG8TQ=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Yellowstone-1883-and-1923-tout-080824-63978c78043a4c749c4928c2dc8dbd60.jpg",
"https://ew.com/thmb/2EwS5qhmldQw_IE7nM1TB7IlgIU=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Twilight-Robert-Pattinson-Kristen-Stewart-spider-monkey-072624-1-9617f98a085842c18334e63b7887e3e2.jpg",
"https://ew.com/thmb/2EwS5qhmldQw_IE7nM1TB7IlgIU=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Twilight-Robert-Pattinson-Kristen-Stewart-spider-monkey-072624-1-9617f98a085842c18334e63b7887e3e2.jpg",
"https://ew.com/thmb/Fs6AAF8x20C79Zfs_jUjLvsOmyU=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Adam-Sandler-Movies-032823-648bb67c357147289bdcb2f7bc417bf3.jpg",
"https://ew.com/thmb/Fs6AAF8x20C79Zfs_jUjLvsOmyU=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Adam-Sandler-Movies-032823-648bb67c357147289bdcb2f7bc417bf3.jpg",
"https://ew.com/thmb/d4uvxH73GgSwHXIlHmXxB08SiP8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Must-List-AUG6-460f75ac30664e78b83f3614bb5257b4.jpg",
"https://ew.com/thmb/d4uvxH73GgSwHXIlHmXxB08SiP8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Must-List-AUG6-460f75ac30664e78b83f3614bb5257b4.jpg",
"https://ew.com/thmb/VXOsrP5pQzWQgULv9B2YqafSONI=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Must-List-July31-4db846ce737245f69aee7bce25660ad7.jpg",
"https://ew.com/thmb/VXOsrP5pQzWQgULv9B2YqafSONI=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Must-List-July31-4db846ce737245f69aee7bce25660ad7.jpg",
"https://ew.com/thmb/S6-Nw80cwKS8dzLZpEUXh_ULK74=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Queenpins-598-08022024-0e7616dd1422485e8301fb414157607f.jpg",
"https://ew.com/thmb/S6-Nw80cwKS8dzLZpEUXh_ULK74=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Queenpins-598-08022024-0e7616dd1422485e8301fb414157607f.jpg",
"https://ew.com/thmb/bYXF8qXycCZwxkwkiqYZJ-l6eF8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/josh-hartnett-trap-080124-bc84dc0bc3fe486a93c079f6e6a74081.jpg",
"https://ew.com/thmb/bYXF8qXycCZwxkwkiqYZJ-l6eF8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/josh-hartnett-trap-080124-bc84dc0bc3fe486a93c079f6e6a74081.jpg",
"https://ew.com/thmb/rOC-gBzlIWb_b0QCzAhXwkY7Q2A=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/sam-jenn-the-bachelorette-081024-c0f2ba119cf84c96adaeea152b12c213.jpg",
"https://ew.com/thmb/rOC-gBzlIWb_b0QCzAhXwkY7Q2A=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/sam-jenn-the-bachelorette-081024-c0f2ba119cf84c96adaeea152b12c213.jpg",
"https://ew.com/thmb/8cYZBANZ-Yg35Ug1F2To_LGpa_Q=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/50-first-dates-081224-bf35b246f4614ab0888f4a43aa15c188.jpg",
"https://ew.com/thmb/8cYZBANZ-Yg35Ug1F2To_LGpa_Q=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/50-first-dates-081224-bf35b246f4614ab0888f4a43aa15c188.jpg",
"https://ew.com/thmb/31SSN3VJosV_wMzHKXu958bYBOU=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/jon-snow-081224-b7b7a32a886a4c71b9f234771df812c6.jpg",
"https://ew.com/thmb/31SSN3VJosV_wMzHKXu958bYBOU=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/jon-snow-081224-b7b7a32a886a4c71b9f234771df812c6.jpg",
"https://ew.com/thmb/GUC_0_yvZ4idxR20lASDM6CEqo8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/TDW-20105_R-d1ad53bd28e0458f8f65b759f73f50f9.jpg",
"https://ew.com/thmb/GUC_0_yvZ4idxR20lASDM6CEqo8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/TDW-20105_R-d1ad53bd28e0458f8f65b759f73f50f9.jpg",
"https://ew.com/thmb/ZziJI8E43nVQe5HNJHhPXCcU9aI=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/x-men-072524-bf2df0534da54cba9e80828af2ebefdf.jpg",
"https://ew.com/thmb/ZziJI8E43nVQe5HNJHhPXCcU9aI=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/x-men-072524-bf2df0534da54cba9e80828af2ebefdf.jpg",
"https://ew.com/thmb/pgclnC2WtrEuqRVQUWazEycJXj4=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/chucky-split-072924-a6f5d4cbe2f1480494c8e9661ecb3d4d.jpg",
"https://ew.com/thmb/pgclnC2WtrEuqRVQUWazEycJXj4=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/chucky-split-072924-a6f5d4cbe2f1480494c8e9661ecb3d4d.jpg",
"https://ew.com/thmb/zeT5Zt5YenP9DVu_1eo8pQmRtn8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Wayne-Brady-the-family-remix-080624-7b0646c1b69547e6b875c89d6209cd93.jpg",
"https://ew.com/thmb/zeT5Zt5YenP9DVu_1eo8pQmRtn8=/282x188/filters:no_upscale():max_bytes(150000):strip_icc()/Wayne-Brady-the-family-remix-080624-7b0646c1b69547e6b875c89d6209cd93.jpg",
"https://privacy-policy.truste.com/privacy-seal/seal?rid=66410a94-db48-4a68-8eae-de35e6397332"
] |
[] |
[] |
[
""
] | null |
[
"Jennifer Arellano",
"www.facebook.com"
] |
2013-08-19T00:00:00
|
I'm Still Not Over ... The twist ending of 'Remember Me'
|
en
|
/favicon.ico
|
EW.com
|
https://ew.com/article/2013/08/19/remember-me-ending-still-not-over/
|
Here at PopWatch, we're reminiscing about the pop culture moments that we still can't get over—no matter how much time has passed.
It's been three years since the release of 2010's Remember Me, starring Robert Pattinson and Emilie de Ravin as two NYU students from different social classes, and similarly discordant family relationships, who end up falling in love. Sounds harmless, albeit even a little boring, right? Well, while I was sunk into my movie chair, going through the motions of this one-note film, soaring on a neutral emotional plane, thinking this run-of-the-mill romance-drama can't get any better or worse, so might as well enjoy the aesthetic pleasures of Pattinson's face and decide what to make for dinner, in a place I thought was a safe space, the movie theater transformed into a bubbling cauldron of audible audience outrage, severe shock, and popcorn projectiles…
… when I saw how Remember Me ended.
It transformed the movie from the ordinary to the extraordinary offensive.
I remember other theatergoers spouting Oh no, they didn't! Oh, my god!, and for the taciturn, simple No, No, No's while distastefully shaking their heads.
For those of you who have not seen the film, the plot takes a positive turn when Ally (de Ravin) forgives Tyler (Pattinson) for lying to her about asking her out on the premise of a dare. Tyler and his father begin mending their tumultuous relationship, and Tyler starts going to class and maintaining a social life again. From the get-go, Tyler's character is a brooding mess, getting into fights, and throwing anger fits, all while chronicling his deepest thoughts in a leather-bound journal. When he gets his life together, you start to root for him, dare I say, even care. So this trajectory of pathos the audience has developed for the character makes the ending all the more obnoxious. You bring us up only to bring us down, Hollywood!
Tyler is supposed to meet his dad (Pierce Brosnan) at his office, in some unidentified NYC high-rise. But his dad is running late. Tyler is waiting patiently and discovers his dad's screensaver on his desktop contains photos of him and his sister. Cut to his little sister's classroom and the teacher starts to write the date on the chalkboard "September … 11 … 2001."
Right?
Thankfully the filmmakers spared us the sight of the crumbling Twin Towers, but they do cut to a shot of Tyler's journal lying in the rubble, with a voice-over of Tyler saying something vaguely poetic.
I've never gotten over this ending because I never could understand the necessity for repurposing a tragedy for a superfluous coda. Nowhere in the film is there an indication that we are watching a pre-9/11 New York, nowhere do we get any signpost that Tyler's dad works at the World Trade Center, and nowhere in the plot does it indicate that Tyler should have to die after improving his life.
Sometimes movie endings will employ a deus ex machina and nicely tie up unanswered plot ends, but this 9/11 ending wasn't answering any mysterious plot points. Sometimes movie endings will employ an M. Night Shyamalan fancy-do-dah, à la Signs and The Sixth Sense, and cause you to re-evaluate your understanding of the plot (and cause a temporary existential crisis) in a satisfying way, but all Remember Me's ending did was cause me to feel offended and befuddled and then wonder why I care so deeply about these sorts of things.
I can think of other movies where the surprise ending illuminates your movie-watching experience and asks your brain to keep chewing on the plot, such as Inception (did it or did it not stop spinning?) or Lost in Translation (what did Bill Murray whisper in her ear?) and Before Sunset (barring the release of Before Midnight, I had wondered, did he go back to his family or sleep with Celine?). But the 9/11 ending of Remember Me will always stick with me as one of the worst cinematic endings ever.
The film was already overshadowed by a Twilight star; why overshadow it with a real-life tragedy too?
Anyone else still outraged by this ending? What are your favorite/worst twist endings so far? Let us know in the comments!
|
||||
3536
|
dbpedia
|
1
| 15
|
https://tangentsusa.wordpress.com/2015/02/09/theory-of-everything-not-quite-what-it-promises/
|
en
|
“The Theory of Everything”: Not Quite What It Promises
|
[
"https://tangentsusa.wordpress.com/wp-content/uploads/2015/02/theory-of-everything-poster.jpg?w=351&h=520",
"https://tangentsusa.wordpress.com/wp-content/uploads/2015/02/x900.jpg?w=639&h=426",
"https://tangentsusa.wordpress.com/wp-content/uploads/2015/02/theory-of-everything-1.jpg?w=554&h=369",
"https://2.gravatar.com/avatar/21cff8af602f5af1a1220aefb9489dd14f1ffb7ac61d1660db9beaac01dc4565?s=140&d=identicon&r=G",
"https://s2.wp.com/i/logo/wpcom-gray-white.png",
"https://s2.wp.com/i/logo/wpcom-gray-white.png",
"https://pixel.wp.com/b.gif?v=noscript"
] |
[] |
[] |
[
""
] | null |
[
"Dan Gorman"
] |
2015-02-09T00:00:00
|
I first learned about Stephen Hawking when I was a kid, watching the episode of “Star Trek: The Next Generation” where Hawking cameos as a hologram of himself, playing cards with Newton, Einstein and Mr. Data. My parents explained who Hawking was and what amazing odds he’d conquered to still communicate with the world. The…
|
en
|
https://s1.wp.com/i/favicon.ico
|
Tangents USA
|
https://tangentsusa.wordpress.com/2015/02/09/theory-of-everything-not-quite-what-it-promises/
|
I first learned about Stephen Hawking when I was a kid, watching the episode of “Star Trek: The Next Generation” where Hawking cameos as a hologram of himself, playing cards with Newton, Einstein and Mr. Data. My parents explained who Hawking was and what amazing odds he’d conquered to still communicate with the world. The man made an incredible impression. I regret not watching his science shows as I got older, but recently I read his memoir, “My Brief History,” and got a better sense of his research interests.
“The Theory of Everything,” a new biopic based mostly on the memoir by Jane Hawking, Stephen’s ex-wife, excels visually and emotionally, conveying just how remarkable this man’s journey has been, but it fails to convey the science fully. That major caveat keeps a very good film – probably one of the best-acted films of the year – from being truly great. Still, I felt that I didn’t waste my money seeing it in theaters, and I suspect most filmgoers will feel the same way, choosing to invest in the emotions over the science.
“Everything” starts at a Cambridge party, where young Ph.D. students Stephen (Eddie Redmayne) and Jane (Felicity Jones) meet cute. They rapidly fall in love, while Stephen finds guidance in Roger Penrose’s new ideas about black holes, as well as the kind tutelage of Prof. Brian Sciama (David Thewlis, basically reprising the affable academic role he performed so well in Harry Potter). Hawking becomes convinced that a black hole exploding could explain the beginning of the universe. Right as he makes this theory, however, Hawking is diagnosed with ALS, then called motor neuron disease, and he begins his inexorable deterioration.
Jane’s determination to keep Stephen alive for as long as possible becomes the driving force for the film. We see their marriage remain happy at first, as their first two children are born and Stephen aces his Ph.D. thesis, but slowly the demands of constant care and the inability to finish her own doctorate make Jane miserable. She briefly finds platonic solace with Jonathan (Charlie Cox), who becomes a tacitly acknowledged third member of their family. The scenes where Hawking masters his electric wheelchair, and where we see Stephen, Jane, and Jonathan making the best of an unusual three-tiered marriage, make a tremendous emotional wallop. We also are engrossed as we see Hawking lose his voice, regain it through the triumphant use of a synthesizer, and finally leave Jane for his edgy, controlling nurse, Elaine (Maxine Peake). The dissolution of Stephen and Jane’s marriage will make even the stoniest of filmgoers reach for their Kleenex.
I suppose I sound as though I’m raving about “The Theory of Everything.” Largely, I was satisfied with the experience of watching the film. Eddie Redmayne gives Hawking a wry sense of humor and distinctive body language in the early scenes – we genuinely like this man before his illness kicks into full gear. Here, Redmayne truly excels, moving far beyond his comfort zone (e.g., the youthful revolutionary tenor in “Les Miserables”) as he contorts his body into atrophied shapes, slurs his speech, and ultimately communicates with mere facial twitches. Were it not for Michael Keaton’s extraordinary, instantly iconic performance in “Birdman, Or (The Unexpected Virtue of Ignorance),” I’d say Redmayne was a lock for the major acting awards. He may be, yet.
I also want to applaud Felicity Jones for the psychological complexity she brings to Jane Hawking. We see Jane go from a sweet young girl in love to an emotionally raw longtime companion, torn between her attraction to Jonathan and her unyielding devotion to Stephen. This devotion makes the end of the Hawkings’ marriage all the more heartbreaking – Jane has sent Jonathan away for Stephen’s sake, only to see the great professor entranced by Elaine’s forceful personality. Through Jones’ remarkably expressive face, we come to understand the complexities of love and the toll of living with a genius who emotionally betrays her. At one scene set at the family’s country house, where Hawking denies his need for live-in medical help, Jones glares at her film husband with such exasperation and ferocity that she instantly became, in my mind, the odds-on favorite for the Best Supporting Actress Oscar. Jones is that good.
The film is also visually brilliant, edited with great acuity and using colorful cinematography to great effect. I’ve rarely seen a film that so elegantly composes shots and uses the arrangement of visual space to comment on the characters’ emotional condition. We are up close with Stephen and his doctor in the hospital, so close to their heads that we feel disoriented – much like the disorientation Stephen must have felt when learning that he was terminally ill. We see blurred images of bodies gliding across a dance floor, lit up in UV light, reflecting Stephen’s description of stars bursting into existence. Foreground and background placements of the members of the four-way love web – Jane, Stephen, Jonathan, Elaine – comment wordlessly on the toll of many taxing years. Director James Marsh and cinematographer Benoit Delhomme have created an intimate ballet on screen.
The visuals and script do well with the science in the first portion of the film, up through Stephen’s declaration of his theory of Hawking radiation emitted from black holes. Powerful visual metaphors underscore the stages of his thought. The dancers reflect his description of novas. A narrow room leading to a lecturing Roger Penrose (Christian McKay) conveys the enveloping nature of the black hole, leading to a singularity – in this case, the singular genius of Penrose. The blurring currents of milk in a coffee cup elegantly show how a black hole swallows light. Glimpses of fire, seen through a half-removed sweater, symbolize Hawking’s vision of black holes emitting radiation and ultimately burning out of existence. Certainly, some of the scientific dialogue to this point is a little pat and superficial, but the visuals and cumulative effect of the dialogue keep us engrossed.
What comes next, however? Brief mentions that quantum mechanics and relativity don’t mix; something about time having no boundaries – in short, a lack of verbal and visual specificity replaces the earlier acuity in capturing Hawking’s thought. As the film becomes an admittedly exceptional domestic drama, the science utterly evaporates from the program. I wanted more stunning metaphors to convey Stephen’s physics discoveries and show to us just why Stephen Hawking is such a remarkable thinker. What a missed opportunity this film represents. The filmmakers could have used the vast canvas of cinema to take viewers on a wide-ranging intellectual voyage, as well as an emotional voyage. Still, maybe this lack of specificity about physics conveys what it is like for ordinary folks to be around a genius like Hawking.
I wanted so much to give “The Theory of Everything” an unrestrained rave. The cinematography alone is worth the price of admission, and Johann Johannsson’s musical score, filled with intricate piano melodies, adds a sense of profound, aching beauty to key scenes, such as when the Hawking family visits the beach. Redmayne gives as good a portrayal of debilitating illness as I’ve ever seen in a film; he easily matches Benedict Cumberbatch’s portrayal of Stephen in the 2004 BBC film, “Hawking.” Jones makes Jane Hawking a secular saint of sorts – this is one of the most three-dimensional women in a film in years.
Unfortunately, writer Anthony McCarten’s handling of the science in the last two-thirds of the film detracts from the film’s overall quality. I can’t recommend as superb a film that doesn’t adequately explain why Stephen Hawking’s life work matters. The earlier BBC film, while focusing only on Hawking’s Ph.D. years and not the later evolution of his thought, did a much more thorough job of portraying the personalities in physics, the theoretical debates, and why Hawking’s first theories made such waves. As I said earlier, though, many people may not care about the superficial treatment of the science. Seeing Hawking deteriorate, master his synthesizer, and ultimately leave his agonized wife will probably be enough for most people seeking a good time at the movies.
In the end, I think more time would have made all the difference. Instead of a quick hour and fifty minutes of screen time, a three-hour film, or better yet a multi-part miniseries, would have allowed the filmmakers to dig into the science more. We might also have seen more of Hawking’s rise to world fame, as well as the scientific challenges to his work that arose in later years and the disintegration of his second marriage to Elaine.
The filmmakers clearly want to tell the story of Jane and Stephen, an admirable goal, hence their desire to cap the story at the end of the Hawkings’ marriage. What frustrates me, though, is that the story of Stephen and Jane continued beyond their divorce. Hawking ultimately divorced Elaine in the 2000s and rekindled a friendship with his ex-wife. Those developments are major parts of Stephen and Jane’s life story. By stopping before that point, the filmmakers imply that they prefer a shallower feel-good story to a truly challenging drama that would take Hawking through the difficulties of his second marriage to a much more powerful dénouement. I suppose that’s the difference between history and Hollywood – history will go to those darker places commercial filmmakers are reticent to visit. Besides, it takes time to explore the nuances of history.
But I give Marsh and his team credit for one last powerful metaphor at the end of the film. Hawking’s later research took away boundaries for time, arguing that time did not exist before the Big Bang. In the final scene, time reverses itself onscreen, so we see Hawking grow young and healthy again, finally ending with him at that Cambridge party. If we reversed time so that time vanished and we were left with just a singularity of mass, what would be there? In this case, we’re left with a good man, who stayed basically good despite his later character flaws. The science represented here only became clearer when I read about Hawking after the film, but the final montage is undeniably moving.
Go see “The Theory of Everything” and marvel at the human journey, then check Hawking’s books and documentaries out from the library to understand the science. Nonetheless, that human journey, coupled with astounding visuals and genuine respect for Stephen Hawking’s work, makes this flawed motion picture one of the better films of the year.
|
||||
3536
|
dbpedia
|
2
| 17
|
https://www.usatoday.com/story/entertainment/movies/2022/06/16/marvel-movies-order-release-date/7616425001/
|
en
|
In what order were the Marvel movies released?
|
[
"https://www.gannett-cdn.com/appservices/universal-web/universal/icons/icon-instagram_24.png"
] |
[] |
[] |
[
""
] | null |
[
"Daryl Perry, USA TODAY",
"Daryl Perry"
] |
2022-06-16T00:00:00
|
The first release of a Marvel movie was 2008's Iron Man followed by the Incredible Hulk in the same year. Here are all the movies in order of release.
|
en
|
USA TODAY
|
https://www.usatoday.com/story/entertainment/movies/2022/06/16/marvel-movies-order-release-date/7616425001/
|
The Marvel movie franchise, also known as the Marvel Cinematic Universe (MCU) started in 2008 with Iron Man. The MCU is divided into four phases, spanning 28 released movies and multiple more on the way. The Infinity Saga, the MCU’s first three phases, contains the first 23 films of the franchise. The term was coined by Marvel Studios president Kevin Feige. The fourth phase started with 2021’s Black Widow. In addition to films, the MCU contains a plethora of TV shows, many of which are available on Disney+.
In what order were Marvel movies released?
There is some debate over how to watch Marvel movies, but a tried and true method is the way they were originally released in theaters, starting with 2008's Iron Man.
Here is the movie release order of the MCU, according to GamesRadar+:
Iron Man (2008)
The Incredible Hulk (2008)
Iron Man 2 (2010)
Thor (2011)
Captain America: The First Avenger (2011)
The Avengers (2012)
Iron Man 3 (2013)
Thor: The Dark World (2013)
Captain America: The Winter Soldier (2014)
Guardians of the Galaxy (2014)
Avengers: Age of Ultron (2015)
Ant-Man (2015)
Captain America: Civil War (2016)
Doctor Strange (2016)
Guardians of the Galaxy Vol. 2 (2017)
Spider-Man: Homecoming (2017)
Thor: Ragnarok (2017)
Black Panther (2018)
Avengers: Infinity War (2018)
Ant-Man and the Wasp (2018)
Captain Marvel (2019)
Avengers: Endgame (2019)
Spider-Man: Far From Home (2019)
Black Widow (2021)
Shang-Chi and the Legend of the Ten Rings (2021)
Eternals (2021)
Spider-Man: No Way Home (2021)
Doctor Strange in the Multiverse of Madness (2022)
Thor: Love and Thunder (2022)
Black Panther: Wakanda Forever (2022)
Watch the Marvel movies in order: Here’s the best way to binge all 28 films
How to watch: ‘Doctor Strange in the Multiverse of Madness' on Disney+
|
|||||
3536
|
dbpedia
|
1
| 42
|
https://anthonybonato.com/2016/08/24/mathematics-in-the-movies/
|
en
|
The Intrepid Mathematician
|
[
"https://anthonybonato.com/wp-content/uploads/2016/08/hidden-figures-alpha-kappa-alpha.jpg?w=628&h=356&crop=1",
"https://i0.wp.com/www.themalaymailonline.com/images/sized/ez/Dev_Patel_FILMFESTIVAL-TORONTO_250416_620_450_70.JPG",
"https://i0.wp.com/science.slc.edu/~jmarshall/courses/2002/fall/cs30/Lectures/week08/TuringMachine.gif",
"https://i0.wp.com/www.eonline.com/eol_images/Entire_Site/20141013/rs_1024x759-141113130840-1024.Alan-Turing-Benedict-Cumberbatch.jl.111314.jpg",
"https://i0.wp.com/news.images.itv.com/image/file/600860/stream_img.jpg",
"https://i0.wp.com/discovermagazine.com/~/media/Images/Issues/2015/jan-feb/fields.jpg",
"https://0.gravatar.com/avatar/0e7d65c7b6a23cdcf0e8749e5a1ee149fa7fda1987e2501f9b6848c10f72aa61?s=70&d=identicon&r=G",
"https://anthonybonato.com/wp-content/uploads/2017/09/science-borealis-146x61.jpg",
"https://s2.wp.com/i/logo/wpcom-gray-white.png",
"https://s2.wp.com/i/logo/wpcom-gray-white.png",
"https://pixel.wp.com/b.gif?v=noscript"
] |
[
"https://www.youtube.com/embed/DhKMfX5rZ0o?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en&autohide=2&wmode=transparent",
"https://www.youtube.com/embed/XYkcuxw4aJM?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en&autohide=2&wmode=transparent",
"https://www.youtube.com/embed/RK8xHq6dfAo?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en&autohide=2&wmode=transparent"
] |
[] |
[
""
] | null |
[] |
2016-08-24T00:00:00
|
Popcorn and math As the 2016 Toronto International Film Festival is about to open in Toronto, I think back on the amazing movies I've seen there with mathematical themes. Mathematicians aren't exactly a movie producer's dream protagonist. We don't blow things up, have superpowers, or save the world from invading aliens (or do we?). Movies rarely,…
|
en
|
https://s1.wp.com/i/favicon.ico
|
The Intrepid Mathematician
|
https://anthonybonato.com/2016/08/24/mathematics-in-the-movies/
|
Popcorn and math
As the 2016 Toronto International Film Festival is about to open in Toronto, I think back on the amazing movies I’ve seen there with mathematical themes. Mathematicians aren’t exactly a movie producer’s dream protagonist. We don’t blow things up, have superpowers, or save the world from invading aliens (or do we?). Movies rarely, if ever, accurately portray what mathematicians do, let alone do justice to their personal lives.
That’s changing, fortunately, with audiences developing diverse and eclectic tastes in their consumption of entertainment. Netflix and other media have exposed viewers to a vast array of films they might never ordinarily see in their local cinema. Another reason why mathematicians are figuring in mainstream movies is that a number of such films that did very well recently on the awards circuit.
Alan Turing and The Imitation Game
Alan Turing was decades ahead of his time, and is considered by many as one of the progenitors of modern computing. Turing machines (as they are called today in computability theory) are abstract representations of digital computers, first introduced by Turing in his 1948 essay “Intelligent Machinery”. A Turing machine is a read/write device, writing or erasing 1’s or 0’s on an infinite tape. This simple notion underlies every practical modern computer, no matter how complex.
The 2015 film The Imitation Game gave wonderful synthesis of Alan Turing’s personal struggles and his outward heroism. He and his team at Bletchley Park had a major impact on the outcome of World War II with their cracking of the German Enigma code.
In the movie, Turing christens the newly invented computer “Christopher”, after a boy he had romantic feelings for from his childhood. The real life Christopher died of tuberculosis, and Turing learns this from his headmaster in a heart-wrenching scene. As an adult, we see Turing as arrogant and unapproachable. One of his discoveries and must-haves on his team was Joan Clarke, who is one of the few able to reach Turing. Together they crack Enigma, only to realize they cannot widely reveal their discovery, for fear of the Germans getting wind and changing their codes. After the war, Turing committed suicide. He had endured the hardship of chemical castration, a sentence imposed on the British government for his homosexuality.
I saw the Imitation Game world premiere at the TIFF in September 2014. After the movie, the cast and director were on stage to answer questions. I was highly impressed by the movie, especially by Benedict Cumberbatch’s portrayal of Alan Turing. In the discussion on stage after the film, Cumberbatch spoke intelligently about Turing’s work on morphogenesis (a topic in mathematical and computational biology that is his most cited paper). He had done his homework! See below for a short video explaining Turing’s work in this area.
And then there is the small matter of the reception of the film. The movie went on to make over 233 million US dollars worldwide, despite its tiny 14 million dollar budget. The movie was highly awarded, receiving The Academy Award for Best Adapted Screenplay.
Hawking and Ramanujan
Two other recent biopics worthy of attention (that both opened at TIFF, and yes, I was at their premiers!) are The Man Who Knew Infinity and The Theory of Everything, about Srivinasa Ramanujan and Stephen Hawking, respectively. You can read my review of Infinity, so I won’t go into detail about that movie here.
Stephen Hawking is a physicist, of course, although his work is highly mathematical. The Theory of Everything lovingly weaves the story of his life, scholarly work, and relationships, all with the backdrop of Hawking’s advancing ALS. Eddie Redmayne is triumphant as Hawking, and deservedly won the Academy Award for Best Actor for his role.
The movie brought in 123 million US dollars, with a budget of 15 million. Redymane won the Oscar for Best Actor. See a theme here?
I love the new Jaguar commercial featuring Hawking. It is fair to say that he can do whatever he wants at this point in his life and career.
Mathematicians are the new vampires
Looking to watch something beyond vampires, zombies, or fifty shades of grey? Try mathematicians!
As is becoming a regular call to arms here, I challenge Hollywood to make a commercial hit out of a movie about Paul Erdős or Emmy Noether. Or make a gripping biopic about such living geniuses as Maryam Mirzakhani (the first woman to win the Fields medal) or Grigori Perelman (the reclusive mathematician who settled the Poincaré conjecture, and turned down his Fields medal).
I’m really looking forward to Hidden Figures, about the African-american women mathematicians and their work on the early space program at NASA. The movie is based on the non-fiction book by Margot Lee Shetterly of the same name, and it focuses on the STEM pioneers Katherine Johnson (who won the Presidential Medal of Freedom in 2015), Dorothy Vaughan and Mary Jackson.
Looking for other ideas for films on mathematics? Contact me for more.
Anthony Bonato
|
||||
3536
|
dbpedia
|
1
| 39
|
https://www.bathingsolutions.co.uk/blog/disabilities/top-films-featuring-disabilities/
|
en
|
Top 12 Movies about People with Disabilities
|
[
"https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2019/05/bs_logo.png",
"https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2018/01/logo1.png",
"https://www.bathingsolutions.co.uk/blog/disabilities/top-films-featuring-disabilities/wp-content/uploads/2019/05/bs_logo.png",
"https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2021/01/home-1.png",
"https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2021/01/design-tools-1.png",
"https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2021/01/configuration-1.png",
"https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2021/01/Group-1.png",
"https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2017/06/film-feature2.jpg 400w, https://www.bathingsolutions.co.uk/nitropack_static/cLQhxUUdGEUqBepQOquCUyNNmqsVlVXi/assets/images/optimized/rev-25053a2/www.bathingsolutions.co.uk/wp-content/uploads/2017/06/film-feature2-300x188.jpg 300w"
] |
[] |
[] |
[
""
] | null |
[
"Bathing Solutions"
] |
2021-06-26T10:26:03+00:00
|
We’ve compiled 12 films featuring disabilities, from Alzheimer’s to ALS, to show the diversity of disabilities that are represented in movie form.
|
en
|
Bathing Solutions
|
https://www.bathingsolutions.co.uk/blog/disabilities/top-films-featuring-disabilities/
|
The way that people are portrayed in popular media can have a real impact on not only how they are viewed by society, but also how people view themselves. Films are one way that many people with disabilities will start to see how society views them, and also experience how other disabled people see the world.
As experts in caring for individuals with disability and mobility issues with walk in baths and walk in showers – we understand how challenging life can become with these barriers in place.
So, we’ve brought together 10 of the best movies about disabilities (in no particular order), from Alzheimer’s to ALS, to show the diversity of disabilities that are represented in film.
1. The Theory of Everything
The first film on our list is the biographical dramatization of the life of the well-known theoretical physicist Stephen Hawking. Based on the novel Travelling to Infinity: My Life with Stephen, by his ex-wife Jane Hawking, this film was critically acclaimed across the globe and deals with Jane’s relationship with Stephen, from its inception, through his diagnosis with ALS, right up until their divorce. This bittersweet love story is both moving and inspirational, absolutely a must see. 7.3/10
Get a FREE Brochure
Simply complete our form to see a full range of bathing solutions & their key features. It takes no time at all!
3. Inside I’m Dancing (Rory O’Shea Was Here)
Also released under the title Rory O’Shea Was Here, this film stars a young James McAvoy, long before he became Professor Xavier. Inside I’m Dancing is the story of two young men with disabilities who live in a residential home for the disabled. The two men reject the ‘protective’ care that they are placed under, and rebel against society’s attitudes towards them – especially pity – and long for independence. 5.8/10
4. Still Alice
Still Alice stars Julienne Moore as the titular Alice, a linguistic professor who gets diagnosed with Alzheimer’s shortly after her 50th birthday. The film follows Alice as her illness progresses, and was widely praised by critics. Julienne Moore won an Oscar, among other awards, for her gripping performance as Alice. Still Alice is one of the few films that treats Alzheimer’s with a delicate sensitivity, but also bravery. Astonishingly delicate and sad, a definite must watch. 7.4/10
5. I Am Sam
Another masterful movie featuring a character with special needs, Sean Penn was nominated for an Oscar for his role as the titular Sam in this 2001 drama. Penn portrays a father with developmental disabilities and Dakota Fanning appears as his young daughter who he must care for. They encounter many challenges, including Sam’s daughter becoming more intellectually advanced than her father, whether Sam is declared a fit parent, and whether or not she can continue to live with him. An emotionally uplifting story, if a little obvious. 4.6/10
8. My Left Foot
The highest rated film on our list, My Left Foot stars Daniel Day-Lewis in one of the best performances of his life – so much so that he won the Oscar for his work. The true story of Irish cerebral palsy victim Christy Brown, who grew up to be a well-known painter, author and fundraiser. My Left Foot is notable for avoiding the Hollywood stereotype of a disabled person, as Brown was not a loveable character, and a notorious alcoholic. My Left Foot does not sugarcoat disability, and presents it in a real and resonating way. 8.1/10
10. Forrest Gump
The next film on our list is an oldie but a goody. Certainly, one of the most iconic movies with a disabled main character. Forrest Gump follows the life of the titular character over several decades. While Forrest’s disability is never explicitly stated, it is assumed that he has a form of autism – long before the disease was really classified the way it is today. Tom Hanks shines in this role, and watching Forrest Gump is sure to bring a smile to anyone’s face. 7.2/10
11. The Peanut Butter Falcon
This heart-warming movie follows Zak, a boy with Down’s Syndrome runs away from the nursing homes he lives at to pursue his dream of becoming a wrestler. On the road he encounters a wayward fisherman played by Shia LaBeouf, who takes him under his wing to help him on his quest. As the pair become friends, the movie highlights the importance of friendships and meaningful connections. Most importantly this movie is the debut of actor Zack Gottsagen, “a disarming performer who creates a sweet and funny character” as Zak. Glenn Kenny wrote in his review in The New York Times. 7.6/10
12. The Father
Based on and co-written by the author of the award-winning play Le Père, this moving film sheds light on the reality of taking care of a loved one with dementia. Anthony, played by Anthony Hopkins, is an 80-year-old man desperately clinging to his independence as his mental state regresses. His daughter, played by Olivia Colman, struggles keeping up with her own life as well as taking care of his father, we get a glimpse into both sides of the story. 8.4/10
Did you watch any of these films? Or did we leave off a much beloved classic? Chat to us on Twitter and let us know.
If you or a loved one is in need of a walk in bath, shower or even a wet room, Bathing Solutions offer a full range of products to aid mobility. Order a free brochure here or call us today to find out more.
|
|||||
3536
|
dbpedia
|
3
| 2
|
https://player.bfi.org.uk/free/film/watch-stephen-hawking-on-black-holes-1979-online
|
en
|
Watch Stephen Hawking on Black Holes online
|
[
"https://player.bfi.org.uk/themes/custom/bfip/images/logo.png",
"https://player.bfi.org.uk/themes/custom/bfip/images/logo.svg",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/N_216927_01of01.jpg?itok=2GQr-ea1",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/N_216927_01of01.jpg?itok=2GQr-ea1",
"https://player.bfi.org.uk/sites/default/files/styles/association/public/association-logos/EAFA_at_UEA_Logo_2.jpg?itok=k_O0ysXn",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/N_216950_01of01.jpg?itok=diU_tVJu",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/N_216950_01of01.jpg?itok=Ie6QSBE_",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/Bumping%2520Race%2520%2528Cambridge%2520May%2520Races%2529.jpg?itok=5UfwqXSq",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/Bumping%2520Race%2520%2528Cambridge%2520May%2520Races%2529.jpg?itok=hev-K0vn",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/N_217098_01of01.jpg?itok=GkWeI3hp",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/N_217098_01of01.jpg?itok=hHM92QQ8",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/N_216924_01of01.jpg?itok=jvZXj_XI",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/N_216924_01of01.jpg?itok=k2snwMDh",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/N_216926_01of01.jpg?itok=unf0n3mK",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/N_216926_01of01.jpg?itok=FzppzI9o",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/N_217117_01of01.jpg?itok=soaavK20",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/N_217117_01of01.jpg?itok=_NBEbTAE",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/baldwins_nigger_1920.jpg?itok=mdVknguo",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/baldwins_nigger_1920.jpg?itok=uPRKDHId",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/Shoot-Your-Shot-02.jpg?itok=KREdlpBS",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/Shoot-Your-Shot-02.jpg?itok=fIvuFrwZ",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/Yellow-04.jpg?itok=Bt5NDkC8",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/Yellow-04.jpg?itok=CC4Ch0a6",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/%25E2%2580%258ELook-Like-You-02.jpeg?itok=2R3w9luT",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/%25E2%2580%258ELook-Like-You-02.jpeg?itok=pEQh3r07",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/NEHEMICH-02.jpg?itok=ba9fjUy4",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/NEHEMICH-02.jpg?itok=-GzhyrNH",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_32x18/public/hero-images/1717526943-default-ovp-poster-image.jpg?itok=Fk8VLsGa",
"https://player.bfi.org.uk/sites/default/files/styles/landscape_480x270/public/hero-images/1717526943-default-ovp-poster-image.jpg?itok=2O8tlmkh",
"https://player.bfi.org.uk/themes/custom/bfip/images/logo-alt.png",
"https://player.bfi.org.uk/themes/custom/bfip/images/logo-alt.svg"
] |
[] |
[] |
[
""
] | null |
[] | null |
How factually accurate is the 1979 American sci-fi movie 'The Black Hole'? Physicist Professor Stephen Hawking sheds light on the matter.
|
en
|
/themes/custom/bfip/images/favicon-16x16.png
|
BFI Player
|
https://player.bfi.org.uk/free/film/watch-stephen-hawking-on-black-holes-1979-online
|
In the year the American science fiction movie 'The Black Hole' is due for release in cinemas, theoretical physicist Professor Stephen Hawking tells us the facts about this phenomena. Hawking was diagnosed with motor neurone disease in his early twenties and over the years his speech deteriorated. Understood by only his close acquaintances, in this interview a colleague translates as he explains his Theory of Black Holes.
In 1979, Professor Hawking became the Lucasian Professor of Mathematics at the University of Cambridge, one of the most prestigious academic posts in the world.
The East Anglian Film Archive, the first and largest Regional Film Archive in England, was established in 1976. Since 1984, EAFA has been owned and operated by the University of East Anglia, Norwich (UEA), to support research and work to preserve our moving image heritage. More than 250 hours are freely available online as examples of the wide range of film which attracts interest the world over.
|
||||
3536
|
dbpedia
|
1
| 81
|
https://nypost.com/2015/02/17/how-the-real-life-inspirations-feel-about-their-oscar-nom-movies/
|
en
|
How the real-life inspirations feel about their Oscar-nom movies
|
[
"https://sb.scorecardresearch.com/p?c1=2&c2=6390601&c3=NYPOST&cj=1&cv=3.6&comscorekw=entertainment",
"https://nypost.com/wp-content/uploads/sites/2/2023/02/button_3_bg-2.png?w=206",
"https://nypost.com/wp-content/uploads/sites/2/2015/02/cover3.jpg?quality=75&strip=all&w=744",
"https://vip.nypost.com/wp-content/uploads/sites/2/2015/02/wild.jpg?w=680&h=450&crop=1",
"https://vip.nypost.com/wp-content/uploads/sites/2/2015/02/sniper.jpg?w=680&h=450&crop=1",
"https://vip.nypost.com/wp-content/uploads/sites/2/2015/02/selma.jpg?w=680&h=450&crop=1",
"https://vip.nypost.com/wp-content/uploads/sites/2/2015/02/imitationgame.jpg?w=680&h=450&crop=1",
"https://vip.nypost.com/wp-content/uploads/sites/2/2015/02/foxcatcher.jpg?w=680&h=450&crop=1",
"https://vip.nypost.com/wp-content/uploads/sites/2/2015/02/theoryeverything.jpg?w=680&h=450&crop=1",
"https://nypost.com/wp-content/uploads/sites/2/2024/08/newspress-collage-9zjpy844x-1723366764649.jpg?quality=75&strip=all&1723352416&w=260&h=174&crop=1",
"https://nypost.com/wp-content/uploads/sites/2/2024/08/trustees-british-museum-87693880.jpg?quality=75&strip=all&w=260&h=174&crop=1",
"https://nypost.com/wp-content/uploads/sites/2/2024/08/13.RodgersBook_web2.jpg?quality=75&strip=all&w=260&h=174&crop=1",
"https://nypost.com/wp-content/uploads/sites/2/2020/10/apple-podcast-badge402x.png",
"https://pagesix.com/wp-content/uploads/sites/3/2024/08/kelly-clarkson-show-episode-j144-87706319.jpg?quality=75&strip=all&w=1024",
"https://decider.com/wp-content/uploads/2024/08/wwhl2_1aaa3d.jpg?quality=75&strip=all&w=322&h=215&crop=1",
"https://nypost.com/wp-content/uploads/sites/2/2024/08/87692076.jpg?quality=75&strip=all&crop=1&w=341&h=227 1x, https://nypost.com/wp-content/uploads/sites/2/2024/08/87692076.jpg?quality=75&strip=all&crop=1&w=682&h=454 2x",
"https://nypost.com/wp-content/uploads/sites/2/2024/08/newspress-collage-9zjpy844x-1723366764649.jpg?quality=75&strip=all&1723352416&crop=1&w=341&h=227 1x, https://nypost.com/wp-content/uploads/sites/2/2024/08/newspress-collage-9zjpy844x-1723366764649.jpg?quality=75&strip=all&1723352416&crop=1&w=682&h=454 2x",
"https://nypost.com/wp-content/mu-plugins/vip-helpers/images/vip-powered-dark-small.png"
] |
[
"https://www.youtube.com/embed/tn2-GSqPyl0?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent",
"https://www.youtube.com/embed/5bP1f_1o-zo?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent",
"https://www.youtube.com/embed/x6t7vVTxaic?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent",
"https://www.youtube.com/embed/S5CjKEFb-sM?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent",
"https://www.youtube.com/embed/PypvNBTdxnY?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent",
"https://www.youtube.com/embed/Salz7uGp72c?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent"
] |
[] |
[
"Movies",
"Entertainment",
"american sniper",
"chris kyle",
"foxcatcher",
"martin luther king jr.",
"oscars",
"oscars 2015",
"selma",
"stephen hawking",
"the imitation game",
"the theory of everything",
"wild"
] | null |
[
"Reed Tucker"
] |
2015-02-17T00:00:00
|
So they’re making a movie about your life? Sounds great — until they screw up the historical details or, worst of all, cast Ashton Kutcher in the lead...
|
en
|
New York Post
|
https://nypost.com/2015/02/17/how-the-real-life-inspirations-feel-about-their-oscar-nom-movies/
|
So they’re making a movie about your life? Sounds great — until they screw up the historical details or, worst of all, cast Ashton Kutcher in the lead role.
Biopics can be dicey business, especially for the real-life figures who inspire them. Not everyone is honored by the process or likes the end result.
Last year was a ridiculously busy one for biopics. And many of those films ended up making the Oscar nomination list.
We’ll learn soon enough how the Academy voters feel about these films, but how about the actual figures? Take a look:
‘Wild’
Reese Witherspoon plays Cheryl Strayed, a once-troubled woman who decided to undertake a 1,100-mile solo hike through the wilderness.
The real Strayed was heavily involved in the filmmaking process and offered Witherspoon plenty of pointers. She also has said that director Jean-Marc Vallée valued her input.
No surprise, then, that Strayed liked “Wild.”
“It’s funny, it never occurred to me that a movie star would play me,” she told Mother Jones. “But now that she is playing me, it’s like, of course, it couldn’t be anyone else . . . Watching the movie for me is uncanny, because they have her wearing the clothes I wore . . . She just became me in a way that’s like, shocking.”
‘American Sniper’
The story of the military’s most lethal marksman has stirred up plenty of controversy since it was released in December — just not any with Chris Kyle’s widow, Taya.
She’s been actively promoting the film and is happy with it. She’s called the making of “American Sniper” “healing” for her.
“[Screenwriter] Jason Hall spent all this time with me, and I’m talking about my memories and my life and my love, and the love of Chris toward me and the kids,” Taya told USA Today. “It was healing for me to be able to give that, and to be able to preserve some of those memories in a different way. It’s been a really beautiful thing.”
‘Selma’
Martin Luther King Jr.’s family has a complicated relationship with “Selma,” the movie that portrays the civil rights leader’s Alabama march.
King’s children are involved in a competing Steven Spielberg biopic about their late father, and as a result, the heirs did not cooperate with “Selma” or allow the filmmakers to use the text of King’s actual speeches.
The family has, however, attended screenings at the studio’s invitation and offered generally positive feedback.
“The film shows that through endurance, you can be successful, and you can do it in a peaceful way,” Martin Luther King III told Variety. “These issues have been here for a long time. But Dr. King’s example showed us that if we are resilient, if we stay the course, we can in fact bring about change.”
King III was skeptical about the accuracy of “Selma” when it came to portraying his mother and father’s relationship.
“How would [director] Ava DuVernay know what existed in the bedroom of my mom and dad? You really have to create some of that,” King III said. “Under the circumstances, I think that the film did the best it could.”
‘The Imitation Game’
The film centers on the efforts of British mathematician Alan Turing to break a Nazi code during World War II. Turing died in 1954. He was gay and did not have any children.
His niece, Rachel Barnes, is apparently enthusiastic about the movie. She has attended screenings and also signed a petition inspired by “The Imitation Game” asking the British government to pardon homosexuals who were convicted under indecency laws.
The family of Alastair Denniston, the commander at Bletchley Park played by Charles Dance, is less enthusiastic. They’ve complained that the portrayal of Denniston as a villain who worked to hamper Turing’s efforts is false.
“He is completely misrepresented,” granddaughter Judith Finch wrote in a letter to the Daily Telegraph. “They needed a baddy and they’ve put him in there without researching the truth about the contribution he made.”
‘Foxcatcher’
Tell us how you really feel about “Foxcatcher,” Mark Schultz.
“I HATE [director] BENNETT MILLER,” Schultz tweeted last December. “I HATE EVERYTHING THAT SCUM TOUCHES. EVERYTHING!!!”
“YOU THINK I’M GOING TO SIT BACK AND WATCH YOU DESTROY MY NAME AND REPUTATION I SWEAT BLOOD FOR. YOU AINT’ SEEN NOTHING YET DUDE,” he also wrote. The tweets were later deleted, and Schultz apologized.
Schultz, who is played by Channing Tatum in the wrestling-world biopic, had been critical of the film late last year. In a Facebook post, he called it “primarily fiction.”
He was especially upset by a scene that suggests that the character based on him had a sexual relationship with John Du Pont (Steve Carell). Schultz has said that he asked Miller to cut the scene, but the director refused.
However, Schultz appears to have now made peace with the film and its portrayal of him.
‘The Theory of Everything’
The biopic about physicist Stephen Hawking gets mixed reviews from its two main players.
Hawking himself has praised star Eddie Redmayne, calling the film “broadly true.”
“I thought Eddie Redmayne portrayed me very well in ‘The Theory of Everything’ movie,” Hawking wrote on his Facebook page. “He spent time with ALS sufferers so he could be authentic. At times, I thought he was me.”
Hawking’s ex-wife and current partner, Jane, doesn’t appear to be as enthusiastic, though she has said it’s a “great privilege” to have a film made about her and her ex-husband.
|
|||||
3536
|
dbpedia
|
2
| 95
|
https://www.statista.com/statistics/187122/movie-releases-in-north-america-since-2001/
|
en
|
U.S. & Canada: movie releases per year 2023
|
[
"https://cdn.statcdn.com/Study/160000/162257-standard.png",
"https://cdn.statcdn.com/Statistic/295000/297533-blank-100.png",
"https://cdn.statcdn.com/Statistic/250000/254669-blank-100.png",
"https://cdn.statcdn.com/Statistic/185000/187300-blank-100.png",
"https://cdn.statcdn.com/Statistic/185000/187171-blank-100.png",
"https://cdn.statcdn.com/static/../CMS/contactperson/ERI851_1715670933.png",
"https://cdn.statcdn.com/static/img/modalEmployeeGroup.png",
"https://cdn.statcdn.com/static/icons/blank.gif",
"https://cdn.statcdn.com/Topic/5431.jpg",
"https://cdn.statcdn.com/Topic/964.jpg",
"https://cdn.statcdn.com/Topic/5417.jpg",
"https://cdn.statcdn.com/Topic/8534.jpg",
"https://cdn.statcdn.com/Topic/5776.jpg"
] |
[] |
[] |
[
""
] | null |
[
"Laura Carollo"
] | null |
In 2023, a total of 504 movies were released in the United States and Canada, up from 456 in the previous year.
|
en
|
Statista
|
https://www.statista.com/statistics/187122/movie-releases-in-north-america-since-2001/
|
Movie releases in the U.S. & Canada 2000-2023
Published by
Number of movies released in the United States and Canada from 2000 to 2023
Source
Show detailed source information?
Register for free
Already a member?
Log in
Source
Use Ask Statista Research Service
Release date
May 2024
More information
Region
Canada, United States
Survey time period
2000 to 2023
Supplementary notes
The date of release is the date of access.
Citation formats
|